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ABSTRACT 
 
Endothelin-1 (ET-1) promotes changes in gene/protein expression in cardiomyocytes leading to 
hypertrophy.  This results from activation of intracellular signalling pathways including small G 
proteins that activate protein kinases.  Thus, ET-1 activates RhoA that stimulates ROCK and PKN, 
and Ras that promotes activation of extracellular signal-regulated kinases 1/2 (ERK1/2).  
Microarrays were used to dissect the roles of ERK1/2 vs RhoA in the cardiomyocyte 
transcriptomic response to ET-1 using PD184352 and C3 endotoxin from C. botulinum (C3T) for 
selective inhibition of the ERK1/2 cascade and RhoA, respectively.  Microarray data were analysed 
using GeneSpring and data were validated by qPCR.  ERK1/2 signalling positively regulated ~65% of 
the early gene expression response to ET-1 with a small (~2%) negative effect, whereas RhoA 
signalling positively regulated ~11% of the early gene expression response to ET-1 with a greater 
(~14%) negative contribution.  Of RNAs non-responsive to ET-1, 66 or 448 were regulated by 
PD184352 or C3T, respectively, indicating that RhoA had a more significant effect on baseline RNA 
expression.  mRNAs upregulated by ET-1 encoded several receptor ligands (e.g. Ereg, Areg) and 
transcription factors (e.g. Abra/STARS, Srf) that potentially propagate the response.  Published 
studies suggest that PKN1 (activated by RhoA) is important in cardiomyocyte gene expression.  
Adenoviruses were generated to overexpress FLAG-tagged PKN1 in cardiomyocytes for protein 
kinase studies.  Unexpectedly, PKN1 was not activated by ET-1, but was activated by oxidative stress, 
insulin, or hyperosmotic shock, stimuli that do not activate RhoA.  Thus, PKN1 is not necessarily an 
effector of RhoA in cardiomyocytes. 
In conclusion, ERK1/2 dominates over RhoA in the early transcriptomic response to ET-1.  
RhoA plays a major role in maintaining baseline RNA expression but, as with upregulation of 
Abra/Srf by ET-1, RhoA may regulate changes in RNA expression over longer times.  However, the 
effects of RhoA on cardiomyocyte gene expression are unlikely to be mediated through PKN1.  
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CHAPTER 1: INTRODUCTION 
 
1.1.  Cardiac growth and development 
 
Cardiomyocytes are the contractile cells of the heart and their synchronous contraction and relaxation 
is responsible for the pumping of blood around the body.  Contractile cardiomyocytes first develop 
early in embryogenesis and continue to divide during cardiac morphogenesis.  Shortly after birth, 
mammalian cardiomyocytes withdraw from the cell cycle and become terminally-differentiated.  
Subsequently, the cardiomyocytes undergo maturational growth as the demands on the heart increase 
with increasing body size.  This postnatal cardiac growth results from an increase in cardiomyocyte 
size with increasing myofibrillar content.  Although this is often called hypertrophy, a better term 
would be eutrophy (Dorn et al, 2003).  In the adult, the heart is subjected to a variety of 
pathophysiological conditions many of which involve a requirement for changes in the power output 
of the heart.  In the instance of a requirement for increased power output, cardiomyocytes undergo a 
true hypertrophy as defined by an increase in the content of the cellular components of the cell in the 
absence of cell division, over and above that which is normally seen at a comparable stage of 
development (Dorn et al, 2003).  Alternatively, as in severe starvation, cardiomyocytes may atrophy 
with an associated reduction in heart size. 
 
Cardiac hypertrophy (as defined clinically) occurs in response to an increased requirement for 
pressure-volume work as in, for example, hypertension (increased pressure work) or valvular 
incompetence (increased volume work).  At first, the response to increased work is beneficial and 
necessary, allowing the heart to maintain or increase its cardiac output.  This is a “compensated” state.  
In the longer term, however, the continuous demand and strain results in a “decompensated” state and 
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heart failure.  The determinants of progression from hypertrophy to failure are not understood (Dorn et 
al, 2003).  Growth of the heart also occurs during chronic exercise training and pregnancy (Lee et al, 
2006;Sliwa et al, 2006).  Such “physiological hypertrophy” is associated with proportional increases in 
the length and width of cardiomyocytes.  It is also characterised by normal or enhanced cardiac 
function (Cuspidi et al, 1991).  In most cases, this adaptational response is reversible and not 
detrimental. 
 
Coronary artery disease is an increasing problem for economically developed countries.  This can lead 
to myocardial infarction as a consequence of blockage in the coronary arteries.  The resulting lack of 
blood supply to a region of the heart leads to cardiomyocyte death.  Following a non-fatal myocardial 
infarction, structural remodelling of the heart is associated with scar formation at the affected area.  In 
order to compensate for lost cardiomyocytes, regional hypertrophy of surviving cardiomyocytes 
develops in the remote myocardium (Sutton and Sharpe, 2000).  More rarely, cardiac hypertrophy is 
associated with monogenic mutations in myofibrillar proteins and these may also lead to changes in 
cardiac morphology (hypertrophic or dilated cardiomyopathies) (Morita et al, 2010).  
 
Oxidative stress (as occurs during ischaemia and on reperfusion) is generally associated with 
cardiomyocyte apoptosis, with high levels inducing necrosis and more moderate levels promoting 
apoptosis.  However, low (sub-toxic) levels of oxidative stress may induce hypertrophy (Sawyer et al, 
2002).  In addition, low levels of oxidative stress may promote cytoprotection and this cytoprotective 
element may facilitate cardiomyocyte hypertrophic growth.  Oxidative stress activates many of the 
same intracellular signalling pathways as the pro-hypertrophic and pro-survival stimuli, but this is 
usually at the levels that promote cell death.  The activation of these pathways in response to oxidative 
stress may simply represent an attempt at cell survival. 
 
 
Chapter 1 
Page | 20  
 
1.2.  Cardiac hypertrophy in experimental systems 
 
The use of neonatal rat ventricular myocytes (NRVMs) in primary culture as an experimental model 
of cardiac hypertrophy is well established, having first been described in the early 1980s (Simpson 
and Savion, 1982;Simpson et al, 1982).  These cells can be maintained in culture for 2 to 4 days 
without any loss of phenotype which is sufficient time to study and detect changes in gene expression 
as well as cell morphology.  On exposure to hypertrophic stimuli, cultured cardiomyocytes exhibit 
many of the features associated with cardiomyocyte hypertrophy in vivo (e.g. increased cell size and 
myofibrillogenesis with associated changes in gene expression; see section 1.3).  Isolated, individually 
cultured adult cardiomyocytes are also used for acute investigations of protein turnover and 
intracellular signalling, but these cells can only be maintained in culture for a short time before the 
phenotype is lost (Hein et al, 2006).  Despite potential advantages, experiments in cultured 
cardiomyocytes cannot entirely recapitulate the scenario of the intact heart, either ex vivo or in vivo.  
Here, cardiomyocytes operate in a three dimensional environment with interactions with other cells 
and the extracellular matrix.  Furthermore, cells in culture are not necessarily exposed to the stresses 
and strains in terms of workload of an intact heart.  It should also be recognised that there is also 
reorganisation of cell surface adhesion proteins as cardiomyocytes adapt from a three dimensional 
environment in vivo to the two dimensional environment in a culture dish, and these will have an 
impact on intracellular architecture.   
 
Cardiac hypertrophy can be studied in vivo, and a number of models have been developed.  One 
model that is frequently used currently is pressure-overload hypertrophy induced by constriction of 
the transverse aorta.  As in many aspects of current medical research, another in vivo approach aimed 
at identifying components of the hypertrophic response involves the use of genetically-modified mice.  
Such studies either now tend to use targeted gene manipulation (deletion or „knock-out‟, replacement 
Chapter 1 
Page | 21  
 
or „knock-in‟) or, as in most of the heart-orientated studies, spatially and/or temporally-controlled 
transgene expression using a cardiospecific promoter (Molkentin and Robbins, 2009).  These genetic 
manipulations in combination with surgical procedures such as aortic constriction provide a powerful 
approach to the study of hypertrophy in vivo.  However, such models have their drawbacks (Cook et 
al, 2009).  
 
1.3.  Stimuli and biochemical features of hypertrophy 
 
Cardiomyocyte hypertrophy is associated with increased cell volume and profile, accumulation of 
total protein and increased myofibrillar assembly.  Little is known of the precise mechanisms that 
cause cardiomyocytes to hypertrophy in vivo.  Ex vivo, stimuli such as mechanical strain and 
neurohumoral factors promote cardiomyocyte hypertrophy and it is likely that these contribute to the 
response in vivo (Devereux and Roman, 1999).  Examples of neurohumoral factors include α-
adrenergic receptor agonists [e.g. noradrenaline, adrenaline (Simpson et al, 1991) and endothelin-1 
(ET-1) (Shubeita et al, 1990)].  These hypertrophic stimuli cause rapid changes in gene expression 
which initiate the hypertrophic response (Clerk et al, 2007a).  Some of the earliest changes involve 
expression of immediate early genes (IEGs) encoding transcription factors (e.g. c-jun, c-fos, Egr-1) 
(Chien et al, 1991).  A longer term characteristic of such hypertrophy is the initiation of a “foetal” 
programme of gene expression with re-expression of genes expressed early in development such as 
atrial natriuretic factor (ANF) (Knowlton et al, 1991;Chien, 1992;Sprenkle et al, 1995).  Other 
characteristics of the “foetal” gene programme include increased expression of skeletal muscle α-actin 
and, in rodents, β-myosin heavy-chain (Calderone et al, 1995).  Contractile proteins (e.g. cardiac 
muscle α-actin, ventricular myosin light-chain 2) are also upregulated over time.  The ANF-related 
peptide, B-type natriuretic peptide (BNP), is expressed throughout hypertrophy and is used as a 
marker of cardiac pathologies (Yamamoto et al, 1996).  This list is far from complete as recent 
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microarray studies indicate (Kennedy et al, 2006;Clerk et al, 2007b;Cullingford et al, 2008;Marshall 
et al, 2010).  
 
Many questions remain unanswered as to which distinct agonists are responsible for the development 
of cardiac hypertrophy in vivo.  One hypothesis is that a variety of factors (vasoactive peptides, 
peptide growth factors, neurotransmitters etc.) are released locally and a combination of these promote 
the ultimate response.  These extracellular factors act at their transmembrane receptors to trigger a 
series of intracellular signalling events which result in hypertrophy.  A number of signalling 
intermediates (e.g. heterotrimeric or monomeric G proteins, protein kinases, protein phosphatases) 
may be involved. 
 
1.4.  Transmembrane receptors associated with cardiomyocyte hypertrophy 
 
Extracellular neurohumoral stimuli are sensed by cardiomyocytes through an array of membrane-
bound receptors.  From the point of view of cardiomyocyte hypertrophy, probably the most important 
are guanine nucleotide-binding protein-coupled receptors (GPCRs) such as those for ET-1 and α1-
adrenergic agonists, and receptors with intracellular tyrosine kinase domains (receptor protein tyrosine 
kinases or RPTKs) such as epidermal growth factor (EGF) receptors.  These receptors activate 
intracellular signalling pathways to elicit their effects (Sugden and Clerk, 1998b). 
 
1.4.1.  G protein-coupled receptors in the heart 
 
GPCRs are the largest family of single polypeptide chain membrane proteins and they mediate many 
cellular responses to hormones and neurotransmitters (Rosenbaum et al, 2009).  They share a common 
structural signature of seven transmembrane α-helices composed predominantly of hydrophobic 
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residues, looping between the extracellular (amino terminus) and intracellular (carboxyl terminus) 
compartments.  GPCRs couple the binding of extracellular agonists to the activation of heterotrimeric 
G proteins tethered to the inner face of the plasma membrane, hence coupling extracellular agonism to 
intracellular responses.  Heterotrimeric G proteins are composed of α, β and γ subunits.  The α and γ 
subunits contain sites for lipid modification (e.g. myristoylation) that localise them to the membrane.  
In the inactive state, α subunits are bound to GDP.  Binding of an extracellular agonist to its GPCR 
induces a conformational change in the receptor that leads to activation of the heterotrimeric G 
protein.  This promotes exchange of GTP for GDP on the α subunit and dissociation of the 
heterotrimer into α.GTP and βγ dimers.  α.GTP subunits couple with an effector to promote 
intracellular signalling.  βγ subunits also target a range of signalling pathways.  The innate GTPase 
activity inherent to the α subunit returns it to the GDP-ligated (i.e. inactive) form.  This is facilitated 
by RGS (regulator of G protein signalling) proteins which enhance the GTPase activity (De Vries et 
al, 2000).  The α.GDP and βγ subunits re-associate, terminating the signal.   
 
There are four main heterotrimeric G protein subfamilies (Gαq/11, Gαi/o, GαS and Gα12/13) based on the 
classification of α subunits, 23 sub-members of which have so far been fully characterised  
(Gudermann et al, 1996;Rosenbaum et al, 2009).  The β and γ subunits are equally diverse with five β 
and eleven γ subunits (Gautam et al, 1998;Smrcka, 2008).  In the heart, GαS signalling is associated 
with activation of β-adrenergic receptors and couples to adenylyl cyclase (Lohse et al, 2003).  This 
stimulates intracellular production of the second messenger cAMP that activates cAMP-dependent 
protein kinase (PKA).  The GαS system is responsible for increasing cardiac contractility through its 
effects on ion movements (L-type Ca
2+
 channels, SERCA2) and myofibrillar proteins (troponin I) 
(Periasamy et al, 1999;Zakhary et al, 1999;MacLennan and Kranias, 2003).  Gαi/o signalling 
antagonises the GαS system either through direct competition with GαS or by increasing the pool of 
free βγ dimers.  In relation to cardiomyocyte hypertrophy, probably the most relevant heterotrimeric G 
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protein subfamilies are Gαq/11 and possibly Gα12/13.  Gα12 and
 
Gα13 participate in cell transformation 
and embryonic development,
 
but the signalling pathways that are regulated by these proteins
 
are not 
fully established.  However, members of the Rho-family monomeric (small) GTPases (Rho, Rac, and 
Cdc42) are particularly implicated in the response.  Gα13 modulates Rho GTPases through the Rho-
specific guanine nucleotide exchange factor (GEF), p115 RhoGEF (Kozasa et al, 1998).  Rho-family 
small G proteins and their roles in cardiomyocytes are discussed in more detail below (see section 
1.5.2).  
 
1.4.2.  Gαq/11 signalling in the heart 
 
ETA receptors (for ET-1) and α1-adrenergic receptors (for noradrenaline or adrenaline) couple through 
Gαq/11 to activate phospholipase Cβ (PLCβ) (Fig. 1.1).  In addition, PLCβ may also be activated by βγ 
dimers.  PLCβ stimulates hydrolysis of the membrane phospholipid, phosphatidylinositol 4,5-
bisphosphate [PtdIns(4,5)P2], producing two second messengers: diacylglycerol (DAG) and inositol 
1,4,5-trisphosphate (InsP3) (Hubbard and Hepler, 2006).  DAG is the physiological activator of 
specific isoforms of protein kinase C (PKC; see section 1.5.1) whereas InsP3 regulates intracellular 
Ca
2+
 movements in many cells (Berridge, 2009).  The role of InsP3 in regulating Ca
2+
 movements in 
excitation-contraction coupling in cardiomyocytes is unclear, but PKCs are activated in 
cardiomyocytes exposed to ET-1 or α-adrenergic receptor agonists (see section 1.5.1).   
 
A number of interventions that are poorly defined biochemically induce the hypertrophic phenotype.  
These include mechanical deformation by stretch (Komuro et al, 1990;Komuro et al, 1996;Yamazaki 
et al, 1996), hypoxia (Ito et al, 1996) and modulation of cell-cell contact (Clark et al, 1998).  The 
hypertrophic action of at least some of these stimuli may be mediated by the release of 
autocrine/paracrine factors such as ET-1 (Ito et al, 1996;Yamazaki et al, 1996).  In addition, 
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hypertrophy induced by either noradrenaline (Kaddoura et al, 1996) or angiotensin II (Aoki et al, 
1998;Sadoshima and Izumo, 1993) could be mediated through local release of ET-1 (Ito et al, 1993).    
 
Transfection experiments directly implicate αq in cardiomyocyte hypertrophy since expression of 
constitutively-active αq in ventricular myocytes stimulates hydrolysis of PtdIns(4,5)P2 and expression 
of ANF (LaMorte et al, 1994).  Furthermore, stimulation of ANF expression by phenylephrine (PE, a 
synthetic α-adrenergic agonist) is attenuated by microinjection of neutralizing antibodies against αq/11 
(LaMorte et al, 1994).  Transgenic mice with cardiac overexpression of wild-type or constitutively-
activated Gαq develop hypertrophy or heart failure depending on the extent of Gαq signalling 
(D'Angelo et al, 1997;Howes et al, 2003).  It should be borne in mind that excessive Gαq may deplete 
PtdIns(4,5)P2 from the membrane and, since PtdIns(4,5)P2 is also the source of the protective 
signalling intermediate, PtdIns(3,4,5)P3, this may lead to cardiomyocyte death (Mende et al, 
1998;Howes et al, 2003).  However, overexpression of an inhibitory peptide (a C-terminal peptide of 
the Gαq subunit) that interferes with Gαq coupling prevents the development of cardiac hypertrophy 
and dysfunction in hearts of mice subjected to pressure-overload (Akhter et al, 1998;Esposito et al, 
2002).  These data support the concept that activation of Gαq/11-signalling pathways in vivo is a critical 
mediator of the hypertrophic response and the transition to heart failure. 
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Figure 1.1. Gαq-coupled receptor signalling. Gq-coupled receptors (e.g. ETA receptors or α1-
adrenergic receptors; α-ARs) activate phospholipase C β (PLCβ) that hydrolyses phosphatidylinositol 
4,5-bisphosphate [PtdIns(4,5)P2] to give diacylglycerol (DAG) and inositol 1, 4, 5-triphosphate 
(InsP3).  DAG activates several isoforms of protein kinase C (PKC) in cardiomyocytes including 
cPKCα, cPKCβ, nPKCδ and nPKCε. 
 
 
1.4.3.  Receptor protein tyrosine kinases  
 
The receptor protein tyrosine kinase (RPTK) family are a category of transmembrane receptors 
consisting of intrinsic protein tyrosine kinase activity and which are found in all multi-cellular 
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eukaryotic organisms. Traditionally, they are linked to the control of cellular growth and 
differentiation.  
  
RPTKs are activated by peptide ligands known as growth factors or cytokines. Such ligands are often 
secreted, soluble proteins but other membrane-bound proteins or extracellular matrix proteins are also 
responsible for RPTK activation.  Ligand binding to RPTKs leads to receptor dimerization and trans-
phosphorylation of the cytoplasmic domains (Schlessinger, 2000). These phosphorylated tyrosine 
residues can then serve as docking sites for SH2 domain-containing signalling or adaptor proteins. 
Such signalling intermediates are activated allosterically upon binding; either as a result of the 
tyrosine phosphorylation itself or due to their close proximity to other substrates at the plasma 
membrane.  
 
More than 50 different genes encoding RPTKs have been characterised in mammals and are organised 
into 14 distinct RPTK subfamilies all of which share almost identical homology in their catalytic 
domains (Friedman and Perrimon, 2006).  The expression of different RPTKs is restricted to specific 
cell types in the organism and the signalling mechanisms associated with the receptor subfamilies 
differ considerably.  In cells where a particular RPTK is expressed, its functions are determined 
mainly by ligand availability and on the localisation of intracellular target proteins.  Although various 
mechanisms for the activation of RPTKs and subsequent propagation of the signalling pathways exist 
in different cell types, for the purposes of the studies conducted in this thesis, the emphasis is on 
RPTK (and in particular insulin and PDGF) signalling in the cardiomyocyte.  
 
In cardiomyocytes, RPTKs are activated by peptide growth factors such as EGF, fibroblast growth 
factors (FGFs), and platelet-derived growth factor (PDGF) (Yarden and Ullrich, 1988).  The 
phosphorylated tyrosines serve as docking sites for intracellular signalling proteins that bind through 
Chapter 1 
Page | 28  
 
SH2 (Machida and Mayer, 2005) or PTB domains (Uhlik et al, 2005).  These include PLCγ that is 
Tyr-phosphorylated (by the RPTK) and activated and, like PLCβ, hydrolyses PtdIns(4,5)P2 to produce 
InsP3 and DAG (Lee and Rhee, 1995).  The Grb2.Sos complex is recruited to the receptor through the 
SH2 domain of Grb2 which also contains an SH3 domain that is constitutively bound to Sos.  Sos is a 
GEF for the small G protein Ras leading to its activation (see section 1.5.2.1).  A third important 
signalling protein recruited to RPTKs is phosphoinositide 3 kinase (PI3K, discussed below in section 
1.5.4).  Insulin also activates a RPTK, but receptors for insulin exist as pre-formed heterotetramers 
(White and Kahn, 1994).  Binding of insulin to the receptor causes a conformational change that 
activates the intracellular tyrosine kinase domain.  This phosphorylates not only the receptor, but also 
insulin receptor substrates 1 and 2 that recruit PI3K to the complex (White and Kahn, 1994).  EGF, 
PDGF and FGF, but not insulin, stimulate cardiomyocyte hypertrophy ex vivo (Clerk et al, 1996). 
 
1.5.  Downstream signalling from transmembrane receptors 
 
1.5.1.  Protein kinase C and cardiac hypertrophy 
 
The best-established signalling pathway downstream of GqPCRs is transmitted via PLCβ through 
PKC (Exton, 1996;Rhee, 2001).  The PKC family of enzymes constitutes a group of phospholipid- 
(phosphatidylserine-) dependent Ser/Thr protein kinases that consist of an N-terminal regulatory 
domain and a C-terminal catalytic domain (Fig. 1.2) (Mellor and Parker, 1998).  The PKC family is 
comprised of at least 11 isoforms and are classified according to their mode of activation, which is 
determined by the N-terminal regulatory domain (Steinberg, 2008).  All require phosphatidylserine for 
their activity.  In addition, the three principal PKC subfamilies are distinguished on the basis of their 
domain structure which dictates their requirements for Ca
2+
 and/or DAG for activation.  The 
“classical” or “conventional” PKCs (cPKCs; cPKCα, the alternatively spliced cPKCβ1 and cPKCβ2, 
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cPKCγ) require both Ca2+ and DAG for activation.  DAG binds to a C1 domain in the regulatory 
region whereas Ca
2+
 binds to a C2 domain.  This results in a conformational change and the 
pseudosubstrate auto-inhibitory domain moves away from the active site and releases the auto-
inhibition.  The “novel” PKCs (nPKCs; nPKCδ, nPKCε, nPKCε, nPKCζ) require DAG to bind to 
their C1 domains for activation, but these enzymes are Ca
2+
-independent and do not possess a C2 
domain.  The “atypical” PKCs (aPKCs; aPKCδ, aPKCη/ι) are independent of both DAG and Ca2+, 
lacking either a C1 or C2 domain. The physiological activators of aPKCs have not been identified 
unambiguously.  PKD, first identified as a PKC homologue and termed PKCκ (Johannes et al, 
1994;Valverde et al, 1994), is now considered to be more closely related to the Ca
2+
/calmodulin 
kinase II family than to PKCs.  PKD is thought to be activated by the bone fide PKCs (cPKCs/nPKCs) 
(Zugaza et al, 1997;Vega et al, 2004;Harrison et al, 2006). 
  
DAG is retained in the membrane following its formation.  Activation of cPKCs and nPKCs by DAG 
is, therefore, associated with their translocation from the soluble fraction of the cell to the membrane.  
Phorbol esters such as phorbol 12-myristate 13-acetate (PMA) mimic DAG but, unlike DAG, are not 
rapidly metabolised, and produce a powerful and sustained translocation and, presumably, activation 
of cPKCs/nPKCs (Nelson and Alkon, 2009).  Additionally, PKCs are regulated by phosphorylation of 
Ser/Thr residues in the catalytic domain. Such phosphorylations are crucial for their activity 
(Steinberg, 2008).  For cPKCs, such phosphorylations are thought to occur as the proteins are 
synthesised, whereas in nPKCs these phosphorylations may be acutely regulated and relate to cell 
stimulation.  PKCs may interact with docking proteins which presumably localise the enzymes in the 
vicinity of their substrates but their identities have not been clearly established (Mochly-Rosen et al, 
1992).   
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All classes of PKCs are expressed in cardiomyocytes and the heart (cPKCα/β, nPKCδ/ε, aPKCδ/ι/η).  
In failing human hearts, the expression of PKC as well as its activity is significantly increased in 
comparison to healthy control hearts (Bowling et al, 1999).  This observation does vary by subtype 
however, with PKCα and PKCβ both being upregulated while PKCε is either upregulated or 
preferentially activated and PKCδ levels are not changed (Dorn and Force, 2005).  In cardiomyocytes, 
transfection of the constitutively-active catalytic domains of different PKCs or PKCs constitutively-
activated by mutations of the pseudosubstrate site strongly implicates PKCs in the hypertrophic 
response.  However, no one particular isoform has been implicated and the identities of the isoforms 
activated by hypertrophic interventions and the roles that they play are still debated (Palaniyandi et al, 
2009).  ET-1 or α-adrenergic agonists activate nPKCδ and nPKCε (Clerk et al, 1994;Hanford et al, 
1994;Clerk et al, 1996).  Because they are dependent on the membrane-bound DAG for their 
activation, this activation was determined by observing their translocation to the particulate fraction of 
the cell.  This translocation is maximal within 30 s but is transient with the kinases redistributing to 
the soluble fraction of the cell within 15 min (Clerk et al, 1994).  Whether these isoforms of PKC are 
active only when bound to DAG, or whether they are recruited to the membrane for activation and 
then released has not been definitively established.  In cardiomyocytes, PMA or ET-1 induces 
phosphorylation of Ser/Thr residues in the catalytic domains of nPKCδ and nPKCε, with additional 
increases in phosphorylation of Tyr residues of nPKCδ (Markou et al, 2006).  PDGF activates PLCγ 
in cardiomyocytes and, although it does not induce a detectable translocation of PKCs to membrane 
fractions of the cell, PDGF does promote Tyr-phosphorylation of nPKCδ and increases its activity 
(Clerk et al, 2006).  
 
Transgenic mice have been used to try to elucidate the roles of the different PKC isoforms in the 
heart.  As is often the case with transgenic mouse models, the situation is confusing.  cPKCα [the 
most prevalent isoform in the human heart (Hahn et al, 2003) appears to regulate cardiomyocyte 
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contractility primarily in a negative manner via modulation of the phosphorylation status of 
phospholamban and SERCA2.  Thus, cPKCα-deficient hearts are hypercontractile and cPKCα-
overexpressing hearts are hypocontractile (Braz et al, 2004).  Deletion of cPKCα protects against 
aortic constriction-induced heart failure but does not prevent the increase in cardiac mass (i.e. the 
heart undergoes compensated hypertrophy).  cPKCβ may be important for the transduction of cardiac 
hypertrophy, contractility and regulation of neonatal cardiac growth (Bowman et al, 1997;Wakasaki et 
al, 1997).  In contrast to cPKCα, overexpression of cPKCβ or constitutively-activated cPKCβ induces 
hypertrophy with failure (i.e. decompensated cardiac hypertrophy).  The transgenic mice 
overexpressing cPKCβ display many of the gross anatomical and contractile features of the 
hypertrophied heart, which can be reversed by inhibiting cPKCβ (Wakasaki et al, 1997).  Although 
the two isoforms of cPKCβ are only present at low abundances in the heart, it is thought that they may 
increase in abundance during heart failure progression and contribute to the pathology (Bowling et al, 
1999).  There has not been a transgenic mouse developed to study PKC in the heart but in vitro 
studies have shown that activation of nPKCδ may be pro-apoptotic (Steinberg, 2004).  High levels of 
oxidative stress (>1 mM H2O2) promotes Tyr-phosphorylation of nPKCδ through inhibition of protein 
tyrosine phosphatases (Rybin et al, 2004).  However, these concentrations of H2O2 are generally 
associated with necrotic death rather than apoptosis or cytoprotection/hypertrophy.  Nevertherless, 
overexpression of constitutively active nPKC promotes apoptosis in cardiomyocytes (Heidkamp et 
al, 2001).   
 
The role of nPKCε in cardiac hypertrophy is still debated, but it is generally accepted to regulate 
ischemia–reperfusion injury and it is implicated in promoting cardiomyocyte hypertrophy (Chen et al, 
2001).  In contrast to the other PKCs, moderate overexpression of constitutively-activated nPKCε 
promotes compensated hypertrophy.  However, high-level or prolonged overexpression of nPKCε 
leads to heart failure (Montgomery et al, 2005).  The phenotype obtained from overexpressing such 
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transgenes which encode signalling proteins, is probably critically dependent on the extent of 
overexpression.  Therefore, it is difficult to draw absolute conclusions with respect to the mechanisms 
inducing cardiac hypertrophy operating in vivo. 
 
Figure 1.2. Protein kinase C (PKC) and PKC-related kinases (PKNs).  The PKC family consists 
of the classical (c) PKCs, novel (n) PKCs, atypical (a) PKCs and the PKNs (or PRKs).  They are 
composed of an N-terminal regulatory domain and a C-terminal catalytic domain separated by a 
„hinge‟ region. In cPKCs, the C1 domain, composed of two similar C1a and C1b regions, is 
responsible for DAG/phorbol ester binding. Complete C1 domains are also present in nPKCs, but 
aPKCs contain only a non-functional hemidomain and do not bind DAG.  In cPKCs, the C2 domain is 
responsible for Ca
2+
 binding and binding of phosphatidylserine. There are also C2-like domains in 
nPKCs and aPKCs.  These do not bind Ca
2+
, but it is not clear whether they bind phospholipids like 
phosphatidylserine. The kinase domain is similar for all PKC family members and, at the C-terminus, 
there is a variable region which may be involved with protein substrate recognition. The PKNs share 
common features with the PKCs, but contain additional N-terminal HR1 sites to which activated small 
G proteins of the Rho-family bind.  
 
 
1.5.2.  Small G proteins  
 
The Ras superfamily of small monomeric G proteins (≈21 kDa) comprises 6 subfamilies [Ras, Rho, 
Rab, Arf (ADP ribosylation factors), Sar1, and Ran], each consisting of multiple sub-members 
(Bishop and Hall, 2000).  Like the α subunits of heterotrimeric G proteins, small G proteins are 
regulated by GDP/GTP binding with the GDP-ligated species being biologically-inactive and the 
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GTP-ligated species being biologically-active (Fig. 1.3).  Activation involves the exchange of GTP for 
GDP; a reaction enhanced by guanine nucleotide exchange factors (GEFs).  The innate GTPase 
activity of the small G protein hydrolyses GTP to GDP, returning the protein to its inactive state.  This 
GTPase activity is low, but is increased by GTPase activating proteins (GAPs).  Guanine nucleotide 
dissociation inhibitors (GDIs) add a further control mechanism by retaining small G proteins in their 
inactive state.  Because they operate in active vs inactive states, small G proteins are often considered 
as molecular switches.  Alternatively, they can be described as molecular timers where the signal is 
propagated only while the G protein is active (Hall and Nobes, 2000).  The conformational change 
associated with activation promotes interaction of the small G protein with various effectors.  All 
small G proteins are lipid modified (farnesylated and prenylated) and associate with membranous lipid 
bilayers in the cell.    
 
The prototypical small G protein, Ras [first identified as an oncogene (Parada et al, 1982)], is 
anchored in the plasma membrane and, in non-myocytes, promotes cell proliferation.  When effectors 
become associated with Ras, they are brought to the membrane where they are activated in the vicinity 
of specific substrates.  The best-studied small G proteins in the heart are those of the Ras family itself 
(H-Ras, K-Ras and N-Ras) and Rho-family (RhoA, Rac1 and Cdc42). 
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Figure 1.3. The Rho GTPase cycle. Rho-family proteins (one of the families of small G proteins) 
cycle between active (GTP-bound) and inactive (GDP-bound) states. When activated, they may bind 
to any of numerous (more than 60 currently identified) target effectors. However, the mechanism is 
controlled by regulatory proteins. Guanine-nucleotide exchange factors (GEFs) catalyse nucleotide 
exchange and mediate activation while GTPase-activating proteins (GAPs) stimulate GTP hydrolysis 
and the return to the GDP-bound state. Guanine nucleotide dissociation inhibitors (GDIs) also regulate 
activation of Rho-family proteins. All Rho GTPases are prenylated at the C terminus, a modification 
that is essential for their function. 
 
 
1.5.2.1.  Ras family small G proteins 
 
H-Ras, K-Ras and N-Ras are expressed in cardiomyocytes (Clerk et al, 2006) and are rapidly activated 
(within 30 s) by a range of stimuli including GqPCR agonists, phorbol esters and peptide growth 
factors (Chiloeches et al, 1999).  Ras activation is implicated in cardiac hypertrophy because 
overexpression of constitutively-active mutated Ras (V12Ras) in cardiomyocytes ex vivo or in vivo 
promotes many features of hypertrophy (Clerk and Sugden, 2000).  Furthermore, inhibitory 
(dominant-negative) N17Ras prevents hypertrophic changes induced by PE in cardiomyocytes 
(Thorburn et al, 1993).  Activated Ras.GTP binds to three important effectors: Raf (an upstream 
Rho-GDP
GEF
GAP
GTP GDP
Pi
Rho-GTP
Different Rho
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Rho-GDP
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component of the ERK1/2 cascade), PI3K (upstream of PKB activation) and Ral.GDS (a GEF for the 
Ras-like Ral proteins) (Clerk and Sugden, 2000).  Ral.GDS is expressed in heart and overexpression 
leads to increased expression of ANF (the hypertrophic gene marker) (Post et al, 2002).  Therefore, 
Ral.GDS may contribute to hypertrophy development, but is expected to not be sufficient for the full 
response.  The ERK1/2 cascade and PI3K signalling are discussed in more detail below (sections 
1.5.3.1 and 1.5.4, respectively). 
 
The Ras-activating signal from ET-1 and other GqPCR agonists is potentially mediated by c/nPKCs 
as shown by the attenuation of Ras activation on downregulation of c/nPKCs by prolonged treatment 
with PMA (as discussed in section 1.5.1) or on chemical inhibition of PKCs (Chiloeches et al, 
1999;Clerk and Sugden, 2000).  Consistent with this, Ras.GTP loading is stimulated in 
cardiomyocytes following acute treatment with PMA (Chiloeches et al, 1999).  Signal transduction 
from PKC to Ras is not fully understood, but PKCs may phosphorylate and regulate the activity of 
GEFs or GAPs necessary for Ras activation.  However, other DAG-responsive proteins include a 
family of Ras.GEFs that may bypass a requirement for PKC activation (Reuther et al, 2002).  With 
respect to RPTKs, stimulation of Ras in cardiomyocytes is probably mediated by adapter proteins 
(GRB2, Shc) which activate the Ras-GEF, Sos, as in other cells (Vojtek and Der, 1998).  This may be 
the mechanism for activation of H-Ras, N-Ras and K-Ras by EGF (Clerk et al, 2006).  However, an 
alternative mechanism appears to be in action downstream of the PDGF receptor since PDGF 
promotes phosphorylation of PLCγ with associated release of DAG and InsP3, and the subsequent 
activation of nPKC (Clerk et al, 2006).   
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1.5.2.2 Rho-family small G proteins 
 
Twenty-two mammalian genes encoding Rho GTPases have been described: three Rho isoforms 
(RhoA, RhoB, and RhoC) three Rac isoforms (Rac1, Rac2, and Rac3), Cdc42, RhoD, Rnd1, Rnd2, 
RhoE/Rnd3, RhoG, TC10, TCL RhoH/TTF, Chp, Wrch-1 Rif, RhoBTB1 and RhoBTB2 (Aspenstrom, 
1999).  Like other regulatory GTPases, they may be viewed as molecular switches cycling between an 
active GTP-bound state and an inactive GDP-bound state.  However, the three Rnd proteins and RhoH 
lack any detectable GTPase activity and are therefore constitutively-active.  These and other Rho 
GTPases, however, are regulated through direct phosphorylation or ubiquitination (Lang et al, 1996), 
but the extent to which these covalent modifications play a role in normal physiology is unclear 
(Wang et al, 2003;Jaffe and Hall, 2005).  In non-myocytes, Rho-family proteins are particularly 
implicated in regulating the actin cytoskeleton to modulate cell shape, adhesion, contractility and 
migration (Jaffe and Hall, 2005).  These changes are elicited by interactions with specific effectors as 
discussed in section 1.5.5.  RhoA, Rac1 and other Rho-family small G proteins also modulate gene 
expression as discussed in section 1.6.2.   
 
Although Rho-family small G proteins are being studied extensively in other cell types, their effects in 
cardiomyocytes are less well understood.  Of all the Rho-family small G proteins, only RhoA, Rac1 
and Cdc42 have been studied in any detail in the heart (Brown et al, 2006).  Both Rac1 and Cdc42 are 
activated in cardiomyocytes, and promote the activation of ERK1/2 and JNKs (but not p38-MAPK) 
(see section 1.5.3 for details on MAPK signalling) in response to ET-1 or hyperosmotic shock (Clerk 
et al, 2001), and may thus be expected to contribute to cardiomyocyte hypertrophy.  Cdc42 is 
particularly implicated in the hypertrophic response to ligands such as cardiotrophin 1 (CT-1) that 
signal through gp130 receptors (Maillet et al, 2009).  Adenoviral infection of cardiomyocytes with 
constructs encoding activated-Rac1 (V12Rac1) increases ANF expression and promotes 
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morphological changes associated with myocyte hypertrophy (Pracyk et al, 1998).  Moreover, 
infection with dominant-negative N17Rac1 inhibits PE-induced hypertrophy (Pracyk et al, 1998).  
RhoA is activated in cardiomyocytes by ET-1 and α-adrenergic agonists (Clerk et al, 2001), and is 
implicated in the hypertrophic response in cultured cardiomyocytes (Brown et al, 2006).  Inhibition of 
RhoA by C3 toxin from C. botulinum (that selectively ribosylates RhoA, RhoB and RhoC on Asn41 
rendering them inactive) suppresses PE-induced hypertrophy (Sah et al, 1996) and enhanced ANF 
expression induced by hypertrophic stimuli (Sah et al, 1996;Thorburn et al, 1997;Aoki et al, 
1998;Hines and Thorburn, 1998).  This also occurs in cardiomyocytes that overexpress dominant-
negative N19RhoA (Hoshijima et al, 1998).  However, the mechanisms by which RhoA influences 
cardiomyocyte hypertrophy are not well understood.   
 
To further study the role of G proteins in the heart, transgenic mice with cardiospecific overexpression 
of RhoA or Rac1 have been developed.  Studies in these transgenic mice have not, however, been 
definitive.  Mice with cardiomyocyte overexpression of wild-type RhoA or constitutively-active 
V14RhoA die prematurely with atrial enlargement and other signs of cardiac failure (Sah et al, 1999).  
These phenotypes, although marked, are very dissimilar from compensated hypertrophy and therefore 
a firm conclusion about the role of RhoA in hypertrophy cannot be drawn from these models alone.  
Rac1 cannot be as easily investigated by conventional gene targeting techniques, because its deletion 
leads to embryonic lethality (Sugihara et al, 1998).  Instead, as with activated-RhoA, the 
manipulations of the Rac1 gene in the heart in order to study the phenotypic consequences of its 
enhanced activity were achieved by the cardiac-specific transgenesis of constitutively-activated 
V12Rac1 (Sussman et al, 2000).  Such attempts to elucidate the role of Rac1 in the heart revealed an 
unusual dichotomy: high-level postnatal expression of Rac1 leads to lethal dilated cardiomyopathy 
whereas lower-level postnatal expression leads to transient hypertrophy in juvenile mice that resolves 
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with age.  Even though the hearts are clearly hypertrophic there is no sign of myofibril disarray 
consistent with compensated hypertrophy.   
 
1.5.3.  The mitogen-activated protein kinase (MAPK) cascades  
 
MAPKs (Fig. 1.4) are a superfamily of Pro-directed protein Ser-/Thr-kinases that are widely 
expressed in all tissues (Seger and Krebs, 1995).  MAPKs themselves are activated by MAPK kinases 
(MKKs).  Activation of MKKs involves their phosphorylation on Ser/Thr residues by MKK kinases 
(MKKKs or MAP3Ks).  In some instances, ill-defined MAP4Ks may phosphorylate and activate 
MAP3Ks.  The signal therefore converges at or above the level of MAPKKKs and is transmitted 
through the amplifying series of proteins by phosphorylation and activation.  Thereafter, these 
divergent phosphorylation cascades activate regulatory molecules (e.g. other downstream protein 
kinases or nuclear transcription factors) initiating a variety of different responses in the cell (Clerk and 
Sugden, 1997b;Sugden and Clerk, 1997).  MAPKs regulate their substrates by phosphorylating 
Ser/Thr residues immediately N-terminal to a Pro residue in the target proteins.  This is facilitated by 
docking domains on the substrate proteins that bind specific MAPKs, thus allowing the MAPKs to 
phosphorylate them.  The „classical‟ MAPKs [ERK1/2, ERK5, JNK1-3 and the four p38-MAPKs (α, 
β, γ and δ)] are phosphorylated and activated by the dual phosphorylation of a Thr and a Tyr residue 
within a Thr-Xaa-Tyr motif in their activation loops and the identity of the Xaa residues determines 
their classification.  ERK1/2 are phosphorylated on a Thr-Glu-Tyr motif with both phosphorylations 
being performed by the dual-specificity kinases, MKK1 and MKK2 (Johnson and Lapadat, 2002).  
ERK5 is phosphorylated on a similar motif by MKK5.  JNKs are activated by phosphorylation of both 
Thr- and Tyr-residues within a Thr-Pro-Tyr motif whereas p38-MAPKs require phosphorylation of a 
Thr-Gly-Tyr motif (Sugden and Clerk, 1998a).  Such motifs in MAPKs have been strongly conserved 
through evolution emphasising their importance in intracellular signalling.  ERK1/2, JNKs and p38-
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MAPKs are activated in cardiomyocytes by GqPCR agonists and other stimuli, with the ERK1/2 
cascade being one of the best-studied and most strongly-activated pathways associated with 
hypertrophic growth of cardiomyocytes (Sugden and Clerk, 1998b). 
 
1.5.3.1.  The ERK cascade and its role in the heart 
 
The prototypical MAPKs are ERK1 and ERK2, which are also known as p44-MAPK (ERK1) and 
p42-MAPK (ERK2).  The ERK1/2 cascade is intimately connected to anabolic processes such as 
growth and proliferation in many cell types (Seger and Krebs, 1995;Kyriakis and Avruch, 1996).  
Substrates include signalling proteins, transcription factors, structural proteins and other protein 
kinases including p90 ribosomal S6 kinases (p90RSKs).  The MKKKs for the ERK1/2 cascade are the 
Raf family (c-Raf, A-Raf and B-Raf), of which c-Raf and A-Raf are activated in cardiomyocytes by 
GqPCR agonists or PMA (Bogoyevitch et al, 1995b).  These activate both MKK1 and MKK2 that 
phosphorylate both ERK1 and ERK2 (Fig. 1.4).  Consistent with the relative degree of activation of c-
Raf (Bogoyevitch et al, 1995b), α1-adrenergic agonists are less effective than PMA or ET-1 
(Bogoyevitch et al, 1994;Bogoyevitch et al, 1996a).  Furthermore, in contrast to ET-1, activation of 
MKK1/2 and ERK1/2 by the α1-adrenergic agonist PE requires PI3K signalling (Clerk et al, 2004) 
(see section 1.5.4).  Activation of ERK1/2 by ET-1 or α1-adrenergic agonists stimulation is transient, 
whereas activation by PMA is more sustained (Bogoyevitch et al, 1994).  Although ANGII activates 
components of the ERK1/2 cascade and the upstream signalling molecules (Sadoshima and Izumo, 
1993;Aoki et al, 1998), it is a weak activator of ERK1/2 in comparison to ET-1 and PMA 
(Bogoyevitch et al, 1995b).  In vivo, ET-1, PE and ANGII also activate ERK1/2 in the heart while 
inhibition of GqPCR signalling prevents this (Akhter et al, 1998).  Inhibitors of the ERK1/2 cascade 
are commercially available, most of which inhibit MKK1/2 activity.  The most selective of these is 
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PD184352 (Davies et al, 2000).  Such compounds are useful in elucidating the role of ERK1/2 
signalling in biological processes. 
 
ERK1/2 signalling is particularly implicated in promoting cardiomyocyte hypertrophy and 
transfection of cardiomyocytes with plasmids expressing constitutively-activated MKK1 stimulates a 
hypertrophic pattern of gene expression (Gillespie-Brown et al, 1995).  Constitutively-activated c-Raf 
also induces such patterns of gene expression and leads to an increased cell profile (Thorburn et al, 
1994;Fuller et al, 1998).  In cardiomyocyte cultures, following exposure to phorbol esters or ET-1, 
activated ERK1/2 rapidly appears in cardiomyocyte nuclei where they can influence gene 
transcription (Chiloeches et al, 1999;Sugden et al, 2011).  Moreover, depletion of ERK1/2 from 
cardiomyocytes inhibits the stimulation of the hypertrophic pattern of gene expression by PE 
(Glennon et al, 1996).  However,  probably the most convincing evidence of a role for ERK1/2 in 
cardiomyocyte hypertrophy is from transgenic mice in which ERK1/2 are cardio-specifically activated 
by expression of constitutively-active MKK1 (Bueno et al, 2000).  The hearts of these mice exhibit a 
compensated „pressure-overload‟ pattern of cardiac hypertrophy with increased cardiac muscle mass 
and ventricular wall thickness (in the absence of chamber enlargement) and enhanced expression of 
hypertrophic marker genes.  They are also resistant to ischaemia-reperfusion injury.  Taken together, 
these findings all heavily implicate the ERK1/2 cascade in cardiac hypertrophy.  Inhibition of the 
ERK1/2 cascade increases the extent of apoptosis and reperfusion injury in isolated hearts after 
ischaemia, highlighting an additional role for ERK1/2 in promoting cytoprotection (Yue et al, 2000).   
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Figure 1.4. The MAPK cascades. The MAPKs at the terminal members of three-tiered cascades in 
which MAPK kinase kinases (MKKKs) phosphorylate and activate MAPK kinases (MKKs) which 
phosphorylate and activate the MAPKs. The three best characterized MAPK cascades (ERK1/2, JNKs 
and the p38-MAPK cascades), and some of their downstream targets (transcription factors, other 
protein kinases) are shown. In the heart the activation of the ERK cascade is coupled strongly to 
agonists that activate PKC (e.g. ET-1, α1-adrenergic agonists). The JNK and p38-MAPK cascades are 
activated by a variety of cellular stresses (e.g. oxidative stress). However, in the heart, GqPCR 
agonists also activate the JNKs and p38-MAPKs. 
 
 
1.5.3.2.  ERK5 
 
ERK5, also known as big MAPK 1 (BMK1), has an N-terminal domain that is homologous to 
ERK1/2, but a unique C-terminus (Lee et al, 1995;Zhou et al, 1995).  MEK5, the MKK for ERK5, is 
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highly specific and does not activate other MAPKs even when overexpressed in cultured cells (Zhou 
et al, 1995).  In non-myocytes, MEK5-ERK5 signalling is activated by growth stimuli (e.g. agonists 
for RPTKs and GPCRs) (Kato et al, 1997;Kamakura et al, 1999), as well as by oxidative and osmotic 
stress (Abe et al, 1996).  The regulation and role of ERK5 in cardiomyocytes has been best studied in 
relation to gp130 receptor signalling (Wang, 2007).  ERK5 is activated by leukaemia inhibitory factor 
(LIF) or CT-1 (gp-130 receptor agonists) in cardiomyocytes, and inhibition of the pathway with 
dominant-negative MKK5 attenuates the hypertrophic response induced by these agonists (Nicol et al, 
2001).  Thus, although gp130 receptors activate other signalling pathways (Fischer and Hilfiker-
Kleiner, 2007), a significant part of the hypertrophic response induced by these receptors appears to 
be mediated through ERK5.  These findings reveal a specific role for MEK5-ERK5 in the induction of 
eccentric cardiac hypertrophy and in transduction of cytokine signals that regulate serial sarcomere 
assembly (Nicol et al, 2001). 
 
1.5.3.3.  JNKs and p38-MAPKs 
 
The JNK subfamily of MAPKs are derived from 3 individual genes, and alternative splicing of the 
transcripts results in at least 10 different transcripts encoding proteins of ~46 or ~54 kDa (Gupta et al, 
1996).  JNK1 and JNK2 genes are expressed in the heart each of which generate 46 and 54 kDa 
isoforms (Force et al, 1996;Sugden and Clerk, 1998a).  There are four p38-MAPK genes (p38-
MAPKα, p38-MAPKβ, p38-MAPKγ and p38-MAPKδ) and alternatively-spliced transcripts produce 
two α and two β isoforms.  p38-MAPKα is easily detected in cardiomyocytes/whole hearts whereas 
there is little detectable p38-MAPKβ (Lemke et al, 2001).  Although p38-MAPKγ and p38-MAPKδ 
are known to be expressed in cardiomyocytes (Lemke et al, 2001;Court NW et al, 2002), their 
functional role is unclear.  Small molecule inhibitors for p38-MAPKα/β (SB203580) are 
commercially available.  
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The upstream dual-specificity MKKs for JNKs and p38-MAPKs are MKK4/7 and MKK3/6, 
respectively.  Their specific MKKKs have not been well studied and are unidentified.  As in other 
cells, the JNK and p38-MAPK cascades are potently activated in the heart (observed both in 
cardiomyocytes and whole heart experiments) by oxidative stress, ischaemia/reperfusion or 
hyperosmotic shock (Sugden and Clerk, 1998a).  The activation of these pathways is cardiotoxic and 
inhibition of them (either by pharmacological or genetic means) in ex vivo or in vivo experiments 
reduces this cardiotoxity (Wang, 2007).  Rac1 and Cdc42 are implicated in the activation of JNKs and 
p38-MAPKs in non-myocytes (Denhardt, 1996).  JNKs and p38-MAPKs (in addition to ERK1/2) are 
also activated in cardiomyocytes by the pro-inflammatory cytokines, IL-1β and TNF-α (Clerk et al, 
1999). 
 
JNKs and p38-MAPKs are activated in cardiomyocytes by GqPCR agonists but to a lesser degree than 
by cellular stresses (Bogoyevitch et al, 1995a;Clerk et al, 1998b).  Although such activation implies 
that JNKs and p38-MAPKs promote cardiomyocyte hypertrophy, their roles in this response are not 
entirely clear, and are often contradictory (Sugden and Clerk, 1998a;Sugden and Clerk, 1998b).  The 
problem is exacerbated because transfection experiments with MKK4 can lead to “cross-talk” between 
different MAPK pathways (Lange-Carter et al, 1993;Thorburn et al, 1997).  However, dominant-
negative JNK constructs inhibit PE-induced ANF expression, specifically implicating the JNK 
cascade in the response (Thorburn et al, 1997).  p38-MAPKs potentially contribute to the hypertrophic 
response (Zechner et al, 1997;Zechner et al, 1998) and may influence apoptosis either to attenuate or 
stimulate the response depending upon the specific stimulus and/or isoform that may be activated 
(Wang et al, 1998).  SB203580 has no effect on the morphological changes induced by 24 h ET-1 or 
PE exposure, but at 48 h cardiomyocytes appear smaller and exhibit poorly defined myofibrillar 
structures (Clerk et al, 1998b).  This suggests that p38-MAPKα and/or p38-MAPKβ is not involved in 
the development of a hypertrophic morphology, but is necessary over a longer period, possibly 
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reflecting a role in cell survival.  Overall, the roles of activated JNKs and/or p38-MAPKs may depend 
on their specific cellular context and which signalling networks are most active at a given time.  For 
GqPCR signalling at least, it seems likely that signals from the different MAPK pathways are 
integrated to elicit the overall response.  For example, although ERK1/2 signalling is required for the 
upregulation of c-jun mRNA, an additional signal through the JNK cascade is required for efficient 
upregulation of c-Jun protein (Clerk et al, 2002).  Since p38-MAPKs are particularly implicated in 
regulating mRNA stability (Dean et al, 2004), signals from this pathway may be integrated with the 
transcriptional response to increase mRNA levels.   
 
In vivo, ischaemia with/without reperfusion is associated with high levels of ROS (Ferrari et al, 1998).  
In the intact isolated rat heart, p38-MAPKα/β and its substrate MAPK-activated protein kinase 2 
(MAPKAPK2) are activated during ischaemia, and their activation is sustained or increased during 
reperfusion (Bogoyevitch et al, 1996b).  The activation of MAPKAPK2 is completely inhibited by 
SB203580, indicating that it is, indeed activated by p38-MAPK.  A well characterised substrate for 
MAPKAPK2 and one which is activated by cellular stresses or GqPCR agonists is the small heat 
shock protein Hsp25/27 (Clerk et al, 1998a).  This phosphorylation may stabilise the actin 
cytoskeleton and, in heart, phosphorylated Hsp25/27 could function as a chaperone for cytoskeletal 
proteins during the remodelling process that occurs during hypertrophy.  As with p90RSKs 
(MAPKAPK1 family kinases), MAPKAPK2 potentially has nuclear targets and may regulate gene 
expression (Gaestel, 2006), although the nuclear role in the cardiac system is not understood (see 
section 1.6.1 for further details).  In contrast to p38-MAPKs, JNKs are not activated during global 
ischaemia but are strongly activated during the reperfusion phase (Bogoyevitch et al, 1995a).  This 
differential activation of JNKs and p38-MAPKs contrasts with most other cell models where these 
two MAPK pathways are activated simultaneously.   
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1.5.4.  Phosophoinositide-3-kinase signalling 
 
The PI3K pathway represents the dominant pathway through which insulin, IGF-1 and other growth 
factors exert their biological effects.  As discussed above, agonist-binding stimulates Tyr-
phosphorylation of the RPTKs and, in the case of insulin and IGF-1, their insulin receptor substrate 
(IRS) proteins.  Of the different classes of PI3K lipid kinases, the best studied are the Class 1A 
kinases that are composed of two subunits (Geering et al, 2007).  The p85 adaptor (regulatory) subunit 
is recruited to phospho-Tyr residues on RPTKs (or IRS1 for insulin signalling).  The p85 adaptor is 
associated with a p110 catalytic subunit.  Binding of p85 to the receptor results in activation of the 
associated p110 catalytic subunit which phosphorylates and converts the membrane-bound 
PtdIns(4,5)P2 to PtdIns(4,5)P3 (Vanhaesebroeck and Alessi, 2000).  PtdIns(3,4,5)P3 remains localised 
in the membrane.  Because of its localisation at the membrane, activated Ras.GTP may bind to and 
activate the catalytic subunit of PI3K directly (Domin and Waterfield, 1997) although the significance 
of this other mechanism of PI3K activation has not been fully investigated.  Alternatively, GqPCRs 
may couple to a different class of PI3K lipid kinase.  Here the mechanism is mediated through the 
p110γ catalytic subunit (a Class 1B PI3K) which is associated with a p101γ adaptor subunit (Andrews 
et al, 2007).  Membrane-localised Gβγ dimers mediate this activation.  The signalling functions of 
PtdIns(3,4,5)P3 formed by PI3K are terminated by the phosphatase, PTEN (phosphatase and tensin 
homologue deleted on chromosome ten) which hydrolyses PtdIns(3,4,5)P3 to produce PtdIns(4,5)P2 
(Oudit and Penninger, 2009). 
 
Signalling intermediates can bind PtdIns(3,4,5)P3 through pleckstrin homology (PH) domains 
including PtdIns(3,4,5)P3-dependent protein kinase 1 (PDK1) (Cohen et al, 1997;Mora et al, 2004) 
and PKB (Akt) (James et al, 1996;Stephens et al, 1998).  PKB, of which there are 3 isoforms (α, β and 
γ), is recruited to the membrane by the increasing amounts of PtdIns(3,4,5)P3.  This results in PKB 
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being brought into close proximity with PDK1 which phosphorylates PKB on Thr308 (for the α 
isoform) thereby activating it.  PKB requires phosphorylation of Ser473 for full activation (and 
possibly to mediate substrate specificity) but the mechanism for phosphorylation of Ser473 is not 
clear (Lawlor and Alessi, 2001).  Activation of PKB leads to the phosphorylation of a number of 
proteins, including phosphorylatable heat- and acid-stable protein I regulated by insulin (PHASI, also 
known as 4E-BP) and p70
S6K
 both of which are implicated in regulating protein synthesis (Ruggero 
and Sonenberg, 2005;Proud, 2006).  However, probably the best characterised PKB substrates are 
glycogen synthase kinase 3 α and β (GSK3α/β), phosphorylation of which results in deactivation 
(Sugden et al, 2008).  The original role identified for GSK3 was to phosphorylate glycogen synthase 
to inhibit its activity.  Inhibiting GSK3 should therefore promote glycogen synthesis by activating 
glycogen synthase thereby allowing insulin to (through activating PI3K, PDK1 and PKB) promote 
glycogen accumulation (e.g. in muscle cells).   
 
Activation of PI3K and PKB is associated with an increased rate of protein synthesis (Vanhaesebroeck 
and Alessi, 2000), a key feature of cardiomyocyte hypertrophy (Pham et al, 2001;Matsui and 
Rosenzweig, 2005).  Insulin and IGF-1 potently stimulate global cardiac protein synthesis (Fuller and 
Sugden, 1986;Fuller et al, 1992).  The increase in protein synthesis is brought about by changes in 
activity of existing translation factors plus long-term upregulation of the ribosomal translational 
machinery.  This appears to be mediated by mTOR (mammalian Target Of Rapamycin) in the context 
of mTOR complex 1 (mTORC1) which also contains RAPTOR and mLST8 (Inoki, 2008;Ma and 
Blenis, 2009).  
 
There have been few studies of endogenous PI3K signalling in cardiomyocytes and most studies use 
inhibitors of PI3K (e.g. LY294002) (Carpenter and Cantley, 1996).  Thus, PKB is potently activated 
in cardiomyocytes (Pham et al, 2000;Clerk et al, 2006) and whole hearts (Huisamen et al, 
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2001;Yamashita et al, 2001) by insulin or IGF1, with slightly lesser stimulation by EGF or PDGF 
(Clerk et al, 2006).  However, there has been no detectable phosphorylation of PI3K isoforms 
themselves by ET-1 or α-adrenergic agonists (Andrews et al, 2007).  H2O2 activates PKB to a similar 
degree as insulin (Pham et al, 2000).  Insulin enhances phosphorylation (inhibition) of GSK3α/β 
(Sugden et al, 2008).  ET-1 also promotes phosphorylation of GSK3α/β in cardiomyocytes but this 
mediated via the ERK1/2 cascade (Markou et al, 2008), so GSK3 may represent a convergence of the 
PI3K/PKB and ERK1/2 signalling pathways.   
 
PI3K and PKB signalling is implicated in modulating cardiomyocyte protein synthesis and inhibition 
of PI3K suppresses both basal and insulin-enhanced protein synthesis (Pham et al, 2000).  The 
pathway is also implicated in cardioprotection since its inhibition in vivo enhances cardiac dysfunction 
and apoptosis in animal models of heart failure (Matsui and Rosenzweig, 2005;Heineke and 
Molkentin, 2006).  Furthermore, cardio-specific overexpression of constitutively-activated PI3K or 
PKB in animals increases heart size (Heineke and Molkentin, 2006).  Thus, PI3K and PKB have been 
strongly implicated in hypertrophy.   
 
1.5.5.  Rho signalling through protein kinases 
 
In non-myocytes, Rho-family small proteins are particularly implicated in regulating the actin 
cytoskeleton to alter cell shape, adhesion, contractility and migration (Jaffe and Hall, 2005).  
Overexpression of constitutively-active RhoA promotes formation of actin stress fibres and focal 
contacts (Kaibuchi et al, 1999).  In contrast, constitutively-active Rac1 stimulates the formation of 
lamellipodia, whilst activated Cdc42 induces formation of filapodia (Jaffe and Hall, 2005).  Rac1 and 
Cdc42 activate WAVE and WASP, respectively, members of the Wiskott-Aldrich syndrome family 
proteins (Miki et al, 1998).  These signal to Arp2/3 to promote the formation of branched actin 
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filaments at the periphery of the cell.  It is possible that the Rho proteins might serve to recruit targets 
to specific locations or complexes in order to facilitate such signalling events such as these.  For 
example, activated RhoA interacts with formins to promote formation of long, unbranched actin 
filaments (Wallar and Alberts, 2003;Higashida et al, 2004).  However, most of the changes are elicited 
by upstream interactions of Rho proteins with specific effectors which exist in closed inactive 
conformations that are relieved through the Rho protein binding (Bishop and Hall, 2000).  Two of the 
best studied effectors for RhoA include Rho-kinases (ROCK1/2) and protein kinase N 1 (PKN1), also 
known as protein kinase C-related kinase 1 (PRK1).  
 
1.5.5.1.  Rho kinases (ROCKs) 
 
ROCKs are serine/threonine kinases (~160 kDa) which were originally characterised as mediators in 
the formation of Rho-induced stress fibres and focal adhesions (Leung et al, 1995;Leung et al, 1996).  
Two ROCK isoforms have been identified: ROCK1 (also known as p160ROCK5) and ROCK2 (also 
known as ROK6 and Rho kinase7).  ROCK1/2 contain an N-terminal protein kinase domain followed 
by a coiled-coil-forming region, a Rho-binding domain and a PH domain (with a cysteine-rich region) 
towards the C-terminus.  The C-terminal domains form an auto-inhibitory region that decreases kinase 
activity of ROCK1/2 (Amano et al, 1999).  The coiled-coil domain interacts with other proteins, while 
the PH domain participates in protein localisation.  The amino acid sequences of the two ROCK 
isoforms share 65% homology overall, with 92% homology in their kinase domains (Nakagawa et al, 
1996).  ROCK1 and ROCK2 mRNAs are expressed ubiquitously in rat tissues (Leung et al, 1996), but 
ROCK2 transcripts are most highly expressed in muscle tissues and in the brain, suggesting that the 
protein might have a specialized role in these cell types (Leung et al, 1995;Kimura et al, 1996).  
Localisation of ROCK1/2 by immunofluorescence techniques shows the protein mainly distributed in 
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the cytoplasm but with a large amount localised to the cell membrane, notably the location of active 
RhoA (Leung et al, 1995;Matsui et al, 1996).    
 
ROCK1/2 kinase activity is moderately enhanced by binding to RhoA.GTP (Ishizaki et al, 
1996;Matsui et al, 1996).  Although a complex between endogenous ROCK1/2 and RhoA has not 
been shown, inhibitors of ROCK1/2 (e.g. the compound Y-27632) and dominant-negative ROCK1 
inhibit the formation of RhoA-induced stress fibres (Amano et al, 1997;Uehata et al, 1997).  Some 
lipids, especially arachidonic acid, activate ROCK1/2 independently of RhoA (Fujisawa et al, 1998).  
Binding of RhoA to ROCK1/2 potentially disrupts the inhibitory interaction between the kinase 
domain and the auto-inhibitory region in the C-terminus producing an open conformation for substrate 
binding.  In support of this mechanism, cleavage of the C-terminal region of ROCK1/2 produces a 
constitutively-active kinase (Ishizaki et al, 1997).  This occurs in vivo during apoptosis, when ROCK1 
is cleaved by caspase-3 to generate an unregulated  kinase domain (Coleman et al, 2001).    
 
The best characterised substrates for ROCK1/2 are myosin light chain phosphatase (MLCP) and LIM 
kinase (LIMK); proteins involved in regulating actin-filament assembly and contractility.  In non-
muscle cells, phosphorylation of the motor protein myosin II is important in regulating actomyosin 
contractility (Yoneda et al, 2005).  Phosphorylation of the regulatory light chain of myosin II induces 
interaction with actin, thereby activating myosin ATPase and resulting in enhanced cell contractility 
(Amano et al, 1996;Totsukawa et al, 2000).  This phosphorylation is balanced by the activities of two 
enzymes, Ca
2+
-dependent MLC kinase (MLCK), and MLCP.  ROCK1/2 appears to promote 
phosphorylation of MLC independently of Ca
2+
 and MLCK, probably through the inhibition of 
MLCP.  MLCP is responsible for the dephosphorylation of MLC, and so negatively regulates 
actomyosin-based contractility (Totsukawa et al, 2000).  MLCP is composed of three subunits: a 
catalytic subunit (protein phosphatase type 1, PP1c), a myosin-binding subunit (MBS, also known as 
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myosin phosphatase target subunit, MYPT1), and a small non-catalytic subunit of unknown function 
(Hartshorne et al, 1998).  Phosphorylation of residues in the C-terminal half of MYPT1 results in the 
inhibition of MLCP activity and a concomitant increase in phosphorylated MLC and cell contractility.  
ROCK1/2 phosphorylates MYPT1 (Kimura et al, 1996) at Thr697, Ser854 and Thr855 and promotes 
such deactivation (Kawano et al, 1999).  Phosphorylation of Thr855 of MYPT1 induces its 
dissociation from myosin (Velasco et al, 2002), which also inhibits myosin phosphatase activity.  
Thr697 phosphorylation is also implicated in the inhibition of MLCP activity (Feng et al, 1999).  
LIMK1/2 are serine/threonine kinases involved regulating actin-filament dynamics.  ROCK1 
phosphorylates LIMK1 at Thr508 (Ohashi et al, 2000) and LIMK2 at Thr505 (Sumi et al, 2001), and 
enhances the ability of LIMKs to phosphorylate cofilin (Maekawa et al, 1999).  Cofilin is an actin-
binding and actin-depolymerising protein that regulates turnover of actin filaments.   Phosphorylation 
of cofilin by LIMKs deactivates its actin-depolymerization activity (Arber et al, 1998;Yang et al, 
1998).  Therefore, the phosphorylation of LIMKs by ROCK1/2 inhibits cofilin-mediated actin-
filament disassembly and leads to an increase in the number of actin filaments.   
 
ROCK1/2 mediates a broad range of cellular responses, such as stress fibre formation, cell 
proliferation and migration, contraction and apoptosis (Bishop and Hall, 2000).  In cardiomyocytes, 
some dominant-negative mutants of ROCK1 inhibit PE-, ET-1- or RhoA-induced hypertrophy 
(Hoshijima et al, 1998;Kuwahara et al, 1999) suggesting that RhoA signalling through ROCK1/2 is 
involved in the hypertrophic response.  However, interpretation of many of these experiments may not 
be simple.  For example, dominant-negative mutants of ROCK1/2 prevent V14RhoA- or PE-induced 
myofibrillogenesis (Hoshijima et al, 1998).  However, this may simply be a result of general 
sequestration of activated RhoA rather than reflecting a further role of ROCK1/2 as a signalling 
intermediate (Clerk and Sugden, 2000).  The kinase-dead construct of ROCK1/2 should be a more 
specific inhibitor of ROCK signalling, but is shown to not prevent PE-induced myofibrillogenesis and 
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has also proved less effective than the dominant-negative mutants in inhibiting myofibrillogenesis or 
ANF expression induced by V14RhoA (Hoshijima et al, 1998).  In contrast, kinase-dead ROCK1/2 
inhibits ET-1-induced BNP expression (Kuwahara et al, 1999).  The role of ROCK1/2 in 
cardiomyocytes requires much further clarification.  It is feasible that the overall response of these 
cells described above is a result of many different signals working together.   
 
1.5.5.2.  Protein kinase N (PKN) 
 
As discussed in section 1.5.1, the PKC superfamily comprises numerous isoforms that are categorised 
into several subfamilies.  The PKN family constitutes a fourth such sub-group.  PKN1, PKN2 and 
PKN3 were identified by molecular cloning, protein purification and PCR-based screens for novel 
PKC isoforms in the mid 1990s (Mukai and Ono, 1994;Palmer et al, 1995b).  PKN1 is highly 
expressed in the heart relative to other tissues, and both PKN1 and PKN2 are expressed in 
cardiomyocytes (Mukai and Ono, 1994;Hashimoto et al, 1998).  PKN3 mRNA is expressed in the 
heart, but whether the protein is expressed in cardiomyocytes is not known (Mukai and Ono, 
1994;Palmer et al, 1995b).    
 
PKNs possess an N-terminal regulatory domain and highly-conserved C-terminal Ser/Thr protein 
kinase catalytic domain linked by a protease-sensitive hinge (Palmer et al, 1995a).  The regulatory 
domain comprises of three homologous repeats of ~70 residues known as ACC1, ACC2 and ACC3 
(previously HR1a, HR1b and HR1c) (Maesaki et al, 1999).  Each has a region of charged amino acids 
followed by a classic leucine zipper with leucine residues every 7 amino acids (Fig. 1.5).  Also within 
the regulatory domain, is a region with homology to C2 domains in other PKCs (although this does 
not bind Ca
2+
) followed by a proline-rich region.  The ACC and the C2-like
 
regions are homologous 
between the PKN isoforms.  The
 
C-terminal part of the C2-like region functions as an auto-inhibitory 
Chapter 1 
Page | 52  
 
region for PKN1, which is sensitive to arachidonic acid (Yoshinaga et al, 1999).  Interestingly, the 
kinase activity
 
of PKN2 is much less sensitive
 
to arachidonic acid than that of PKN1 (Yu et al, 
1997;Oishi et al, 1999).  Based on the overall homology with other PKCs, it seems probable that 
PKNs adopt a “closed” conformation when inactive, with insertion of a pseudo-substrate region 
within the N-terminal domain into the C-terminal catalytic site (Peng et al, 1996;Kitagawa et al, 
1998).  Activation presumably relieves this inhibition, allowing the kinase to access substrates for 
phosphorylation.  
 
ACC regions act as binding interfaces with other proteins [e.g. the anchoring protein CG-NAP 
(centrosome and golgi localized
 
PKN associated protein) (Takahashi et al, 1999)].  PKN2 also has 
proline-rich regions containing sequences
 
for SH3 domain recognition (Shibata et al, 2001).  This lies 
between the C2-like
 
region and the catalytic domain of the enzyme.  This Pro-rich region
 
is absent 
from PKN1.  Proteins such as the tyrosine kinase adaptor protein (NCK; also known as Grb4) which 
have SH3 domains
 
have been reported to associate with PKN2 (Quilliam et al, 1996;Braverman and 
Quilliam, 1999).  All members of the PKC superfamily, including PKNs, appear to require lipids 
(usually phospholipids) for activation.  As well as arachidonic acid, PKNs have been reported as being 
activated by cardiolipin, PtdIns(4,5)P2, PtdIns(3,4,5)P3 and lysophospholipids (Morrice et al, 1994;Yu 
et al, 1997).  Some studies suggest that the extreme C-terminus of the protein is required for this lipid 
sensitivity (Amano et al, 1999), although it seems probable that, by analogy with other PKCs, the 
actual lipid binding regions should lie within the N-terminal regulatory domain.  Of note, 
calcium/phosphatidylserine/diolein,
 
a combination of potent activators of PKCs, does not
 
increase the 
PKN activity (Kitagawa et al, 1995;Palmer et al, 1995a). 
 
PKN1 binds to and is activated by Rho-family small G proteins, notably RhoA, RhoB and Rac1, in 
their active GTP-bound states.  Rho proteins are also responsible for the location of PKN1, with RhoB 
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causing localisation to an endosomal compartment in fibroblasts, a translocation event which is 
associated with the accumulation of a more phosphorylated form of the kinase (Mellor et al, 1998).  
Rho-binding is mediated through the ACC1 and ACC2 domains of PKN1.  PKN2 may be similarly 
activated, although there are conflicting data (Quilliam et al, 1996;Vincent and Settleman, 1997).  
PKN1/2 is regulated by phosphorylation and, as with other AGC family protein kinases, PKN1/2 are 
phosphorylated on a critical residue in their activation loops (T774 for PKN1, T816 for PKN2 
according to the human sequence).  The
 
activation loop site mutants (T774A for PKN1 and T816A for 
PKN2)
 
result in a complete loss of kinase activity (Mukai et al, 1994).  Rho-dependent activation of 
PKN1
 
via PDK1 has also been reported where activated RhoA binds
 
to PKN1 and induces a 
conformational change that facilitates binding to PDK1 (Parekh et al, 2000).  PDK1 phosphorylates 
PKN1 in the activation
 
loop and stimulates the kinase activity of PKN1.  This
 
model adds to a study in 
vivo in which overexpression
 
of RhoB recruits PDK1 to an endosomal compartment only when
 
PKN1 
is co-expressed, suggesting that a complex
 
is formed between these molecules (Flynn et al, 2000).  
However, there are other phosphorylation sites in PKNs including T64, S377, T504, S534, S577, 
S579, S612 and T778 (Fig. 1.5) (Peng et al, 1996;Yoshinaga et al, 1999).  At least some of these are 
auto-phosphorylations, but the functional role of these phosphorylations is not clear.  For PKN2, 
activation loop phosphorylation by PDK1 may not
 
be a crucial point of regulation because co-
expression of PDK1 with PKN2 only slightly activates
 
the enzyme compared to the increase in the 
activation loop site
 
phosphorylation (Flynn et al, 2000).  PKN2 also associates with MEKK2 but not 
MEKK3 with MEKK2 having been shown to profoundly enhance PKN2 activity (Yu et al, 1997).  
Interestingly, kinase-dead MEKK2 also activates PKN2 to a lesser degree, suggesting that 
oligomerization of MEKK2 and PKN2 may be sufficient to regulate the kinase activity of PKN2 
(Singer et al, 1996). 
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PKN1/2 efficiently phosphorylates peptide
 
substrates based on the pseudo-substrate sequence of PKC 
in vitro and phosphorylates the same sites in MARCKS and vimentin as PKC (Palmer et al, 
1996;Matsuzawa et al, 1997).  In some cases, however, PKN1 phosphorylates different sites of the 
same protein from those phosphorylated by PKC in vitro [e.g. with the microtubule-associated 
protein, Tau (Taniguchi et al, 2001)].  Physiological
 
substrates of PKN1/2 are not well established and 
the kinase
 
activity of PKN1/2 is generally studied in relation
 
to common substrates such as MBP, and 
PKC-based peptide substrates. 
 
 
Figure 1.5. PKN1 structure and potential phosphorylation sites.  The N-terminal regulatory region 
contains HR1 domains and a C2-like domain.  This is linked to the C-terminal catalytic domain by a 
hinge region.  PKN1 requires phosphorylation of the activation loop T774 (in the human protein) for 
activity, potentially mediated by PDK1.  Other residues are also phosphorylated. Numbers in boxes 
above the schematic represent established phosphorylations (Peng et al, 1996). Putative 
phosphorylations are below in italics (from PhosphoSite Plus, Cell Signaling Technology; 
www.phosphosite.org).     
 
 
1.5.5.2.1.  Physiological role of PKNs 
 
As described in section 1.5.5, RhoA is particularly implicated in the regulation of actin cytoskeletal 
structures and, consistent with their activation by RhoA, a number of studies suggest that PKN1/2 are 
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associated with and/or phosphorylate cytoskeletal structures.  PKN1/2 also binds to RhoB which is 
associated with vesicle trafficking, particularly of endosomes and other studies suggest that these 
kinases may play a role in this context (Watanabe et al, 1996;Mellor et al, 1998).  The role of PKN1/2 
in the regulation of the cytoskeleton has also been proposed following the report of disruption of the 
fibroblast actin stress fibres by the expression of a kinase-dead PKN2 (Vincent and Settleman, 1997).  
PKN1 can interact with α-actinin (Mukai et al, 1997) so is potentially anchored to the cytoskeleton, 
and phosphorylates vimentin and glial fibrillary acidic protein (GFAP) in their head domains 
(Matsuzawa et al, 1997).  This phosphorylation results in inhibition of polymerisation (Mukai et al, 
1996b;Matsuzawa et al, 1997).  In the brain, PKN1 is enriched in neuronal cells and is associated with 
neurofibrillary tangles in human brain samples from Alzheimers patients and it phosphorylates Tau in 
its microtubule binding domain.   
 
Hyperosmotic shock promotes association of PKN1 with intracellular vesicles and the association of 
PKN1 with both cytoskeletal structures and vesicles may well influence protein trafficking.  Thus, 
overexpression of RhoB acts via PKN1/2 to promote trafficking of the epidermal growth factor (EGF) 
receptor in HeLa cells (Gampel et al, 1999).  Furthermore, insulin stimulation of PKN1 is associated 
with trafficking of the glucose transporter Glut4 to the plasma membrane to increase glucose uptake in 
adipocytes (Standaert et al, 1998).  However, the true cellular targets for the PKN family in these 
processes are not yet well characterised and the precise mechanism by which PKN1 influences vesicle 
trafficking is unknown.  As discussed below, RhoA promotes changes gene expression, classically via 
MRTFs/SRF (section 1.6.2).  However, PKN1/2 may modulate gene expression given that it migrates 
to the nucleus in response to cellular stresses (heat shock, arsenite, serum-starvation) (Mukai et al, 
1996a).  Here, PKN1/2 may activate heat shock factor 1 (HSF1) to promote expression of chaperones 
including αB-crystallin (Kitagawa et al, 1998).  It may also interact with androgen receptors or 
phosphorylate histone H3 to facilitate gene expression more generally (Metzger et al, 2003).  
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Alternatively, PKN1/2 may modulate gene expression via NFθB or MAPK cascades (p38-MAPKγ 
and/or JNKs).  PKN1 and PKN2 have also been shown to play a role in apoptosis, being activated by 
caspase-3 (Takahashi et al, 1998) and being involved in the regulation of PKB (Koh et al, 2000).  
With the activity of PKN1/2 involved in so many processes linked to disease progression, further 
dissection of their role and regulation is of widespread interest, quite apart from within the field of 
cardiovascular signalling. 
 
There are limited data on the role of PKN1/2 in the heart.  Overexpression of constitutively-activated 
PKN1 in cardiomyocytes promotes expression of an ANF-promoter-driven luciferase reporter 
probably via the SRE, suggesting that PKN1 plays a role in hypertrophy (Morissette et al, 2000).  A 
very recent study suggests that PKN1 is important in cardioprotection.  Thus, phosphorylation of the 
activation loop T774 residue is increased in mouse hearts subjected to ischaemia (45 min) and 
reperfusion (24 h), or in cardiomyocytes exposed to H2O2 to induce apoptosis (Takagi et al, 
2010;Kajimoto et al, 2011).    
 
1.6.  Signalling to gene expression in cardiomyocytes 
 
Cardiomyocyte hypertrophy is associated with activation of various intracellular signalling pathways 
leading to changes in gene expression and resulting in phenotypic changes.  There are two main 
mechanisms by which hypertrophic stimuli regulate cardiomyocyte gene expression: (i) protein kinase 
cascades in which the signal is transmitted through the cytoplasm, resulting in phosphorylation of 
nuclear-localised transcription factors to modulate their trans-activating activities; (ii) 
phosphorylation/dephosphorylation of transcriptional regulators in the cytoplasm which migrate to the 
nucleus to regulate gene expression.  Through such core mechanisms, intracellular signalling 
pathways converge on individual gene promoters where they become integrated with other systems 
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for transcriptional regulation including histone acetylation/deacetylation for DNA 
unwinding/rewinding and DNA methylation for gene silencing.  In cardiomyocytes, four major 
pathways have been identified that are likely to play a significant role in regulating cardiomyocyte 
gene expression: MAPKs (Roux and Blenis, 2004;Yoon and Seger, 2006;Clerk et al, 2007a), RhoA 
signalling (Kuwahara et al, 2005;Kuwahara et al, 2007), PI3K signalling through PKB 
(Vanhaesebroeck and Alessi, 2000;Matsui and Rosenzweig, 2005), and dephosphorylation of nuclear 
factor of activated T cells (NFATs) by calcineurin (Rusnak and Mertz, 2000;Wilkins and Molkentin, 
2004).  Of these, MAPKs (particularly ERK1/2 signalling) and RhoA are potently activated by 
hypertrophic stimuli (such as ET-1) that signal through GqPCR receptors.  
 
1.6.1.  Regulation of gene expression by MAPK signalling 
 
The wide range of biological functions of the MAPKs are mediated through
 
phosphorylation of 
several substrates, including phospholipases, transcription factors, and cytoskeletal proteins. 
Substrates of MAPKs include groups of protein kinases termed MAPK-activated protein kinases 
(MKs) such as p90RSKs, mitogen- and stress-activated protein kinases 1/2 (Msk1/2), MAPK 
interaction protein kinase 1 (Mnk1) and MAPKAPK2/3 (Roux and Blenis, 2004).  Such kinases 
provide additional amplification steps in the MAPK cascades.  Between different MAPKs there is 
considerable specificity with respect to the protein kinase substrates which each MAPK 
phosphorylates.  ERK1/2 mainly phosphorylate p90RSKs while p38-MAPKα/β primarily 
phosphorylate MAPKAPK2 (Roux and Blenis, 2004).  However, ERK1/2 or p38-MAPKs may 
phosphorylate Msk1/2 making this a possible point of integration of the two signals and indicating 
that cellular
 
stresses and mitogens induce specific and overlapping responses. 
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MAPKs and MKs phosphorylate a number of transcription factors, many of which are implicated in 
cardiac responses (Clerk et al, 2007a).  The different MAPKs can phosphorylate many of the same 
transcription factors and the specific MAPK that does phosphorylate a specific transcription factor 
most likely depends on co-localisation, its affinity for the substrate and on the relative amounts of 
kinase and substrate.  Since the transcription factors regulated by MAPKs are generally considered to 
be nuclear localised, MAPKs and/or MKs presumably translocate to the nucleus upon activation in 
order to exert their effects.  For ERK1/2, there is evidence that activated ERK1/2 become localised in 
the nucleus of cardiomyocytes (Chiloeches et al, 1999;Sugden et al, 2011). However, although 
transcription factor substrates of JNKs and p38-MAPK signalling are also nuclear-localised, nuclear 
localisation of these MAPKs has not been demonstrated in cardiomyocytes.  As described above, 
hypertrophic stimuli and cellular stresses all activate ERK1/2, JNKs and p38-MAPKs in 
cardiomyocytes despite producing distinct phenotypic changes.  Notably, in cardiomyocytes, 
approximately 70% of the mRNAs with altered expression induced by ET-1 (up to 4h) appear to 
require some degree of ERK1/2 signalling (Kennedy et al, 2006;Cullingford et al, 2008). 
  
Of the various MAPK substrates identified, transcription factors that may be involved in hypertrophy 
include c-Jun, c-Fos, ATF2, ternary complex factors (Elk1, SAP1a) and MEF2C, though it should be 
noted that transcription factors may also be phosphorylated and activated by MKs.  Though originally 
identified as a substrate of ERK1/2, phosphorylation of c-Jun is mediated principally by JNKs 
(Kyriakis and Avruch, 1996), whereas ATF2 may be phosphorylated by JNKs or p38-MAPKs 
(Raingeaud et al, 1995;Gupta et al, 1996).  These phosphorylations increase the trans-activating 
activities of c-Jun and ATF2 (Cohen, 1997a).  c-Jun/ATF2 heterodimers bind to cAMP response 
element-like consensus sequences in the regulatory regions of genes (Hai and Curran, 1991).  This 
may be particularly important in the transcription of c-jun mRNA itself, an early response to 
hypertrophic stimulation or cell stress (Chien et al, 1991).  Both c-Jun and ATF2 are phosphorylated 
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in cardiomyocytes in response to hypertrophic agonists or cellular stresses (Clerk and Sugden, 
1997a;Clerk et al, 1999;Clerk et al, 2002).  p38-MAPKs may phosphorylate and activate MEF2C 
(Han et al, 1997), a third transcription factor that may regulate expression of c-jun and other genes.  
Apart from c-jun mRNA, expression of c-fos mRNA is an early hallmark of the hypertrophic 
response.  An important regulatory site in the c-fos gene is a serum response element (SRE), through 
which (in non-myocytes) MAPKs regulate c-Fos expression through the SRE.  Thus, ERK1/2, JNKs 
and p38-MAPKs co-operate to phosphorylate and activate ternary complex factors such as Elk1 and 
SAP1 which act in conjunction with SRF at the SRE.  Heterodimers of c-Fos and c-Jun proteins bind 
to AP1 regulatory sites present in the promoter regions of many genes.  Upregulation of c-Fos and c-
Jun may thus occur as a consequence of activation of MAPKs and presumably contributes to 
increased expression of a variety of other genes through binding to AP1 sites.   
 
mRNA stability and the regulation of mRNA decay is a major control point in gene expression and 
one which is as important as mRNA transcription.  In non-myocytes, the p38-MAPK pathway is 
important in post-transcriptional regulation of inflammatory genes and p38-MAPKs have a role in 
regulating both the translation and the stability of inflammatory mRNAs (Dean et al, 2004).  Since 
p38-MAPK(s) are activated by hypertrophic stimuli or cellular stresses (Clerk et al, 1998b), this 
pathway may play a similar role in cardiomyocytes.  Signals propagated through the ERK1/2 cascade 
also regulate the translation of specific mRNAs (Rajasekhar et al, 2003;Tominaga et al, 2005).  This 
modulation is thought to be through the phosphorylation of RNA-binding proteins (RBPs).  RBPs 
associate with groups of mRNAs in the nucleus and cytoplasm and are implicated in pre-mRNA 
splicing, recruitment of mRNA to the ribosomes and in translational control (Keene and Lager, 2005).  
Such association of different RBPs with specific pools of mRNAs and the subsequent regulation of 
translation has led to a model of regulated and co-ordinated gene/protein expression in eukaryotes that 
is termed the post-transcriptional operon (Keene and Lager, 2005).  Whether or not this occurs in 
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cardiomyocytes is currently unknown.  Once mRNA has been translated and proteins have been 
synthesized, proteins may be further phosphorylated to enhance their stability.  In other cells, If 
ERK1/2 signalling remains active after the IEG-encoded protein products (e.g. c-Fos) are translated, 
the sustained signal can lead to phosphorylation of the IEG products themselves and a prolonging of 
their expression and activity in the nucleus thereby regulating the cellular response.  However, if the 
signal is transient, the IEG products are less stable and are degraded by the proteasome (Murphy and 
Blenis, 2006).  In cardiomyocytes, phosphorylation of c-Jun by JNKs may stabilise the protein for 
efficient upregulation (Clerk et al, 2002). 
 
1.6.2.  Regulation of gene expression by Rho-family proteins 
 
Although mainly recognised for their role in regulating actin in the cytoskeleton, Rho proteins also 
modulate signalling pathways and gene expression (Ridley, 2001).  For Rac1 and Cdc42, the effects 
may be indirect given that they stimulate p21-activated kinases (PAKs) (Bagrodia and Cerione, 1999) 
which may regulate JNKs and p38-MAPK signalling and thus influence transcription factor activities.  
However, the direct consequences of Rac1/Cdc42 on gene expression remain to be explored.  The 
molecular mechanisms by which cytoskeletal proteins may modulate pro-hypertrophic transcriptional 
pathways are not well understood.  However, RhoA signalling through Abra/STARS to SRF is one 
such system that operates in cardiomyocytes (Kuwahara et al, 2005).   
 
Abra/STARS is a muscle-specific actin-binding protein localised to the sarcomere (Arai et al, 2002) 
that is upregulated in mouse models of cardiac hypertrophy and in myopathic human hearts 
(Kuwahara et al, 2007).  Cardiac-specific and stress-inducible expression of Abra/STARS is mediated 
by a proximal promoter containing an essential MEF2-binding site.  MEF2 (a member of the same 
MADs box transcription factor family as SRF) is particularly implicated in pathological remodelling 
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of the adult heart in response to stress signalling (Naya et al, 2002;Xu et al, 2006).  Cardiac 
overexpression of Abra/STARS in vivo and in vitro increases the expression of SRF-dependent foetal 
cardiac genes and sensitizes the heart to biomechanical stresses induced by transverse aortic banding 
and calcineurin signalling (Kuwahara et al, 2007).  It is therefore proposed that Abra/STARS acts as 
an intermediary between MEF2 and SRF, thus modulating the cardiac stress response.  Abra/STARS 
appears to regulate SRF-dependent gene expression through myocardin and myocardin-related 
transcription factors MRTF-A (MAL/MKL1) and MRTF-B (MKL2) that act as transcriptional co-
activators of SRF (Wang et al, 2002;Miralles et al, 2003;Han et al, 2004).  Myocardin is found 
specifically in cardiac and smooth muscle cells and is sufficient and necessary for the normal 
expression of SRF-dependent smooth muscle genes (Wang et al, 2001;Li et al, 2003).  MRTFs, 
however, are expressed in a wide range of cell types (Wang et al, 2002).  Several studies suggest that 
PKN may be involved in transcriptional regulation.  For example, PKN1 can regulate SRF-dependent 
transcription, and is also implicated in regulating gene expression via p38-MAPKs (Marinissen et al, 
2001;Gudi et al, 2002;Deaton et al, 2005).   
 
SRF activity is sensitive to the state of actin polymerisation and is inhibited by globular-actin (G-
actin) monomers.  Actin polymerisation induced by activated RhoA, stimulates SRF activity by 
depleting the pool of inhibitory G-actin (Hill et al, 1995;Copeland and Treisman, 2002;Posern et al, 
2002).  In this scenario, Abra/STARS induces nuclear translocation of myocardin/MRTFs and 
stimulates SRF-dependent transcription (Fig. 1.6) (Miralles et al, 2003;Kuwahara et al, 2005).  SRF 
regulates the expression of immediate early and muscle-specific genes by binding to the SRE (also 
known as a CArG box) (Miano, 2003;Pipes et al, 2006).  As discussed above, SRF activity is 
regulated by (i) the phosphorylation of Ets domain family transcription factors (Janknecht et al, 1993) 
and (ii) the RhoA/actin pathway (Hill et al, 1995;Sotiropoulos et al, 1999;Murai and Treisman, 2002).  
Phosphorylation of TCFs by MAPK
 
signalling promotes their binding with SRF and onto genes
 
that 
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contain Ets-binding sites adjacent to the SRE (Janknecht et al, 1993), thereby enhancing or 
suppressing SRF activity,
 
depending on the promoter (Wang et al, 2004).  Alternatively, the 
activation
 
of such genes targeted by SRF in response to RhoA signalling can depend
 
on actin 
polymerisation. This is a TCF-independent
 
mechanism (Sotiropoulos et al, 1999;Gineitis and 
Treisman, 2001).  The crucial involvement of SRF in cardiovascular development and the induction of 
foetal cardiac genes during cardiac hypertrophy has been demonstrated (Sprenkle et al, 1995;Nelson et 
al, 2005).  Deletion of SRF in embryonic heart leads to lethal cardiac defects with reduced expression 
of cardiac specific genes (Miano et al, 2004;Parlakian et al, 2004), whereas overexpression of SRF in 
the postnatal heart leads to cardiomyopathy with increased foetal cardiac gene expression (Zhang et 
al, 2001).  Caspase cleavage of SRF results in dominant-negative SRF which may cause the decrease 
of SRF target genes in the heart (Chang et al, 2003). 
 
Figure 1.6. A model for the involvement of Abra/STARS in actin dynamics and signalling 
to SRF. The distribution of actin between the polymerised (F-actin) and monomeric (G-actin) states is 
determined by actin treadmilling. Actin monomers are added to the plus-end and are removed from 
the minus-end of actin filaments. Abra/STARS promotes the formation of F-actin and activates RhoA, 
which also promotes actin polymerisation. RhoA activates Rho kinase (ROCK) and other effectors 
leading to the stimulation of SRF activity. 
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It is assumed that the effects of Rho-family proteins on cardiomyocytes are exerted mainly via 
MAPKs and/or the contractile actin thin filaments.  However, little is known of how Rho signalling 
through the actin cytoskeleton influences intracellular signalling events in cardiomyocytes.  
Furthermore, even though Rho-family small G proteins are implicated in hypertrophy in 
cardiomyocytes, of the 22 members (many of which are expressed in cardiomyocytes), only RhoA, 
Rac1 and Cdc42 have been studied in detail.  Microarray data show that many other Rho-family 
proteins are expressed in cardiomyocytes (Clerk et al, 2007a) and in adult human heart biopsies 
(Prasad et al, 2008).  In cardiomyocytes, Rnd1 and RhoB are upregulated in response to ET-1 or H2O2 
whereas Rnd3 is upregulated only by H2O2 (Cullingford et al, 2008).  Given that Rnd family members 
are constitutively-active and antagonise RhoA signalling, changes in expression of Rnd1/3 may have 
profound effects on the actin cytoskeleton in myocytes. 
 
1.6.3.  Changes in gene expression in cardiomyocyte hypertrophy 
 
Since the early studies of gene expression in the heart (Izumo et al, 1988;Iwaki et al, 1990;Yamazaki 
et al, 1995), there has been limited progress in understanding of how gene expression is regulated as 
cardiomyocyte hypertrophy or apoptosis develops.  Using microarrays, it is possible to explore the 
changes in cardiac gene expression globally.  However, in the vast majority studies in the 
heart/cardiomyocyte that utilise microarrays, the focus is on identifying such changes that are 
associated with the latter stages of disease either in human/rodent hearts or in hearts of transgenic 
mice with chronic overexpression of signalling components and not on the changes which may lead to 
that state.  In the few studies which have focused on the early, potentially initiating changes in gene 
expression, much insight has been gained by using a simple system such as cultured cardiomyocytes 
in order to study global changes as the response to different stimuli develop.  
  
Chapter 1 
Page | 64  
 
In one such a study using an early generation of microarrays (Affymetrix rat U34A microarrays), 
short-term (2 – 4 h) changes in gene expression induced in cardiomyocytes by ET-1 alone or in 
combination with an ERK1/2 cascade inhibitor (U0126) were investigated (Kennedy et al, 2006).  
Specifically, the 78 genes showing significantly altered expression with ET-1 formed five clusters: (i) 
three clusters showing upregulation by ET-1 according to time course (4 h > 2 h; 2 h > 4 h; 2 h~4 h) 
with at least partial inhibition by U0126; (ii) a cluster of 11 genes upregulated by ET-1 but unaffected 
by U0126 suggesting regulation through signalling pathways other than ERK1/2; (iii) a cluster of six 
genes downregulated by ET-1 with attenuation by U0126.  These data therefore indicated that the 
majority of changes in gene expression induced by ET-1 were mediated by the ERK1/2 cascade.  
 
A more detailed microarray study using a later generation of Affymetrix arrays (Affymetrix rat 230 
2.0 comprising of >31000 probesets) was conducted (Cullingford et al, 2008).  Here the early 
transcriptional responses of cardiomyocytes to ET-1 were investigated more precisely over the initial 
4 h of the response.  Consistent with the previous study (Kennedy et al, 2006), most (~80%) of 
transcripts upregulated at 30 minutes encoded established proteins and required ERK1/2 signalling.  
By using the protein synthesis inhibitor cyclohexamide, IEG and second phase RNAs were defined.  
IEGs exhibited differential temporal and transient regulation, with expression of second phase RNAs 
within 1 h.  Such phasic regulation of early transcriptional responses induced by ET-1 in 
cardiomyocytes indicates that signals are propagated beyond the primary signalling pathways through 
transcriptional networks leading to phenotypic changes (presumably hypertrophy).  Such temporal 
regulation of RNA expression extends to subtoxic (0.04 mM) or apoptotic concentrations (0.2 mM) of 
H2O2  (Clerk et al, 2007b), suggesting that phasic signal propagation is a common theme in gene 
regulation and the cardiomyocyte response.   
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With respect to the response to ET-1, of the mRNAs that are regulated within the first 1 – 2 h, a large 
proportion may be classified as “regulatory”, encoding transcription factors or intra/inter-cellular 
signalling molecules which potentially modulate gene expression at later times.  The genes identified 
at 2 – 4 h are not generally IEGs and are presumably regulated by IEG products.  Cardiomyocyte 
hypertrophy or apoptosis may therefore probably develop as a consequence of sequential “waves” of 
gene expression that eventually culminate in the overall phenotypic response.  The relative 
significance of ERK1/2 and RhoA signalling (both rapidly and strongly activated by ET-1) in 
regulating the cardiomyocyte transcriptome is unknown.  The major aim in this thesis is to establish 
the significance of ERK1/2 and/or RhoA in these early cardiomyocyte transcriptomic responses to 
ET-1. 
 
1.7.  Recombinant adenoviruses 
 
Recombinant adenoviruses are a versatile method of gene delivery and expression that can be utilised 
in a wide variety of cell types.  Several features of adenovirus biology make them an appropriate 
vector system for cardiomyocyte research.  For example, unlike retroviruses (RNA viruses that 
undergo reverse transcription and infect proliferating cells), adenoviruses can also infect and transfer 
genetic material into cells that have withdrawn from the cell cycle and no longer divide (such as 
cardiomyocytes) and cells which replicate slowly in vivo (such as endothelial cells).  In addition to 
this, high virus titres and a high-level of gene expression are reliably obtainable using adenoviruses - 
an important consideration in protein overexpression experiments in mammalian cells.  
 
Prior to the widespread use of adenoviral-mediated gene transfer in neonatal cardiomyocytes, the 
majority of gene expression studies utilised transient gene transfer techniques in the primary cultures 
(Gustafson et al, 1987).  However, such transient transfection results in only 10-20% of the 
Chapter 1 
Page | 66  
 
cardiomyocytes being transfected (Kass-Eisler et al, 1993).  Adenoviral infection results in virtually 
100% of the cells acquiring the transgene and does not require the use of damaging treatments such as 
electroporation, which often has a deleterious effect on large numbers of cells in the culture. 
 
The most commonly used adenoviral vector is human adenovirus serotype 5.  This virus is replication 
defective due to the deletion of the E1 and E3 genes.  The E1 gene is necessary for the assembly of 
infectious virus particles but is provided by an adenovirus packaging cell line (e.g. HEK-293) during 
virus production.  The E3 gene encodes proteins involved in evading host immunity and is in fact 
dispensable.  Apart from making the virus incapable of replicating itself, these deletions also create 
space in the virus genome for the foreign DNA (i.e. the gene of interest) to be incorporated. 
 
1.7.1. Control adenoviruses (empty vector) 
 
For any experiment involving the introduction of foreign DNA into cells using adenoviruses, it is 
important to control for any non-specific effects of the virus by using an empty vector negative 
control. The adenoviral vectors used in protein expression experiments have been engineered to 
exhibit minimal toxicity to the cells due to the fact that as much of the viral genome as possible has 
been removed. However, there are still possible mechanisms for the activation of adverse cellular 
responses following infection
 
with these modified viruses.  For example, simply the presence of 
foreign DNA in the nucleus may cause activation of elements of the immune response. Therefore, 
these empty vector control adenoviruses allow the effective monitoring of the cellular effects of the 
infection process and the delivery of the adenoviral vector, without any additional effects of the 
overexpressed transgene.  Such empty vector controls are especially important when a reference point 
is necessary for comparing the specific knockdown of a gene. 
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1.7.2. Virus quantification 
 
Adenovirus quantification is a necessary step in the production of an adenoviral-mediated protein 
overexpression system as used in this project (chapter 6).  This quantification involves counting the 
number of effective viruses in a specific volume thereby determining the infectious dose to be applied 
to the cardiomyocytes in culture.  Virus quantification can be achieved by a viral plaque-based assay 
which determines the number of plaque forming units (PFU) in a virus sample which is a measure of 
virus quantity.  Traditionally, this assay is based on a microbiological method using agar in multi-well 
plates. Confluent monolayers of HEK-293 cells are infected with adenovirus at different dilutions 
before being covered with agar.  A viral plaque forms from an infected cell within the monolayer 
lysing and spreading the infection to neighbouring cells which are then also infected.  The plaques 
generated can be counted using an optical microscope.  The PFU is a functional measurement rather 
than simply an absolute quantity of viral particles.  In other words, virus particles that are defective or 
which fail to infect their host cell will not result in a plaque and will not be counted.  The PFU/ml 
represents the concentration of viable virus particles in the preparation and assumes that each plaque 
is representative of one infective virus particle.  More rapid variations of this technique are now 
commonly used.  These utilise fluorescently-labelled antibodies specific for the virus antigen to 
measure the level of infection without the need for a plaque to form.  
 
1.7.2.1. Multiplicity of infection (MOI) 
 
The multiplicity of infection (MOI) refers the ratio of viable adenoviral particles to infection targets 
(e.g. cardiomyocytes in the culture dish).  The actual number of adenoviral particles that will infect a 
given number of cultured cells is calculated by a statistical process which takes into account that some 
cells may be infected by more than one virus particle while others may not absorb any.  In 
Chapter 1 
Page | 68  
 
cardiomyocytes, a range of 10 - 25 MOI results in ~95% infection after 48 h; beyond 100 MOI, there 
has been observable cell loss due to necrosis reported (Long et al, 1997; Martin et al, 1997; Clark et 
al, 2003 ). 
 
1.8.  Hypothesis and approach 
 
The hypothesis for this thesis is that ET-1 signals through Rho-family small G proteins to influence 
cardiomyocyte gene expression and that RhoA signalling (in addition to ERK1/2) contributes to the 
early transcriptional response to ET-1.  Here, I have explored the regulation of expression of Rho-
family proteins in cardiomyocytes in response to ET-1 in comparison with oxidative stress and pro-
inflammatory cytokines.  Using microarrays with validation by quantitative PCR, I assessed the 
importance of RhoA compared with ERK1/2 signalling in the transcriptional response of 
cardiomyocytes to ET-1.  The role of PKN1, as a potential effector of RhoA in regulating changes in 
gene expression induced by ET-1, was investigated. 
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CHAPTER 2:  GENERAL METHODS 
 
2.1.  Materials and reagents 
 
Unless otherwise stated, general laboratory chemicals were obtained from Sigma-Aldrich or VWR.  
For other reagents, see Appendix I.  Deionised water was used to prepare general solutions (such as 
buffers) and gels.  Milli-Q water was used for tissue culture and PCR. 
 
GeneChip rat genome 230 2.0 microarrays and 1st and 2nd strand cDNA synthesis kits were from 
Affymetrix.  cRNA was biotin-labelled using a BioArray high-yield RNA transcript labelling kit from 
Enzo Diagnostics.  The PKN1 IMAGE clone was from GeneService (UK).  The AdEasy™ XL 
adenoviral vector system was from Stratagene (UK).  Peptide AKRRRKGSFFYGG was custom-
synthesised by Severn Biotech Ltd.  High-Capacity cDNA Reverse Transcription Kits from Applied 
Biosystems (Life Technologies Ltd) was used for standard cDNA synthesis.  Oligonucleotide primers 
were custom-synthesised by Eurofins MWG Operon, Germany. 
 
2.1.1.  Inhibitors 
 
Further details of inhibitors used are given in Table 2.1.  Inhibitors (1000-fold the final concentration 
unless otherwise stated) were added directly to cardiomyocytes in culture with pre-incubation for the 
times specified. 
  
Chapter 2 
Page | 70  
 
Table 2.1. Inhibitors.  
Inhibitor Target Supplier Solvent used 
Final 
conc. 
Pre-incubation 
(min) 
Calyculin A 
Protein 
phosphatases 
1 and 2A 
Calbiochem DMSO 200 nM 20 
LY294002 PI3K 
Alexis 
Biochemicals 
DMSO 50 µM 10 
HA-1077 
ROCKs and 
PKNs 
Calbiochem H2O 20 µM 30 
Y-27632 
ROCKs and 
PKNs 
Alexis 
Biochemicals 
H2O 10 µM 10 
Cell-permeating 
exoenzyme C3 
transferase from C. 
botulinum 
RhoA/B/C Cytoskeleton Inc. 
20 μg/ml in 
glycerol (66% 
v/v)  
1 µg/ml 120 
PD184352 
MKK1/2 
(ERK1/2 
cascade) 
Alexis 
Biochemicals 
DMSO 2 µM 10 
 
2.2.  Antibodies 
 
Antibody details and the conditions used in Western blotting are given in Table 2.2.  Details of gels 
for Western blotting gels are in Appendix II. 
 
2.3.  Primary cultures of neonatal cardiomyocytes 
 
Cardiomyocytes were dissociated from the ventricles of 2- to 4-day-old Sprague-Dawley rat hearts by 
an adaptation of the method of Iwaki et al, 1990.  Rat pups (Harlan Laboratories, UK) were sacrificed 
by cervical dislocation prior to decapitation.  Hearts were removed immediately under sterile 
conditions.  Ventricles were separated from atria and other tissues, and were washed in sterile 
digestion buffer [116 mM NaCl, 20 mM HEPES (pH 7.35), 0.8 mM Na2HPO4, 5.6 mM glucose, 5.4 
mM KCl, 0.8 mM MgSO4].  Ventricular tissue was dissected into small pieces (approximately 2 
mm
3
), and the cardiomyocytes dissociated by sequential digestion with collagenase (0.4 mg/ml) and  
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Table 2.2. Antibodies.  
Protein 
Mol 
wt. (kDa) 
Final 
dilution 
Supplier (catalogue 
no.) 
Host species 
Gel 
acrylamide 
conc. (%) 
RhoA 21 1/800 
Cell Signaling 
Technology (2117) 
Rabbit 
monoclonal 
12% 
RhoB 21 1/1000 
Cell Signaling 
Technology (2098) 
Rabbit 
polyclonal 
12% 
RhoC 24 1/500 
Santa Cruz 
Biotechnology (sc-
12116) 
Goat polyclonal 12% 
Rnd1 26 1/500 
Santa Cruz 
Biotechnology (sc-
25029) 
Goat polyclonal 12% 
Rnd2 25.4 1/500 
Santa Cruz 
Biotechnology (sc-
1945) 
Goat polyclonal 12% 
Rnd3 27 1/500 
Santa Cruz 
Biotechnology (sc-
1946) 
Goat polyclonal 12% 
Phospho-PKN1 
(Thr774)/PKN2 
(Thr816) 
120/140 1/1000 
Cell Signaling 
Technology (2611) 
Rabbit 
polyclonal 
8% 
PKN2 140 1/1000 
Cell Signaling 
Technology (2612) 
Rabbit 
polyclonal 
8% 
Phospho-ERK1 
(Thr203/Tyr205)/ 
phospho-ERK2 
(Thr183/Tyr185) (in rat) 
44/42 1/1000 
Cell Signaling 
Technology (4377) 
Rabbit 
monoclonal 
10% 
ERK1/2 44/42 1/1000 
Cell Signaling 
Technology (4695) 
Rabbit 
monoclonal 
10% 
Phospho-p38 MAPK 
(Thr180/Tyr182) 
38 1/1000 
Cell Signaling 
Technology (9216) 
Mouse 
monoclonal 
10% 
p38-MAPK 38 1/1000 
Cell Signaling 
Technology (9212) 
Rabbit 
polyclonal 
10% 
Phospho-JNK1/2 
(Thr183/Tyr185) 
46/54 1/1000 
Cell Signaling 
Technology (4671) 
Rabbit 
monoclonal 
10% 
JNK1/2  46/54 1/1000 
Cell Signaling 
Technology (9252) 
Rabbit 
polyclonal 
10% 
Phospho-PKB (Thr308) 60 1/1000 
Cell Signaling 
Technology (9275) 
Rabbit 
polyclonal 
10% 
Phospho-PKB (Ser473) 60 1/1000 
Cell Signaling 
Technology (9271) 
Rabbit 
polyclonal 
10% 
PKB 60 1/1000 
Cell Signaling 
Technology  (9272) 
Rabbit 
polyclonal 
10% 
Phospho-
MYPT1(Thr853) 
140 1/1000 
Cell signalling 
Technology (4563) 
Rabbit 
polyclonal 
8% 
MYPT1 140 1/1000 
Cell Signaling 
Technology (2634) 
Rabbit 
polyclonal 
8% 
FLAG 
not 
applicable 
1/1000 
Sigma-Aldrich UK 
(F9291) 
Mouse 
(monoclonal 
BioM2) 
8  – 12% 
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pancreatin (0.6 mg/ml) in digestion buffer.  Digestion was carried out in a sterile 100 ml Schott bottle 
with agitation in a water bath (37°C).  The supernatant from the first digest (10 ml, 5 min, 160 
cycles/min) was removed and discarded.  Following the second digest (10 ml, 20 min, 136 
cycles/min), the supernatant cell suspension was transferred to a sterile Falcon centrifugation tube (50 
ml).  The proteolytic enzymes were inactivated by the addition of foetal calf serum (FCS, 2 ml).  Cells 
were recovered by centrifugation (5 min, 60 × g), gently resuspended in FCS (4 ml) and set aside in an 
incubator (37°C, 5% CO2).  The ventricular remains were similarly dissociated into cardiomyocytes 
with 4 sequential digests (10 ml; 2 × 25 min, 112 cycles/min; 20 min, 136 cycles/min; 10 min, 136 
cycles/min; 37
o
C).  Cells were resuspended as before and pooled.  The pooled cells were recovered by 
centrifugation (5 min, 60 × g) and the cell pellet was resuspended in plating medium [DMEM/medium 
199 (4:1 (v/v)), 15% (v/v) FCS, 100 units/ml penicillin and streptomycin].   
 
The resulting cell suspension was pre-plated for 30 min on uncoated 60 mm Primaria culture dishes 
(BD BioSciences via VWR) to remove non-myocytes (e.g. fibroblasts and endothelial cells, which 
attach to the culture plates and are then discarded).  The non-adhering viable cardiomyocytes in a 
sample of the cell suspension were identified by Trypan Blue exclusion and quantified in a 
haemocytometer.  Cardiomyocytes were plated on Primaria culture dishes pre-coated with sterile 
gelatin (1% w/v) at a density of 4 × 10
6
 cells/60 mm dish or 2 × 10
6
 cells/35 mm dish.  Cells were 
maintained in an atmosphere containing 5% CO2 at 37°C.  After 18 h, cardiomyocytes were confluent 
and beating spontaneously.  The plating medium was removed and replaced with serum-free 
maintenance medium [DMEM/medium 199 (4:1 (v/v)), 100 units/ml penicillin and streptomycin] for 
a further 24 h incubation until experimentation. 
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2.4.  Preparation of cardiomyocyte extracts for Western blotting 
 
Cardiomyocytes were treated for the times indicated.  Concentrated stock solutions of agonists and 
inhibitors were added directly to the tissue culture medium.  Following incubations (37°C in an 
atmosphere of 5% CO2), cells were washed three times in ice-cold phosphate-buffered saline (PBS) 
and scraped into ice-cold homogenisation buffer [20 mM β-glycerophosphate (pH 7.5), 50 mM NaF, 2 
mM EDTA, 10 mM benzamidine, 0.2 mM Na3VO4, 5 µM dithiothreitol and 1% (v/v) Triton X100] 
containing protease inhibitors [200 µM leupeptin, 10 µM trans-epoxy succinyl-l-leucylamido-(4-
guanidino)butane (E64) and 300 µM phenyl methyl sulphonyl fluoride (PMSF)] and the protein Ser-
/Thr- phosphatase inhibitor microcystin LR (4 µM).  Extracts were centrifuged (5 min, 10,000 × g, 
4°C).  The supernatants were retained and samples (5 µl) thereof taken for protein assays (Section 
2.5).  The remaining extracts were boiled with 0.33 vol SDS-PAGE sample buffer [330 mM Tris-HCl 
(pH 6.8), 10% (w/v) SDS, 133 mM dithiothreitol, 13% (v/v) glycerol and 0.2 mg/ml bromophenol 
blue] and stored at -20°C.   
 
2.5.  Protein quantification 
 
The concentration of protein in the cell extracts was determined using the BioRad Bradford protein 
assay (Bradford, 1976).  Standard curves were constructed using a stock solution of bovine serum 
albumin (BSA, 0.2 mg/ml, standard curve of 1 – 10 µg BSA in 100 µl deionised H2O).  Sample 
protein extracts (2 µl) were diluted in deionised H2O to a final volume of 100 µl.  BioRad Bradford 
protein assay reagent (1/5 dilution in H2O, filtered through Whatman filter paper No. 1) was added 
with mixing (30 s).  Samples were incubated (10 min, room temperature) for colour development and 
absorbances measured at 595 nm.  Protein concentrations were determined by interpolation.   
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2.6.  Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western blot analysis 
 
Proteins (10 – 25 µg, as indicated) were resolved by SDS-PAGE using a mini Protean® 3 system (Bio-
Rad) and full-range molecular weight rainbow markers.  The percentage of acrylamide in the gel 
ranged between 8 and 14% (see Appendix II for the stacking/resolving gel recipes) depending on the 
molecular weight of the protein under investigation (Table 2.2).  Electrophoresis was performed (200 
V, 45 – 60 min) in SDS-PAGE running buffer [25 mM Tris base, 192 mM glycine, 0.1% (w/v) SDS].  
Gels were equilibrated with transfer buffer [25 mM Tris base, 192 mM glycine, 20% (v/v) methanol] 
and proteins transferred (12 V, 60 min) to nitrocellulose membranes soaked in transfer buffer using 
Trans-Blot
®
 SD Semi-Dry Electrophoretic Transfer Cells (Bio-Rad).  Membranes were incubated (30 
min, room temperature) with 5% (w/v) non-fat milk powder in Tris-buffered saline (20 mM Tris-HCl 
pH 7.5, 137 mM NaCl) containing 0.01% (v/v) Tween 20 (TBST) to block non-specific binding of 
antibodies.  Membranes were washed in TBST (3 × 5 min, room temperature) before incubation with 
primary antibodies (Table 2.2) in TBST containing 5% (w/v) BSA (16 h, 4°C).  Membranes were 
again washed in TBST (3 × 5 min, room temperature) and incubated with horseradish-peroxidase 
(HRP) conjugated secondary antibodies [1/5000 in TBST containing 1% (w/v) non-fat milk powder] 
for 1 h at room temperature.  Membranes were then finally washed in TBST (3 × 5 min, room 
temperature).   
 
Immunoreactive bands were detected by enhanced chemiluminescence with luminol reagent and 
visualised by exposing the membranes to Hyperfilm MP for up to 15 min.  Scanning densitometry was 
used for quantitative analysis of the band intensities using an ImageScanner III (GE Healthcare) and 
ImageQuant 7.0 (GE Healthcare).  Alternatively, an ImageQuant 350 digital imager (GE Healthcare) 
was used for analysing blots.  In this case, ECL DualVue Western blotting markers were used 
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(consisting of two types of protein marker: pre-stained colour indicator proteins for gel orientation 
confirmation of protein transfer, and recombinant proteins tagged with a 15 residue RNase S-Tag 
peptide that are visible by digital imaging when used in conjunction with a ribonuclease S-protein - 
HRP conjugate) with ECL Plus Western blotting detection reagents.  ImageQuant 7.0 software was 
used to analyse the visible bands on the digital image. 
 
2.7.  Assay for activated GTP-bound Rho-family proteins 
 
2.7.1.  Preparation of RBD-glutathione-S-transferase (RBD-GST) fusion protein 
 
The recombinant Rho binding domain (RBD) from murine rhotekin (residues 7-89) (Ren et al, 
1999;Clerk et al, 2001;Sahai et al, 2001) was expressed as a glutathione-S-transferase (GST) fusion 
protein in E. coli.  The rhotekin RBD interacts specifically with the GTP-bound form of Rho-family 
proteins and, in conjunction with Western blotting, serves as an activation-specific probe for RhoA, 
RhoB or RhoC.   
 
RBD-GST fusion protein was expressed and purified in association with Professor Peter Sugden.  E. 
coli BL21 (DE3 pLysS) were transformed with a pGEX-4T-1 plasmid encoding the rhotekin RBD-
GST (a gift from Dr Erik Sahai and Professor Christopher Marshall, Institute of Cancer Research, 
UK).  Glycerol stocks of the bacteria were prepared by adding 40% sterile glycerol [final 
concentration 15% (v/v)] to aliquots of bacterial cultures.  Stocks were stored at -80°C.  Bacteria were 
grown in 2 l flasks with 100 ml Lennox broth (LB) (20 g/l) containing ampicillin (50 µg/ml) and 
chloramphenicol (10 µg/ml) (16 h, 37°C).  Further LB broth (400 ml) containing ampicillin and 
chloramphenicol was then added.  After 1 h, the bacteria were in the log phase of growth.  Bacteria 
were induced to express RBD-GST by addition of 1 mM isopropyl-β-D-thiogalactopyranoside (5 h, 
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37°C).  Following induction, bacteria were harvested by centrifugation (15 min, 3000 × g, 4°C) and 
the pellets frozen in liquid nitrogen.  Pellets were thawed in RBD-GST homogenisation buffer [4 ml/g 
of pellet: 50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 2 mM EGTA, 2 mM EDTA, 1 mM benzamidine, 
10 mM β-mercaptoethanol, 0.2 mM PMSF, 0.1 mM N-tosyl-L-phenylalanine chloromethyl ketone, 10 
µg/ml leupeptin and 1% (v/v) Triton X100].  Bacteria were disrupted and DNA sheared using a 
Polytron sonicating homogeniser.  Debris was removed by centrifugation (30 min, 20,000 × g, 4°C).  
Supernatants were retained and Brij 35 was added to a final concentration of 0.03% (v/v).  Aliquots 
(250 µl) of the crude bacterial extract were stored at -80°C.  Immediately before assays (see below), 
bacterial extract (50 µl) was incubated with glutathione-Sepharose (50 µl) for 2 h with rotation at 4°C) 
in individual microfuge tubes, then washed 3 × in ice-cold Buffer A [20 mM Tris-HCl (pH 7.4), 2 mM 
EDTA, 100 mM KCl, 5 mM MgCl2, 5 mM NaF, 0.2 mM Na3VO4, 10% (v/v) glycerol, 1% (v/v) 
Triton X-100, 0.5% (v/v) 2-mercaptoethanol and 10 mM benzamidine].  The glutathione-Sepharose 
beads to which the rhotekin RBD-GST was bound were collected by centrifugation (2 min, 10,000 × 
g, 4°C) and followed by careful removal of the supernatants. 
 
2.7.2.  RhoA.GTP affinity binding assay 
 
Cardiomyocytes were washed 3 × with ice-cold PBS and extracted by scraping into 150 µl Buffer A 
containing protease inhibitors (200 µM leupeptin, 10 µM E64 and 300 µM PMSF) and 4 µM 
microcystin LR.  Lysates were centrifuged (5 min, 10,000 × g, 4°C).  A sample (50 µl) was taken to 
assess total input levels of RhoA.  Remaining extracts were incubated with mixing (16 h, 4°C) with 
rhotekin RBD-GST prebound (as described above) to glutathione-Sepharose beads.  Following 
incubation, the beads were washed 4 × with ice-cold Buffer A (1 ml), resuspended with Buffer A (30 
µl) and boiled with SDS-PAGE sample buffer (0.33 vol.).  The RhoA input and activated RhoA were 
analysed by Western blotting (Table 2.2).     
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2.8.  RNA preparation and cDNA synthesis 
 
Total RNA was extracted using RNA-Bee.  Cardiomyocytes (4 × 10
6
 cells) were scraped into RNA-
Bee (1 ml).  After adding chloroform (200 µl, 5 min), the samples were shaken vigorously (30 s) and 
incubated on ice (10 min).  Samples were centrifuged (15 min, 12,000 × g, 4°C) to separate the 
phases.  To precipitate RNA, isopropanol (500 µl) was added to the upper phase (350 µl) and samples 
were incubated (room temperature, 10-15 min).  RNA was collected by centrifugation (5 min, 12,000 
× g, 12°C).  The supernatants were discarded and RNA pellets washed twice with 80% ethanol (1 ml) 
with centrifugation (5 min, 7500 × g, 12°C) between washes before air-drying (5 min).  RNA was 
resuspended in nuclease-free water (50 µl), RNA concentrations were determined from absorbance 
(A) at 260 nm, and RNA purity was assessed from A260/A280 ratios with values of 1.9–2.1 being 
considered acceptable.   
 
cDNAs were synthesised using High Capacity cDNA Reverse Transcription (RT) Kits with random 
primers.  Random primers ensure that the first strand synthesis occurs efficiently with all species of 
RNA molecules present, including mRNA and rRNA.  RNA (1 µg) was mixed with random primers 
(0.5 µg) and dNTP mix (10 mM).  Concentrated RT buffer (10 × RT buffer, 2 µl) and Multiscribe 
Reverse Transcriptase [1 µl, 200 units] were added and the volume made up to 20 µl with nuclease-
free water.  Samples were incubated in a thermocycler (Step 1: 10 min, 25°C; Step 2: 120 min, 37°C; 
Step 3: 5 min, 85°C) and were stored at -20°C. 
 
2.9.  Primer design and quantitative polymerase chain reaction (qPCR) 
 
Gene sequences were obtained from NCBI Entrez Gene (www.ncbi.nlm.nih.gov) and information on 
gene structures was obtained from Ensembl (www.ensembl.org).  Primers for qPCR were designed to 
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produce an ideal amplicon size of 50-150 bp, to be within 1000 bp of the 3‟ end of the mRNA, to have 
a predicted primer melting temperatures (Tm) of 60-65°C and, where possible, with primer sets 
crossing an exon boundary (Table 2.3).  Primer suitability was confirmed with PrimerExpress 
software for Real-Time PCR (version 3.0; Applied Biosystems). 
 
qPCR was performed using a Real-Time PCR system (Model 7500, Applied Biosystems) with optical 
96-well reaction plates containing (in each well) SYBR Green Jump Start Taq Readymix (12.5 µl),  
oligonucleotide primers (5 µl, 5 pmol each of the forward and reverse primers) and cDNA template 
(7.5 µl, diluted 15-fold in water).  qPCR conditions were routinely: 50°C for 2 min, 95°C for 10 min 
(Jump Start Taq polymerase activation step), followed by 40 cycles of 95°C for 15 s and 59°C for 60 
s.  qPCR was performed using absolute quantification with the standard curve protocol.  Following 
qPCR, dissociation curve analysis was routinely performed to check for aberrant amplification 
products (e.g. primer-dimers).  Values for selected RNAs were normalised to glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) expression and then to control (zero time) values. 
 
2.10.  Sample preparation for microarray analysis 
 
2.10.1.  Cardiomyocyte cultures 
 
Primary cultures of neonatal ventricular myocytes were prepared as previously described (Section 
2.3).  To minimize variation resulting from differences between preparations of cardiomyocytes, RNA 
from three individual experiments was pooled to generate a single sample set.  Four sets of pooled 
  
 
 
Table 2.3. Primers for qPCR. Oligonucleotide primer sequences were designed and synthesised for the qPCR validation of microarray data.  Nucleotide 
positions in the mRNA transcripts are shown in parentheses for each primer.  mRNA sequences (accession numbers provided) encoded by established 
genes were obtained from the Rat Genome Database (rgd.mcw.edu, viewed at www.ncbi.nlm.nih.gov/entrez). 
Gene Accession no. Size (bp) Forward primer Reverse primer 
Abra  NM_175844  90 CCTTGCACTCCCAGGCAA (691-708)  ACCTGCCTTTCAAGTTGTCCAC (759-780)  
Angptl4 NM_199115  132 TACAGACTCAACTCAAGGCTC (765-785)  GTCAAGAGGTCAATCTGGC  (876-896)  
Arc  NM_019361.1  87 GATTGCCCAGCTGGAACCT (403-423)  CAGACACGAGCAGTTACCAACAC  (470-490) 
Areg  NM_017123  71 TCGCAGCTATTGGCATCATTA (611-633)  TTCTGCTTCTTCATATTCCCTGAA (658-681)  
Bdnf NM_012513.2  94 GATGCTCAGCAGTCAAGTGC (537-557)  CCTCATAGACATGTTTGCG (612-630)  
Bmp2 NM_017178  93 CATCACGAAGAAGCCATCG (395-413)  CTCATCAGTAGGGACAGAAC (468-487)  
Clcf1 NM_207615 127 GACCTACCTGAACTACCTGG (401-421)  AGCCTGTCATTGAGGCTTCG (509-527)  
Crem NM_017334  107 ACTGATGAGGAGACTGACC (79-97)  ACCACACCTTGTGGCAAAGC (166-185)  
Csf3 NM_017104  167 CTTGCAGCAGACAAAGTGCC (453-472)  GCTTTCCATCTGCTGCCAGA (501-620)  
Egr1  NM_012551  117 CTATGAGCACCTGACCACAGAGTC (561-584)  GCAACCGAGTCGTTTGGCT (659-677)  
Egr2  NM_053633  121 CTGGAGATGGCATGATCAACA (507-527)  TCTGGTTTCTAGGCGCAGAG (608-627)  
Egr3  NM_017086 122 CAATCTGTACCCCGAGGAGATC (66-87)  ACATTCTCTGTAGCCATCTGAGTGTAA (161-187)  
Egr4  NM_019137 101 TCCTGGAGGCGACTTCTTGA (317-336)  GCCCTCCAGGAAGCAGGA (399-417)  
Ereg  NM_021689  82 CACCGAGAGAAGGATGGAGACT (123-144)  GGGAACCAAGGCAAAGCA (187-204)  
Gapdh NM_002046  113 CCAAGGTCATCCATGACAACTT (552-573)  AGGGGCCATCCACAGTCTT (626-664)  
Hbegf  NM_012945  106 GGAGAGTGCAGATACCTGAAGGA (384-406)  GTCAGCCCATGACACCTCTGT (469-489)  
Icam1  NM_012967  132 CATCACTGTGTATTCGTTCC  (250-270)  CACTACTGAGAGCTGTGTCCG (361-381)  
InhbA  NM_017128  94 GAATGAACTCATGGAGCAGACCT (504-529)  AATGCAGTGTCTTCCTGGCTG (577-597)  
IL-6  NM_012589  157 GAGTTGTGCAATGGCAATTC (266-285)  ACTCCAGAAGACCAGAGCAG (403-422)  
Klf4  NM_053713 175 TCAAGAGCTCATGCCACCGG (1180-1199)  CTCGCCTGTGTGAGTTCGCA (1335-1354)  
Klf6 NM_031642 98 GCTCCCACTTGAAAGCACATC (641-658)  TTCTTGCAAAACGCCACTCA (729-738)  
Klf15 NM_053536  74 TGCGGCTGGAGGTTTTCA (1347-1354)  TCACACCCGAGTGAGATCGT (1411-1420)  
LOC363060 NM_001014209  108 CAACCTACACAGTGACAGTC (191-210)  ACTTCTCGTATGCTCCGCTC (279-298)  
LOC365395  NM_207615.2  92 CATCAACTCCGCAGCTTAG (304-324)  CGAGGAGGATTGAAGTCAG (377-395)  
LOC498272 XM_573497.3 98 CAGTGCTACCAGAGATCAAG (286-306)  CCAGCTAGAAGAAGAACTGC (364-383)  
RhoA NM_057132  134 ACGGGAAGCAGGTAGAGTTG (342-364)  CTAAACTATCAGGGCTGTCG (455-475)  
RhoB NM_022542  134 CTATGACTACCTCGAGTGCT (543-564)  TCATAGCACCTTGCAGCAGT (657-677)  
RhoC  XM_215659 136 AAAACATCCTGACAGCCTGG (454-474) ATGCTCATCTTGCCTCAGGT (569-589)  
Rnd1 NM_001013222  110 CTATCCCGAGACCTATGTGC (302-323)  TACGGAGAGCCTGAGGTATC (390-411) 
Rnd3 NM_001007641 119 GACACTGTCCAGAGTTTCTG (212-231)  GACACTGTCCAGAGTTTCTG (310-330)  
Pvr NM_017076.1  148 CTATGAGTGTCAGATTGCCACG (343-364)  CAGAGATGCATTTGGCCACG (470-490)  
Ptges NM_021583  135 AAGTCAGGCTGCGGAAGAAG (123-142)  GGTAGATCGTCTCCATGTCG (240-259)  
Slc25a25  NM_145677  80 GACTGCCCATGCTCAATGAGT (2945-2965)  TTTCCTCATCAGGCCATTCTG (3004-3024)  
Srf NM_001109302  81 CATGAAGAAGGCTTATGAGCTGTC (820-843)  TACACATGGCCTGTCTCACTGG (879-900)  
Tfpi2  NM_173141.1  94 CTGAGACTGTGGAATCTGC (201-221)  CTAAGTTATTCCCTTGGGCAG (264-284) 
Tnfaip3  NM_009397.2 155 CGAGAGATCATCCACAAAGC (151-171) GTACTGACAAGCTGCATGC (285-305)  
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samples were prepared for hybridisation to separate Affymetrix Genechips (i.e. four separate sets of 
samples were analysed for each condition prepared from a total of 12 cardiomyocyte preparations).  
Two separate unstimulated control samples were prepared and hybridised simultaneously with each 
set of samples. 
 
2.10.2.  Preparation of cRNA for hybridisation to rat genome 230 2.0 microarrays 
 
RNA samples prepared as described in Section 2.8 were further purified and concentrated using a 
RNeasy MinElute Cleanup kit (Qiagen).  cDNA synthesis was performed using a Affymetrix 1
st
 and 
2
nd
 Strand cDNA synthesis kit.  First strand cDNA synthesis was performed in two steps.  Total RNA 
(10 µg in nuclease-free water) was incubated (70°C, 10 min) with a T7-oligo (dT) primer (50 mM) 
and polyA
+
 controls [provided by the Microarray Centre in the Clinical Sciences Centre (CSC), 
Hammersmith Campus, Imperial College London].  Integrating polyA
+
 controls into assays 
conveniently monitors the entire target labelling process and allows evaluation of assay sensitivity, 
consistency and dynamic range especially across different experiments.  Superscript II reverse 
transcriptase [1 µl (200 units)] with dNTPs (10 mM) and 5  First Strand Buffer (4 µl, constituents 
not specified by Affymetrix) were added to each sample and each reaction was made up to a final 
volume of 20 µl using nuclease-free water before incubation (42°C, 1 h).  In the second step, the 
primed RNA was converted to double-stranded cDNA using RNase H to generate 3‟-OH ends suitable 
for filling-in and extension by DNA Polymerase I.  The double-stranded cDNA thus generated is a 
faithful representation of the initial mRNA pool.  For this second-strand cDNA synthesis, samples 
were incubated (16°C, 2 h) with DNA ligase [1 µl (100 units)], DNA polymerase I [1 µl (200 units)] 
and RNaseH [0.5 µl (50 units)] in 5  Second Strand Buffer (6 µl, constituents not specified by 
Affymetrix).  Each reaction was made up to a final volume 30 µl with nuclease-free water.  To purify 
the cDNA products after first and second strand cDNA synthesis, an Affymetrix GeneChip Sample 
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Cleanup kit was used.  cDNA binding buffer (1 ml, constituents not specified by Affymetrix) was 
added to the samples before centrifuging in a cDNA Cleanup column (2 min, 8000 × g, room 
temperature).  The purified cDNA was eluted from the column filter using a high salt elution buffer 
(50 µl, unspecified details). 
 
In order to prepare the fluorescently-labelled cRNA target sequences that bind to the 
oligodeoxynucleotide probe sequences of the microarrays, the purified double-stranded cDNA 
(prepared as described above) was used as a template to synthesise biotin-labelled cRNA.  The cRNA-
probeset oligodeoxynucleotide hybrids have a higher melting temperature than their DNA-DNA 
hybrid equivalents and therefore the single-stranded cRNA targets offer higher target avidity and 
greater sensitivity than cDNA species.  The protocol used produces hybridisable biotin-labelled cRNA 
targets by in vitro transcription from the bacteriophage T7 RNA polymerase promoters.  Use of T7 
RNA polymerase allows amplification of the cDNA templates into single-stranded cRNA in vitro.  
Because of their single-stranded nature, the cRNA species are strand-specific and hybridise more 
effectively to probes because the target population does not self-hybridise.  The ENZO Labelling kit 
uses two different labelled nucleotides (biotin-CTP and biotin-UTP) to label the cRNA.  The biotin-
labelled cRNA targets that are hybridised to microarrays of DNA probes can be detected directly by a 
reporter molecule linked to streptavidin. 
 
cRNA was synthesised from cDNA (4 µg) using the using the ENZO BioArray™ HighYield™ RNA 
Transcript Labelling Kit (T7) kit consisting of 10 × biotin-labelled NTPs [4 µl/sample (10 µM)] and 
20 × T7 RNA polymerase [2 µl/sample (200 units]) in 10  High Yield (HY) reaction buffer (4 
µl/sample, unspecified details).  RNase inhibitor [4 µl/sample (100 units)] was also added.  The 
reactions were incubated at 37°C for 5 h.  Following cRNA synthesis, an aliquot (2 µl) was taken for 
quality assessment by examination of the A260/A280 ratio.  RNA concentrations were determined from 
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A260 and then standardised to 0.2 µg/µl by addition of nuclease-free water.  The size distribution of 
RNA was also evaluated by denaturing agarose gel analysis.  The expected cRNA profile is a 
distribution of sizes from 250–5500 nt with most of the RNA between 600–1200 nt.   
 
Fragmentation of cRNA targets before hybridization onto microarrays is critical in obtaining optimal 
assay sensitivity.  Fragmentation of the antisense cRNA and hybridisation to the Affymetrix rat 
genome 230 2.0 arrays was performed at the CSC Microarray Centre (Hammersmith Campus, 
Imperial College London) according to the manufacturer‟s protocol. Specific details of the procedure 
are unavailable but following this process, raw hybridisation data are generated and primary analysis 
conducted with Affymetrix GeneChip operating system (GCOS).  Data (.CEL files) were imported 
into GeneSpring 10.0.2 (Agilent Technologies) as tab-delimited text files.  For details on the analysis 
of the microarray data, see section 4.2.5. 
 
2.11.  Overexpression of PKN1 using adenoviral vectors 
 
2.11.1.  FLAG-tagged adenoviral vectors 
 
Adenoviral vectors that allow N-terminal labelling of expressed proteins with a FLAG sequence 
(DYKDDDDK) are routinely prepared using the AdEasy™ XL Adenoviral Vector System 
(Stratagene).  The FLAG sequence was first introduced between the BglII and NotI restriction sites in 
the multiple cloning site (MCS) of the pShuttle-CMV vector (Fig. 2.1) by synthesis of an 
oligonucleotide cassette containing the FLAG sequence preceded by an ATG start codon.  Stocks of 
this construct were prepared by Dr Steve Fuller.  The complementary oligonucleotides used, with the 
FLAG-encoding sequence underlined, were:  
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Fwd = 5’-GATCTACCATGGACTACAAAGACGATGACGACAAGGGTACCGTCGACGC-3’ 
Rev =  5’-GGCCGCGTCGACGGTACCCTTGTCGTCATCGTCTTTGTAGTCCATGGTA-3’ 
 
These oligonucleotides were warmed and allowed to anneal to generate double-stranded 
oligodeoxynucleotide with “sticky” ends: 
 
This double-stranded oligodeoxynucleotide was then phosphorylated using T4 polynucleotide kinase, 
resulting in a cassette flanked by BglII and NotI sites, which was then ligated into the MCS of 
pShuttle-CMV using the corresponding restriction sites.  This strategy avoids the potential difficulty 
of cutting both the BglII and KpnI sites which lie immediately adjacent to each other in the pShuttle-
CMV MCS.  By this strategy, the KpnI-NotI fragment of MCS was replaced with an identical KpnI-
NotI sequence which could be used in further manipulations.  Stocks of this pShuttle-CMV vector 
were stored at -80°C. 
 
2.11.2.  Preparation of adenoviral vectors overexpressing PKN1 
 
To facilitate identification, separation and immunoprecipitation of overexpressed PKN1, the 
adenovirally-encoded PKN1 was tagged with a FLAG
®
 sequence (DYKDDDDK) at its N-terminus.  
Adenoviral vectors overexpressing rat PKN1 were prepared using the AdEasy™ XL Adenoviral 
Vector System.  PKN1 was cloned from a sequence-verified IMAGE (Integrated Molecular Analysis 
of Genomes and their Expression) cDNA clone (Geneservice, UK).  The PKN1 clone was provided in 
E. Coli within a pCMV-SPORT6 plasmid vector with ampicillin resistance and was provided streaked 
GATCTACCATGGACTACAAAGACGATGACGACAAGGGTACCGTCGACGC
ATGGTACCTGATGTTTCTGCTACTGCTGTTCCCATGGCAGCTGCGCCGG
Bgl II
Not ISal I
5’ 3’
3’ 5’
Kpn I
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onto LB agar (50 µg/ml ampicillin).  Using a sterile spreader, this was re-streaked onto ampicillin 
plates (50 µg/ml ampicillin) and incubated overnight (37°C) to obtain single colonies.  One colony 
was then picked and cultured overnight in LB broth (5 ml, 20 g/l) containing ampicillin (50 µg/ml).  
Aliquots (200 µl) of the remaining bacterial suspension (with 0.5 vol. 15% glycerol added) were 
stored at -80°C. 
 
Before the preparation of the glycerol stocks, a sample of bacteria was harvested by centrifugation (15 
min, 3000 × g, room temperature) and the pellet was sampled using a sterile toothpick for use in a 
PCR reaction.  The high temperatures of the PCR lyses the bacteria allowing the DNA to be used 
directly as a template. Standard PCR conditions for amplifying PKN1 DNA were:  
 94°C for 5 min 
 5 cycles of (94°C, 30 s; 60°C, 30 s; 72°C, 8 min) 
 5 cycles of (94°C, 30 s; 55°C, 30 s; 72°C, 8 min) 
 30 cycles of (94°C, 30 s; 50°C, 30 s; 72°C, 8 min) 
 
The 50 µl PCR reaction mix to which the bacteria were added consisted of 5 × Pfu reaction buffer (10 
µl), Pfu polymerase (1.25 units, 1 µl), a dNTP mix (2 mM of each nucleotide, 5µl), nuclease-free 
water (32 µl) and the forward and reverse primers (1 nM, 1 µl each primer) designed to the 5‟ 
initiation (ATG) and 3‟ stop codons of PKN1 (See Appendix III for PKN1 sequence).  Primers were 
designed to add restriction enzyme sites (KpnI on forward primer and HindIII on reverse primer as 
underlined in sequences below) onto the amplified PKN1 DNA in order to facilitate its insertion into 
the MCS downstream to and in-frame with the previously-inserted FLAG sequence in the pShuttle-
CMV vector (as described in section 2.11.1).  The MCS of pShuttle-CMV is sandwiched between a 
CMV promoter and an SV40 polyadenylation signal.  The „transgene‟ lying 3‟ to the CMV promoter 
is thus expressed in mammalian cells under the control of the highly-efficient CMV promoter.  
Sequences of the PKN1 primers were as follows: 
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PKN1-Forward: 5’-GACGACAAGGGTACCATGGCCGGCGACGCCGTG-3’  
PKN1-Reverse: 5’-CTTATCTAGAAGCTTCTAATAGCCTCCTGCCAC-3’  
 
Following the PCR reaction, the sample (50 µl) was mixed with 0.1 vol SDS gel-loading buffer 
(11 mM EDTA pH 8.0, 3.3 mM Tris-HCl, 0.017% SDS, 0.015% bromophenol blue) and was loaded 
on a 0.7% agarose gel impregnated with SYBR Safe DNA gel stain (10 µg/ml).  SYBR Safe gel stain 
is a fluorescent dye that intercalates with double-stranded DNA allowing visualisation.  Following 
electrophoresis (30 min, 100 V), amplified PKN1 (Fig. 2.1A) flanked by the additional KpnI and 
HindIII sites (underlined in primer sequence above) was visualised using an ultraviolet light imager.  
PKN1 DNA is 2838 bp in length (excluding the additional 12 base pairs of the two restriction sites). 
 
To extract and purify PKN1 DNA from the agarose gel, a QIAquick Gel Extraction Kit was used.  The 
PKN1 DNA was excised from the gel using a scalpel and dissolved in a buffer QG (200 µl/100 mg of 
gel; buffer constituents not specified by Qiagen).  The dissolved gel mix was applied to a spin column.  
Nucleic acids adsorb to the silica filter in the high-salt conditions of buffer QG.  Having centrifuged 
the column (2 min, 10,000 × g, room temperature), the filter was washed twice with ethanol (500 µl, 
80% v/v) and purified PKN1 DNA eluted with nuclease-free water (50 µl).  Purified PKN1 DNA (1 
µg) was digested (37°C, 90 min) firstly using KpnI [1 µl (10 units)] in NEB buffer 1 (10 mM bis-Tris-
propane-HCl, 10 mM MgCl2, 1mM dithiothreitol) and purified using the spin columns as before.  The 
DNA was then digested (37°C, 90 min) with HindIII [1 µl (10 units)] in NEB buffer 2 (10 mM Tris-
HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM dithiothreitol), purified using spin columns and eluted with 
nuclease-free water (30 µl).  The PKN1 flanked by cut restriction sites was then ligated into the 
FLAG-pShuttle-CMV MCS, downstream and in-frame with the FLAG tag sequence as described 
above (Fig. 2.1B).  This ligation was achieved by digesting the FLAG-pShuttle plasmid with KpnI 
and HindIII and column-purification as described above for the PKN1 insert.  The KpnI/HindIII-  
Chapter 2 
Page | 86  
 
 
 
Figure 2.1. Vector map of pShuttle-FLAG-CMV containing PKN1. (A) PKN1 DNA flanked by 
the additional KpnI and HindIII sites was amplified by PCR from an IMAGE clone and was 
visualised under UV light. PKN1 DNA is 2838 base pairs in size excluding the additional 12 base 
pairs of the restriction sites. The PKN1 band can be seen at approximately 3000 bp in the lane with 
Pfu polymerase added to the reaction mix (+ Pol).  For a control lane, polymerase was absent (- Pol) 
and no amplified DNA was detectable. M represents a marker lane with 5 µl 1 kb DNA ladder. (B)  
The original pShuttle vector was obtained from Stratagene. Dr Steve Fuller engineered a version of 
this vector where a FLAG
 
sequence was introduced between the BglII and NotI restriction sites in the 
multiple cloning site (MCS) of the pShuttle-CMV vector.  The cloned and amplified PKN1 sequence 
with added restriction sites (KpnI and HindIII) was then inserted downstream of the FLAG sequence 
in the MCS and was under the control of the CMV promoter.  
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digested PKN1 insert (1 µg), KpnI/HindIII-digested FLAG-pShuttle vector (0.5 µg) and T4 DNA 
ligase [1 µl (20 units) in 5 × ligase reaction buffer (4 µl, buffer constituents not specified by 
Invitrogen)] were incubated (26°C, 1 h) to achieve ligation. 
 
The ligated pShuttle-CMV-FLAG-PKN1 (2 µl, containing ~0.1 µg plasmid) was added gently to  
calcium-competent DH5α E. coli cells (100 µl) which were then heat-shocked (30 min on ice, 45 s at 
42°C, 2 min on ice) to transform the cells.  LB broth (1 ml, 20 g/ml) was added and the bacteria were 
incubated (1 h, 37°C, 250 rpm) in a rotary incubator before spreading onto agar plates containing 
kanamycin (1 mg/ml).  Following culture overnight (37°C), fifteen colonies were picked for PCR 
screening as before using primers specific to PKN1 and the adjoining restriction sites.  PCR products 
were electrophoresed on agarose gels (30 min, 100 V) and visualised under UV light.  In positive 
clones, a PCR product encoding the ~3000 bp PKN1 was amplified providing a means of positive 
identification and confirmation of successful transformation of the DH5α E. coli (Fig. 2.2).  Seven (of 
the fifteen clones selected) were positive for PKN1 and were incubated overnight (37°C, 250 rpm) in 
LB broth (5 ml, 20 g/ml) containing kanamycin (1 mg/ml).  Alkaline lysis (mini-prep) was employed 
to isolate the pShuttle-CMV-FLAG-PKN1 vector from the seven amplified samples.  The cultures 
were transferred to individual sterile microfuge tubes and the bacteria recovered by centrifugation (2 
min, 10,000 × g, 12°C).  The pellets were resuspended in STE solution (500 µl; 100 mM NaCl, 10 
mM Tris-HCl pH 8.0, 1 mM EDTA) and re-pelleted by centrifugation (5 min, 12,000 × g, 12°C).  The 
pellets were resuspended in ice-cold Solution I (100 µl; 25 mM Tris-HCl pH 8.0, 50 mM EDTA, 
4mg/ml lysozyme) by vortexing.  Solution II was added (200 µl; 0.2 M NaOH, 1% SDS) and tubes 
inverted 5× to mix.  Following incubation (5 min, room temperature), ice-cold solution III (150 µl; 
5M potassium acetate) was added and mixed by vortexing.  Samples were incubated on ice (5 min) 
and then centrifuged (5 min, 12,000 × g, 12°C) to remove debris.  To remove contaminating proteins, 
the supernatants (~500 µl) were transferred to new tubes and equal volumes of phenol and chloroform 
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(500 µl of each) were added.  Samples were mixed by vortexing, and then centrifuged (15 min, 14,000 
× g, 4°C) to separate the phases.  The aqueous, DNA-containing phase (~350 µl) was transferred to 
sterile tubes and the DNA precipitated. 
 
For ethanol-precipitation of the pShuttle-CMV-FLAG-PKN1 vector, sodium acetate (100 µl, 3 M) 
was added to the samples followed by ethanol (1 ml, 100%).  Following incubation (20 min, -20°C), 
DNA was recovered by centrifugation (15 min, 14,000 × g, 4°C).  The pellet was washed in ethanol (1 
ml, 80%) and re-pelletted by centrifugation (5 min, 10,000 × g, 4°C).  The pellet was then air-dried 
(10 min) and resuspended in nuclease-free water (50 µl).  Four of the seven samples were selected at 
this point for sequencing in order to confirm the presence of the full-length (non-mutated) FLAG-
PKN1 sequence in the vector.  This was achieved using primers which spanned the entire FLAG-
PKN1 sequence, each primer being ~800 bp apart; see Appendix III.  Samples were prepared and sent 
for sequencing using an ABI 3100 Genetic Analyser at the Advanced Biotechnology Centre, Imperial 
College London. 
 
Figure 2.2. Cloned PKN1 and recombination screening by PCR. Positive PKN1 clones from 
transformed DH5α E. coli were identified and sequenced plasmid DNA was heat-shocked into E. coli, 
incubated and plated on kanamycin plates overnight. Colonies were picked and the PKN1 detected by 
PCR. Seven of the fifteen colonies were positive for PKN1. These clones were incubated in LB broth 
(5 ml, 10 ng/ml kanamycin) over night. Following this, the DNA plasmid was isolated and purified as 
described.   
 
Cloned
PKN1
+ + + + + + +- - - - - - - -M
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pShuttle-CMV-FLAG-PKN1 plasmids were linearised using PmeI [1 µl (10 units), 1 h, 37°C] in NEB 
buffer 4 (20 mM Tris-acetate, 50 mM potassium acetate, 10 mM magnesium acetate, 1 mM 
dithiothreitol) and were used to transform BJ5183-AD-1 calcium-competent bacteria as described 
above for DH5α cells.  Transformed bacteria were then plated onto kanamycin-enriched (1 mg/ml) 
agarose plates to screen for transformation (Fig. 2.3).  Kanamycin resistance and colony growth 
confirmed that transformation had occurred.  The BJ5183-AD-1 cells are pre-transformed with the 
pAdEasy-1 plasmid which contains the human adenovirus serotype 5 (Ad5) genome with genes E1 
and E3 deleted.  BJ5183-AD-1 cells also possess the machinery necessary for homologous 
recombination between the pShuttle-CMV-FLAG-PKN1 and the adenoviral pAdEasy-1 vectors.  
Recombination exchanges the ampicillin resistance gene of the pAdEasy-1 vector for the kanamycin 
resistance gene of pShuttle-CMV-FLAG-PKN1, enabling antibiotic selection of recombinants.  Four 
clones were screened by PCR (as before with the same conditions and primers) to check for the 
presence of the FLAG-PKN1 gene and therefore to confirm recombination.  The four positive clones 
were picked with a sterile toothpick which was used to inoculate LB broth (5 ml, 20 g/ml) which was 
incubated overnight in order to amplify the bacteria.  Following this amplification, plasmid DNA was 
isolated from the BJ5183-AD-1 cells by alkaline lysis (as described above).  These recombinants were 
screened by digestion of the adenoviral plasmid (0.5 µg) with Pac1 [1 µl (10 units) in 5 × NEB buffer 
4; 30 min, 37°C].  There is one Pac1 restriction site in the original pShuttle plasmid and one in the 
pAdEasy plasmid (Fig. 2.3).  Effective recombination will therefore result in two distinct fragments 
following Pac1 digestion.  These fragments were visualised following electrophoresis (30 min, 100 V) 
through a 0.7% (w/v) agarose gel and exposure to UV light as before.  In all four cases, a positive 
result was observed. 
 
The four confirmed PKN1 recombinant pAdEasy-1 plasmid samples were then amplified in the 
recombination-deficient bacterial cell line, XL10-Gold.  The transformation of these cells with the 
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FLAG-PKN1-pAdEasy-1 plasmid (2 µg) was conducted as before for the DH5α and the BJ5183-AD-
1 cells.  Following an overnight incubation in LB broth (5 ml, 20 g/ml) containing kanamycin (1 
mg/ml), recombinant PKN1-pAdEasy-1 plasmid DNA was purified by the alkaline lysis method as 
before.  The PKN1-pAdEasy-1 plasmid DNA (1 µg) was then used to infect HEK-293 cells (plated at 
~100 cells/mm
2
 in a 60 mm dish, 37°C), using the FuGENE transfection agent (1 µl).  FuGENE forms 
a complex with the plasmid DNA and facilitates its transport into the cells.  The HEK-293 cell line 
provides the deleted viral E1 and E3 genes in trans to enable mature recombinant adenoviral particles 
to be produced (Fig. 2.3).  The infectivity of the virus was amplified by three further infections of 
HEK-293 cells (grown in DMEM containing 10% FCS, 100 units/ml penicillin/streptomycin and 5.6 
mM glucose, 5% CO2, 37°C). 
 
2.11.3.  Adenoviral infection of cardiomyocytes 
 
For adenoviral infection of cardiomyocytes, serum-rich medium (as described in section 2.3) was 
withdrawn from cardiomyocyte cultures (4 × 10
6
 cells/60 mm dish) approximately 6 h before addition 
of the adenovirus encoding FLAG-PKN1 (AdV-FLAG-PKN1).  As before, this was replaced with 
serum-free maintenance medium (as described in section 2.3) and AdV-FLAG-PKN1 (5 µl) was 
added directly to cardiomyocytes in this medium. At 20 h after infection, cardiomyocytes were used 
for further experimentation (no further change of medium).  In preliminary experiments, the 
multiplicities of infection were titrated and the relative level of overexpression of FLAG-PKN1 was 
assessed by Western blotting for the FLAG epitope (described in further detail in Chapter 4, section 
4.2.2).   
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Figure 2.3. Production of recombinant adenovirus using the AdEasy XL adenoviral vector 
system. Kanamycin resistance and colony growth confirms transformation. The BJ5183-AD1 cells are 
pre-transformed with a pAdEasy-1 plasmid which contains the machinery necessary for the 
homologous recombination reaction between the shuttle vector and pAdEasy-1. Recombination 
exchanges the ampicillin resistance gene of pAdEasy-1 for the kanamycin resistance gene of pShuttle-
CMV, allowing antibiotic selection of recombinants. Confirmed PKN1 recombinant pAdEasy-1 was 
amplified in the recombination-deficient bacterial cell line, XL10-Gold.  Purified recombinant PKN1 
pAdEasy-1 plasmid DNA was used to transfect HEK293 cells, a cell line which provides the deleted 
viral genes to enable mature recombinant adenoviral particles to be produced.  
Kanamycin
Pac1
pCMV-promoter
SV40 polyA
MCS including FLAG-PKN1
pShuttle-
FLAG-CMV
Plasmid vector
map
Left arm homology
PmeI
Right arm homology
Linearise with PmeI
Transform 
BJ5183-AD1 cells 
and select for 
Kana resistance
pAd-easy
Adenoviral
plasmid
pShuttle-CMV-
FLAG-PKN1 
plasmid
Homologous 
Recombination
in vivo in bacteria
Virus production in 
HEK-293 cells
Regions of homologous 
recombination
Ampicillin
resistance
gene
Pac1
site
Chapter 2 
Page | 92  
 
2.12.  Immunoprecipitation of FLAG-PKN1 and PKN1 activity assay 
 
2.12.1.  FLAG-PKN1 immunoprecipitation 
 
Cardiomyocytes were infected with AdV-FLAG-PKN1 (1/800, generation 4) as described in Section 
2.11.3.  Cardiomyocytes were extracted in Buffer A (150 µl) containing protease and phosphatase 
inhibitors (Section 2.7.2) and extracts were centrifuged (5 min, 10,000 × g, 4°C).  The supernatants 
were removed and a sample of extract (50 µl) was boiled with SDS-PAGE sample buffer (0.33 vol.).  
The remaining cardiomyocyte extract (~200 µl) was added to 20 µl pre-washed (3 × 1 ml Buffer A) 
EZ-view
TM
 Red ANTI-FLAG M2-conjugated agarose beads and incubated overnight with rotation 
(4°C).  The matrix contains anti-FLAG M2 monoclonal antibodies covalently attached to red-coloured 
agarose to facilitate visualisation following centrifugation.  The slurries were centrifuged (5 min, 
10,000 × g, 4°C) and a portion (50 µl) of the supernatant was retained and boiled with SDS-PAGE 
sample buffer (0.33 vol) (supernatant extract).  The EZ-view beads (with FLAG-PKN1 bound) were 
washed (3 × 1 ml Buffer A), resuspended in Buffer A (30 µl) and boiled with SDS-PAGE sample 
buffer (0.33 vol.).  They were then analysed by Western blotting using antibodies against FLAG or 
phospho-PKN1 (See Table 2.2 and Chapter 6).   
 
2.12.2.  In vitro FLAG-PKN1 kinase assays 
 
FLAG-PKN1 was immunoprecipitated as described above (Section 2.12.1) except that processing was 
terminated immediately before addition of SDS-PAGE sample buffer.  Instead, the agarose beads 
(with FLAG-PKN1 bound) were washed with Buffer A (3 × 1 ml) and once with kinase assay buffer 
[1 ml, 50 mM HEPES (pH 7.3), 1 mM EDTA, 1 mM benzamidine, 0.3 mM Na3VO4, 5% (v/v) 
glycerol, 0.1% (v/v) Triton X-100].  The pellets were resuspended in kinase assay buffer (45 µl) 
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containing PKN1 substrate peptide (AKRRRKGSFFYGG, 100 µM) and PKA inhibitor (8 µM, 
TYANFASGRTGRRNAI).  Assays were initiated by the addition of [γ-32P]ATP/MgCl2 (5 µl, 1 mM 
ATP containing 0.5 µCi [γ-32P]ATP, 200 mM MgCl2).  After incubation (30 min, 30°C), the assays 
were terminated with EDTA (10 µl, 0.5 M, pH 7.5), centrifuged (1 min, 10,000 × g, 4°C) and 
supernatants (40 µl) were spotted onto Whatman P81 papers (approx 2 × 1 cm).  The papers were 
washed in 75 mM H3PO4 (4 × 15 min) and 
32
P incorporation was measured by Čerenkov counting in a 
scintillation counter.  The EZ-view/FLAG-PKN1 beads were then washed in kinase assay buffer (4 × 
1 ml), resuspended in the same buffer (30 µl) and boiled with SDS-PAGE sample buffer (0.33 vol).  
The samples were Western blotted for FLAG or phospho-PKN1 (see above).   
 
2.13.  Fast Protein Liquid Chromatography (FPLC) 
 
Cardiomyocyte proteins were partially-purified by Mono-Q ion-exchange chromatography (ÅKTA 
system, HR5/5 column, GE Healthcare) by Professor Angela Clerk.  Cardiomyocytes (8 × 10
6
 cells) 
were scraped into ice-cold homogenisation buffer (20 mM β-glycerophosphate (pH 7.5), 50 mM NaF, 
2 mM EDTA, 10 mM benzamidine, 0.2 mM Na3VO4, 5 µM dithiothreitol and 1% (v/v) Triton X100] 
containing 200 µM leupeptin, 10 µM E64, 300 µM PMSF and 4 µM microcystin LR).  Samples were 
centrifuged (5 min, 10,000 × g, 4°C) and applied to the column pre-equilibrated with 50 mM HEPES 
(pH 7.3), 1 mM EDTA, 1 mM benzamidine, 0.3 mM Na3VO4, 5% (v/v) glycerol and 0.1% (v/v) 
Triton X-100.  Following a 16 ml isocratic wash, proteins were eluted with a linear NaCl (0.18 - 0.36 
M) gradient in the same buffer over 18 ml (0.5 ml fractions, 0.5 ml/min flow-rate).  Samples of each 
fraction and boiled with SDS-PAGE sample buffer (0.33 vol.) for Western blotting (as described in 
Section 2.6). 
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CHAPTER 3: REGULATION OF EXPRESSION OF RHOA, RHOB, RHOC, 
RND1 AND RND3 IN CARDIOMYOCYTES 
 
3.1.  Introduction 
 
Rho-family small G proteins are implicated in cardiac hypertrophy but, of the 22 members, only 
RhoA, Rac1 and Cdc42 have been studied in the heart (Aspenstrom, 1999;Kaibuchi et al, 1999;Clerk 
and Sugden, 2000) and their functions are not well understood.  RhoA and Rac1 are activated in 
cardiomyocytes by hypertrophic stimuli and are implicated in hypertrophy (Brown et al, 2006).  Most 
attention has focused on RhoA which is activated by ET-1 (Clerk et al, 2001) but, although activated 
RhoA may mediate aspects of cardiomyocyte hypertrophy, there is currently no agreement on the 
role(s) of RhoA in the heart (Miyamoto et al, 2010).  
 
Previously, microarray experiments of the early transcriptional response of cardiomyocytes to ET-1 
identified changes in expression of mRNAs encoding Rho-family proteins (Kennedy et al, 
2006;Cullingford et al, 2008).  The expression of RhoB and Rnd3 mRNAs was significantly 
upregulated by ET-1 at 1 h (2.64-fold and 1.89-fold, respectively), whilst expression of Rnd1 mRNA 
was increased 4.84-fold following incubation with ET-1 for 2 h.  The early changes in mRNA 
expression in cardiomyocytes exposed to concentrations of H2O2 that induce apoptosis (0.2 mM) or 
are non-toxic (0.04 mM)
 
have also been studied using microarrays (Kemp et al, 2003;Clerk et al, 
2007b).  The expression of RhoB was upregulated 2.1-fold at 2 h, Rnd1 mRNA expression was 
increased 2.8-fold at 4 h and Rnd3 mRNA was upregulated 1.8-fold at 4 h in response to 0.2 mM 
H2O2.  These early changes in mRNA expression profiles may modulate the adaptive responses of 
cardiomyocytes to the environment.  Although microarrays provide an indication of changes in 
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mRNA expression, it is necessary to validate these changes using additional approaches.  Here, I have 
used qPCR to validate the changes in expression of mRNAs encoding selected Rho-family proteins 
induced by ET-1 or H2O2 and confirmed that these changes are reflected at the protein level by 
Western blotting.  Given accumulating evidence to indicate that IL-1β and TNFα also contribute to the 
development of cardiac pathologies (Mann, 2003;Yndestad et al, 2007), I also compared the effects of 
these pro-inflammatory cytokines on expression of mRNAs encoding the selected Rho-family 
proteins.   
 
3.2.  Methods 
 
Cardiomyocytes (see section 2.3) were unstimulated (Control, 0 min) or were exposed to 100 nM ET-
1, 0.2 mM H2O2, 100 ng/ml recombinant rat IL-1β or 10 ng/ml recombinant rat TNFα for the times 
indicated.  All agonists were prepared as 1000-fold stock solutions in water.  Total RNA was 
extracted using RNA Bee and cDNAs synthesized using random primers as described in section 2.8.  
Forward and reverse primers for the genes RhoA, RhoB, RhoC, Rnd1 and Rnd3 were designed for 
qPCR (Table 2.3).  qPCR was performed using absolute quantification with the standard curve 
protocol.  Values for selected RNAs were normalised to Gapdh expression and then to control values.   
Protein samples were prepared as in section 2.4 and analysed by immunoblotting using 12% (w/v) 
polyacrylamide gels.  Proteins were transferred to nitrocellulose and incubated with antibodies to 
RhoA, RhoB, RhoC, Rnd1 and Rnd3 (Table 2.2).  The bands were visualised by enhanced 
chemiluminescence and were quantified by scanning densitometry using ImageQuant 7.0 software.  
The values were normalised to the controls.  Results are means ± SEM (n = 3 or 4 independent 
myocyte preparations).  Statistical analysis of the data was performed with Graphpad Prism 4 using 
one-way ANOVA with a Tukey multiple comparisons post-test.   
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3.3.  Results 
 
3.3.1.  ET-1 modulates expression of mRNAs encoding RhoA, RhoB, RhoC, Rnd1 
and Rnd3 
 
Cardiomyocytes were exposed to 100 nM ET-1 for up to 6 h and mRNA expression examined by 
qPCR (Fig. 3.1).  RhoA mRNA expression increased in response to ET-1 with maximal expression at 
6 h (2.2 ± 0.2-fold relative to controls) (Fig. 3.1A).  RhoB mRNA expression was significantly 
increased within 15 min of stimulation (4.2 ± 0.3-fold) with maximal expression (8.1 ± 1.5-fold) at 30 
min (Fig. 3.1B).  The increase in expression of RhoB mRNA was transient and returned to basal 
levels within 90 min.  RhoC mRNA expression levels showed no significant change in response to 
ET-1 although there may have been some increase by 6 h (1.7 ± 0.6-fold) (Fig. 3.1C).  Over a longer 
time course this may have increased to statistically significant levels.  Rnd1 mRNA expression 
increased to a greater relative degree than RhoA/B/C with maximal expression at 1.5 h (32.7 ± 16.3-
fold) (Fig. 3.1D).  The high level of Rnd1 mRNA expression decreased but remained elevated relative 
to controls even at 6 h (13.5-fold).  A lesser, though significant, increase in Rnd3 mRNA expression 
was also detected (2.3 ± 0.5-fold following 6 h exposure to ET-1) (Fig. 3.1E).   
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Figure 3.1. ET-1 modulates expression of mRNAs encoding RhoA, RhoB, RhoC, Rnd1 and 
Rnd3 in cardiomyocytes. Cardiomyocytes were exposed to ET-1 (100 nM) for the times indicated.  
RNA was extracted and expression of mRNAs encoding RhoA (A), RhoB (B), RhoC (C), Rnd1 (D) 
or Rnd3 (E) was assessed by qPCR.  Results are means ± SEM for 3 or 4 independent cardiomyocyte 
preparations. *p<0.05, **p<0.01, ***p<0.001 one-way ANOVA with Tukey post-test. 
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3.3.2.  H2O2 upregulates expression of RhoB and Rnd1 mRNAs  
 
Cardiomyocytes were exposed to 0.2 mM H2O2 for up to 6 h and mRNA expression examined by 
qPCR (Fig. 3.2).  RhoB mRNA expression increased in response to H2O2 with maximal upregulation 
of expression within 1 h (4.3 ± 0.7-fold relative to controls) (Fig. 3.2A).  In contrast to ET-1 (Fig. 
3.1B), the return to basal levels of RhoB mRNA expression appeared more gradual (over ~4 h).  Rnd1 
mRNA expression was upregulated to a lesser extent (2.5 ± 0.1-fold) and was maximal at 6 h (Fig. 
3.2B).  No change in expression of RhoA mRNA was detected in cardiomyocytes exposed to H2O2 
(Fig. 3.2C), nor was there any change in expression of RhoC (Fig. 3.2D) or Rnd3 (Fig. 3.2E) mRNAs. 
 
3.3.3.  IL-1β or TNFα increase expression of Rnd1 mRNA  
 
Cardiomyocytes were exposed to 100 ng/ml IL-1β or 10 ng/ml TNF-α for up to 6 h and mRNA 
expression examined by qPCR (Fig. 3.3).  In response to IL-1β, expression of Rnd1 mRNA increased 
gradually with maximal expression at 6 h (3.5 ± 0.6-fold relative to controls) (Fig. 3.3A).  TNFα also 
stimulated an increase in expression of Rnd1 mRNA, but with maximal expression at 2 h (3.7 ± 0.6-
fold) (Fig. 3.3B).  No significant changes in mRNA expression were observed for the other Rho-
family members studied in response to either IL-1β or TNFα (RhoA: Fig. 3.3, C and D; RhoB: Fig. 
3.3, E and F; RhoC: Fig. 3.3, G and H; Rnd3: Fig. 3.3, I and J). 
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Figure 3.2. H2O2 increases expression of RhoB and Rnd1 mRNAs in cardiomyocytes. 
Cardiomyocytes were exposed to H2O2 (0.2 mM) for the times indicated.  RNA was extracted and 
expression of mRNAs encoding RhoB (A), Rnd1 (B), RhoA (C), RhoC (D) or Rnd3 (E) was assessed 
by qPCR. Results are means ± SEM for 3 or 4 independent cardiomyocyte preparations. *p<0.05, 
**p<0.01, ***p<0.001 one-way ANOVA with Tukey post-test. 
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Figure 3.3. IL-1β or TNFα increase expression of Rnd1 mRNA in cardiomyocytes. 
Cardiomyocytes were exposed to IL-1β (100 ng/ml) or TNFα (10 ng/ml) for the times indicated.  
RNA was extracted and expression of mRNAs encoding Rnd1 (A and B), RhoA (C and D), RhoB (E 
and F), RhoC (G and H) or Rnd3 (I and J) was assessed by qPCR.  Results are means ± SEM for 3 or 
4 independent cardiomyocyte preparations. *p<0.05 and **p<0.01 one-way ANOVA with a Tukey 
post-test.  
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3.3.4.  Regulation of expression of RhoA, RhoB, RhoC, Rnd1 and Rnd3 proteins 
by ET-1 or H2O2 
 
The effects of ET-1 and H2O2 on the total levels of RhoA, RhoB, RhoC, Rnd1 and Rnd3 proteins were 
examined by Western blotting (Figs. 3.4 and 3.5).  A notable increase in expression of RhoA protein 
was observed from ~2 h exposure to ET-1, but the increase was statistically significant only at 6 h (2.2 
± 0.5-fold relative to controls) (Fig. 3.4A).  With H2O2, there was no significant change in RhoA 
protein expression (Fig. 3.4B).  RhoB protein expression was upregulated by ET-1 with a maximal 
increase at 1 h (3.5 ± 0.5-fold) (Fig. 3.4C).  The expression of RhoB protein was transient with a 
gradual return to basal levels by 6 h.  RhoB protein was also transiently upregulated in response to 
H2O2 (Fig. 3.4D).  This was maximal at 1-1.5 h (3.4 ± 0.4-fold) and returned to near basal levels 
within 2 h.  RhoC protein expression was gradually increased in response to ET-1, with significant 
increases at 4 h (1.8 ± 0.1-fold) and 6 h (2.1 ± 0.2-fold) (Fig. 3.4E).  H2O2 had no effect on levels of 
expression of RhoC protein (Fig. 3.4F).  Rnd1 protein expression was gradually increased in response 
to ET-1 and was maximal at 6 h (2.7 ± 0.4-fold) (Fig. 3.5A).  Rnd1 protein expression also increased 
in response to H2O2 and was also maximal at 6 h (4.9 ± 0.8-fold) (Fig. 3.5B).  In response to ET-1, 
Rnd3 protein expression was upregulated more rapidly, with maximal expression at 2 h (2.6 ± 0.2-
fold) (Fig. 3.5C).  There was no significant change in Rnd3 protein abundance following exposure to 
H2O2 (Fig. 3.5D). 
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Figure 3.4. The effects of ET-1 or H2O2 on expression of RhoA, RhoB and RhoC proteins in 
cardiomyoytes. Cardiomyocytes were exposed to 100 nM ET-1 (A, C, E) or 0.2 mM H2O2 (B, D, F) 
for the times indicated.  Expression of RhoA (A and B), RhoB (C and D) or RhoC (E and F) proteins 
was assessed by Western blotting. Representative immunoblots are shown (upper panels) with 
densitometric quantification (lower panels). Results are means ± SEM for 3 or 4 independent 
cardiomyocyte preparations. *p<0.05, **p<0.01, ***p<0.001 one-way ANOVA with Tukey post-test. 
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Figure 3.5. The effects of ET-1 or H2O2 on expression of Rnd1 or Rnd3 proteins in 
cardiomyocytes. Cardiomyocytes were exposed to 100 nM ET-1 (A, C) or 0.2 mM H2O2 (B, D) for 
the times indicated.  Expression of Rnd1 (A, B) or Rnd3 (C, D) protein was assessed by Western 
blotting. Representative immunoblots are shown (upper panels) with densitometric quantification 
(lower panels). Results are means ± SEM for 3 or 4 independent cardiomyocyte preparations. *p<0.05 
and ***p<0.001 one-way ANOVA with Tukey post-test. 
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3.4.  Discussion 
 
Cardiac hypertrophy is associated with changes in gene expression (Hoshijima and Chien, 2002;Dorn 
et al, 2003).  However, there is still substantial debate regarding the signalling mechanisms that 
regulate these changes.  Attention has focused on the Rho-family small G proteins in relation to 
cardiomyocyte hypertrophy because of their involvement in cytoskeletal reorganisation (Aspenstrom, 
1999;Brown et al, 2006) with the assumption that early activation of, for example, RhoA (Sah et al, 
1996;Kuwahara et al, 2005), is important in the developing response.  This may be the case, but 
microarray data (Kennedy et al, 2006;Clerk et al, 2007b;Cullingford et al, 2008) that is validated here 
indicate that the response is much more complex with changing expression of Rho-family proteins 
once the signal has been initiated.  
 
3.4.1.  Expression and potential role of RhoA in cardiomyocytes 
 
A great deal of evidence has accumulated to implicate RhoA in cytoskeletal regulation, mediating 
cellular events such as changes in cell morphology, cell motility and cytokinesis (Burridge and 
Wennerberg, 2004).  In cardiomyocytes, the regulation of RhoA is of much interest given that (i) 
RhoA is very rapidly activated by ET-1 (Clerk et al, 2001) and (ii) it influences gene expression 
through SRF (Kuwahara et al, 2005;Brown et al, 2006).  This raises the question of the degree to 
which RhoA signalling contributes to the large changes in gene expression induced by ET-1 
(Cullingford et al, 2008), a question which is addressed in Chapter 4.  As discussed in Chapter 1 
(sections 1.5.2.2 and 1.6.2) several studies implicate RhoA in cardiac hypertrophy.  With this in mind, 
it is important to examine the regulation of RhoA expression (not just activation) in the 
cardiomyocytes.   
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Previous microarray studies failed to identify any significant increase in RhoA mRNA expression in 
response to ET-1 (Kennedy et al, 2006;Cullingford et al, 2008).  However, these studies focused only 
on changes in mRNA expression up to 4 h.  Here, I determined that there was some increase in RhoA 
mRNA expression at 4 h, but ET-1 significantly enhanced RhoA mRNA expression by 6 h (Fig. 
3.1A), a pattern of regulation that was reflected at the protein level (Fig. 3.4A).  Since both mRNA 
and protein were still increasing in abundance at the final time-point studied, this increase could 
continue and maximum levels of expression of RhoA mRNA and protein in response to ET-1 were 
almost certainly not reached.  Further studies over an extended time course would be useful.  Such 
changes in expression of RhoA over a prolonged period are in accord with the timescale of large 
cytoskeletal changes, such as myofibril formation and organisation, that RhoA signalling may regulate 
(Wang et al, 1997;Hoshijima et al, 1998).  It should be noted that, although RhoA protein expression 
is readily detected in cardiomyocytes and this increases in response to ET-1, this is not necessarily 
indicative of activated (i.e. GTP-bound) RhoA and further studies of the degree of activation of RhoA 
are necessary.  In contrast to ET-1, neither oxidative stress (Figs. 3.2C and 3.4B) nor IL-1β or TNFα 
(Fig. 3.3, C and D) altered RhoA mRNA/protein expression.   
 
3.4.2.  Expression and potential role of RhoB in cardiomyocytes 
 
Functionally, RhoB is most particularly associated with endosomes and protein trafficking (Ellis and 
Mellor, 2000;Ridley, 2006).  Upregulation of RhoB may therefore facilitate protein trafficking during 
cardiomyocyte remodelling.  In cardiomyocytes, previous microarray experiments identified changes 
in expression of RhoB mRNA in response to ET-1 or H2O2 (Clerk et al, 2007b;Cullingford et al, 
2008).  Here, using qPCR, maximal RhoB mRNA expression observed in response to ET-1 occurred 
at 30 min (~8-fold relative to control) and, in accordance with the previous data (Cullingford et al, 
2008), at 1 h RhoB mRNA expression had declined to ~4.5-fold relative to control (Fig. 3.1B).  
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Although, this is higher than that observed with the microarray data (~2.6-fold relative to controls at 1 
h), this is most likely due to the use of different techniques.  Both in this thesis and in related work 
(Cullingford et al, 2008), qPCR usually detects greater relative changes in expression than is detected 
with microarrays.  The rapid and transient upregulation in RhoB mRNA expression observed here is 
not only in accordance with data previously gathered through microarray experiments but, by 
investigating earlier time-points, has furthered our understanding of the response.  The early changes 
in RhoB mRNA expression induced in cardiomyocytes by H2O2 (2, 4, or 24 h) was also previously 
identified using microarrays (Clerk et al, 2007b).  Previously, at 2 h (the earliest time point studied), 
RhoB mRNA expression was ~2.1-fold whereas maximal expression of RhoB mRNA was detected at 
1 h by qPCR (~4.5-fold relative to controls) (Fig. 3.2A).  By 2 h, this reduced to ~2-fold relative to 
controls, consistent with the microarray data.  As with ET-1, the upregulation of RhoB mRNA in 
response to H2O2 was transient and the return to control levels was rapid.   
 
Basal levels of RhoB protein were readily detected in unstimulated cardiomyocytes (Fig. 3.4, C and 
D) in contrast to previous studies indicating that RhoB is not expressed in cardiomyocytes (Aoki et al, 
1998).  In the early phases of this project, I tried the antibody used by Aoki et al. (1998) but could not 
detect any bands.  The data obtained here were with an alternative antibody from a different supplier.  
Thus, the likely explanation for the discrepancy between the study by Aoki et al and this study is 
different sensitivities of the two antibodies.  However, the antibodies also recognise different epitopes 
of the protein.  The effective antibody was raised to residues near the C-terminus whereas the 
ineffective antibody targeted an N-terminal epitope.  The transient upregulation in RhoB mRNA 
expression induced by either ET-1 or H2O2 was reflected in similar increases in abundance of RhoB 
protein (Fig. 3.4, C and D).  Importantly, maximal upregulation of RhoB protein abundance occurred 
later (1.5–2 h) than maximal upregulation of the mRNA, presumably accounting for the time taken for 
protein translation. 
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There is considerable interest in the role of RhoB during vascular and cardiac development.  RhoB is 
activated in endocardial cells, and is required for their migration and cardiac valve formation (Combs 
and Yutzey, 2009).  Other studies suggest that RhoB may be involved in vesicle trafficking and in the 
regulation of PKB and cell survival (Adini et al, 2003).  In cancer cells, RhoB induces growth 
inhibition and apoptosis and in some cells it can suppress PKB activity (Prendergast and Oliff, 2000).  
In addition to its localisation to endosomes and possibly other cellular membranes (Ellis and Mellor, 
2000;Fernandez-Borja et al, 2005;Ridley, 2006), RhoB is also detected at the nucleus of PC12 cells, 
suggesting a possible role in trafficking to/from the nucleus (Zalcman et al, 1995).  Evidence such as 
this, albeit not from studies performed in cardiomyocytes, poses interesting questions regarding the 
rapid upregulation of RhoB observed here. 
 
3.4.3.  RhoC in cardiomyocytes 
 
RhoC is most commonly associated with melanoma cells where it is highly expressed and may 
enhance metastasis (Clark et al, 2000).  It is also widely implicated in cell locomotion (Wheeler and 
Ridley, 2004).  Although RhoC was identified at the same time as RhoA (Madaule and Axel, 1985), it 
has received less attention, possibly because of its extensive homology to RhoA and over-expression 
studies indicate that, like RhoA, it induces stress fibres in fibroblasts (Ridley, 2001).  RhoC may have 
arisen through incomplete duplication of RhoA and then evolved separately (Karnoub et al, 2004).  
Despite the similarity between RhoA, RhoB and RhoC (85% homology), some regulators and 
effectors preferentially interact with different proteins (Wheeler and Ridley, 2004).  Thus, although 
RhoC is structurally highly homologous to RhoA and RhoB, it may have different cellular functions.  
Nevertheless, especially within the cardiovascular field, RhoC is often grouped together with RhoA 
and RhoB, with the three proteins collectively referred to as Rho.   
 
Chapter 3 
Page | 108  
 
The previous microarray studies showed no significant change in expression of RhoC mRNAs in 
response to ET-1 or H2O2 (Clerk et al, 2007b;Cullingford et al, 2008).  This, and the lack of any 
significant modulation of RhoC mRNA levels by IL-1β or TNFα, was confirmed here using qPCR 
(Figs. 3.1C, 3.2D, 3.3G, 3.3H).  However, although not statistically significant, ET-1 did increase 
RhoC mRNA transcription gradually by 4-6 h (Fig. 3.1C).  Endogenous expression of RhoC protein in 
cardiomyocytes was easily detected by Western blotting (Fig. 3.4, E and F) and this was increased by 
4 h with ET-1 (Fig. 3.4E), consistent with the increase in mRNA expression.   
 
3.4.4.  Rnd1 and Rnd3 in cardiomyocytes 
 
Rnd1 and Rnd3 were identified as being upregulated in cardiomyocytes in response to ET-1 or H2O2 
(Clerk et al, 2007b;Cullingford et al, 2008).  Given that they are considered to be constitutively-active 
(Mellor et al, 1998;Wennerberg et al, 2003), their upregulation is potentially of great significance and 
requires further study.  Here, the changes in Rnd1 and Rnd3 mRNA expression were investigated in 
greater detail by qPCR.  ET-1 stimulated a large, transient, ~30-fold increase in Rnd1 mRNA levels 
within 90 min (Fig. 3.1D), with a significant ~2-fold increase in Rnd3 mRNA expression at 1 h (Fig. 
3.1E).  Although Rnd3 mRNA expression levels in these experiments are consistent with previous 
observations in microarray experiments (i.e. maximal upregulation at ~1 h), this was not the case for 
Rnd1 for which maximal expression was observed at 90 min rather than 4 h.  Furthermore, the level of 
Rnd1 upregulation observed in the qPCR experiment far exceeds that of the microarray study (~30-
fold vs ~5-fold).  As mentioned earlier, qPCR generally detects greater relative fold changes than 
microarrays.  The discrepancies (especially the time of maximal upregulation) could relate to 
expression of splice variants or simply reflect experimental differences.  The primers used in the 
qPCR were designed specifically to span one or more introns as compared with the microarray 
probeset which targets the 3‟ UTR.  Therefore, assessment of differentially-expressed alternatively-
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spliced variants may provide an explanation.  The upregulation in Rnd1 and Rnd3 mRNA abundance 
was also observed at the protein level.  ET-1 induced a sustained increase in Rnd1 protein abundance 
that continued to rise throughout the 6 h time course (Fig. 3.5A).  Although the change in protein 
expression was less dramatic than that of Rnd1 mRNA, the increase was clear and appeared unabated 
by 6 h.  Rnd3 protein levels also increased, but this was more rapid than for Rnd1.  For either Rnd1 or 
Rnd3, the protein was readily detected in unstimulated cardiomyocytes, an interesting observation 
given that they are considered to be constitutively-active and potentially antagonise RhoA activation 
(Riento et al, 2003;Wennerberg et al, 2003).   
 
With oxidative stress, the increase in the mRNA levels for Rnd1 was less pronounced but more 
sustained (Fig. 3.2B).  It was also very consistent with the microarray data (Clerk et al, 2007b).   
However, Rnd3 mRNA expression appeared unchanged by H2O2 (Fig. 3.2E), in contrast to the 
microarray data which detected an increase of ~1.84-fold (Clerk et al, 2007b).  The difference may 
reflect experimental variation or alternatively-spliced variants.  In response to H2O2, the protein 
abundance of Rnd1 and Rnd3 was also increased, consistent with the increase in mRNA expression 
(Figs. 3.5 B and D).  Rnd1 was the only Rho-family protein for which the mRNA was upregulated by 
both TNFα and IL-1β (Figs. 3.3, A and B).  IL-1β induced a more sustained response that continued to 
increase at 6 h whilst TNFα promoted a transient change in Rnd1 mRNA expression. 
 
Overall, changes in expression of either Rnd1 or Rnd3 are expected to antagonise RhoA function and 
therefore promote collapse of the actin cytoskeleton.  One can speculate that either Rnd1 or Rnd3 
might therefore play a role in cardiomyocyte remodelling during hypertrophy or apoptosis.   However, 
exposure of cardiomyocytes to any of the treatments described did not induce a global collapse of the 
cytoskeleton given that the cells remained adherent to the tissue culture dish [other cells "round up" 
(Chaves-Olarte et al, 1999)].  Any effect must therefore be relatively subtle and may be exerted on an 
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underlying actin cytoskeleton rather than the actin filaments in the myofibrillar apparatus.  Further 
characterisation of the non-sarcomeric actin cytoskeleton in cardiomyocytes [of which there is 
previous evidence (Chaponnier and Gabbiani, 2004)] may be necessary.    
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CHAPTER 4:  SIGNALLING THROUGH ERK1/2 VS RHOA IN REGULATING 
THE ET-1-RESPONSIVE CARDIOMYOCYTE TRANSCRIPTOME 
 
4.1.  Introduction 
 
ET-1 activates a complicated system of intracellular signalling which culminates in changes in gene 
expression and the development of a hypertrophic response (Bogoyevitch et al, 1994;Sugden, 
2003;Kennedy et al, 2006;Cullingford et al, 2008).  Although much is known of the signalling 
pathways activated by ET-1, less is known about the genes it regulates.  ET-1 potently activates the 
ERK1/2 cascade (Bogoyevitch et al, 1994;Clerk et al, 1994) and RhoA (Charron et al, 2001;Clerk et 
al, 2001) in cardiomyocytes, two pathways which are particularly associated with regulation of 
transcription (Clerk et al, 2007a).  ERK1/2 phosphorylate transcription factors [e.g. Elk1 (Murai and 
Treisman, 2002)] to modulate their activity and therefore regulate IEG expression.  RhoA is 
implicated in regulating cardiomyocyte gene expression by stimulation of actin "treadmilling" that 
leads to activation of Abra/STARS.  This promotes the translocation of MRTFs to the nucleus where 
they co-operate with SRF to promote gene expression (Pipes et al, 2006).  Exactly which genes are 
regulated by these individual signalling pathways and different transcription factors remains to be 
established.   
 
IEGs (i.e. genes which are regulated by changes in activity of existing transcription factors) encode 
"regulatory" proteins which directly influence cell function and "structural" proteins.  The former 
include transcription factors that modulate downstream gene expression and soluble mediators that 
stimulate further cycles of intracellular signalling.  Some IEGs are known, but it is thought that many 
remain to be identified.  It is probable that the important “regulatory” IEGs will be stimulus-specific 
Chapter 4 
Page | 112  
 
and cell type-specific.  They would be expected to have a dominant effect on downstream gene 
expression and changes in cell phenotype.  Immediate early “regulatory” genes presumably regulate 
downstream gene expression and feed into additional phases of gene expression which eventually 
culminate in the precise phenotypic changes.  However, although the significance for these initial 
stages of gene expression changes is great, these events are not well defined.   
 
By mapping the early transcriptional responses induced by ET-1 in cardiomyocytes (Cullingford et al, 
2008), it was established that a large proportion of the very early changes in IEG expression (within 
30 min - 1 h) require ERK1/2 or ERK5 signalling.  This was achieved using U0126, a selective 
inhibitor of MEK1/2 and MKK5 the upstream kinases for ERK1/2 and ERK5, respectively 
(Kamakura et al, 1999;Davies et al, 2000).  In the context of ET-1 stimulation of NRVMs, whilst 
many changes in expression of IEGs occur over the first 1-2 hours, possibly the greatest number of 
changes in gene expression occurs over 2 - 4 h (Kennedy et al, 2006;Cullingford et al, 2008).  
Importantly, U0126 also inhibits a large proportion of RNAs that were changed in response to 
stimulation with ET-1 during this later phase of gene expression (2 - 4 h) (Kennedy et al, 2006).  
However, the majority of the IEG response occurs at ~1 h (Cullingford et al, 2008) and the relative 
contribution of ERK1/2 vs RhoA at this early point is unknown. 
 
Here, I used small molecule inhibitors to establish the significance of ERK1/2 vs RhoA signalling in 
regulating the baseline and ET-1-responsive cardiomyocyte transcriptome.  I used PD184352 at 2 µM 
as a potent and selective inhibitor of MEK1/2 and therefore of the ERK1/2 cascade (Davies et al, 
2000).  The efficacy of PD184352 is high because it suppresses the activity of MEK1 and inhibits its 
activation by upstream kinases (Cohen, 1997b).  In comparison, I used C3 transferase (C3T) from 
Clostridium botulinum which inactivates only RhoA, RhoB and RhoC (Vogelsgesang et al, 2007).  A 
modified form was used in which highly purified C3T is linked to a cell penetrating moiety through a 
Chapter 4 
Page | 113  
 
disulfide bond that allows rapid uptake into cells.  In the cytoplasm, the disulfide bond is reduced and 
C3T diffuses throughout the cell.    
 
4.2.  Methods 
 
4.2.1.  Treatment of cardiomyocytes and assays for activated Rho-family proteins 
and phosphorylated MAPKs 
 
Cardiomyocytes were unstimulated (Controls), exposed to PD184352 (2 µM), C3T (1 or 5 µg/ml) or 
ET-1 (100 nM), or exposed to ET-1 following pre-treatment with PD184352 (10 min) or C3T (120 
min).  ET-1, PD184352 or C3T were added directly to the tissue culture medium.  Cells were also 
exposed to inhibitor alone for the full duration of the incubation time.  All samples were harvested 
together at the end of the experiment.  To study GTP-loading (i.e. activation) of RhoA, RhoB and 
RhoC, a GST-fusion protein was used containing the Rho-binding domain of murine rhotekin (GST-
RBD; see section 2.7.1).  Total protein extracts were used for the isolation of GTP-bound Rho protein 
which was analysed by immunoblotting using 12% (w/v) polyacrylamide gels (section 2.7.2).  Total 
and phosphorylated MAPKs were analyzed by Western blotting using 10% (w/v) polyacrylamide gels 
(section 2.6).  The bands were visualised by enhanced chemiluminescence.  Total MAPK and 
phospho-MAPK levels were quantified using ImageQuant 7.0 software.  Phospho-MAPK expression 
was normalised to the abundance of total MAPKs.  Similarly, levels of GTP-bound Rho proteins were 
normalised to the abundance of total Rho proteins in individual samples.  The values are expressed 
relative to controls.   
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4.2.2.  Immunostaining 
 
Cardiomyocytes were cultured on glass coverslips coated with gelatine [1% (w/v)] followed by 
laminin (20 µg/ml).  Following either no further treatments (control) or exposure to ET-1 or inhibitors 
alone, or to ET-1 in the presence of inhibitors, cells were washed three times with ice-cold PBS and 
fixed in 3.7% (v/v) formaldehyde in PBS (10 min, room temperature).  Cardiomyocytes were 
permeabilised with 0.1% (v/v) Triton X-100 in PBS (10 min, room temperature) and non-specific 
binding was inhibited with 1% (w/v) BSA in PBS containing 0.1% (v/v) Triton X-100 (10 min, room 
temperature).  All subsequent incubations were at 37ºC in a humidified chamber and coverslips were 
washed three times in PBS after each stage.  Cardiomyocytes were incubated with mouse monoclonal 
antibodies to troponin T (1/40, 60 min), then with anti-mouse immunoglobulin secondary antibodies 
coupled to Alexa-Fluor 488 (1/200, 60 min).  Coverslips were mounted using fluorescence mounting 
medium and viewed with a Zeiss Axioskop fluorescence microscope using a 100× oil-immersion 
objective.  Digital images captured using a Canon PowerShot G3 camera were converted to greyscale 
and reduced in size using Adobe Photoshop 7.0.   
 
4.2.3.  RNA preparation and microarray analysis 
 
Cardiomyocytes were unstimulated (Controls, 2 per preparation), exposed to ET-1 (1 h), PD184352 
(70 min) or C3T (3 h), or exposed to ET-1 (1 h) following pre-treatment with PD184352 (10 min) or 
C3T (2 h).  Total RNA was extracted using RNA Bee (section 2.8).  cDNA and labelled cRNA were 
prepared, and microarray analysis performed (section 2.10.2).  The data were archived with 
ArrayExpress (www.ebi.ac.uk/arrayexpress) under accession numbers E-MEXP-1977 and E-MEXP-
2516.  Data (.CEL files) were imported into GeneSpring 10.0.2 (Agilent Technologies) as tab-
delimited text files and were normalised using MAS5.  Normalisation per gene was to the two 
Chapter 4 
Page | 115  
 
corresponding controls within each sample set, generating a measure of relative fold change.   
Probesets were selected for analysis if present or marginal in all controls or all of any of the 
treatments, and filtered according to fold change (>1.5-fold) with any condition (ET-1, C3T, 
PD184352, C3T/ET-1 or PD184352/ET-1) relative to controls.  Probesets with statistically significant 
changes (false discovery rate, FDR<0.05) were identified by one-way ANOVA with Student-
Newman-Keuls (SNK) post test, applying a Benjamini and Hochberg multiple testing correction. 
Normally, when a p-value of 0.05 is determined, there is a 5% chance that the result is a false positive.  
While this is acceptable for a single test, if multiple tests on the data are conducted, this can result in 
too many false positives.  The FDR assigns an adjusted p-value to each test (i.e. reduces the p-value 
threshold) and thereby controls the number of false positives in the tests that result in a significant 
result.  In other words, a p-value of 0.05 means that 5% of all tests result in false positives but an FDR 
adjusted p-value of 0.05 means that 5% of significant tests will result in false positives. The latter is 
therefore a more stringent method of controlling for false positives. However, it is also less 
conservative than some other approaches (e.g. Bonferroni correction) and therefore has a greater 
ability to find truly significant results.  In the case of the microarray data, the FDR was applied to the 
entire grouped data and not on an individual gene basis.  Supervised clustering was then performed.  
RNAs were clustered according to >1.5-fold change with ET-1 (Group A), >1.5-fold change with 
PD184352 or PD184352/ET-1 (Group B), >1.5-fold change with C3T or C3T/ET-1 (Group C).  
Group A was clustered according to upregulation or downregulation with ET-1 and significant 
difference (inhibition or enhancement) for ET-1 vs PD184352/ET-1 or C3T/ET-1.  Groups B and C 
were clustered according to upregulation or downregulation with inhibitor alone or inhibitor plus ET-
1.    
 
Gene identities for all selected probesets were confirmed by BLAST search of the probeset sequences 
using the Entrez nucleotide database (www.ncbi.nlm.nih.gov/BLAST).  Further BLAST searches for 
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unassigned sequences were performed against the rat genome 
(www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=10116) and, since the rat genome 
is still less well annotated, the mouse genome 
(www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=10090; cross-species 
megaBLAST).  Genes were classified as far as possible using GeneOntology classifications associated 
with rat, mouse and human orthologs (NCBI Entrez Gene; www.ncbi.nlm.nih.gov/entrez), taking into 
account both probable Function and Process.  For genes with conflicting potential functions, further 
searches were performed using PubMed (www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed) to ascertain 
probable biochemical function.    
 
4.2.4.  Validation of microarray results by qPCR 
 
Total RNA was extracted and cDNAs synthesized as described in section 2.8.   Forward and reverse 
primers for Abra, Areg, Bmp2, Ereg, Slc25a25, Hbegf, SRF, IL-6, Klf4, Klf6, Klf15, Egr1, Egr2, 
Egr3, Egr4 and Inhba were designed for qPCR (Table 2.3).  qPCR was performed using absolute 
quantification with the standard curve protocol.  Values for selected RNAs were normalised to Gapdh 
expression and then to control values.    
 
4.2.5.  Statistical analysis 
 
Statistical analysis was performed using Graphpad Prism 4.  A one-way ANOVA with a multiple 
comparisons Tukey or Newman-Keuls post-test was conducted in order to establish the statistical 
significance of the effect of ET-1 relative to the unstimulated control.  Densitometric analysis and 
qPCR data are shown as means ± SEM (n = 3 or 4 independent myocyte preparations). 
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4.3.  Results 
 
4.3.1.  Selective inhibition of ERK1/2 signalling and RhoA signalling by PD184352 
and C3T 
 
Experiments were performed to confirm the efficacy and selectivity of the inhibitors.  The incubation 
times with ET-1 were selected according to the time at which individual signalling components are 
substantially activated: 30 s for RhoA.GTP loading (Clerk et al, 2001), 5 min for activation of 
ERK1/2 (Clerk et al, 1996) or p38-MAPKs (Clerk et al, 1998b), 15 min for activation of JNKs 
(Bogoyevitch et al, 1995a).  For inhibitor studies, cells were pre-treated with inhibitor for a minimum 
period required to provide adequate inhibition of the pathways (10 min for PD184352; 2 h for C3T) 
prior to addition of ET-1 for the appropriate times.  PD184352 (2 µM) inhibited baseline ERK1/2 
activity in control cells and entirely ablated the increase in ERK1/2 phosphorylation induced by ET-1 
(5 min) (Fig. 4.1A).  There was no effect of PD184352 on the baseline activities of p38-MAPKs or 
JNKs, or on the increase in activities induced by ET-1 (Fig. 4.1B).    
 
C3T (1 µg/ml) inhibited basal RhoA activation (GTP-loading) and the activation of RhoA induced by 
ET-1 (Fig. 4.2A).  At a higher concentration (5 µg/ml), C3T had a greater inhibitory effect on both 
basal RhoA.GTP levels and the increase in RhoA.GTP induced by ET-1.  The rate of migration of 
RhoA.GTP through the polyacrylamide gels was also reduced in the cells exposed to 5 µg/ml C3T.  
C3T (1 µg/ml) had no effect on the basal activities of ERK1/2, p38-MAPK or JNKs or on the increase 
in activities induced by ET-1 (Fig. 4.2B).  Although RhoB.GTP and RhoC.GTP were detected in the 
cardiomyocyte extracts, no increase in response to ET-1 was observed and C3T had no effect on basal 
levels in the affinity purification assay (Fig. 4.2C).  The effects of C3T may therefore be presumed to 
be largely mediated through RhoA.  Although RhoA modulates actin structures, 1 µg/ml C3T had no 
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overt effects on cardiomyocyte myofibrillar structure or on the increase in myofibrillar organisation 
induced by ET-1 (Fig. 4.3).  However, 5 µg/ml C3T caused some reduction in myofibrillar content 
with disruption of myofibrillar structure both in the basal state and following treatment with ET-1.  
Pre-treating cardiomyocytes with 1 µg/ml C3T for 2 h was adopted for all further experiments given 
that this was sufficient to inhibit RhoA.GTP in the absence of further modification of the protein (as 
indicated by reduced gel mobility) or disruption of cardiomyocyte structure. 
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Figure 4.1. Inhibition of ERK1/2 activation by PD184352.  Cardiomyocytes were unstimulated 
(Control) or exposed to 100 nM ET-1, 2 µM PD184352 or ET-1 in the presence of PD184352.  
Incubation times with ET-1 were 5 min for activation of ERK1/2 or p38-MAPK, or 15 min for 
activation of JNKs.  (A) Phosphorylated (upper panel) or total (centre panel) ERK1/2 were assessed 
by Western blotting.  Densitometric analysis is shown in the lower panel as means ± SEM (n = 5 
independent experiments).  *p<0.001 relative to control, #p<0.001 relative to ET-1 alone (one-way 
ANOVA with Tukey post-test). (B) Phosphorylated or total p38-MAPKs (upper blots) or JNKs (lower 
blots) were assessed by Western blotting.  The experiment was repeated with similar results. 
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Figure 4.2.  Inhibition of RhoA activation by C3T.  Cardiomyocytes were unstimulated (Control) or 
exposed to 100 nM ET-1, 1 or 5 µg/ml C3T (2 h pre-treatment) or ET-1 in the presence of C3T.  
Incubation times with ET-1 were 30 s (for activation of RhoA), 5 min (for activation of ERK1/2 or 
p38-MAPKs), or 15 min (for activation of JNKs). (A) Affinity purified RhoA.GTP (upper panel) and 
total RhoA (centre panel) were assessed by Western blotting.  Blots are representative of 4 
independent experiments.  Densitometric analysis is provided in the lower panels.  Results are means 
± SEM (n = 4). *p<0.01 relative to controls, #p<0.001 relative to ET-1 alone (one way ANOVA with 
Tukey post-test). (B) Phosphorylated or total ERK1/2 (upper blots), p38-MAPKs (centre blots) or 
JNKs (lower blots) were assessed by Western blotting.  The experiment was repeated with similar 
results. (C) Cardiomyocytes were exposed to ET-1 for the times indicated with or without pre-
treatment with C3T.  Affinity purified RhoB.GTP (upper image) and RhoC.GTP (lower image) were 
assessed by Western blotting.  The experiment was repeated with similar results.   
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Figure 4.3. Effects of different concentrations of C3T on cardiomyocyte cytoskeletal 
morphology. Cardiomyocytes were unstimulated (Control) or exposed to 100 nM ET-1 (24 h), 1 or 5 
µg/ml C3T (2 h pre-treatment) or ET-1 in the presence of C3T.  Cardiomyocytes were immunostained 
with antibodies to troponin T.  The experiment was repeated with similar results.   
 
 
4.3.2.  Regulation of cardiomyocyte RNA expression through the ERK1/2 or RhoA 
signalling pathways 
 
In order to compare the significance of ERK1/2 signalling vs RhoA signalling in regulating the early 
changes in RNA expression in cardiomyocytes exposed to ET-1, a microarray approach was 
employed.  Cardiomyocytes in culture were exposed to C3T (1 µg/ml, 3 h), PD184352 (2 µM, 70 
min) or ET-1 (100 nM, 1 h) alone, or either C3T or PD184352 with ET-1 together.  With regard to the 
latter two treatments, the cardiomyocytes were first pre-treated with either PD184352 (10 min) or C3T 
(2 h) before ET-1 was added without changing the tissue culture medium.  Transcriptional profiling 
was performed with Affymetrix Rat Genome 230 2.0 microarrays using Agilent GeneSpring software 
for analysis.  16285 probesets were detected in the cardiomyocyte transcriptome.  In some cases, this 
included multiple probesets for the same gene.  Of these 16285 probesets, 1323 RNAs were 
Control 1 μg/ml C3T 5 μg/ml C3T
ET-1 1 μg/ml C3T + ET-1 5 μg/ml C3T + ET-1
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significantly changed in one or more conditions (>1.5-fold change; FDR<0.05).  This means the RNA 
expression levels were upregulated or downregulated >1.5-fold relative to unstimulated cells in 
cardiomyocytes exposed to PD184352, C3T, or ET-1 alone, or to a combination of inhibitor and ET-1 
(i.e.  PD184352/ET-1 or C3T/ET-1).  By comparing the patterns of expression for these 1323 RNAs, 
the different RNAs were grouped or “clustered” according to their ET-1 response and the effects of 
PD184352 (Tables 4.1 – 4.6; Figs. 4.4 and 4.5) or C3T (Tables 4.7 – 4.13; Figs. 4.6 and 4.7) on the 
ET-1 response and on baseline RNA expression. 
 
4.3.2.1.  The effects of PD184352 on changes in cardiomyocyte RNA expression 
induced by ET-1 
 
Of the 1323 RNAs that were significantly changed in response to any condition, 273 were upregulated 
by ET-1 (1 h).  Of these, 83 RNAs were unaffected by PD184352 (Group I; Table 4.1 and Fig. 4.4A).  
Of the remaining 190 RNAs, the upregulation of 184 RNAs induced by ET-1 was inhibited by 
PD184352 (Group IIa; Table 4.2 and Fig. 4.4A) while the upregulation of only 6 RNAs was further 
enhanced following PD184352 treatment (Group IIb; Table 4.3 and Fig. 4.4A).  In contrast, 115 
RNAs were significantly downregulated in response to ET-1 (1 h).  Of these, the downregulation of 
69 was inhibited by PD184352 (Group IV; Table 4.4 and Fig. 4.4B).  For this group, the levels of 
RNA expression, having been downregulated by ET-1, remained at control levels when the ERK1/2 
cascade was inhibited by PD184352 (i.e. the effect of PD184352 was to alleviate the negative 
regulation of ET-1 on gene expression).   PD184352 had no significant effect on 46 RNAs that were 
downregulated in response to ET-1 and their levels of expression remained low in comparison to the 
untreated control cells (Group III; Table 4.5 and Fig 4.4B).   
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PD184352 had only a minor effect on baseline RNA expression in cardiomyocytes with few RNAs 
significantly upregulated or downregulated by PD184352 alone or (despite a negligible effect of ET-1 
alone) together with ET-1 (Groups Va/b and VIa/b; Table 4.6 and Figs. 4.5A and 4.5B).   Importantly, 
in either case, ET-1 alone had a negligible effect on RNA expression and therefore the alterations in 
RNA expression are attributed to action of the inhibitor.  In these clusters there were 28 RNAs 
upregulated and 38 RNAs which were downregulated by PD184352. 
 
By combining the numbers of RNAs that are either upregulated or downregulated in response to ET-1 
and which then have these changes in their expression further altered when pre-treated with 
PD184352, it is possible to establish the proportion of the ET-1 response that the ERK1/2 cascade 
regulates.  Thus, ERK1/2 signalling positively regulates ~67% of the early gene expression changes in 
response to ET-1 with a small (~2%) negative effect, and plays a minor role in regulating baseline 
gene expression. 
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Table 4.1. RNAs upregulated by ET-1 and unaffected by PD184352. Cardiomyocytes were 
unstimulated (Control) or exposed to ET-1 (100, 1 h), PD184352 (PD; 2 µM, 70 min) or ET-1 
following pre-treatment with PD184352 for 10 min (PD/ET-1). RNA profiles were assessed using 
microarrays. RNAs significantly upregulated by ET-1 were selected (>1.5-fold change, FDR<0.05) 
and those without significant inhibition or enhancement of the response with PD184352 identified 
(p<0.05 one-way ANOVA with SNK post-test).  Raw values are provided for Controls and expression 
relative to Controls is provided for PD, ET-1 and PD/ET-1 treatments.  Results are means for 4 
separate hybridisations.  For multiple probesets for the same RNA, individual raw values are provided 
for controls and, since the relative fold changes were similar, the mean values are provided for the 
treatments.  RNAs are listed alphabetically according to gene symbol. 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1379311_at, 
1380772_at, 
1397437_at 
Arid5a Transcription 407, 184, 273 1.09 2.03 1.78 
1390850_at AS: Adfp Potential AS sequences 100 1.44 2.23 1.32 
1398037_at AS: Plk2 Potential AS sequences 111 0.96 2.12 1.55 
1386062_at AS: Rnd3 Potential AS sequences 69 1.34 2.53 1.45 
1384659_at AS: Sfp295 Potential AS sequences 39 1.39 1.91 2.24 
1375538_at AS: Vcl Potential AS sequences 4828 1.27 1.70 1.54 
1369807_at Bdkrb1 Receptors 104 1.68 2.26 1.76 
1368050_at Ccnl1 Signalling 953 1.12 2.21 2.32 
1380063_at Ch25h Metabolism 590 0.42 8.86 10.94 
1389573_at Chac1 Channels/pumps/transporters 1060 1.25 2.55 2.36 
1389368_at Cnksr3 Not established 790 1.25 1.67 1.38 
1369737_at, 
1378925_at, 
1387714_at, 
1393550_at 
Crem Transcription 
114, 362, 116, 
99 
1.15 1.97 1.80 
1367631_at Ctgf Agonists 12573 0.80 1.90 1.95 
1368290_at Cyr61 Adhesion/ECM 711 0.74 9.32 9.45 
1372722_at Dnajb4 Protein synthesis/modification 1288 1.07 2.27 2.17 
1372385_at Dusp8 Signalling 387 1.16 1.52 1.88 
1385251_at Fam110c Cytoskeleton/myofibrillar 78 1.15 3.35 2.81 
1375043_at Fos Transcription 238 0.84 14.99 9.16 
1388792_at Gadd45g Signalling 1816 1.09 2.42 2.09 
1374903_at Gcnt2 Protein synthesis/modification 291 0.92 1.56 1.32 
1382351_at Gem Signalling 384 1.17 2.06 2.09 
1369113_at Grem1 Agonists 144 0.95 1.57 1.41 
1394022_at Id4 Transcription 654 1.02 1.63 1.67 
1388587_at Ier3 Signalling 5086 0.78 1.58 1.62 
1396539_at Intron:Actn1 Introns 247 0.93 5.63 4.23 
1391753_at Intron:Ankrd1 Introns 1012 0.40 1.82 1.43 
1394451_at Intron:Anxa1 Introns 432 0.96 2.81 2.22 
1392250_at Intron:Anxa2 Introns 96 1.13 2.07 1.39 
1397030_at Intron:Atp2b1 Introns 104 0.96 2.02 1.27 
1396834_at Intron:Braf Introns 79 1.44 1.52 1.45 
1390618_at Intron:Creb5a Introns 119 1.25 1.77 1.47 
1397449_at Intron:Enah Introns 378 0.69 1.97 1.75 
1391373_at Intron:Enah Introns 206 0.93 1.87 1.62 
1394750_at Intron:Fhl1 Introns 171 0.96 2.32 2.02 
1380230_at Intron:Gch Introns 57 1.08 1.86 2.18 
1382982_at Intron:Gnb1 Introns 200 0.99 1.67 1.37 
1381651_at Intron:March7 Introns 385 1.11 1.63 1.51 
1380311_at Intron:Ppp1r12a Introns 186 1.13 2.28 1.85 
1381430_at Intron:Rheb Introns 37 0.55 2.34 1.76 
1391215_at Intron:Samd4 Introns 227 0.94 1.85 1.68 
1380701_at Intron:Ssfa2 Introns 260 0.94 1.51 1.17 
1397115_at Intron:Tbc1d1 Introns 86 1.61 2.06 1.50 
1373623_at Itpkc Signalling 355 1.27 1.68 1.35 
1387260_at Klf4 Transcription 1339 1.13 3.42 2.98 
1376700_at Lima1 Cytoskeleton/myofibrillar 1391 0.97 1.72 1.76 
1381798_at Lmo7 Adhesion/ECM 747 0.88 1.51 1.22 
1371350_at,  Mat2a Metabolism 3636 1.03 1.80 1.65 
1367796_at Mgat1 Protein modification 1004 0.99 1.52 1.46 
1385028_at Mirhg1 Non-protein coding 108 0.94 1.95 1.48 
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Table 4.1.  (Continued) 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1374290_at, 
1396435_at 
Mirn143/145 Non-protein coding 338, 192 0.98 2.17 1.91 
1398020_at Mirn23b Non-protein coding 268 0.92 1.67 1.84 
1371692_at Mllt11 Not established 1539 0.92 1.54 1.17 
1371595_at, 
1397164_at 
Neat1 Non-protein-coding 2697, 771 0.99 2.17 2.01 
1368488_at Nfil3 Transcription 700 1.15 3.09 3.19 
1374767_at Npepo Protein synthesis/modification 1116 0.99 1.74 1.50 
1386935_at Nr4a1 Transcription 578 1.87 19.01 15.32 
1389918_at Palld Cytoskeleton/myofibrillar 847 0.99 2.04 1.48 
1385229_at Pcdh20 Adhesion/ECM 123 1.15 1.64 1.49 
1368303_at Per2 Transcription 295 1.17 1.80 1.47 
1369862_at Pim1 Signalling 88 1.15 1.78 1.37 
1376724_at Prkab2 Signalling 261 1.06 1.66 1.58 
1383322_at Rasl11b Signalling 1218 1.07 2.50 2.78 
1373989_at, 
1392688_at 
Rassf1 Signalling 696, 126 0.94 1.77 1.55 
1389258_at Rnf138 Protein synthesis/modification 268 0.92 1.51 1.19 
1382500_at, 
1391607_at 
Sesn2 Metabolism 673, 1034 1.05 1.56 1.46 
1387408_at Siah2 Protein synthesis/modification 182 1.14 1.88 1.45 
1372347_at Skil Transcription 2020 1.06 1.63 1.46 
1377404_at, 
1387623_at, 
1393559_at, 
1396101_at 
Stc1 Agonists 
1948, 389, 
1794, 1231 
0.91 1.51 1.82 
1367570_at Tagln Cytoskeleton/myofibrillar 3236 1.01 1.55 1.55 
1374529_at, 
1394109_at 
Thbs1 Adhesion/ECM 8617, 4256 0.90 3.14 2.62 
1383005_at Tmem49 Not established 730 0.77 1.65 1.43 
1373401_at Tnc Adhesion/ECM 933 1.19 2.49 1.73 
1369407_at Tnfrsf11b Receptors 1498 0.94 1.90 2.17 
1381070_at Tslp Agonists 171 0.92 1.50 1.45 
1384892_at Unknown Unknown 139 1.11 1.85 1.45 
1380223_at Unknown Unknown 58 1.50 1.63 1.19 
1398059_at Unknown Unknown 83 1.34 1.52 1.43 
1380399_at Unknown Unknown 220 0.97 1.51 0.99 
1397283_at Unknown Unknown 146 1.26 1.79 1.65 
1372905_at, 
1398476_at 
Vcl Cytoskeleton/myofibrillar 3414, 930 1.09 1.62 1.34 
1384709_at Vgll3 Transcription 167 0.90 1.50 1.42 
1395896_at Zfp295 Transcription 124 1.19 1.75 1.81 
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Table 4.2. RNAs upregulated by ET-1 and inhibited by PD184352. Cardiomyocytes were 
unstimulated (Control) or exposed to ET-1 (100 nM, 1 h), PD184352 (PD; 2 µM, 70 min) or ET-1 following 
pre-treatment with PD184352 for 10 min (PD/ET-1).  RNA profiles were assessed using microarrays. RNAs 
significantly upregulated by ET-1 were selected (>1.5-fold change, FDR<0.05) and those with significant 
inhibition of the response were identified (p<0.05 one-way ANOVA with SNK post-test).  Raw values are 
provided for Controls and expression relative to Controls is provided for PD, ET-1 and PD/ET-1 treatments.   
Results are means for 4 separate hybridisations. For multiple probesets for the same RNA, individual raw 
values are provided for controls and, since the relative fold changes were similar, the mean values are provided 
for the treatments.  RNAs are listed alphabetically according to gene symbol. 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1390881_at Abra Signalling 437 0.94 3.05 1.82 
1368223_at Adamts1 Protein synthesis/modification 1357 0.85 2.83 2.20 
1374610_at Agpat9 Metabolism 339 1.07 1.99 1.08 
1373843_at, 
1382206_a_at, 
1385566_at, 
1386764_at 
Akap2 Signalling 
4997, 902, 172, 
427 
0.98 1.87 1.27 
1372069_at Ankrd15 Signalling 1959 0.90 1.54 0.99 
1386065_at Ankrd57 Not established 329 0.80 2.56 1.33 
1367614_at Anxa1 Signalling 5199 1.03 1.99 1.35 
1387068_at Arc Not established 259 0.91 4.60 1.09 
1369871_at Areg Agonists 58 0.61 16.88 2.68 
1377750_at Arhgef3 Signalling 349 1.01 2.36 1.27 
1372964_at, 
1382312_at 
Arid5b Transcription 1656, 501 1.02 2.18 1.56 
1376275_at Arl5b Signalling 490 0.93 1.85 1.17 
1385961_at AS:Klf5 Potential AS 117 1.23 4.50 1.70 
1374429_at AS:Pim1 Potential AS 1386 1.27 2.27 1.64 
1382171_at AS:Tsc22d2 Potential AS 753 0.98 2.97 1.45 
1385870_at AS:Zfp281 Potential AS 59 0.92 2.29 1.24 
1395981_at Ascc3 RNA binding/processing 65 1.20 1.64 0.93 
1369268_at Atf3 Transcription 453 1.72 13.68 7.37 
1389402_at Axud1 Signalling 283 1.43 9.35 3.86 
1374433_at Bach1 Transcription 982 0.71 1.53 0.81 
1373494_at, 
1389465_at 
Bcr Signalling 899, 949 0.96 2.83 1.45 
1368677_at Bdnf Agonists 155 1.00 1.63 1.26 
1368945_at, 
1398270_at 
Bmp2 Agonists 142, 472 1.00 2.08 1.21 
1386994_at, 
1386995_at 
Btg2 Transcription 914, 1100 1.14 7.70 2.85 
1379935_at Ccl7 Agonists 4224 0.68 1.93 1.48 
1377869_at Ccrn4l Transcription 402 0.81 10.33 2.97 
1375910_at Cdc42ep3 Signalling 3695 0.82 1.79 1.27 
1367601_at, 
1367602_at 
Cited2 Transcription 2160, 2119 1.02 4.85 3.01 
1385827_at Clcf1 Agonists 58 0.45 2.07 0.93 
1373866_at Coq10b Metabolism 1303 1.14 2.88 2.20 
1390628_at, 
1396225_at 
Cpeb2 RNA binding/processing 603, 75 1.16 1.70 1.45 
1373525_at, 
1379666_at 
Dcun1d3 Not established 337, 293 0.92 1.80 1.15 
1388589_at Dot1l DNA regulation 687 1.06 2.57 1.52 
1368146_at, 
1368147_at 
Dusp1 Signalling 1884, 281 0.61 3.02 2.51 
1394028_at Dusp10 Signalling 192 1.00 1.94 0.97 
1388082_at, 
1393119_at 
Dusp4 Signalling 113, 1286 0.68 1.82 0.94 
1368124_at Dusp5 Signalling 473 0.57 5.02 0.90 
1377064_at, 
1387024_at 
Dusp6 Signalling 1211, 2234 0.06 2.87 0.18 
1369519_at Edn1 Agonists 293 0.94 1.51 1.10 
1368321_at Egr1 Transcription 4265 0.05 4.72 0.27 
1387306_a_at, 
1398266_a_at 
Egr2 Transcription 487, 157 0.27 7.04 0.98 
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Table 4.2.  (Continued). 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1369545_at, 
1392791_at 
Egr3 Transcription 222, 180 0.68 27.14 2.47 
1387442_at Egr4 Transcription 10 1.20 72.13 2.00 
1374143_at Epha2 Adhesion/ECM 351 0.40 1.75 0.67 
1369587_at, 
1385150_at 
Ereg Agonists 171, 132 1.14 3.52 1.66 
1373093_at Errfi1 Signalling 1544 0.74 7.28 2.72 
1369182_at F3 Receptors 151 0.96 5.59 3.08 
1377938_at Fam100a Not established 1045 0.94 1.59 1.22 
1383295_at Fam110a Not established 165 0.97 1.82 1.03 
1382059_at, 
1392747_at 
Fbxo30 Protein modification 488, 339 0.98 1.83 1.46 
1368336_at Fdx1 Metabolism 2218 1.02 2.09 1.12 
1388496_at Flnc Cytoskeleton/myofibrillar 2243 1.07 1.54 1.00 
1368489_at Fosl1 Transcription 303 0.81 5.65 1.36 
1370623_at, 
1383516_at, 
1386637_at, 
1392894_at 
Fgl2 Adhesion/ECM 
504, 305, 328, 
689 
1.06 1.95 1.26 
1373035_at, 
1387530_a_at 
Fosl2 Transcription 1556, 187 1.02 1.60 1.16 
1383222_at Frmd6 Not established 785 1.04 1.52 1.15 
1372750_at, 
1387843_at 
Fst Agonists 454, 358 0.87 4.18 1.30 
1373513_at, 
1387221_at 
Gch Metabolism 175, 276 0.96 1.93 1.74 
1370688_at, 
1372523_at 
Gclc Metabolism 942, 1155 0.97 1.58 0.97 
1387548_at Has2 Adhesion/ECM 440 0.84 7.38 3.27 
1368983_at Hbegf Agonists 481 0.99 2.86 1.32 
1383519_at Hk2 Metabolism 945 0.86 1.57 0.97 
1375852_at Hmgcr Metabolism 1982 0.87 1.77 1.33 
1370454_at, 
1370997_at 
Homer1 Receptors 172, 38 1.00 5.24 1.26 
1368247_at, 
1370912_at 
Hspa1a/1b Protein folding 335, 432 1.16 3.17 2.48 
1387202_at Icam1 Adhesion/ECM 2088 0.84 2.50 1.62 
1368878_at, 
1388872_at 
Idi1 Metabolism 4209, 2059 0.94 1.68 1.25 
1372389_at Ier2 Signalling 684 0.65 3.57 1.00 
1389355_at, 
1389882_at 
Ier5 Not established 2153, 116 0.84 4.16 1.87 
1367795_at Ifrd1 Transcription 1242 1.00 5.31 2.12 
1370692_at, 
1387273_at 
Il1rl1 Receptors 170, 1127 0.98 2.63 1.16 
1369191_at Il6 Agonists 131 0.93 12.87 7.10 
1369012_at, 
1383486_at 
Inhba Agonists 265, 212 0.73 5.08 1.93 
1367894_at Insig1 Metabolism 5314 0.93 1.56 1.08 
1379543_at Intron:Arhgap10 Introns 42 0.94 2.01 0.84 
1380195_at Intron:Atp2b1 Introns 317 1.01 1.59 1.09 
1381864_at Intron:Cacna2d1 Introns 72 1.16 2.38 1.52 
1390723_at Intron:Ctnna1 Introns 243 0.79 2.71 1.09 
1375475_at Intron:Dusp5 Introns 116 0.84 5.80 0.46 
1397223_at Intron:Fgd6 Introns 80 1.22 1.51 1.09 
1379106_at Intron:Fgrf1 Introns 145 0.91 2.00 0.93 
1381343_at Intron:Frmd6 Introns 218 1.10 1.61 1.06 
1385757_at Intron:Homer1 Introns 280 1.12 1.71 1.15 
1390671_at Intron:Igf1r Introns 179 0.89 1.73 1.25 
1378489_at, 
1383828_at 
Intron:Klf14 Introns 88, 89 1.02 4.06 1.00 
1396877_at Intron:Lamc1 Introns 522 0.65 2.38 1.39 
1379089_at Intron:Myh9 Introns 501 0.94 2.34 1.91 
1397112_at Intron:Pctk2 Introns 170 0.87 2.04 1.15 
1393782_at Intron:Plagl1 Introns 66 0.76 3.31 0.75 
1379477_at Intron:Pdcd6ip Introns 144 1.13 2.00 1.37 
1381253_at Intron:Slc12a2 Introns 140 1.14 2.12 1.61 
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Table 4.2.  (Continued). 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1375490_at, 
1377212_at 
Intron:Stard13 Introns 156, 116 0.88 1.62 0.94 
1378447_at Intron:Thrap1 Introns 181 0.87 3.74 1.05 
1382036_at Intron:Tln1 Introns 274 0.85 1.88 1.23 
1398691_at Intron:Tsc22d2 Introns 92 0.96 5.38 1.95 
1371091_at Irs2 Signalling 888 0.63 2.20 1.41 
1385649_at Itga5 Adhesion/ECM 955 1.06 1.53 1.16 
1387788_at Junb Transcription 1447 0.98 1.76 1.31 
1368363_at, 
1394039_at 
Klf5 Transcription 363, 320 1.16 2.89 1.37 
1387060_at, 
1388986_at, 
1395557_at 
Klf6 Transcription 
1085, 1896, 
592 
0.66 4.33 3.29 
1393728_at Lif Agonists 333 0.64 9.73 1.46 
1376632_at Lmcd1 Transcription 1063 1.09 2.81 1.69 
1377610_at Lmod2 Cytoskeleton/myofibrillar 2287 1.09 2.61 1.80 
1380229_at Maff Transcription 289 0.89 2.22 1.28 
1372211_at Mafk Transcription 845 0.78 1.77 1.17 
1372520_at, 
1373225_at 
Mcl1 Signalling 4775, 2687 0.86 1.58 0.98 
1383288_at, 
1384427_at 
Mdm2 Protein modification 1362, 717 1.04 1.80 1.20 
1378867_at Mirn221/222 Non-protein coding 85 0.62 11.42 0.92 
1382017_at Mirn322/503 Non-protein coding 270 0.99 1.55 1.11 
1391643_at Mirn224-2/27a/23a Non-protein coding 1163 0.66 2.63 1.01 
1372904_at, 
1384900_at 
Mobkl2b Signalling 724, 246 0.96 1.70 1.31 
1368308_at Myc Transcription 648 0.51 3.89 1.39 
1370174_at Myd116 Not established 1424 0.97 2.26 1.89 
1378032_at Nfkbiz Transcription 1216 1.05 3.30 2.47 
1369007_at Nr4a2 Transcription 128, 13 1.20 18.05 8.32 
1369067_at, 
1393389_at 
Nr4a3 Transcription 126, 119 1.76 24.68 9.24 
1368683_at Oldlr1 Receptors 1712 0.88 1.86 1.47 
1384254_at Otud1 Protein modification 1396 0.86 5.93 2.59 
1383224_at Pard6b Adhesion/ECM 232 1.22 3.25 1.08 
1385116_at Pcdhb21 Adhesion/ECM 57 1.07 1.50 1.08 
1390814_at, 
1399081_at 
Peli1 Not established 910, 537 0.94 2.01 1.71 
1368860_at Phlda1 Signalling 250 0.25 5.63 0.72 
1396561_x_at Piga Metabolism 73 1.18 1.51 1.10 
1387269_s_at Plaur Receptors 452 0.83 2.45 1.07 
1368106_at Plk2 Signalling 2462 0.70 3.97 2.39 
1369029_at Plscr1 Metabolism 554 0.80 1.56 1.04 
1367841_a_at Prl8a9 Agonists 52 0.96 2.33 0.80 
1368527_at Ptgs2 Metabolism 421 0.92 18.06 6.18 
1370193_at Ptp4a1 Signalling 3227 0.96 1.54 1.15 
1370177_at PVR Receptors 1029 0.78 2.14 1.26 
1373730_at Rbm33 RNA binding/processing 548 1.08 1.50 1.10 
1379714_at, 
1381341_at 
rCG_43687 Not established 116, 145 1.09 4.05 1.30 
1373679_at RGD1306119 Not established 469 1.01 1.90 0.83 
1388945_at RGD1311307 Not established 457 0.92 1.92 1.16 
1383001_at, 
1383874_at, 
1394278_at 
RGD1560812 Not established 236, 333, 287 1.00 3.13 1.07 
1368144_at, 
1387074_at 
Rgs2 Signalling 955, 1566 0.79 6.79 3.24 
1394527_at Ripk2 Signalling 163 1.03 1.54 0.92 
1381279_at Ripk2 Signalling 623 0.93 2.55 1.11 
1381533_at Rnd1 Signalling 1217 1.14 2.89 1.78 
1376066_at, 
1377663_at, 
1394077_at 
Rnd3 Signalling 
1253, 1516, 
757 
0.81 1.79 1.06 
1371774_at Sat Metabolism 3921 1.06 2.31 1.41 
1368487_at Serpinb2 Protein synthesis/modification 268 1.19 23.75 3.09 
1368519_at,  Serpine1 Protein synthesis/modification 377, 163 0.93 18.58 10.51 
1372417_at Sertad1 Transcription 938 1.07 1.85 1.24 
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Table 4.2.  (Continued). 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1368519_at, 
1392264_s_at 
Serpine1 Protein synthesis/modification 377, 163 0.93 18.58 10.51 
1372417_at Sertad1 Transcription 938 1.07 1.85 1.24 
1367802_at Sgk Signalling 1619 0.79 2.85 0.95 
1367853_at Slc12a2 Channels/pumps/transporters 966 1.00 1.60 1.19 
1370314_at Slc20a1 Channels/pumps/transporters 2408 0.86 1.58 1.15 
1371754_at Slc25a25 Channels/pumps/transporters 290 0.84 5.05 3.58 
1368596_at Snf1lk Signalling 467 0.94 2.31 1.26 
1374864_at Spry2 Signalling 1266 0.33 3.03 0.86 
1374829_at, 
1388842_at 
Srf Transcription 429, 2731 0.91 1.85 1.43 
1372510_at, 
1384331_at 
Srxn1 Metabolism 750, 464 0.96 4.82 1.27 
1377340_at Tfpi2 Protein synthesis/modification 287 0.66 2.23 1.01 
1367859_at Tgfb3 Agonists 1096 0.87 1.59 1.12 
1368901_at, 
1375951_at 
Thbd Receptors 99, 217 0.94 2.20 1.08 
372926_at, 
1375138_at, 
1389836_a_at 
Timp3 Protein synthesis/modification 
553, 1691, 
2370 
0.94 1.55 1.28 
1374446_at, 
1385407_at 
Tiparp Protein synthesis/modification 2268, 1314 0.87 1.64 1.19 
1385641_at Tnfaip3 Transcription 1045 0.93 3.08 1.46 
1371194_at Tnfaip6 Adhesion/ECM 723 1.18 4.39 3.26 
1371785_at Tnfrsf12a Receptors 4417 1.01 2.12 1.40 
1371019_at Trib1 Signalling 526 0.71 2.14 0.92 
1384163_at Trp53inp1 Signalling 1560 0.95 1.54 1.19 
1375031_at Ttn Cytoskeleton/myofibrillar 338 1.13 1.56 1.04 
1378165_at, 
1387750_at 
Twist1 Transcription 445, 103 0.90 3.83 1.00 
1379910_at Uap1 Metabolism 1091 0.92 2.87 1.35 
1390248_at Unknown Unknown 132 1.19 1.59 1.05 
1395119_at Unknown Unknown 281 0.95 1.70 0.95 
1395168_at Unknown Unknown 140 1.13 1.56 1.15 
1376403_at Unknown Unknown 199 1.05 2.84 1.23 
1378754_at Unknown Unknown 429 1.21 2.12 1.51 
1392108_at Unknown Unknown 94 1.11 3.39 1.88 
1373651_at Unknown Unknown 425 0.64 1.95 0.95 
1379584_at Unknown Unknown 259 0.61 1.86 1.06 
1385578_at Utp14b RNA binding/processing 180 1.27 1.78 1.16 
1377778_at Vof16 Not established 302 0.87 3.17 1.28 
1389119_at Xirp1 Cytoskeleton/myofibrillar 2408 0.88 1.82 0.98 
1373767_at Zfand2a Not established 746 0.96 1.62 1.01 
1375130_at, 
1383905_at, 
1388868_at 
Zfand5 Transcription 657, 469, 3626 0.99 1.81 1.18 
1382642_at, 
1385869_at 
Zfp281 Transcription 1054, 977 0.79 2.45 1.32 
1387870_at Zfp36 RNA binding/processing 1447 0.90 2.86 1.76 
1373106_at Zfp36l2 RNA binding/processing 1966 1.17 1.78 1.23 
1373680_at Znf697 Transcription 343 0.86 2.35 1.11 
1388130_at Zyx Cytoskeleton/myofibrillar 5625 0.96 1.56 1.27 
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Table 4.3. RNAs upregulated by ET-1 and enhanced by PD184352. Cardiomyocytes were 
unstimulated (Control) or exposed to ET-1 (100 nM, 1 h), PD184352 (PD; 2 µM, 70 min) or ET-1 following 
pre-treatment with PD184352 for 10 min (PD/ET-1).  RNA profiles were assessed using microarrays. RNAs 
significantly upregulated by ET-1 were selected (>1.5-fold change, FDR<0.05) and those with significant 
enhancement of the response were identified (p<0.05 one-way ANOVA with SNK post-test).  Raw values are 
provided for Controls and expression relative to Controls is provided for PD, ET-1 and PD/ET-1 treatments. 
Results are means for 4 separate hybridisations.  For multiple probesets for the same RNA, individual raw 
values are provided for controls and, since the relative fold changes were similar, the mean values are provided 
for the treatments.  RNAs are listed alphabetically according to gene symbol. 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1369788_s_at, 
1374404_at, 
1389528_s_at 
Jun Transcription 853, 511, 1429 1.29 2.77 5.38 
1375248_at, 
1376569_at, 
1386041_a_at, 
1394068_x_at 
Klf2 Transcription 
812, 648, 134, 
210 
1.76 2.66 5.91 
1373403_at LOC684871 Not established 92 2.93 3.30 5.03 
1376937_at RGD1565927 Not established 1083 1.00 1.77 2.40 
1369958_at Rhob Signalling 2621 1.30 2.89 4.14 
1370287_a_at, 
1379936_at, 
1395794_at 
Tpm1 Cytoskeleton/myofibrillar 
2294, 2137, 
1431 
1.04 1.53 1.79 
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Figure 4.4. Regulation of ET-1-responsive 
RNA expression through the ERK1/2 
cascade. Cardiomyocytes were unstimulated 
(Control) or exposed to ET-1, PD184352 (PD) 
or ET-1 together with PD184352 (PD/ET-1).  
Changes in RNA expression were determined 
using GeneSpring analysis to identify 
transcripts with significant changes in 
expression (>1.5-fold) with or without a 
significant effect of the inhibitor (one-way 
ANOVA with Newman-Keuls post-test and 
Benjamini-Hochberg false discovery rate correction). (A) Upregulated by ET-1 with no effect (Group 
I), inhibition (Group IIa) or enhancement by PD184352 (Group IIb). (B) Downregulated by ET-1 with 
no effect (Group III) or inhibition by PD184352 (Group IV).  Heatmaps represent all probesets in each 
group [Log2 scale; -2.5 (cyan) through 0 (black) to 2.5 (red)]. Histograms are means ± SEM (numbers 
of transcripts in parentheses). Statistical analysis of each group was performed: *p<0.001, **p<0.05 
relative to Control; #p<0.001, relative to ET-1 alone (one-way ANOVA with Newman-Keuls post-
test). 
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Table 4.4. RNAs downregulated by ET-1 and inhibited by PD184352.  Cardiomyocytes were 
unstimulated (Control) or exposed to ET-1, PD184352 or ET-1 following pre-treatment with PD184352 for 
(PD/ET-1).   RNA profiles were assessed using microarrays.   RNAs significantly downregulated by ET-1 were 
selected (>1.5-fold change, FDR<0.05) and those with significant inhibition of the response were identified 
(p<0.05 one-way ANOVA with SNK post-test).   Raw values are provided for Controls and expression relative 
to Controls is provided for PD, ET-1 and PD/ET-1 treatments.   Results are means for 4 separate hybridisations.   
For multiple probesets for the same RNA, individual raw values are provided for controls and, since the relative 
fold changes were similar, the mean values are provided for the treatments.  RNAs are listed alphabetically 
according to gene symbol. 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1390931_at Adamts15 Protein synthesis/modification 1070 1.17 0.54 0.67 
1383848_at Adrb1 Receptors 627 1.02 0.44 0.66 
1389264_at Ankrd54 Not established 376 0.86 0.57 0.83 
1373287_at Atoh8 Transcription 863 1.25 0.43 0.88 
1370823_at Bambi Receptors 960 1.33 0.62 1.00 
1385627_at, 
1398482_at 
Bcl3 Transcription 652, 503 1.29 0.48 0.61 
1384214_a_at Ccnt2 Transcription 211 0.92 0.54 0.93 
1368813_at, 
1387343_at 
Cebpd Transcription 1479, 2974 0.79 0.42 0.92 
1368025_at Ddit4 Signalling 1910 1.34 0.30 0.76 
1376612_at Dtwd1 Not established 252 1.10 0.65 0.93 
1373114_at Dtx4 Signalling 1566 0.95 0.65 0.75 
1393058_at Eid2 Transcription 490 0.97 0.62 0.93 
1374530_at Fzd7 Receptors 339 1.06 0.66 0.98 
1374234_at Hkr3 Transcription 246 1.01 0.66 0.88 
1389675_at, 
1391026_at 
Ier5l Not established 999, 1430 1.29 0.32 0.45 
1378945_at Intron:Aco2 Introns 241 0.86 0.58 0.84 
1396420_at Intron:Baz1b Introns 170 0.93 0.64 1.02 
1385506_at Intron:Cdon Introns 298 1.32 0.58 0.81 
1392650_at Intron:Csnk2a1 Introns 320 0.99 0.63 0.86 
1398560_at Intron:Dscr1l1 Introns 145 1.01 0.41 0.80 
1376522_at Intron:Fabp3 Introns 318 1.20 0.46 0.76 
1393540_at Intron:Myh6 Introns 512 0.96 0.62 0.78 
1393406_at Intron:Rbx1 Introns 311 0.96 0.65 0.95 
1392317_at Intron:Scl33a1 Introns 121 1.03 0.49 0.76 
1368073_at Irf1 Transcription 907 1.12 0.41 0.72 
1368249_at, 
1381396_s_at 
Klf15 Transcription 931, 288 1.01 0.40 0.76 
1378332_at, 
1389479_at, 
1393150_at 
Klf3 Transcription 
1254, 1744, 
1242 
0.98 0.60 0.82 
1381065_at LOC499120 Not established 670 0.92 0.64 1.02 
1381267_at LOC691468 Not established 138 0.92 0.57 1.00 
1372060_at Lysmd4 Not established 413 0.90 0.56 0.70 
1376718_at Mblac1 Not established 499 0.97 0.61 1.00 
1396481_at Mirn1-2/-133a-1 Non-protein coding 75 0.47 0.34 1.28 
1388525_at Pik3ip1 Signalling 1024 1.26 0.53 0.75 
1378484_at Rasl12 Signalling 684 0.92 0.58 0.76 
1385253_at RGD1304610 Not established 173 1.07 0.64 0.95 
1374364_at RGD1562335 Not established 392 0.98 0.51 0.77 
1374756_at RGD1562665 Not established 181 1.05 0.35 0.84 
1390249_at Sept14 Signalling 503 0.87 0.65 0.91 
1375121_at, 
1394025_at 
Smad6 Transcription 944, 650 1.06 0.63 0.97 
1393262_at Smad9 Transcription 454 1.12 0.65 1.02 
1373219_at Snai1 Transcription 1379 1.05 0.27 0.37 
1397220_at Snhg7 Non-protein-coding 657 0.93 0.64 0.99 
1372633_at Spg20 Trafficking 684 0.97 0.64 0.81 
1390215_at Ston2 Trafficking 127 1.20 0.64 1.02 
1383282_at Thap11 DNA regulation 566 1.08 0.65 0.94 
1390928_at Tigd2 DNA regulation 267 0.87 0.41 0.79 
1391027_at Trim65 Not established 370 0.90 0.58 0.81 
1371131_a_at Txnip Transcription 5283 1.31 0.65 0.77 
1389419_at Unknown Unknown 576 0.87 0.55 0.90 
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Table 4.4.  (Continued) 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1389714_at Unknown Unknown 201 0.91 0.65 0.85 
1381619_at Unknown Unknown 131 1.06 0.38 0.91 
1383977_a_at Unknown Unknown 152 1.05 0.37 0.71 
1389084_at Unknown Unknown 377 0.99 0.47 0.67 
1378117_at Unknown Unknown 317 1.17 0.64 0.94 
1393512_at Unknown Unknown 192 1.15 0.63 0.85 
1383058_at Unknown Unknown 2498 1.29 0.45 0.83 
1391863_at Unknown Unknown 348 1.30 0.18 0.56 
1380914_at, 
1393652_at 
Zbtb1 Transcription 209, 534 1.04 0.64 0.87 
1377154_at Zfp157 Transcription 251 1.04 0.58 0.80 
1372205_at Zfp278 Transcription 417 1.12 0.66 0.88 
1393438_at Zfp316 Transcription 203 1.20 0.62 0.93 
1370984_at Zfp46 Transcription 660 1.23 0.66 0.85 
1386793_at Zfp61 Transcription 183 1.16 0.42 0.79 
1381282_at Zfp768 Transcription 277 1.04 0.64 0.88 
1386633_at Zfp869 Transcription 276 0.89 0.60 0.89 
1385597_at Znf124 Transcription 83 1.24 0.39 0.68 
1389366_at Znf553 Transcription 432 1.06 0.51 0.75 
1372699_at Znf775 Transcription 201 0.97 0.54 0.74 
1384432_at Zscan12 Transcription 199 1.07 0.62 0.89 
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Table 4.5.  RNAs downregulated by ET-1 and not affected by PD184352.   Cardiomyocytes were 
unstimulated (Control) or exposed to ET-1, PD184352 or ET-1 following pre-treatment with PD184352 
(PD/ET-1).   RNA profiles were assessed using microarrays.  RNAs significantly downregulated by ET-1 were 
selected (>1.5-fold change, FDR<0.05) and those without significant change of the response were identified 
(p<0.05 one-way ANOVA with SNK post-test).   Raw values are provided for Controls and expression relative 
to Controls is provided for PD, ET-1 and PD/ET-1 treatments.   Results are means for 4 separate hybridisations.   
For multiple probesets for the same RNA, individual raw values are provided for controls and, since the relative 
fold changes were similar, the mean values are provided for the treatments.  RNAs are listed alphabetically 
according to gene symbol. 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
1390974_a_at Adat2 RNA binding/processing 392 0.85 0.61 0.88 
1381153_at Anapc4 Protein synthesis/modification 284 0.86 0.58 0.78 
1374493_at Bmf Signalling 424 1.17 0.63 0.71 
1389145_at Cdc42ep2 Signalling 635 0.91 0.61 0.70 
1390024_at Clec2d/g Receptors 1686 0.81 0.64 0.61 
1398710_at Cyp2u1 Metabolism 427 0.95 0.58 0.73 
1383205_at Dact2 Not established 186 1.15 0.66 0.76 
1391741_a_at Fam78a Not established 338 0.94 0.63 0.73 
1390995_at Fkbpl Protein synthesis/modification 316 1.08 0.65 0.79 
1389404_at Foxs1 Transcription 553 0.58 0.54 0.58 
1389871_at Got2 Metabolism 91 0.90 0.63 0.90 
1387036_at Hes1 Transcription 1576 1.12 0.58 0.54 
1387028_a_at Id1 Transcription 3595 0.84 0.61 0.64 
1380168_at Intron:Etv4 Introns 140 0.64 0.66 0.75 
1391171_at Intron:Itm2b Introns 303 1.18 0.59 0.63 
1392578_at Intron:Mgp Introns 626 0.49 0.21 0.10 
1397165_at Intron:Smarca2 Introns 148 0.77 0.62 0.63 
1374786_at Intron:Tia1 Introns 151 1.08 0.49 0.74 
1390776_at, 
1394251_x_at 
Irx3 Transcription 1232, 566 0.49 0.66 0.48 
1390969_at Kcne4 Channels/pumps/transporters 1275 0.92 0.62 0.74 
1389988_at Kctd2 Channels/pumps/transporters 989 0.93 0.67 0.79 
1385431_at LOC688018 Signalling 250 0.78 0.63 0.78 
1374693_at Parp16 Metabolism 459 0.95 0.55 0.63 
1384262_at Ppp1r3b Signalling 487 0.90 0.49 0.62 
1384937_at Rbak Transcription 112 1.32 0.53 0.76 
1380314_at RGD1563072 Not established 280 0.99 0.66 0.85 
1392170_at Rwdd3 Not established 180 0.91 0.66 0.74 
1367920_at S1pr2 Receptors 622 0.90 0.61 0.70 
1397522_at Sbf1 Signalling 315 0.76 0.65 0.62 
1383589_at Snai2 Transcription 515 1.16 0.62 0.84 
1369584_at, 
1377092_at 
Socs3 Signalling 732, 2404 1.05 0.56 0.67 
1388786_at Synpo Cytoskeleton/myofibrillar 2163 0.99 0.66 0.75 
1393153_at Tardbp RNA binding/processing 234 1.17 0.66 0.90 
1397692_at Tia1 Protein synthesis/modification 133 1.02 0.52 0.73 
1393649_at Tmpo Transcription 102 1.19 0.55 0.62 
1397527_at Trim47 Not established 784 0.89 0.54 0.74 
1378547_at Unknown Unknown 437 1.00 0.66 0.79 
1377629_at Unknown Unknown 380 1.01 0.65 0.77 
1379454_at Unknown Unknown 150 1.10 0.65 0.77 
1383919_at Unknown Unknown 154 0.81 0.64 0.74 
1381077_at Unknown Unknown 176 0.91 0.63 0.79 
1392605_at Unknown Unknown 181 0.94 0.62 0.88 
1378367_at Unknown Unknown 143 1.43 0.61 0.77 
1377045_at Unknown Unknown 286 0.88 0.58 0.59 
1376358_at Unknown Unknown 98 1.19 0.45 0.76 
1391507_at Znf467 Transcription 385 1.06 0.60 0.62 
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Table 4.6. RNAs regulated in cardiomyocytes by PD184352 alone or in the presence of ET-1.   
Cardiomyocytes were unstimulated (Control) or exposed to ET-1, PD184352 or ET-1 with pretreatment with 
PD184352 (PD/ET-1).   RNA profiles were assessed using microarrays.  RNAs not regulated by ET-1 alone but 
significantly regulated by PD or PD/ET-1 were selected (>1.5-fold change, FDR<0.05) and clustered.   Raw 
values are provided for Controls.  Expression relative to controls is provided for PD, ET-1 and PD/ET-1 
treatments.   Results are means for 4 separate hybridisations.   For multiple probesets for of the same RNA, 
individual raw values are provided for controls and, since the relative fold changes were similar, the mean 
values are provided for the treatments.  RNAs in each group are listed alphabetically according to gene symbol. 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
PD184352 upregulation of baseline RNA expression     
1382413_at AS:Nup155 Potential AS 63 1.66 1.13 1.14 
1385706_at AS:Tes Potential AS 77 1.53 1.41 1.19 
1387713_a_at Fcer1a Receptors 57 1.51 1.17 0.89 
1372016_at Gadd45b Signalling 618 1.64 1.37 1.88 
1396919_at Intron:Prkwnk1 Introns 42 2.10 1.44 1.40 
1385177_at Intron:Sorbs1 Introns 100 1.51 1.50 1.29 
1379914_at Klf11 Transcriptional regulation 391 1.78 0.76 1.49 
1378074_at Pdk4 Regulation of metabolism 330 1.62 0.99 1.01 
1381497_at Unknown Unknown 30 2.42 1.70 1.58 
1380925_at Unknown Unknown 66 1.73 0.87 1.33 
1383029_at Unknown Unknown 43 1.73 1.41 1.01 
1396637_at Unknown Unknown 69 1.64 1.36 1.08 
PD184352 downregulation of baseline RNA expression     
1382778_at AS:Dusp6 Potential AS 567 0.03 2.07 0.12 
1369415_at Bhlhb2 Transcriptional regulation 1247 0.63 1.06 0.69 
1369815_at Ccl3 Agonists 939 0.65 0.97 0.62 
1369529_at Csf3 Agonists 152 0.37 0.72 1.07 
1387316_at Cxcl1 Agonists 6292 0.64 1.40 1.01 
1368760_at Cxcl2 Agonists 576 0.48 1.31 0.58 
1389894_at Dlc1 Signalling 210 0.55 0.80 0.76 
1379790_at Dll4 Agonists 435 0.55 0.95 0.67 
1387270_at Hhex Transcriptional regulation 283 0.46 0.84 0.48 
1368592_at, 
1371170_a_at 
Il1a Agonists 371, 283 0.65 0.98 0.54 
1392024_at Intron:Spred1 Introns 128 0.43 1.08 0.66 
1376648_at Mycn Transcriptional regulation 356 0.64 0.83 0.81 
1382138_at Nrarp Not established 323 0.60 1.05 0.59 
1398287_at Plau Protein synthesis/modification 323 0.64 0.92 0.65 
1393638_at Ptger4 Receptors 632 0.48 1.05 0.75 
1373777_at Rgs16 Signalling 547 0.64 1.39 0.93 
1392529_at Spry4 Signalling 1421 0.41 1.22 0.58 
1391384_at Tnf Agonists 122 0.20 0.88 0.09 
1388821_at Trib2 Signalling 2240 0.67 0.99 0.94 
1376426_at Unknown Unknown 93 0.61 1.13 1.09 
1379141_at Unknown Unknown 82 0.58 1.12 1.00 
1392788_at Unknown Unknown 240 0.34 1.25 0.55 
PD184352/ET-1 upregulation of baseline RNA expression     
1389546_at Amotl2 Adhesion/ECM 3427 0.96 1.26 1.70 
1385925_at AS:Glipr2 Potential AS 1269 1.08 1.13 1.58 
1394940_at Fam46a Not established 2033 0.89 1.30 1.53 
1397197_at Intron:SerinC3 Introns 139 1.08 1.31 1.53 
1390471_at, 
1391841_at, 
1395350_at 
Intron:Tpm1 Introns 768, 1869, 311 1.04 1.38 1.61 
1378081_at Intron:Tsc22d1 Introns 254 1.15 1.46 1.54 
1387264_at Kcnk6 Channels/pumps/transporters 198 1.02 1.35 2.02 
1369393_at Map3k8 Signalling 219 1.39 0.82 1.95 
1380682_at Mex3b RNA processing 345 1.16 1.15 1.91 
1374650_at, 
1396053_at 
Nedd9 Cytoskeleton/myofibrillar 625, 262 1.20 1.34 1.67 
1377994_at Pmaip1 Signalling 159 1.04 1.37 1.60 
1367957_at Rgs3 Signalling 1140 1.41 1.04 2.38 
1392990_at Sox17 Transcriptional regulation 517 1.47 0.92 1.62 
1384842_s_at Tnfrsf6 Receptors 456 1.02 1.18 1.55 
1395645_at Unknown Unknown 744 0.92 1.17 1.83 
1381334_at Unknown Unknown 219 0.91 1.02 1.74 
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Table 4.6.  (Continued). 
 
Probeset Gene symbol Classification Control PD ET-1 PD/ET-1 
   (Raw values) (Relative to controls) 
PD184352/ET-1 downregulation of baseline RNA expression     
1389230_at Arrdc3 Not established 2677 0.72 0.96 0.66 
1371953_at Ccng2 Signalling 622 0.97 0.77 0.65 
1379238_at Ctdspl Signalling 256 0.71 0.69 0.66 
1370097_a_at, 
1373661_a_at, 
1389244_x_at 
Cxcr4 Receptors 
1642, 1564, 
1585 
0.71 0.79 0.58 
1376084_a_at Espl1 Protein synthesis/modification 190 0.89 0.96 0.59 
1380617_at Gimap5 Signalling 343 0.72 0.90 0.66 
1383661_at Hs3st3b1 Protein synthesis/modification 100 0.67 0.91 0.60 
1391320_at Intron:Hspbap1 Introns 134 1.11 0.85 0.67 
1396973_at Intron:Phf15 Introns 108 1.11 0.81 0.53 
1368486_at Irs3 Signalling 119 1.05 0.68 0.58 
1379211_at Pdgfrb Receptors 487 1.41 0.69 0.66 
1379313_at Ptpre Receptors 113 0.92 1.02 0.66 
1389353_at Sema6d Receptors 936 0.73 0.77 0.63 
1388746_at Serpine3 Protein synthesis/modification 78 1.31 1.17 0.50 
1389742_at Zfp217 Transcriptional regulation 530 0.76 0.83 0.59 
1386721_at, 
1393990_at 
Znf503 Transcriptional regulation 813, 905 0.70 0.80 0.53 
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Figure 4.5. Regulation of baseline cardiomyocyte RNA expression through the ERK1/2 cascade.  
Cardiomyocytes were unstimulated (Control) or exposed to ET-1, PD184352 (PD) or ET-1 together 
with PD184352 (PD/ET-1). Changes in RNA expression were determined using microarrays using 
GeneSpring analysis to identify transcripts with significant changes in expression (>1.5-fold) with or 
without a significant effect of the inhibitor (one-way ANOVA with Newman-Keuls post-test and 
Benjamini-Hochberg false discovery rate correction). (A) Upregulation (Group Va) or downregulation 
(Group Vb) by PD184352. (B) Upregulation (Group VIa) or downregulation (Group VIb) by PD/ET-
1. Heatmaps represent all probesets in each group [Log2 scale; -2.5 (cyan) through 0 (black) to 2.5 
(red)]. Histograms are means ± SEM (numbers of transcripts in parentheses).  Statistical analysis of 
each group was performed: *p<0.001, **p<0.05 relative to Control; #p<0.001, relative to ET-1 alone 
(one-way ANOVA with Newman-Keuls post-test). 
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4.3.2.2.  Effects of C3T on changes in gene expression induced by ET-1 
 
For the cardiomyocytes treated with C3T, the patterns were markedly different from those treated with 
PD184352.  Of the 273 RNAs upregulated by ET-1, the majority (198 of the 273) were unaffected by 
C3T (Group I; Table 4.7 and Fig. 4.6A).  For 18 RNAs that were upregulated in response to ET-1, a 
minor, yet significant inhibition in expression was detected in cells pre-treated with C3T (Group IIa; 
Table 4.8 and Fig. 4.6A).  The average inhibition was 20.1%.  ET-1-induced upregulation of 57 RNAs 
was significantly enhanced by C3T (Group IIb; Table 4.9 and Fig. 4.6A).  Of the 115 RNAs that were 
downregulated by ET-1, the expression levels of 89 RNAs were unaffected by C3T and they remained 
at their downregulated level of expression (Group III; Table 4.10 and Fig. 4.6B).  However, ET-1-
induced downregulation in expression of 26 RNAs was significantly inhibited by C3T (Group IV; 
Table 4.11 and Fig. 4.6C).   
 
C3T profoundly affected baseline RNA expression alone or (despite a negligible effect of ET-1 alone) 
together with ET-1.  The baseline expression of 222 RNAs was upregulated (Groups Va and VIa; 
Table 4.12, Figs. 4.7A and 4.8B].  In contrast, there were 226 RNAs for which the baseline level of 
expression was downregulated by C3T (Groups Vb and VIb; Table 4.13, Figs. 4.7A and 4.7B).  As for 
ERK1/2 signalling, it is possible to “calculate” the regulatory role that RhoA assumes in the 
cardiomyocyte response to ET-1.  Thus, RhoA signalling positively regulates only ~11% of the IEG 
response to ET-1 with negative regulation of ~14% of the response.  However, it appears to have a 
significant role in regulating baseline gene expression.    
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Table 4.7. RNAs upregulated by ET-1 and not affected by C3T.  Cardiomyocytes were unstimulated 
(Control) or exposed to ET-1, C3T or ET-1 following pre-treatment with C3T (C3T/ET-1).  RNA profiles were 
assessed using microarrays.  RNAs significantly upregulated by ET-1 were selected (>1.5-fold change, 
FDR<0.05) and those without any significant inhibition or enhancement of the response were identified 
(p<0.05 one-way ANOVA with SNK post-test).  Raw values are provided for Controls and expression relative 
to Controls is provided for C3T, ET-1 and C3T/ET-1 treatments. Results are means for 4 separate 
hybridisations.  For multiple probesets for the same RNA, individual raw values are provided for controls and, 
since the relative fold changes were similar, the mean values are provided for the treatments.  RNAs are listed 
alphabetically according to gene symbol. 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1373843_at, 
1382206_a_at, 
1385566_at, 
1386764_at 
Akap2 Signalling 
4997, 902, 
172, 427 
0.97 1.87 1.97 
1372069_at Ankrd15 Signalling 1959 0.98 1.54 1.57 
1367614_at Anxa1 Signalling 5199 1.14 1.99 2.09 
1369871_at Areg Agonists 58 2.59 16.88 19.33 
1377750_at Arhgef3 Signalling 349 0.95 2.36 2.70 
1379311_at, 
1380772_at, 
1397437_at 
Arid5a Transcription 407, 184, 273 1.16 2.03 2.00 
1372964_at, 
1382312_at 
Arid5b Transcription 1656, 501 1.04 2.18 2.23 
1376275_at Arl5b Signalling 490 1.22 1.85 2.11 
1390850_at AS:Adfp Potential AS 100 2.46 2.23 3.13 
1385961_at AS:Klf5 Potential AS 117 1.09 4.50 4.80 
1398037_at AS:Plk2 Potential AS 111 1.04 2.12 2.13 
1386062_at AS:Rnd3 Potential AS 69 1.56 2.53 2.24 
1384659_at AS:Sfp295 Potential AS 39 1.87 1.91 1.97 
1385870_at AS:Zfp281 Potential AS 59 1.15 2.29 2.40 
1395981_at Ascc3 RNA binding/processing 65 1.35 1.64 1.34 
1369268_at Atf3 Transcription 453 1.88 13.68 12.69 
1389402_at Axud1 Signalling 283 1.48 9.35 10.28 
1374433_at Bach1 Transcription 982 1.00 1.53 1.57 
1369807_at Bdkrb1 Receptors 104 1.43 2.26 3.02 
1386994_at, 
1386995_at 
Btg2 Transcription 914, 1100 1.47 7.70 7.45 
1377869_at Ccrn4l Transcription 402 1.30 10.33 10.52 
1375910_at Cdc42ep3 Signalling 3695 0.95 1.79 1.80 
1380063_at Ch25h Metabolism 590 1.16 8.86 7.49 
1389573_at Chac1 Channels/pumps/transporters 1060 1.27 2.55 2.38 
1367601_at, 
1367602_at 
Cited2 Transcription 2160, 2119 1.08 4.85 4.87 
1389368_at Cnksr3 Not established 790 1.01 1.67 1.65 
1373866_at Coq10b Metabolism 1303 1.42 2.88 2.89 
1367631_at Ctgf Agonists 12573 0.96 1.90 2.07 
1368290_at Cyr61 Adhesion/ECM 711 1.04 9.32 8.23 
1373525_at, 
1379666_at 
Dcun1d3 Not established 337, 293 1.08 1.80 1.69 
1372722_at Dnajb4 Protein synthesis/modification 1288 1.05 2.27 2.16 
1368146_at, 
1368147_at 
Dusp1 Signalling 1884, 281 1.09 3.02 3.00 
1394028_at Dusp10 Signalling 192 0.80 1.94 1.91 
1368124_at Dusp5 Signalling 473 1.29 5.02 5.95 
1377064_at, 
1387024_at 
Dusp6 Signalling 1211, 2234 1.09 2.87 2.87 
1372385_at Dusp8 Signalling 387 1.06 1.52 1.86 
1368321_at Egr1 Transcription 4265 1.52 4.72 4.51 
1387306_a_at, 
1398266_a_at 
Egr2 Transcription 487, 157 1.23 7.04 5.18 
1369545_at, 
1392791_at 
Egr3 Transcription 222, 180 1.69 27.14 21.09 
1387442_at Egr4 Transcription 10 3.05 72.13 54.94 
1374143_at Epha2 Adhesion/ECM 351 1.08 1.75 2.10 
1373093_at Errfi1 Signalling 1544 1.79 7.28 7.89 
1369182_at F3 Receptors 151 1.60 5.59 6.86 
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Table 4.7.  (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1377938_at Fam100a Not established 1045 1.00 1.59 1.52 
1383295_at Fam110a Not established 165 1.04 1.82 1.76 
1385251_at Fam110c Cytoskeleton/myofibrillar 78 1.64 3.35 4.27 
1368336_at Fdx1 Metabolism 2218 1.15 2.09 2.34 
1388496_at Flnc Cytoskeleton/myofibrillar 2243 0.90 1.54 1.61 
1375043_at Fos Transcription 238 2.00 14.99 12.67 
1373759_at FosB Transcription 40 3.98 151.16 114.37 
1368489_at Fosl1 Transcription 303 1.61 5.65 5.88 
1373035_at,  Fosl2 Transcription 1556, 187 1.28 1.60 1.69 
1383222_at Frmd6 Not established 785 1.22 1.52 1.78 
1373513_at, 
1387221_at 
Gch Metabolism 175, 276 1.15 1.93 2.08 
1370688_at, 
1372523_at 
Gclc Metabolism 942, 1155 1.04 1.58 1.72 
1374903_at Gcnt2 Protein synthesis/modification 291 1.10 1.56 1.54 
1387548_at Has2 Adhesion/ECM 440 1.53 7.38 6.83 
1368983_at Hbegf Agonists 481 1.04 2.86 3.34 
1383519_at Hk2 Metabolism 945 0.82 1.57 1.36 
1375852_at Hmgcr Metabolism 1982 1.04 1.77 1.69 
1370454_at, 
1370997_at 
Homer1 Receptors 172, 38 1.39 5.24 4.24 
1368247_at, 
1370912_at 
Hspa1a/1b Protein synthesis/modification 335, 432 1.53 3.17 2.88 
1394022_at Id4 Transcription 654 0.90 1.63 1.55 
1368878_at, 
1388872_at 
Idi1 Metabolism 4209, 2059 0.93 1.68 1.47 
1372389_at Ier2 Signalling 684 1.31 3.57 3.61 
1388587_at Ier3 Signalling 5086 1.66 1.58 2.07 
1389355_at, 
1389882_at 
Ier5 Not established 2153, 116 1.38 4.16 5.42 
1367795_at Ifrd1 Transcription 1242 1.25 5.31 5.29 
1367894_at Insig1 Metabolism 5314 1.01 1.56 1.58 
1396539_at Intron:Actn1 Introns 247 1.02 5.63 5.31 
1391753_at Intron:Ankrd1 Introns 1012 0.99 1.82 1.78 
1394451_at Intron:Anxa1 Introns 432 1.02 2.81 2.48 
1392250_at Intron:Anxa2 Introns 96 1.36 2.07 1.87 
1379543_at Intron:Arhgap10 Introns 42 1.38 2.01 1.92 
1397030_at Intron:Atp2b1 Introns 104 1.28 2.02 1.83 
1380195_at Intron:Atp2b1 Introns 317 1.09 1.59 1.75 
1396834_at Intron:Braf Introns 79 1.34 1.52 1.40 
1381864_at Intron:Cacna2d1 Introns 72 1.27 2.38 2.37 
1390618_at Intron:Creb5a Introns 119 1.10 1.77 1.84 
1390723_at Intron:Ctnna1 Introns 243 1.16 2.71 2.32 
1375475_at Intron:Dusp5 Introns 116 1.44 5.80 5.64 
1397449_at Intron:Enah Introns 378 0.94 1.97 1.86 
1391373_at Intron:Enah Introns 206 1.18 1.87 2.07 
1397223_at Intron:Fgd6 Introns 80 1.46 1.51 1.83 
1379106_at Intron:Fgrf1 Introns 145 1.20 2.00 2.43 
1394750_at Intron:Fhl1 Introns 171 1.06 2.32 2.41 
1381343_at Intron:Frmd6 Introns 218 0.86 1.61 1.27 
1380230_at Intron:Gch Introns 57 1.10 1.86 2.23 
1382982_at Intron:Gnb1 Introns 200 1.17 1.67 1.68 
1385757_at Intron:Homer1 Introns 280 1.18 1.71 1.73 
1390671_at Intron:Igf1r Introns 179 1.14 1.73 1.62 
1378489_at, 
1383828_at 
Intron:Klf14 Introns 88, 89 1.46 4.06 3.88 
1396877_at Intron:Lamc1 Introns 522 1.32 2.38 2.32 
1381651_at Intron:March7 Introns 385 1.33 1.63 1.58 
1397112_at Intron:Pctk2 Introns 170 1.40 2.04 2.23 
1379477_at Intron:Pdcd6ip Introns 144 1.17 2.00 1.91 
1393782_at Intron:Plagl1 Introns 66 1.71 3.31 3.38 
1380311_at Intron:Ppp1r12a Introns 186 1.32 2.28 1.79 
1381430_at Intron:Rheb Introns 37 1.47 2.34 2.21 
1391215_at Intron:Samd4 Introns 227 1.12 1.85 1.82 
1380701_at Intron:Ssfa2 Introns 260 1.02 1.51 1.56 
1375490_at,  Intron:Stard13 Introns 156 1.12 1.62 1.97 
1397115_at Intron:Tbc1d1 Introns 86 1.42 2.06 1.58 
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Table 4.7.   (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1378447_at Intron:Thrap1 Introns 181 1.22 3.74 3.60 
1382036_at Intron:Tln1 Introns 274 1.17 1.88 1.81 
1385649_at Itga5 Adhesion/ECM 955 0.97 1.53 1.72 
1369788_s_at, 
1374404_at, 
1389528_s_at 
Jun Transcription 
853, 511, 
1429 
1.16 2.77 2.45 
1387788_at Junb Transcription 1447 1.35 1.76 2.02 
1375248_at, 
1376569_at, 
1386041_a_at, 
1394068_x_at 
Klf2 Transcription 
812, 648, 
134, 210 
1.70 2.66 2.84 
1387260_at Klf4 Transcription 1339 1.53 3.42 3.59 
1368363_at, 
1394039_at 
Klf5 Transcription 363, 320 0.98 2.89 2.66 
1387060_at, 
1388986_at, 
1395557_at 
Klf6 Transcription 
1085, 1896, 
592 
1.05 4.33 3.97 
1376700_at Lima1 Cytoskeleton/myofibrillar 1391 1.03 1.72 1.69 
1381798_at Lmo7 Adhesion/ECM 747 0.94 1.51 1.38 
1377610_at Lmod2 Cytoskeleton/myofibrillar 2287 1.00 2.61 2.27 
1373403_at LOC684871 Not established 92 1.13 3.30 3.44 
1380229_at Maff Transcription 289 1.22 2.22 2.76 
1371350_at, 
1387737_at 
Mat2a Metabolism 3636, 1288 1.19 1.80 1.85 
1383288_at, 
1384427_at 
Mdm2 Protein synthesis/modification 1362, 717 1.14 1.80 1.75 
1367796_at Mgat1 Protein synthesis/modification 1004 1.00 1.52 1.62 
1385028_at Mirhg1 Non-protein coding 108 1.27 1.95 2.06 
1374290_at,  Mirn143/145 Non-protein coding 338, 192 0.99 2.17 1.77 
1378867_at Mirn221/222 Non-protein coding 85 2.17 11.42 12.15 
1391643_at Mirn224-2/27a/23a Non-protein coding 1163 1.04 2.63 2.55 
1398020_at Mirn23b Non-protein coding 268 1.21 1.67 1.81 
1382017_at Mirn322/503 Non-protein coding 270 1.06 1.55 1.36 
1371692_at Mllt11 Not established 1539 0.94 1.54 1.90 
1372904_at, 
1384900_at 
Mobkl2b Signalling 724, 246 1.00 1.70 1.67 
1368308_at Myc Transcription 648 1.20 3.89 3.47 
1370174_at Myd116 Not established 1424 1.11 2.26 2.36 
1368488_at Nfil3 Transcription 700 1.06 3.09 2.97 
1374767_at Npepo Protein synthesis/modification 1116 1.06 1.74 1.60 
1386935_at Nr4a1 Transcription 578 2.12 19.01 19.13 
1369007_at Nr4a2 Transcription 128, 13 1.59 18.05 21.10 
1369067_at, 
1393389_at 
Nr4a3 Transcription 126, 119 2.49 24.68 25.82 
1384254_at Otud1 Protein synthesis/modification 1396 0.97 5.93 5.91 
1389918_at Palld Cytoskeleton/myofibrillar 847 1.06 2.04 1.66 
1383224_at Pard6b Adhesion/ECM 232 1.09 3.25 3.59 
1385116_at Pcdhb21 Adhesion/ECM 57 1.31 1.50 1.26 
1390814_at, 
1399081_at 
Peli1 Not established 910, 537 0.98 2.01 1.84 
1368303_at Per2 Transcription 295 0.93 1.80 1.48 
1368860_at Phlda1 Signalling 250 1.17 5.63 7.17 
1396561_x_at Piga Metabolism 73 1.17 1.51 1.31 
1369862_at Pim1 Signalling 88 1.25 1.78 1.94 
1368106_at Plk2 Signalling 2462 1.01 3.97 3.75 
1376724_at Prkab2 Signalling 261 1.19 1.66 1.52 
1367841_a_at Prl8a9 Agonists 52 1.06 2.33 1.93 
1383322_at Rasl11b Signalling 1218 1.11 2.50 2.44 
1373989_at, 
1392688_at 
Rassf1 Signalling 696, 126 1.16 1.77 1.86 
1373730_at Rbm33 RNA binding/processing 548 1.10 1.50 1.34 
1379714_at, 
1381341_at 
rCG_43687 Not established 116, 145 1.18 4.05 3.74 
1383001_at, 
1383874_at, 
1394278_at 
RGD1560812 Not established 236, 333, 287 1.13 3.13 3.37 
1381923_at RGD1564664 Not established 349 1.22 2.24 2.57 
1376937_at RGD1565927 Not established 1083 0.83 1.77 1.51 
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Table 4.7.   (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1368144_at, 
1387074_at 
Rgs2 Signalling 955, 1566 1.13 6.79 7.48 
1369958_at Rhob Signalling 2621 1.75 2.89 3.25 
1394527_at Ripk2 Signalling 163 1.29 1.54 1.68 
1389258_at Rnf138 Protein synthesis/modification 268 1.12 1.51 1.40 
1371774_at Sat Metabolism 3921 1.27 2.31 2.49 
1368519_at, 
1392264_s_at 
Serpine1 Protein synthesis/modification 377, 163 1.31 18.58 19.41 
1372417_at Sertad1 Transcription 938 1.02 1.85 1.71 
1367802_at Sgk Signalling 1619 1.06 2.85 2.41 
1387408_at Siah2 Protein synthesis/modification 182 0.96 1.88 1.61 
1372347_at Skil Transcription 2020 1.16 1.63 1.73 
1367853_at Slc12a2 Channels/pumps/transporters 966 1.17 1.60 1.51 
1368596_at Snf1lk Signalling 467 1.35 2.31 2.65 
1374864_at Spry2 Signalling 1266 0.85 3.03 2.94 
1374829_at, 
1388842_at 
Srf Transcription 429, 2731 1.02 1.85 1.79 
1377404_at, 
1387623_at, 
1393559_at, 
1396101_at 
Stc1 Agonists 
1948, 389, 
1794, 1231 
0.88 1.51 1.32 
1367570_at Tagln Cytoskeleton/myofibrillar 3236 0.97 1.55 1.79 
1367859_at Tgfb3 Agonists 1096 0.93 1.59 1.88 
1368901_at, 
1375951_at 
Thbd Receptors 99, 217 1.37 2.20 2.67 
1374529_at, 
1394109_at 
Thbs1 Adhesion/ECM 8617, 4256 1.55 3.14 3.57 
1374446_at, 
1385407_at 
Tiparp Protein synthesis/modification 2268, 1314 1.04 1.64 1.55 
1383005_at Tmem49 Not established 730 1.17 1.65 1.94 
1370287_a_at, 
1379936_at, 
1395794_at 
Tpm1 Cytoskeleton/myofibrillar 
2294, 2137, 
1431 
0.99 1.53 1.53 
1371019_at Trib1 Signalling 526 1.17 2.14 2.29 
1384163_at Trp53inp1 Signalling 1560 1.00 1.54 1.55 
1375031_at Ttn Cytoskeleton/myofibrillar 338 1.25 1.56 1.70 
1376403_at Unknown Unknown 199 1.24 2.84 2.30 
1384892_at Unknown Unknown 139 1.40 1.85 1.87 
1380223_at Unknown Unknown 58 1.44 1.63 1.24 
1390248_at Unknown Unknown 132 1.51 1.59 1.96 
1398059_at Unknown Unknown 83 1.24 1.52 1.35 
1380399_at Unknown Unknown 220 1.30 1.51 1.31 
1392108_at Unknown Unknown 94 1.06 3.39 4.19 
1373651_at Unknown Unknown 425 1.08 1.95 2.53 
1397283_at Unknown Unknown 146 1.18 1.79 1.90 
1385578_at Utp14b RNA binding/processing 180 1.13 1.78 1.23 
1372905_at, 
1398476_at 
Vcl Cytoskeleton/myofibrillar 3414, 930 0.89 1.62 1.46 
1384709_at Vgll3 Transcription 167 0.90 1.50 1.38 
1377778_at Vof16 Not established 302 1.60 3.17 3.18 
1382642_at, 
1385869_at 
Zfp281 Transcription 1054, 977 1.07 2.45 2.31 
1395896_at Zfp295 Transcription 124 1.21 1.75 1.70 
1387870_at Zfp36 RNA binding/processing 1447 1.46 2.86 3.19 
1373106_at Zfp36l2 RNA binding/processing 1966 1.19 1.78 2.10 
1373680_at Znf697 Transcription 343 1.37 2.35 2.95 
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Table 4.8. RNAs upregulated by ET-1 and inhibited by C3T.  Cardiomyocytes were unstimulated 
(Control) or exposed to ET-1, C3T or ET-1 following pre-treatment with C3T (C3T/ET-1).  RNA profiles were 
assessed using microarrays. RNAs significantly upregulated by ET-1 were selected (>1.5-fold change, 
FDR<0.05) and those with significant inhibition of the response were identified (p<0.05 one-way ANOVA 
with SNK post-test).  Raw values are provided for Controls and expression relative to Controls is provided for 
C3T, ET-1 and C3T/ET-1. Results are means for 4 separate hybridisations.  For multiple probesets for the same 
RNA, individual raw values are provided for controls and, since the relative fold changes were similar, the 
mean values are provided for the treatments.  RNAs are listed alphabetically according to gene symbol. 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1390881_at Abra Signalling 437 0.86 3.05 2.52 
1368223_at Adamts1 Protein synthesis/modification 1357 0.97 2.83 2.47 
1386065_at Ankrd57 Not established 329 1.16 2.56 2.05 
1387068_at Arc Not established 259 1.07 4.60 3.35 
1369519_at Edn1 Agonists 293 0.87 1.51 1.30 
1382059_at, 
1392747_at 
Fbxo30 Protein synthesis/modification 488, 339 0.96 1.83 1.55 
1379089_at, 
1380155_at 
Intron:Myh9 Introns 501, 850 0.94 2.34 2.01 
1381253_at Intron:Slc12a2 Introns 140 1.28 2.12 1.67 
1398691_at Intron:Tsc22d2 Introns 92 1.22 5.38 3.99 
1371091_at Irs2 Signalling 888 0.99 2.20 1.84 
1372520_at, 
1373225_at 
Mcl1 Signalling 4775, 2687 1.07 1.58 1.56 
1385229_at Pcdh20 Adhesion/ECM 123 0.94 1.64 1.20 
1376066_at, 
1377663_at, 
1394077_at 
Rnd3 Signalling 
1253, 1516, 
757 
0.95 1.79 1.52 
1371754_at Slc25a25 Channels/pumps/transporters 290 1.15 5.05 3.57 
1377340_at Tfpi2 Protein synthesis/modification 287 1.31 6.72 4.53 
1385641_at Tnfaip3 Transcription 1045 2.1 12.12 4.92 
1378165_at, 
1387750_at 
Twist1 Transcription 445, 103 0.83 3.83 3.17 
1395168_at Unknown Unknown 140 0.92 1.56 1.06 
1379584_at Unknown Unknown 259 0.98 1.86 1.41 
1388130_at Zyx Cytoskeleton/myofibrillar 5625 0.90 1.56 1.38 
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Table 4.9. RNAs upregulated by ET-1 and enhanced by C3T.  Cardiomyocytes were unstimulated 
(Control) or exposed to ET-1, C3T or ET-1 following pre-treatment with C3T (C3T/ET-1).  RNA profiles were 
assessed using microarrays. RNAs significantly upregulated by ET-1 were selected (>1.5-fold change, 
FDR<0.05) and those with significant enhancement of the response were identified (p<0.05 one-way ANOVA 
with SNK post-test).  Raw values are provided for Controls and expression relative to Controls is provided for 
C3T, ET-1 and C3T/ET-1.  Results are means for 4 separate hybridisations.  For multiple probesets for the 
same RNA, individual raw values are provided for controls and, since the relative fold changes were similar, 
the mean values are provided for the treatments. RNAs in each group are listed alphabetically according to gene 
symbol. 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1374610_at Agpat9 Metabolism 339 1.23 1.99 2.76 
1374429_at AS:Pim1 Potential AS 1386 1.39 2.27 2.71 
1382171_at AS:Tsc22d2 Potential AS 753 1.43 2.97 3.53 
1375538_at AS:Vcl Potential AS sequences 4828 1.48 1.70 2.16 
1373494_at, 
1389465_at 
Bcr Signalling 899, 949 1.45 2.83 3.58 
1368677_at Bdnf Agonists 155 1.02 1.63 2.41 
1368945_at, 
1398270_at 
Bmp2 Agonists 142, 472 1.60 2.08 3.01 
1379935_at Ccl7 Agonists 4224 1.79 1.93 2.36 
1368050_at Ccnl1 Signalling 953 1.29 2.21 2.67 
1385827_at Clcf1 Agonists 58 2.57 2.07 4.98 
1390628_at, 
1396225_at 
Cpeb2 RNA binding/processing 603, 75 1.30 1.70 1.96 
1369737_at, 
1378925_at, 
1387714_at, 
1393550_at 
Crem Transcription 
114, 362, 
116, 99 
1.48 1.97 2.88 
1388589_at Dot1l DNA regulation 687 1.29 2.57 3.50 
1388082_at, 
1393119_at 
Dusp4 Signalling 113, 1286 1.06 1.82 1.99 
1369587_at, 
1385150_at 
Ereg Agonists 171, 132 2.11 3.52 5.60 
1370623_at, 
1383516_at,  
Fgl2 Adhesion/ECM 504, 305 1.16 1.95 2.38 
1372750_at, 
1387843_at 
Fst Agonists 454, 358 1.37 4.18 4.59 
1388792_at Gadd45g Signalling 1816 1.09 2.42 3.08 
1382351_at Gem Signalling 384 1.34 2.06 2.40 
1369113_at Grem1 Agonists 144 1.02 1.57 2.15 
1387202_at Icam1 Adhesion/ECM 2088 1.97 2.50 3.81 
1370692_at, 
1387273_at 
Il1rl1 Receptors 170, 1127 1.17 2.63 3.22 
1369191_at Il6 Agonists 131 4.94 12.87 24.02 
1383486_at Inhba Agonists 265, 212 1.97 5.08 10.84 
1373623_at Itpkc Signalling 355 1.50 1.68 2.22 
1393728_at Lif Agonists 333 4.14 9.73 17.88 
1376632_at Lmcd1 Transcription 1063 1.23 2.81 4.05 
1374594_at, 
1397729_x_at 
LOC363060 Not established 54, 67 1.10 3.91 13.93 
1397632_at LOC498272 Unknown 1132 1.56 4.02 7.51 
1372211_at Mafk Transcription 845 1.16 1.77 2.16 
1371595_at, 
1397164_at 
Neat1 Non-protein coding 2697, 771 1.56 2.17 2.67 
1378032_at Nfkbiz Transcription 1216 1.75 3.30 4.30 
1368683_at Oldlr1 Receptors 1712 1.83 1.86 3.07 
1387269_s_at Plaur Receptors 452 1.52 2.45 3.78 
1369029_at Plscr1 Metabolism 554 1.38 1.56 2.77 
1368527_at Ptgs2 Metabolism 421 4.46 18.06 24.44 
1370193_at Ptp4a1 Signalling 3227 1.13 1.54 1.68 
1370177_at Pvr Receptors 1029 1.51 2.14 3.09 
1373679_at RGD1306119 Not established 469 1.30 1.90 2.27 
1381279_at Ripk2 Signalling 623 1.35 2.55 2.97 
1381533_at Rnd1 Signalling 1217 1.39 2.89 4.02 
1368487_at Serpinb2 Protein synthesis/modification 268 9.81 23.75 34.81 
1382500_at,  Sesn2 Metabolism 673, 1034 1.22 1.56 1.81 
1370314_at Slc20a1 Channels/pumps/transporters 2408 1.15 1.58 1.85 
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Table 4.9.  (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1372510_at, 
1384331_at 
Srxn1 Metabolism 750, 464 1.54 4.82 5.95 
1372926_at, 
1375138_at, 
1389836_a_at 
Timp3 Protein synthesis/modification 
553, 1691, 
2370 
0.98 1.55 1.89 
1373401_at Tnc Adhesion/ECM 933 1.81 2.49 4.33 
1371194_at Tnfaip6 Adhesion/ECM 723 2.68 4.39 7.37 
1369407_at Tnfrsf11b Receptors 1498 1.52 1.90 2.55 
1371785_at Tnfrsf12a Receptors 4417 1.42 2.12 2.92 
1381070_at Tslp Agonists 171 1.40 1.50 1.89 
1379910_at Uap1 Metabolism 1091 4.80 2.87 6.98 
1378754_at Unknown Unknown 429 1.13 2.12 2.80 
1395119_at Unknown Unknown 281 1.25 1.70 2.55 
1389119_at Xirp1 Cytoskeleton/myofibrillar 2408 0.94 1.82 2.24 
1373767_at Zfand2a Not established 746 1.27 1.62 2.27 
1375130_at, 
1383905_at, 
1388868_at 
Zfand5 Transcription 
657, 469, 
3626 
1.31 1.81 2.05 
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Table 4.10. RNAs downregulated by ET-1 and not affected by C3T. Cardiomyocytes were 
unstimulated (Control) or exposed to ET-1, C3T or ET-1 following pre-treatment with C3T (C3T/ET-1). RNA 
profiles were assessed using microarrays.  RNAs significantly downregulated by ET-1 were selected (>1.5-fold 
change, FDR<0.05) and those without any significant inhibition of the response were identified (p<0.05 one-
way ANOVA with SNK post-test).  Raw values are provided for Controls and expression relative to Controls is 
provided for C3T, ET-1 and C3T/ET-1.  Results are means for 4 separate hybridisations.  For multiple 
probesets for the same RNA, individual raw values are provided for controls and, since the relative fold 
changes were similar, the mean values are provided for the treatments.  RNAs are listed alphabetically 
according to gene symbol. 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1390931_at Adamts15 Protein synthesis/modification 1070 1.13 0.54 0.64 
1390974_a_at Adat2 RNA binding/processing 392 0.87 0.61 0.75 
1381153_at Anapc4 Protein synthesis/modification 284 0.86 0.58 0.66 
1389264_at Ankrd54 Not established 376 0.90 0.57 0.62 
1373287_at Atoh8 Transcription 863 1.05 0.43 0.45 
1370823_at Bambi Receptors 960 0.86 0.62 0.62 
1374493_at Bmf Signalling 424 0.81 0.63 0.62 
1384214_a_at Ccnt2 Transcription 211 1.07 0.54 0.62 
1389145_at Cdc42ep2 Signalling 635 1.52 0.61 0.75 
1398710_at Cyp2u1 Metabolism 427 0.97 0.58 0.49 
1368025_at Ddit4 Signalling 1910 0.87 0.30 0.33 
1376612_at Dtwd1 Not established 252 0.97 0.65 0.60 
1373114_at Dtx4 Signalling 1566 0.87 0.65 0.60 
1393058_at Eid2 Transcription 490 1.15 0.62 0.74 
1391741_a_at Fam78a Not established 338 0.98 0.63 0.52 
1390995_at Fkbpl Protein synthesis/modification 316 0.91 0.65 0.64 
1389404_at Foxs1 Transcription 553 1.02 0.54 0.64 
1374530_at Fzd7 Receptors 339 0.86 0.66 0.60 
1389871_at Got2 Metabolism 91 1.03 0.63 0.61 
1374234_at Hkr3 Transcription 246 1.14 0.66 0.82 
1389675_at, 
1391026_at 
Ier5l Not established 999, 1430 0.89 0.32 0.34 
1378945_at Intron:Aco2 Introns 241 0.92 0.58 0.68 
1396420_at Intron:Baz1b Introns 170 1.21 0.64 0.74 
1385506_at Intron:Cdon Introns 298 1.00 0.58 0.50 
1392650_at Intron:Csnk2a1 Introns 320 1.05 0.63 0.73 
1398560_at Intron:Dscr1l1 Introns 145 0.63 0.41 0.28 
1380168_at Intron:Etv4 Introns 140 1.00 0.66 0.72 
1376522_at Intron:Fabp3 Introns 318 0.91 0.46 0.44 
1391171_at Intron:Itm2b Introns 303 0.99 0.59 0.58 
1393540_at Intron:Myh6 Introns 512 0.83 0.62 0.56 
1392317_at Intron:Scl33a1 Introns 121 0.99 0.49 0.60 
1397165_at Intron:Smarca2 Introns 148 0.90 0.62 0.69 
1374786_at Intron:Tia1 Introns 151 1.17 0.49 0.60 
1390776_at, 
1394251_x_at 
Irx3 Transcription 1232, 566 1.36 0.66 0.87 
1390969_at Kcne4 Channels/pumps/transporters 1275 0.84 0.62 0.60 
1389988_at Kctd2 Channels/pumps/transporters 989 1.07 0.67 0.68 
1378332_at, 
1389479_at, 
1393150_at 
Klf3 Transcription 1254, 1744, 1242 0.93 0.60 0.60 
1381065_at LOC499120 Not established 670 1.04 0.64 0.73 
1385431_at LOC688018 Signalling 250 0.69 0.63 0.65 
1372060_at Lysmd4 Not established 413 0.87 0.56 0.50 
1376718_at Mblac1 Not established 499 0.95 0.61 0.67 
1396481_at Mirn1-2/-133a-1 Non-protein coding 75 0.77 0.34 0.25 
1374693_at Parp16 Metabolism 459 0.82 0.55 0.50 
1384262_at Ppp1r3b Signalling 487 0.86 0.49 0.51 
1384937_at Rbak Transcription 112 1.04 0.53 0.53 
1385253_at RGD1304610 Not established 173 0.95 0.64 0.61 
1380314_at RGD1563072 Not established 280 0.85 0.66 0.67 
1392170_at Rwdd3 Not established 180 1.10 0.66 0.65 
1367920_at S1pr2 Receptors 622 0.94 0.61 0.75 
1397522_at Sbf1 Signalling 315 0.79 0.65 0.78 
1390249_at Sept14 Signalling 503 1.09 0.65 0.67 
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Table 4.10.  (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1375121_at, 
1394025_at 
Smad6 Transcription 944, 650 0.94 0.63 0.66 
1383589_at Snai2 Transcription 515 0.84 0.62 0.50 
1372633_at Spg20 Signalling 684 0.88 0.64 0.61 
1388786_at Synpo Cytoskeleton/myofibrillar 2163 0.90 0.66 0.62 
1393153_at Tardbp RNA binding/processing 234 0.89 0.66 0.61 
1383282_at Thap11 DNA regulation 566 1.08 0.65 0.75 
1397692_at Tia1 Protein synthesis/modification 133 0.98 0.52 0.63 
1390928_at Tigd2 DNA regulation 267 0.75 0.41 0.34 
1393649_at Tmpo Transcription 102 1.08 0.55 0.73 
1397527_at Trim47 Not established 784 0.88 0.54 0.65 
1391027_at Trim65 Not established 370 0.91 0.58 0.61 
1376358_at Unknown Unknown 98 1.12 0.45 0.70 
1377045_at Unknown Unknown 286 0.98 0.58 0.67 
1377629_at Unknown Unknown 380 0.90 0.65 0.59 
1378117_at Unknown Unknown 317 0.96 0.64 0.55 
1378367_at Unknown Unknown 143 1.18 0.61 0.52 
1378547_at Unknown Unknown 437 0.93 0.66 0.81 
1379454_at Unknown Unknown 150 0.90 0.65 0.81 
1381077_at Unknown Unknown 176 0.91 0.63 0.70 
1381619_at Unknown Unknown 131 1.27 0.38 0.47 
1383058_at Unknown Unknown 2498 0.91 0.45 0.48 
1383919_at Unknown Unknown 154 0.87 0.64 0.63 
1383977_a_at Unknown Unknown 152 1.06 0.37 0.53 
1389419_at Unknown Unknown 576 0.98 0.55 0.58 
1389714_at Unknown Unknown 201 0.79 0.65 0.77 
1391863_at Unknown Unknown 348 1.16 0.18 0.24 
1392605_at Unknown Unknown 181 0.87 0.62 0.72 
1393512_at Unknown Unknown 192 1.00 0.63 0.56 
1377154_at Zfp157 Transcription 251 0.86 0.58 0.50 
1372205_at Zfp278 Transcription 417 0.99 0.66 0.63 
1393438_at Zfp316 Transcription 203 0.94 0.62 0.75 
1370984_at Zfp46 Transcription 660 0.92 0.66 0.61 
1386793_at Zfp61 Transcription 183 0.91 0.42 0.40 
1381282_at Zfp768 Transcription 277 0.62 0.64 0.51 
1385597_at Znf124 Transcription 83 0.88 0.39 0.28 
1389366_at Znf553 Transcription 432 0.90 0.51 0.60 
1372699_at Znf775 Transcription 201 0.98 0.54 0.54 
1384432_at Zscan12 Transcription 199 1.05 0.62 0.59 
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Table 4.11. RNAs downregulated in cardiomyocytes by ET-1 and inhibited by C3T. 
Cardiomyocytes were unstimulated (Control) or exposed to ET-1, C3T or ET-1 following pre-treatment with 
C3T (C3T/ET-1). RNA profiles were assessed using microarrays. RNAs significantly downregulated by ET-1 
were selected (>1.5-fold change, FDR<0.05) and those with significant inhibition of the response were 
identified (p<0.05 one-way ANOVA with SNK post-test). Raw values are provided for Controls and expression 
relative to Controls is provided for C3T, ET-1 and C3T/ET-1 treatments. Results are means for 4 separate 
hybridisations.  For multiple probesets for the same RNA, individual raw values are provided for controls and, 
since the relative fold changes were similar, the mean values are provided for the treatments. RNAs are listed 
alphabetically according to gene symbol. 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1383848_at Adrb1 Receptors 627 1.19 0.44 0.61 
1385627_at, 
1398482_at 
Bcl3 Transcription 652, 503 1.55 0.48 0.73 
1368813_at, 
1387343_at 
Cebpd Transcription 1479, 2974 1.10 0.42 0.70 
1390024_at Clec2d/g Receptors 1686 1.05 0.64 0.99 
1383205_at Dact2 Not established 186 1.00 0.66 1.30 
1387036_at Hes1 Transcription 1576 1.29 0.58 0.87 
1387028_a_at Id1 Transcription 3595 1.20 0.61 0.91 
1392578_at Intron:Mgp Introns 626 1.05 0.21 0.65 
1393406_at Intron:Rbx1 Introns 311 1.10 0.65 0.89 
1368073_at Irf1 Transcription 907 1.06 0.41 0.57 
1368249_at, 
1381396_s_at 
Klf15 Transcription 931, 288 0.94 0.40 0.34 
1381267_at LOC691468 Not established 138 1.08 0.57 0.81 
1388525_at Pik3ip1 Signalling 1024 0.86 0.53 0.44 
1378484_at Rasl12 Signalling 684 0.62 0.58 0.38 
1374364_at RGD1562335 Not established 392 1.06 0.51 0.68 
1374756_at RGD1562665 Not established 181 1.15 0.35 0.75 
1393262_at Smad9 Transcription 454 0.95 0.65 0.56 
1373219_at Snai1 Transcription 1379 1.04 0.27 0.34 
1397220_at Snhg7 Non-protein-coding 657 1.22 0.64 0.87 
1369584_at, 
1377092_at 
Socs3 Signalling 732, 2404 1.29 0.56 0.84 
1390215_at Ston2 Signalling 127 0.83 0.64 0.99 
1371131_a_at Txnip Transcription 5283 1.16 0.65 0.87 
1389084_at Unknown Unknown 377 0.98 0.47 0.59 
1380914_at, 
1393652_at 
Zbtb1 Transcription 209, 534 1.09 0.64 0.58 
1386633_at Zfp869 Transcription 276 1.04 0.60 0.77 
1391507_at Znf467 Transcription 385 0.70 0.60 0.42 
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Figure 4.6.  Regulation of ET-1-
responsive RNA expression through 
RhoA. Cardiomyocytes were unstimulated 
(Control) or exposed to ET-1, C3T or ET-1 
together with C3T (C3T+ET-1). Changes in RNA expression were determined using microarrays 
using GeneSpring analysis to identify transcripts with significant changes in expression (>1.5-fold) 
with or without a significant effect of the inhibitor (one-way ANOVA with Newman-Keuls post-test 
and Benjamini-Hochberg false discovery rate correction). (A) Upregulated by ET-1 with no effect 
(Group I), inhibition (Group IIa) or enhancement by C3T (Group IIb). (B) Downregulated by ET-1 
with no effect (Group III) or (C) inhibition by C3T (Group IV).  Heatmaps are for probesets in each 
group [Log2 scale; -2.5 (cyan) through 0 (black) to 2.5 (red)]. Histograms are means ± SEM (numbers 
of transcripts in parentheses). Statistical analysis of each group was performed: *p<0.001, **p<0.05 
relative to Control; #p<0.001, relative to ET-1 alone (one-way ANOVA with Newman-Keuls post-
test).  
 
 
Chapter 4 
Page | 150  
 
Table 4.12. RNAs upregulated by C3T alone or C3T in the presence of ET-1.  Cardiomyocytes were 
unstimulated (Control) or exposed to ET-1, C3T or ET-1 following pre-treatment with C3T (PD/ET-1). RNA 
profiles were assessed using microarrays. RNAs not significantly regulated by ET-1 alone but significantly 
upregulated by C3T or C3T/ET-1 were selected (>1.5-fold change, FDR<0.05) and clustered.  Raw values are 
provided for Controls and expression relative to Controls is provided for C3T, ET-1 and C3T/ET-1 treatments.  
Results are means for 4 separate hybridisations. For multiple probesets for the same RNA, individual raw 
values are provided for controls and, since the relative fold changes were similar, the mean values are provided 
for the treatments. RNAs in each group are listed alphabetically according to gene symbol. 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
C3T upregulation of baseline RNA expression     
1388924_at Angptl4 Agonists 657 2.55 0.75 1.84 
1379483_at AS:Bhlhe40 Potential AS 925 2.01 1.31 2.09 
1393252_at AS:Fbln1 Potential AS 6380 1.54 1.14 1.43 
1393006_at AS:Fubp3 Potential AS 120 1.62 1.25 1.44 
1381990_at AS:Galnt1 Potential AS 137 1.88 1.15 1.79 
1389905_at AS:Gas1 Potential AS 2452 1.65 0.92 1.21 
1377413_at AS:Lsm14a Potential AS 193 1.53 1.22 1.57 
1376848_at AS:Myo10 Potential AS 1113 1.66 0.96 1.70 
1382365_at AS:Nlk Potential AS 232 1.57 0.96 1.45 
1393494_at AS:Pdgf1 Potential AS 367 1.65 0.97 1.80 
1375687_at AS:Rab14 Potential AS 3363 1.51 1.09 1.35 
1383599_at AS:Rbbp4 Potential AS 4261 1.52 1.12 1.42 
1375921_at AS:Rcn1 Potential AS 985 1.64 1.17 1.63 
1375268_at AS:Rps27l Potential AS 1028 1.53 1.30 1.54 
1380200_at AS:Zeb1 Potential AS 118 1.68 1.07 1.36 
1374117_at Baiap2 Signaling 150 1.62 1.15 1.58 
1385853_at Baz1a Transcription 131 1.54 1.10 1.63 
1374034_at Cars Protein synthesis/modification 882 1.67 1.17 1.91 
1369814_at Ccl20 Agonists 340 1.52 1.10 1.77 
1368921_a_at, 
1387952_a_at, 
1390659_at 
Cd44 Adhesion/ECM 852, 1236, 1772 1.69 1.32 2.21 
1379381_at Ciita Transcription 78 1.50 1.40 1.34 
1384969_at Col24a1 Adhesion/ECM 274 1.57 1.01 1.49 
1387170_at Csnk2a1 Signaling 268 1.77 0.91 1.43 
1368200_at Cx3cl1 Agonists 869 1.57 0.92 1.33 
1387316_at Cxcl1 Agonists 6292 2.16 1.40 2.26 
1368760_at Cxcl2 Agonists 576 1.74 1.31 3.00 
1370633_at, 
1370634_x_at, 
1388032_a_at 
Cxcl3 Agonists 929, 936, 772 1.56 1.15 2.08 
1387648_at Cxcl5 Agonists 2152 2.22 0.98 2.16 
1397508_at Ddx18 RNA binding/processing 185 1.51 0.90 1.41 
1389803_at Erbb4 Receptors 103 1.56 1.33 1.29 
1379077_at Fam181b Not established 76 1.64 0.94 0.84 
1374643_at Fat4 Adhesion/ECM 234 1.52 1.22 1.55 
1372016_at Gadd45b Signaling 618 1.64 1.37 1.85 
1387659_at Gda Metabolism 2724 1.54 1.06 1.45 
1380410_at, 
1385926_at 
Glipr2 Not established 483, 358 1.64 1.21 1.62 
1379535_at Intron:Ccnh Introns 78 1.52 1.20 1.22 
1397045_at Intron:Chst11 Introns 99 1.66 1.28 1.51 
1378843_at Intron:Dnajb6 Introns 102 1.57 1.48 1.53 
1378783_at, 
1379114_at, 
1396378_at 
Intron:Mast4 Introns 351, 120, 214 1.78 1.18 1.62 
1376098_a_at Intron:Myo1g Introns 758 1.55 1.49 1.91 
1381133_at Intron:Plcb1 Introns 112 1.55 0.99 1.33 
1385177_at Intron:Sorbs1 Introns 100 1.54 1.50 1.36 
1395372_at Itgb8 Adhesion/ECM 217 1.67 0.96 1.03 
1395966_at Kctd14 Channels/pumps/transporters 145 1.52 0.80 1.11 
1369610_at Lin7c Trafficking 221 1.53 1.32 1.30 
1390790_a_at Lipg Metabolism 154 1.56 1.04 1.78 
1374028_at LOC500974 Not established 263 1.55 1.07 1.38 
1369393_at Map3k8 Signaling 219 1.58 0.82 1.32 
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Table 4.12.  (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1369410_at 
Mitochondrial 
genome 
DNA regulation 871 1.84 1.39 1.74 
1368657_at Mmp3 Protein synthesis/modification 112 1.57 1.18 1.98 
1370968_at Nfkb1 Transcription 2247 1.51 1.00 1.79 
1389538_at Nfkbia Transcription 1524 1.96 0.71 1.42 
1368438_at, 
1370669_a_at, 
1379607_at, 
1385381_at 
Pde10a Signaling 
550, 415, 389, 
347 
2.12 0.94 1.62 
1376737_at Plcxd3 Signaling 1049 1.58 0.99 1.53 
1379312_at Pprc1 Transcription 491 1.52 1.06 1.53 
1368014_at Ptges Metabolism 271 1.86 1.16 2.15 
1373923_at, 
1384391_at, 
1393351_at 
Rdh10 Metabolism 340, 244, 337 1.82 0.99 1.85 
1382489_at RGD1564964 Not established 325 1.55 1.18 1.01 
1373777_at Rgs16 Signaling 547 1.50 1.39 1.81 
1367849_at, 
1376062_at 
Sdc1 Adhesion/ECM 1447, 195 1.55 1.31 2.09 
1392556_at Shroom3 Cytoskeleton/myofibrillar 262 1.50 1.06 1.31 
1374845_at Slc25a37 Channels/pumps/transporters 353 1.59 0.93 1.49 
1377916_at Slfn2 Not established 1195 1.82 1.16 2.11 
1367998_at Slpi Protein synthesis/modification 3863 2.14 0.99 1.81 
1387617_at Tpm3 Cytoskeleton/myofibrillar 757 1.80 1.30 1.79 
1392598_at Unknown Unknown 1153 1.80 1.21 1.93 
1377823_at Unknown Unknown 311 1.80 0.98 1.55 
1398703_at Unknown Unknown 210 1.70 1.13 1.42 
1385569_at Unknown Unknown 250 1.68 0.98 1.61 
1397316_at Unknown Unknown 107 1.57 1.18 1.06 
1384562_at Unknown Unknown 538 1.56 1.31 1.90 
1377889_at Urb1 Protein synthesis/modification 209 1.52 1.11 1.50 
1393140_at Zc3h12a Transcription 347 1.64 1.17 1.38 
     
C3T/ET-1 upregulation of baseline RNA expression     
1387101_at Acsl4 Metabolism 2518 1.17 1.36 1.52 
1393730_at Adamts4 Protein synthesis/modification 790 1.31 1.11 1.66 
1390383_at Adfp Metabolism 4251 1.17 1.41 1.74 
1368946_at, 
1388813_at 
Arf2 Signaling 597, 715 1.21 1.34 1.57 
1375014_at Arl4c Signaling 371 1.28 1.18 1.50 
1386521_at AS:Akap2 Potential AS 129 1.09 1.23 1.56 
1375183_at, 
1385923_at 
AS:Id4 Potential AS 198, 97 1.23 1.58 1.81 
1390983_at AS:Itga6 Potential AS 144 1.31 1.29 1.78 
1375676_at AS:Lin7c Potential AS 342 1.39 1.16 1.73 
1391424_at AS:MiRNA  Potential AS 116 1.04 1.27 1.64 
1371130_at AS:Mmd Potential AS 150 1.23 1.15 1.81 
1379747_at AS:Prss35 Potential AS 355 1.38 1.21 2.20 
1375986_at AS:Ptgs2 Potential AS 194 1.36 1.46 2.34 
1394643_at AS:Qtrtd1 Potential AS 310 1.44 1.10 1.52 
1385706_at AS:Tes Potential AS 77 1.20 1.41 2.15 
1371193_at AS:Tnfaip6 Potential AS 41 2.80 3.27 6.16 
1371980_at Atad3a DNA regulation 577 1.30 0.92 1.51 
1367624_at Atf4 Transcription 7702 1.16 1.39 1.53 
1389397_at Atp13a3 Channels/pumps/transporters 842 1.23 1.18 1.57 
1370050_at, 
1386426_at 
Atp2b1 Channels/pumps/transporters 1321, 1005 1.42 1.10 1.69 
1378134_at Atp8b1 Channels/pumps/transporters 435 1.19 1.45 1.83 
1385254_at Atr Signaling 80 1.22 1.06 1.55 
1370869_at Bcat1 Metabolism 1460 1.17 1.06 1.58 
1368118_at Bcl10 Signaling 1596 1.22 1.30 1.52 
1370650_s_at Bdkrb2 Receptors 119 1.67 1.21 2.98 
1369815_at Ccl3 Agonists 939 1.25 0.97 1.78 
1382603_at Cd274 Receptors 214 1.19 1.06 1.65 
1387951_at Cd55 Protein synthesis/modification 160 1.11 1.22 1.92 
1393365_at Chd1 DNA regulation 192 1.07 1.30 1.55 
1393003_at Chst11 Metabolism 526 1.13 1.12 1.52 
1386783_at ChSy-2 Adhesion/ECM 108 1.23 1.07 1.51 
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Table 4.12.  (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1380287_at Creb5 Transcription 185 1.17 1.34 1.65 
1368685_at Cspg4 Adhesion/ECM 257 1.53 1.04 1.82 
1367940_at Cxcr7 Receptors 1294 1.37 1.30 1.60 
1389155_at Dos Not established 236 1.18 1.30 1.54 
1388686_at Dscr1 Signaling 7390 1.09 1.42 1.54 
1377023_at Dusp2 Signaling 454 1.09 1.38 1.68 
1371840_at Edg1 Receptors 4385 0.97 1.45 1.54 
1383353_at Efnb2 Adhesion/ECM 427 1.08 1.45 1.78 
1369736_at, 
1371527_at 
Emp1 Signaling 1574, 4157 0.86 1.41 1.55 
1373535_at Enah Cytoskeleton/myofibrillar 2302 0.97 1.26 1.52 
1384687_at, 
1388666_at 
Enc1 Cytoskeleton/myofibrillar 181, 1488 1.29 1.38 1.59 
1377213_at Ern1 Signaling 354 1.17 1.38 1.76 
1373917_at Etf1 Protein synthesis/modification 1789 1.19 1.30 1.52 
1368851_at Ets1 Transcription 1805 1.01 1.43 1.51 
1368550_at Foxq1 Transcription 152 1.17 1.15 1.62 
1368947_at Gadd45a Signaling 2344 1.08 1.44 1.76 
1377761_at Gfpt2 Metabolism 4521 1.39 1.42 1.88 
1367705_at, 
1386908_at 
Glrx1 Metabolism 440, 581 1.00 1.36 1.60 
1388953_at Gnl3 Signaling 1773 1.31 1.15 1.53 
1388243_at Gpr176 Receptors 1384 1.10 1.29 1.50 
1376828_at Gprc5a Receptors 457 1.23 1.35 2.06 
1370365_at Gss Metabolism 575 1.21 1.10 1.68 
1397587_at Hdac5 Transcription 175 1.11 1.37 1.57 
1383685_at Heatr1 RNA binding/processing 310 1.34 1.22 1.59 
1395012_at Herc4 Protein synthesis/modification 64 1.18 1.47 1.89 
1387076_at Hif1a Transcription 5540 1.41 1.19 1.67 
1391560_at Hivep1 Transcription 317 1.14 1.26 1.68 
1388309_at Hmga1 Transcription 2297 1.15 1.29 1.61 
1368592_at, 
1371170_a_at 
Il1a Agonists 371, 283 1.15 0.98 1.66 
1398256_at Il1b Agonists 382 1.44 1.14 2.42 
1392386_at Intron:Cflar Introns 395 1.26 1.27 1.68 
1374166_at Intron:Grtp1 Introns 1156 1.01 1.39 1.51 
1397999_at Intron:Irs2 Introns 117 1.23 1.44 1.52 
1377910_at Intron:Nol5 Introns 134 1.26 1.41 1.66 
1382020_at Intron:Spag9 Introns 479 1.13 1.53 1.70 
1390458_at Intron:Tnrc15 Introns 109 1.15 1.44 1.72 
1384574_at Intron:Ugdh Introns 147 1.44 1.34 1.71 
1387346_at Itgb1 Adhesion/ECM 6243 1.29 1.10 1.51 
1375866_at, 
1390000_at 
Jmjd3 Transcription 570, 1124 1.20 1.41 1.79 
1389374_at Kifc3 Signaling 446 1.11 0.93 1.50 
1376089_at Ldlr Receptors 3580 1.07 1.28 1.51 
1373233_at Lhfpl2 Not established 875 1.19 1.23 1.60 
1383906_at Lincr Protein synthesis/modification 401 1.23 1.20 1.55 
1368055_a_at Lmna Cytoskeleton/myofibrillar 2888 1.09 1.30 1.57 
1396949_at LOC298139 Not established 87 1.03 1.22 1.72 
1378540_at LOC678970 Not established 651 1.32 1.14 1.55 
1381434_s_at LOC681027 Not established 693 1.06 1.28 1.61 
1376436_at Lysmd3 Not established 704 1.12 1.47 1.56 
1388858_at Map2k3 Signaling 2308 1.18 1.37 1.95 
1376690_at Med21 Transcription 763 1.08 1.36 1.54 
1389911_at Metrnl Not established 1972 1.06 1.46 1.64 
1388990_at Mki67ip RNA binding/processing 1445 1.28 1.22 1.53 
1372808_at Mthfd2 Metabolism 805 1.28 1.34 1.78 
1374797_at Ncapd2 DNA regulation 659 1.28 1.44 1.60 
1375989_a_at Nfkb2 Transcription 849 1.43 1.14 1.76 
1371259_at Ngfb Agonists 227 1.41 1.16 2.24 
1368173_at Nol5 RNA binding/processing 1937 1.29 1.33 1.52 
1383614_at Nuak2 Signaling 319 1.28 1.49 1.97 
1368747_at Nup98 Signaling 169 1.20 1.27 1.55 
1388198_at Nupl1 Signaling 181 1.23 1.43 1.63 
1374157_at Pde4b Signaling 2177 1.21 1.17 1.63 
1371684_at Pelo Protein synthesis/modification 1834 1.20 1.43 1.73 
Chapter 4 
Page | 153  
 
Table 4.12.   (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1384950_at, 
1395655_at 
Pi4k2b Signaling 230, 800 1.26 1.30 1.61 
1372725_at Plscr2 Metabolism 200 1.23 1.20 1.52 
1392534_at Pmepa1 Not established 1691 1.18 1.14 1.51 
1375061_at, 
1396171_at 
Ppil4 Protein synthesis/modification 564, 496 1.12 1.34 1.54 
1377858_at Prdm2 Transcription 120 1.28 1.45 2.14 
1382154_at Ptpn12 Signaling 1974 1.23 1.23 1.65 
1391899_at Purb Transcription 188 1.17 1.59 1.70 
1384089_at Rabgef1 Signaling 286 1.24 1.47 1.91 
1390576_at Rbm15 RNA binding/processing 489 1.28 1.41 1.68 
1393569_at Rbm18 RNA binding/processing 610 1.24 1.26 1.54 
1382074_at Rnf19b Protein synthesis/modification 437 1.31 1.25 1.75 
1368914_at, 
1395442_at 
Runx1 Transcription 545, 222 1.41 1.16 1.88 
1386890_at S100a10 Channels/pumps/transporters 4808 1.09 1.38 1.62 
1367721_at Sdc4 Adhesion/ECM 4388 1.46 1.38 1.97 
1391946_at Selp Adhesion/ECM 352 1.48 0.98 1.81 
1399071_at Sertad2 Transcription 712 1.38 1.20 1.55 
1388132_at Sfpq RNA binding/processing 1352 1.22 1.26 1.52 
1389203_at Sh3bp5l Not established 495 1.31 1.29 1.87 
1372896_at 
Similar to 
Hmm889 
Not established 163 0.94 1.43 1.52 
1369160_a_at, 
1379739_at 
Slc4a7 Channels/pumps/transporters 175, 656 1.31 1.39 1.79 
1368391_at, 
1368392_at 
Slc7a1 Channels/pumps/transporters 1415, 1467 1.19 1.37 1.62 
1390298_at Snag1 Signaling 1661 1.35 1.20 1.85 
1383210_at Sox11 Transcription 240 1.12 1.23 1.51 
1397618_at Spag9 Signaling 339 1.15 1.12 1.56 
1377595_at Ssfa2 Cytoskeleton/myofibrillar 1358 1.08 1.43 1.57 
1391871_at Stard13 Signaling 772 1.07 1.30 1.61 
1371679_at Synpo2 Cytoskeleton/myofibrillar 3409 1.11 1.20 1.54 
1383889_at Taf1a Transcription 258 1.38 1.27 1.53 
1371554_at Tcap Cytoskeleton/myofibrillar 1402 1.22 1.46 1.95 
1389409_at Tes Not established 283 1.12 1.31 1.58 
1383660_at Thoc4 RNA binding/processing 352 1.35 1.26 1.60 
1367712_at Timp1 Protein synthesis/modification 8370 1.33 1.43 1.83 
1379429_at Tmed5 Signaling 825 1.17 1.16 1.51 
1374484_at Tmem39a Not established 906 1.37 1.40 1.75 
1384842_s_at Tnfrsf6 Receptors 456 1.35 1.18 1.73 
1374945_at Trmt61a RNA binding/processing 427 1.48 1.05 1.52 
1370139_a_at Trpc6 Channels/pumps/transporters 74 1.20 0.98 1.76 
1376100_at Tubb5/6 Cytoskeleton/myofibrillar 3533 1.04 1.29 1.54 
1374893_at Uck2 Metabolism 794 1.14 1.09 1.58 
1367938_at Ugdh Metabolism 4151 1.37 1.44 1.94 
1372442_at Uhmk1 Signaling 904 1.18 1.22 1.51 
1380143_at Unknown Unknown 386 1.65 1.12 1.87 
1396251_at Unknown Unknown 78 1.14 1.46 1.82 
1386265_at Unknown Unknown 209 1.18 1.27 1.80 
1380365_at Unknown Unknown 71 1.53 1.50 1.75 
1395645_at Unknown Unknown 744 1.36 1.17 1.67 
1390778_at Unknown Unknown 577 1.49 1.06 1.62 
1391674_at Unknown Unknown 289 1.28 1.18 1.61 
1392184_at Unknown Unknown 235 1.27 1.00 1.59 
1390503_at Unknown Unknown 199 1.10 1.42 1.55 
1374940_at Usp36 Protein synthesis/modification 914 1.21 1.26 1.51 
1388265_x_at Vcan Adhesion/ECM 252 1.42 1.39 1.60 
1383022_at, 
1391217_at 
Zc3h12c Not established 298, 447 1.35 1.27 1.56 
1389152_at Zfyve27 Not established 251 1.53 1.20 1.69 
 
Chapter 4 
Page | 154  
 
C
o
n
tr
o
l
C
3
T
E
T
-1
C
3
T
+
E
T
-1
0.0
0.5
1.0
Group Vb (65)
* *
*
#
0.0
1.0
2.0
*
**
*
#
Group Va (74)Group V
C
o
n
tr
o
l
C
3
T
E
T-
1
C
3
T
+
E
T-
1
A
R
N
A
 e
x
p
re
s
s
io
n
 (
re
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
C
o
n
tr
o
l
C
3
T
E
T
-1
C
3
T
+
E
T
-1
0.0
0.5
1.0
* *
*
#
Group VIb (161)
0.0
1.0
2.0
* *
*#
Group VIa (148)
B
R
N
A
 e
x
p
re
s
s
io
n
 (
re
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
Group VI
C
o
n
tr
o
l
C
3
T
E
T-
1
C
3
T
+
E
T-
1
 
Figure 4.7. Regulation of baseline RNA expression through RhoA.  
Cardiomyocytes were unstimulated (Control) or exposed to ET-1, C3T or ET-1 
together with C3T (C3T+ET-1). Changes in RNA expression were determined 
using microarrays using GeneSpring analysis to identify transcripts with 
significant changes in expression (>1.5-fold) with or without a significant effect 
of the inhibitor (one-way ANOVA with Newman-Keuls post-test and 
Benjamini-Hochberg false discovery rate correction). (A) Upregulation (Group 
Va) or downregulation (Group Vb) by C3T. (B) Upregulation (Group VIa) or 
downregulation (Group VIb) by C3T/ET-1. Heatmaps are for probesets in each 
group [Log2 scale; -2.5 (cyan) through 0 (black) to 2.5 (red)]. Histograms are 
means ± SEM (numbers of transcripts in parentheses).  Statistical analysis of 
each group was performed: *p<0.001, **p<0.05 relative to Control; #p<0.001, 
relative to ET-1 alone (one-way ANOVA with Newman-Keuls post-test). 
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Table 4.13. RNAs downregulated by C3T alone or C3T in the presence of ET-1.  Cardiomyocytes 
were unstimulated (Control) or exposed to ET-1, C3T  or ET-1 following pre-treatment with C3T (PD/ET-1). 
RNA profiles were assessed using microarrays. RNAs not significantly regulated by ET-1 alone but 
significantly downregulated by C3T or C3T/ET-1 were selected (>1.5-fold change, FDR<0.05) and clustered. 
Raw values are provided for Controls and expression relative to Controls is provided for C3T, ET-1 and 
C3T/ET-1. Results are means for 4 separate hybridisations. For multiple probesets for the same RNA, 
individual raw values are provided for controls and, since the relative fold changes were similar, the mean 
values are provided for the treatments. RNAs in each group are listed alphabetically according to gene symbol. 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
C3T downregulation of baseline RNA expression   
1382296_at, 
1394483_at 
Adamts5 Protein synthesis/modification 299, 1052 0.63 0.98 0.60 
1371824_at Ak3l1 Metabolism 414 0.64 0.89 0.64 
1387796_at Alox15 Metabolism 497 0.67 0.88 0.66 
1388370_at, 
1392937_at 
Ccni Signaling 4950, 1765 0.61 0.90 0.57 
1369083_at, 
1382809_at 
Cirbp RNA binding/processing 457, 361 0.57 0.82 0.58 
1368648_at Cox4i2 Metabolism 584 0.51 0.91 0.50 
1367739_at Cox8h Metabolism 3838 0.47 1.06 0.48 
1387874_at Dbp Transcription 504 0.66 0.82 0.52 
1368174_at Egln3 Metabolism 3489 0.62 1.12 0.75 
1372735_at Eif3k Protein synthesis/modification 3241 0.62 0.94 0.55 
1389297_at Ero1l Protein synthesis/modification 1903 0.61 1.08 0.67 
1377713_at Foxn3 Transcription 1493 0.61 0.94 0.62 
1379654_at Giyd2 DNA regulation 231 0.60 0.78 0.52 
1379939_a_at 
Intron:RGD130
6063 
Introns 337 0.66 0.95 0.62 
1374060_at Irs1 Signaling 940 0.65 0.79 0.55 
1393310_at Itch Protein synthesis/modification 529 0.63 0.92 0.69 
1393226_at Itgav Adhesion/ECM 1208 0.61 1.11 0.73 
1372737_at Ldb3 Cytoskeleton/myofibrillar 1430 0.66 0.95 0.77 
1367628_at Lgals1 Adhesion/ECM 7415 0.62 0.99 0.63 
1373387_at LOC688717 Not established 2402 0.65 1.02 0.64 
1385487_at Lsm1 RNA binding/processing 952 0.64 1.04 0.83 
1367609_at Mif Agonists 7209 0.64 0.98 0.62 
1377720_x_at 
Mitochondrial 
genome 
DNA regulation 6917 0.67 0.98 0.66 
1372623_at Mlec Metabolism 660 0.66 1.06 0.95 
1380447_a_at Mrps18c Protein synthesis/modification 796 0.60 1.02 0.58 
1372295_at Narf Cytoskeleton/myofibrillar 1136, 456 0.59 0.85 0.54 
1375220_at Ndufa11 Metabolism 7788 0.65 0.99 0.60 
1388489_at Ndufa3 Metabolism 4953 0.55 0.94 0.54 
1386951_at Ndufa5 Metabolism 3773 0.50 0.96 0.50 
1389059_at Nfix Transcription 1638 0.66 0.97 0.60 
1367479_at Nola3 RNA binding/processing 4989 0.61 1.01 0.61 
1371166_at Nos3 Metabolism 494 0.64 0.95 0.60 
1381888_x_at Pacrgl Not established 98 0.57 0.88 0.88 
1384824_at Pcdh18 Adhesion/ECM 590 0.64 0.82 0.69 
1398884_at Pfdn5 Protein synthesis/modification 3092 0.62 0.97 0.62 
1383749_at Phospho1 Metabolism 344 0.51 0.88 0.58 
1375053_at Pknox2 Transcription 375 0.66 0.99 0.76 
1372556_at Polr2l Transcription 4363 0.60 0.99 0.58 
1374884_at Ppm1d Signaling 206 0.52 0.79 0.70 
1367813_at Ppp1r14a Signaling 415 0.53 0.84 0.63 
1393638_at Ptger4 Receptors 632 0.51 1.05 0.63 
1370982_at Pygm Metabolism 2319 0.65 0.83 0.68 
1389033_at RGD1306917 Not established 2172 0.59 0.96 0.58 
1373596_at RGD1310423 Not established 659 0.60 0.71 0.58 
1383643_at RGD1560328 Not established 6011 0.61 0.96 0.61 
1371410_at RGD1564058 Not established 3824 0.64 0.98 0.64 
1377728_at RGD1565641 Not established 1848 0.61 0.99 0.58 
1372585_at RGD1566254 Not established 1641 0.66 0.83 0.64 
1371573_at Rpl36a Protein synthesis/modification 13224 0.58 1.09 0.59 
1376110_at Rpp25 RNA binding/processing 1513 0.59 0.70 0.44 
1375954_at S100a13 Channels/pumps/transporters 760 0.54 0.85 0.58 
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Table 4.13.  (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1391387_s_at Slbp RNA binding/processing 523 0.65 0.88 0.61 
1368965_at Slc16a3 Channels/pumps/transporters 3321 0.65 0.96 0.65 
1387130_at Slc40a1 Channels/pumps/transporters 725 0.64 0.84 0.56 
1368082_at Slc4a2 Channels/pumps/transporters 725 0.64 0.93 0.57 
1397584_at Snora78 Non-protein-coding 647 0.42 0.85 0.42 
1387138_at Tac2 Agonists 496 0.66 0.85 0.62 
1388782_at Tcf21 Transcription 1657 0.65 1.28 0.78 
1390832_at Tmcc3 Not established 852 0.64 0.69 0.37 
1371452_at Ubl7 Protein synthesis/modification 1177 0.58 0.88 0.57 
1392935_at Unknown Unknown 950 0.65 0.98 0.70 
1388754_at Unknown Unknown 3212 0.59 0.88 0.60 
1382280_at Uqcrc2 Metabolism 3858 0.59 0.80 0.59 
1397604_at Vbp1 Protein synthesis/modification 355 0.45 0.80 0.47 
1368067_at Zfp148 Transcription 1128 0.60 0.88 0.53 
       
C3T/ET-1 downregulation of baseline RNA expression     
1373302_at, 
1391791_at 
Acer2 Metabolism 374, 304 0.75 0.93 0.59 
1377381_at Actn2 Cytoskeleton/myofibrillar 670 0.68 0.86 0.64 
1395414_at Agl Metabolism 190 0.85 0.71 0.66 
1370708_a_at Akr1c14 Metabolism 329 0.64 0.64 0.55 
1367985_at Alas2 Metabolism 322 0.83 0.87 0.64 
1377725_at Anp32a Signaling 599 0.68 0.82 0.66 
1393051_at Armcx1 Not established 840 0.75 0.77 0.63 
1375698_at AS:Rpl7 Potential AS 529 0.95 0.73 0.62 
1381838_at Bivm Not established 329 1.01 0.79 0.65 
1367898_at Bnip3l Signaling 3216 0.72 0.90 0.64 
1382185_at C1qtnf2 Agonists 309 0.71 0.75 0.60 
1374307_at Camk2n1 Signaling 851 0.82 0.88 0.64 
1374275_at Car11 Metabolism 350 0.84 0.79 0.60 
1371953_at Ccng2 Signaling 622 0.74 0.77 0.52 
1368976_at Cd38 Receptors 141 0.76 1.02 0.66 
1373812_at Cdkn1b Signaling 2389 0.78 0.76 0.59 
1370225_at Cited4 Transcription 1104 0.87 0.74 0.58 
1389598_at Cln6 Protein synthesis/modification 577 0.70 0.81 0.61 
1371629_at Cxxc5 Not established 2212 0.88 0.68 0.65 
1385630_at Ddx26b RNA binding/processing 65 1.16 1.07 0.53 
1383641_at, 
1393415_at 
Ednra Receptors 1726, 1230 0.93 0.82 0.65 
1388503_at Eid1 Transcription 3294 0.87 0.78 0.66 
1391241_at Etv1 Transcription 164 0.82 0.87 0.65 
1379625_at Fam164a Not established 341 0.69 0.88 0.66 
1392510_at Fam180a Not established 511 0.67 0.96 0.57 
1374298_at Fam40b Not established 239 0.64 0.79 0.46 
1371566_at Fbxl22 Protein synthesis/modification 4854 0.67 0.96 0.61 
1392886_a_at Fcrla Receptors 353 0.88 0.94 0.55 
1376593_at Foxo3 Transcription 1468 0.85 0.79 0.62 
1385601_at Frg1 RNA binding/processing 208 0.80 0.83 0.66 
1373838_at Fut4 Protein synthesis/modification 632 1.02 0.67 0.64 
1388395_at G0s2 Not established 6041 0.68 0.83 0.47 
1374125_at Gata5 Transcription 568 1.08 0.70 0.66 
1381469_a_at Gigyf1 Signaling 394 0.82 0.81 0.63 
1390233_at Gli2 Transcription 183 0.75 0.94 0.62 
1374541_at Gys1 Metabolism 1974 0.69 0.92 0.60 
1388608_x_at Hba-a1 Metabolism 8822 0.69 0.90 0.62 
1371332_at Hist1h1c DNA regulation 6296 0.76 0.79 0.57 
1381208_at Hist3h2a DNA regulation 89 0.61 0.68 0.50 
AFFX_Rat_Hexokinas
e_3/M_at 
Hk1 Metabolism 1149, 1010 0.69 0.73 0.65 
1373992_at Iigp1 Signaling 435 0.72 0.83 0.64 
1382258_at Intron:Arhgef3 Introns 176 0.97 0.92 0.65 
1384841_at Intron:Ctsc Introns 478 0.81 0.90 0.58 
1396641_at Intron:Tmpo Introns 310 0.97 0.68 0.65 
1368486_at Irs3 Signaling 119 0.87 0.68 0.66 
1384312_at Irx1 Transcription 177 1.19 0.82 0.64 
1392981_at Irx4 Transcription 2241 1.07 0.68 0.58 
1369782_a_at Kcnj11 Channels/pumps/transporters 315 0.97 0.76 0.48 
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Table 4.13.   (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1368911_at Kcnj8 Channels/pumps/transporters 986 0.78 0.74 0.54 
1395182_at Klhl20 Cytoskeleton/myofibrillar 314 0.90 0.89 0.59 
1379462_at Ksr1 Signaling 386 0.78 0.86 0.65 
1383169_at Lifr Receptors 1672 0.92 0.76 0.57 
1376983_at LOC682834 Not established 64 1.03 0.67 0.58 
1374860_at LOC684993 Not established 625 0.85 0.86 0.66 
1373172_at LOC687356 Not established 575 0.91 0.72 0.63 
1373659_at LOC688257 Not established 445 0.98 0.76 0.60 
1389425_at LOC688261 Not established 268 0.76 0.84 0.63 
1385299_at Lpar4 Receptors 367 0.88 0.75 0.62 
1379374_at Lppr4 Signaling 74 0.67 0.77 0.64 
1389727_at Lrrc10 Cytoskeleton/myofibrillar 1007 0.86 0.77 0.58 
1385243_at Maf Transcription 1395 0.75 0.76 0.62 
1375673_at Map3k1 Signaling 512 0.91 0.77 0.66 
1370948_a_at Marcks Cytoskeleton/myofibrillar 4277 0.67 0.84 0.60 
1388540_at Maz Transcription 551 0.80 0.84 0.64 
1393276_at Med31 Transcription 580 0.73 0.85 0.59 
1371479_at Mettl7a Metabolism 620 0.75 0.79 0.57 
1373333_at MGC109340 Protein synthesis/modification 148 0.77 0.93 0.64 
1367858_at Mmp11 Protein synthesis/modification 775 0.83 0.70 0.65 
1372597_at Mrpl14 Protein synthesis/modification 639 0.69 0.88 0.62 
1394182_at Mtmr4 Signaling 237 0.70 0.77 0.60 
1389474_at Mylip Protein synthesis/modification 324 0.85 0.71 0.58 
1390711_at Myo9a Cytoskeleton/myofibrillar 169 0.82 0.93 0.61 
1368566_a_at Ndufv3 Metabolism 3255 0.68 0.98 0.65 
1372959_at Nme4 Metabolism 385 0.73 0.83 0.57 
1373839_at Nope Not established 1095 0.75 0.89 0.65 
1383644_at Npr3 Receptors 109 0.85 0.74 0.58 
1389554_at Nr2f2 Transcription 977 0.79 0.74 0.53 
1371849_at Nt5dc2 Not established 758 0.81 0.84 0.62 
1367507_at Nudt22 Not established 496 0.78 0.84 0.64 
1390139_a_at Obsl1 Cytoskeleton/myofibrillar 838 0.72 0.73 0.62 
1377955_at Orai2 Not established 296 0.93 0.77 0.64 
1391530_a_at Oxsm Metabolism 279 1.06 0.74 0.63 
1383327_at, 
1383328_x_at 
Pdcd4 Signaling 435, 585 0.70 0.79 0.61 
1379211_at Pdgfrb Receptors 487 1.23 0.69 0.66 
1382053_at Pear1 Receptors 825 0.89 1.02 0.66 
1388044_at Pfkfb2 Metabolism 153 0.97 0.73 0.66 
1368700_at Plcl1 Signaling 171 0.68 1.02 0.56 
1376494_at Pole3 DNA regulation 163 1.17 1.13 0.60 
1385393_at, 
1393743_at, 
1395518_at 
Ppargc1a Transcription 367, 582, 642 0.81 0.84 0.59 
1386653_at, 
1390156_a_at 
Prickle2 Not established 601, 561 0.69 0.70 0.63 
1376672_at Prox1 Transcription 681 0.90 0.82 0.62 
1378978_a_at Prr12 Not established 314, 237 0.81 0.77 0.64 
1370259_a_at Pthr1 Receptors 637 0.84 0.82 0.65 
1368674_at Pygl Metabolism 954 0.74 0.87 0.63 
1377902_a_at Rad52 DNA regulation 272 0.89 0.73 0.61 
1377187_at Rbm12b RNA binding/processing 300 0.98 0.68 0.66 
1382749_at Rbm5 RNA binding/processing 1648 0.88 0.69 0.64 
1385518_at RGD1304931 Not established 240 0.86 1.14 0.66 
1392928_at RGD1305721 Not established 143 0.77 0.91 0.54 
1382235_at RGD1306809 Not established 327 0.77 0.89 0.66 
1374023_at RGD1307170 Not established 641 0.82 0.81 0.64 
1372202_at RGD1310553 Not established 743 0.97 0.77 0.66 
1397579_x_at RGD1359127 Not established 411 0.78 0.72 0.54 
1388624_at RGD1561113 Not established 1363 0.76 0.88 0.60 
1373696_at RGD1564859 Not established 581 0.87 0.77 0.60 
1376927_at RGD1564978 Not established 304 0.89 0.74 0.60 
1372370_at Rpusd4 RNA binding/processing 247 0.84 0.71 0.62 
1373427_at Rragd Signaling 382 0.89 0.90 0.64 
1389748_at, 
1395294_at 
Runx1t1 Transcription  536, 403 0.81 0.81 0.64 
1389437_at Sall2 Transcription 407 0.92 0.75 0.60 
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Table 4.13.   (Continued) 
 
Probeset Gene symbol Classification Control C3T ET-1 C3T/ET-1 
   (Raw values) (Relative to controls) 
1372698_at Samd1 Not established 917 0.86 0.81 0.66 
1367593_at Sepw1 Metabolism 963 0.69 0.97 0.63 
1390387_at Sh3d19 Not established 422 0.85 0.82 0.66 
1374932_at 
Similar to 
Gm6484 
Not established 272 0.63 0.64 0.40 
1393516_at Slc16a12 Channels/pumps/transporters 413 0.82 0.81 0.67 
1374200_at Slc29a3 Channels/pumps/transporters 338 0.78 0.83 0.64 
1383253_at Slc30a1 Channels/pumps/transporters 1036 0.67 0.98 0.61 
1385171_s_at Smtnl2 Not established 487 0.80 0.92 0.65 
1379662_a_at, 
1386282_x_at 
Snrk Signaling 1659, 307 0.76 0.88 0.55 
1373239_at Snx33 Signaling 708 0.80 0.74 0.53 
1389460_at Socs6 Signaling 366 0.87 0.67 0.59 
1390864_at Sos1 Signaling 288 0.87 0.81 0.63 
1390819_at Tef Transcription 614 0.87 0.96 0.64 
1393517_at Tmc6 Not established 269 0.77 0.90 0.67 
1377857_at Tmem196 Not established 227 0.71 1.00 0.62 
1384195_at Tmem45a Not established 2624 0.67 0.94 0.63 
1373578_at Trim2 Not established 618 0.84 0.97 0.57 
1378592_at Trim59 Not established 242 0.93 0.70 0.62 
1378324_at Ttc30b Not established 205 0.80 0.67 0.53 
1367953_at Tyro3 Signaling 318 0.79 0.80 0.65 
1392493_at Ubn2 Not established 294 0.67 0.88 0.50 
1388919_at Unknown Unknown 337 0.91 0.79 0.66 
1377462_at Unknown Unknown 197 0.89 0.86 0.66 
1384135_at Unknown Unknown 358 0.87 0.77 0.63 
1378602_at Unknown Unknown 298 0.94 0.71 0.61 
1389618_at Unknown Unknown 957 0.88 0.86 0.60 
1391885_at Unknown Unknown 187 0.82 0.81 0.60 
1382228_at Unknown Unknown 451 0.98 0.69 0.58 
1398727_at Unknown Unknown 1244 0.91 0.96 0.58 
1378808_at Unknown Unknown 304 0.96 0.73 0.56 
1386002_at Unknown Unknown 179 0.84 0.69 0.53 
1394184_at Unknown Unknown 112 1.00 0.73 0.50 
1384269_at Unknown Unknown 66 0.55 0.76 0.49 
1387227_at Wipf1 Cytoskeleton/myofibrillar 1382 0.69 0.84 0.61 
1384029_at Xpa DNA regulation 242 0.73 0.84 0.60 
1376376_at Zbtb44 Transcription 410 0.83 0.71 0.57 
1382199_at Zcchc14 Not established 762 0.88 0.68 0.67 
1386106_at, 
1388672_at 
Zcchc24 Not established 622, 1884 0.84 0.80 0.59 
1393120_at Zfp251 Transcription 465 0.93 0.79 0.65 
1397467_at Zfp329 Transcription 214 0.89 0.71 0.47 
1393127_at Zfp358 Transcription 877 0.76 0.78 0.62 
1390148_a_at Zfp395 Transcription 837 0.75 0.92 0.59 
1393360_at Zfp426l Transcription 1095 0.92 0.72 0.62 
1389445_at Zfp688 Not established 379 0.98 0.68 0.59 
1370589_at Zfp709 Transcription 131 1.02 0.64 0.55 
1383540_at Zfp780b Transcription 256 0.97 0.85 0.64 
1382362_at Zfp87 Transcription 327 0.90 0.68 0.59 
1372030_at Zfyve21 Not established 1226 0.90 0.82 0.66 
1390425_at Zik1 Transcription 169 0.98 0.79 0.61 
1376917_at, 
1390945_at 
Znf292 Transcription 441, 351 0.95 0.70 0.63 
1384517_at Znf496 Transcription 871 0.73 0.73 0.63 
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4.3.3.  qPCR validation of the microarray data 
 
The microarray data for 16 selected RNAs were validated by qPCR.  The different RNAs were 
selected for validation on the basis of their responses to the different treatments.  All were upregulated 
by ET-1.  Four mRNAs encoding transcription factors were selected that were inhibited by either 
PD184352 or C3T: Abra, Srf, Egr2 and Egr3 (Tables 4.2 and 4.8; Figs. 4.4A, Group IIa and 4.6A, 
Group IIa).  Absolute relative changes differ with the two techniques but, qualitatively, the qPCR data 
showed a high degree of correlation with the microarray results as shown by the linear regression 
coefficient (r) for qPCR vs microarray data.  For either Abra (Fig. 4.8A) or Srf (Fig. 4.8B), PD184352 
and C3T had a similar effect on ET-1-induced upregulation of mRNA expression and inhibited the 
response by ~50%.  For Egr2 (Fig. 4.8C) or Egr3 (Fig. 4.8D), PD184352 had a more profound 
inhibitory effect and reduced mRNA expression to control levels whereas C3T inhibited the response 
by ~50% (notably, this inhibition was only significant for Egr3 in the qPCR data and not Egr2 or 
Egr1).  For all four RNAs, either inhibitor alone had little effect on mRNA expression.   
 
Four mRNAs were selected that, according to microarray data, were inhibited by PD184352 only 
(Tables 4.2 and 4.7; Figs. 4.4A, Group IIa and 4.6A, Group I).  These encoded the EGF receptor 
ligands, Areg and Hbegf, and transcription factors, Egr1 and Egr4.  Again, the relative changes in 
expression of the mRNAs as determined by qPCR and microarray differed considerably but the 
pattern remained consistent as indicated by the liner regression coefficient.  As with the previous 4 
RNAs, PD184352 had a much greater inhibitory effect on ET-1-induced upregulation than C3T.  ET-1 
induced upregulation of RNAs for Areg, Hbegf, Egr1 and Egr4 were all inhibited between 92 – 100% 
by PD184352 (Fig. 4.9, A – D).  However, in each case, the effect of C3T on RNA expression was 
insignificant. 
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The change in expression of four mRNAs that were enhanced by C3T but inhibited by PD184352 
were also validated.  All were mRNAs encoding receptor ligands: Ereg, IL-6, Inhba and Bmp2 
(Tables 4.2 and 4.9; Figs. 4.4A, Group IIa and 4.6A, Group IIb).   For these transcripts, C3T enhanced 
mRNA expression consistently whether in cells treated with C3T alone or together with ET-1 (Fig. 
4.10, A - D).  PD184352 completely abolished ET-1-induced upregulation of these RNAs.  The final 
group of mRNAs selected for validation showed minimal sensitivity to either inhibitor.  The RNAs for 
the transcriptions factors Klf4 and Klf5 and the solute carrier, Slc25a25 were all upregulated by ET-1 
(Tables 4.1 and 4.7; Figs. 4.4A, Group I and 4.6A, Group I), whereas Klf15 was downregulated by the 
agonist (Tables 4.4 and 4.11; Figs. 4.4B, Group IV and 4.6C, Group IV).  The inhibitors had no effect 
on these changes and level of RNA expression remained either elevated or, in the case of Klf15, 
reduced further following addition to the cells (Fig. 4.11, A – D). 
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Figure 4.8. Validation of microarray data by qPCR: RNAs inhibited by C3T or PD184352. 
Cardiomyocytes were unstimulated (Control) or exposed to ET-1, C3T, PD184352 or ET-1 together 
with C3T (C3T/ET-1) or PD (PD/ET-1).  ET-1 responsive mRNAs that were inhibited by either C3T 
or PD184352 were measured by qPCR (A, Abra; B, Srf; C, Egr2; D, Egr3).  qPCR results shown 
alone in panels (i) and in comparison with microarray data in panels (ii). Results are relative to 
controls and are means ± SEM (n = 4 or 5). *p<0.05 relative to Control; #p<0.05 relative to ET-1 
(one-way ANOVA repeated measures with Newman-Keuls post-test). The linear regression 
coefficient is provided (r) for qPCR vs microarray data. 
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Figure 4.9. Validation of microarray data by qPCR data: RNAs inhibited by PD184352. 
Cardiomyocytes were unstimulated (Control) or exposed to ET-1, C3T, PD184352 or ET-1 together 
with C3T (C3T/ET-1) or PD (PD/ET-1).  ET-1 responsive mRNAs that were inhibited by PD184352 
were measured by qPCR (A, Areg; B, Hbegf; C, Egr1; D, Egr4).  qPCR results shown alone in panels 
(i) and in comparison with microarray data in panels (ii).  Results are relative to controls and are 
means ± SEM (n = 4 or 5).  *p<0.05 relative to Control; #p<0.05 relative to ET-1 (one-way ANOVA 
repeated measures with Newman-Keuls post-test).  The linear regression coefficient is provided (r) for 
qPCR vs microarray data. 
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Figure 4.10. Validation of microarray data by qPCR data: RNAs enhanced by C3T and 
inhibited by PD184352. Cardiomyocytes were unstimulated (Control) or exposed to ET-1, C3T, 
PD184352 or ET-1 together with C3T (C3T/ET-1) or PD (PD/ET-1).  ET-1 responsive mRNAs that 
were enhanced by C3T but inhibited by PD184352 were measured by qPCR (A, Ereg; B, IL-6; C, 
InhbA; D, Bmp2).  qPCR results shown alone in panels (i) and in comparison with microarray data in 
panels (ii).  Results are relative to controls and are means ± SEM (n = 4 or 5). *p<0.05 relative to 
Control; #p<0.05 relative to ET-1.  The linear regression coefficient is provided (r) for qPCR vs 
microarray data. 
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Figure 4.11. Validation of microarray data by qPCR data: RNAs minimally sensitive to 
PD184352 or C3T. Cardiomyocytes were unstimulated (Control) or exposed to ET-1, C3T, 
PD184352 or ET-1 together with C3T (C3T/ET-1) or PD (PD/ET-1).  ET-1 responsive mRNAs that 
were insensitive to either drug were measured by qPCR (A, Slc25a25; B, Klf15; C, Klf4; D, Klf6). 
qPCR results shown alone in panels (i) and in comparison with microarray data in panels (ii).  Results 
are relative to controls and are means ± SEM (n = 4 or 5). *p<0.05 relative to Control; #p<0.05 
relative to ET-1 (one-way ANOVA repeated measures with Newman-Keuls post-test).  The linear 
regression coefficient is provided (r) for qPCR vs microarray data. 
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4.4.  Discussion 
 
Several studies in the late 1980‟s focused on changes in gene expression associated with cardiac 
hypertrophy studying, for example, the effects of peptide growth factors (Parker et al, 1990), 
hemodynamic load (Mulvagh et al, 1987), ET-1 (Neyses et al, 1993) or α1-adrenergic receptor 
stimulation (Lee et al, 1988).  These studies did, indeed, identify several important changes that are 
used as hypertrophic markers [e.g. enhanced ANF re-expression, up-regulation of skeletal muscle α-
actin and β-myosin heavy-chain expression (Calderone et al, 1995)].  With the advent of microarrays 
(Schena et al, 1995;Kononen et al, 1998), it has become possible to explore changes in cardiac and 
cardiomyocyte mRNA expression on a more global scale.  The focus of many such studies has been 
the investigation of changes in gene expression associated with end-stage disease in human or rodent 
hearts (Hwang et al, 2002;Kittleson et al, 2004;Yung et al, 2004) or in the hearts of transgenic mice 
with chronic overexpression of signalling components [e.g. in hearts chronically overexpressing 
activated PKB (Matsui et al, 2002)].  The focus of this study was the early changes in gene expression 
which may lead to that end-state and, by using small molecular inhibitors, the goal was to gain insight 
into the global roles of ERK1/2 and RhoA in regulating cardiomyocyte RNA expression in this early 
phase. 
 
4.4.1.  ET-1-induced gene expression regulation is initially dominated by ERK1/2 
signalling 
 
ET-1 is well-established as a powerful hypertrophic agonist (Bogoyevitch et al, 1993;Bogoyevitch et 
al, 1994) and has substantial effects on cardiomyocyte gene expression.  Here, the focus was only on 
the initial changes.  Fold-change cut-offs have been widely used in microarray analyses to identify 
probesets that are differentially expressed between experimental and control samples.  However, a 
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technical consideration is what cut-off value to use in order to determine significant differential 
expression in the data.  Here, a cut off of 1.5 fold up- or down-regulation was chosen to define 
differential expression based on recommendations in previously published microarray inhibitor 
studies.  For example, Peart et al. 2005 and Raouf et al 2008 explain that genes may be considered to 
be differentially expressed if there is a fold-change of ≥1.5 (and p < 0.05 after adjustment for multiple 
testing).  These criteria are thought to typically result in more biologically meaningful groups of genes 
than p-values alone.  While the biological significance of a particular fold-change probably depends 
on the gene and on the experimental context, one can assume that there is a minimum fold-change 
threshold below which differential expression is probably not of significance for a gene.  The fact that 
the qPCR validations of fold-changes were mostly successful would imply that this fold-change cut-
off was an appropriate one.   
 
At the early time point of only 1 h of ET-1 exposure, 273 RNAs were detected as significantly 
upregulated (Figs. 4.4A and 4.6A) and 115 RNAs were detected as significantly downregulated (Figs. 
4.4B and 4.6, B and C).  Of these 388 RNAs, expression of 259 (i.e. ~67%) was modified by inclusion 
of the ERK1/2 pathway inhibitor, PD184352.  Thus, ERK1/2 was identified as a significant node in 
this early phase of gene expression induced by ET-1.  This was particularly the case with respect to 
positive regulation of RNA expression in response to ET-1 (190 RNAs out of 273 that were 
upregulated; ~70%) (Tables 4.2 and 4.3; Fig. 4.4A).  In contrast to ERK1/2 signalling, although RhoA 
is potently and rapidly activated by ET-1 in cardiomyocytes (Fig. 4.2A), it appears to play a less 
significant role in modulating the changes in gene expression induced by ET-1.  Co-incubation of 
cells with C3T suggested that RhoA had some positive effects on RNA expression in response to ET-
1 (Fig. 4.6A; Group IIa), but had a greater negative effect (Fig. 4.6A; Group IIb).  Of the 273 RNAs 
that were upregulated by ET-1, for ~73% co-incubation with C3T had no effect on the ET-1-induced 
response (Table 4.7 and Fig. 4.6A; Group I).    
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Although it is thought that activated RhoA mediates one or more aspects of the hypertrophic response 
of the cardiomyocyte, there is currently little understanding of its precise role.  For example, Thorburn 
et al. (1997) suggested that RhoA regulates changes in gene expression but not the morphological 
changes induced by PE.  More recent studies indicate that activated RhoA influences the activities of 
members of the MEF2 family of MADS-box transcription factors (Marinissen et al, 2001) and/or 
GATA transcription factors (Yanazume et al, 2002).  This is consistent with a role for RhoA as a 
regulator of gene transcription as suggested as early as 1996 (Sah et al, 1996).  However, these 
previous studies did not examine the role of RhoA in global transcriptional regulation at early times 
following hypertrophic stimulation.  From the data presented in this chapter, it seems that RhoA-
dependent changes may become more apparent at much later time points as a consequence of earlier 
alterations in gene expression under the regulation of other pathways altogether such as the ERK1/2 
pathway (Fig. 4.12).  The fact that there are RNAs which are not apparently regulated by the either the 
ERK1/2- or RhoA-dependent signalling pathways implies that there must be other signalling systems 
operative within the cardiomyocyte that are required to elicit the necessary changes in gene expression 
during hypertrophy.  One can speculate that these pathways may include other MAPKs (p38-MAPKs 
or JNKs) which are activated through pathways that PD184352 does not inhibit, but which are 
activated by ET-1 (Fig. 4.1). 
 
The data for the effects of ERK1/2 inhibition by PD184352 are consistent with other studies that also 
identify ERK1/2 as a key node in the early gene expression changes in response to growth stimuli.  
With respect to RhoA signalling, previous studies suggest that it plays a more positive role in 
regulating RNA expression.  For example, statins (presumed to selectively inhibit RhoA, though this 
is debatable, see section 4.4.1) inhibit the expression of the fibrosis-related factor CTGF (connective 
tissue growth factor) in human fibroblasts (Cicha et al, 2008).  In cardiomyocytes, mRNA encoding 
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the pro-apoptotic Bcl2-family protein, Bax, is increased by overexpression of RhoA, indicating a 
positive transcriptional regulation (Del Re et al, 2007).  Matricellular protein cysteine-rich 61 (Cyr61) 
mRNA expression is inhibited by C3 toxin and is thus presumed to be positively regulated by RhoA 
(Walsh et al, 2008).  Although CTGF and Cyr61 (but not Bax) were upregulated by ET-1 in this study 
(Table 4.7; Fig. 4.6A, Group I), their upregulation was not inhibited by C3T.  The reasons for this 
may reflect the methods used here, the times point studied, stimulus and/or specific cell types.  
Interestingly, there was a convergence in ERK1/2 and RhoA signalling resulting in an increase in 
expression of Abra and Srf mRNAs (Tables 4.2 and 4.8 and Fig. 4.7A/B).  RhoA signalling may 
therefore be of greater significance in positively regulating RNA expression over longer time periods.  
These conclusions are summarised in Fig. 4.12. 
 
It was notable that ET-1, signalling through ERK1/2, regulated the expression of several 
paracrine/autocrine factors including the Egf receptor ligands amphiregulin (Areg), epiregulin (Ereg) 
and heparin-binding epidermal growth factor (Hbegf).  These data were validated consistently (Figs. 
4.9 and 4.10).  There is also ERK1/2-dependent regulation of gp130 ligands (e.g. interleukin 6, IL-6) 
(Fig. 4.10B) and ligands of the TGFβ superfamily (e.g. inhibin βA, Inhba; bone morphogenic protein 
2, Bmp2) (Fig. 4.10, C and D).  These, along with major changes in transcription factor expression 
(e.g. Srf, Egr family, Klf family), are likely to propagate the hypertrophic response.  Understanding 
and investigating such networks and the links between stimuli, signalling, transcription factor and 
gene expression is a challenge for the future.  In conclusion, whereas RhoA signalling is significant in 
maintaining baseline RNA expression, ERK1/2 signalling is dominant in the acute response to ET-1 
and plays a generally positive role in RNA expression. 
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Figure 4.12. Schematic of signalling and gene expression responses to ET-1 in cardiomyocytes. 
Agonists (e.g. ET-1) activate intracellular signalling pathways including small G proteins and protein 
kinases.  C3 toxin (C3T) and PD184352 inhibit activation of RhoA and ERK1/2, respectively.  
Intracellular signalling pathways modulate expression of immediate early genes (IEGs) including 
Abra/Srf that participate in RhoA-mediated regulation of cardiomyocyte hypertrophy.  These and 
other transcription factors (TFs) promote expression of downstream genes.  Agonists are also 
produced that act in autocrine/paracrine loops to initiate further cycles of signalling/gene expression.  
These networks eventually culminate in hypertrophy.   
 
 
4.4.1.  The use of small molecule inhibitors, PD184352 and C3T, for dissecting the 
roles of ERK1/2 and RhoA signalling  
 
PD184352 is a highly selective, small-molecule inhibitor of one of the key components of the ERK1/2 
pathway (MEK1/MEK2), thereby effectively inhibiting the phosphorylation of ERK1/2 and signal 
propagation through this pathway.  A potential problem in using PD184352 to identify physiological 
roles of the ERK1/2 cascade is that it has also been reported to inhibit the activation of ERK5 by 
inhibiting MKK5 (Kamakura et al, 1999).  It was subsequently shown however, that PD184352 is in 
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fact a much weaker inhibitor of the MKK5/ERK5 pathway than the classical ERK1/2 cascade and in 
fact blocks activation of the ERK1/2 cascade entirely at concentrations where the activation of MKK5 
and ERK5 is unaffected (Mody et al, 2001).  It was at this concentration (2 µM) of PD184352 that this 
microarray study discussed here was conducted.  
 
C3T specifically promotes ADP ribosylation of RhoA at Asn41.  This interferes with the ability of 
RhoA to interact with its targets, thereby inhibiting the functions of RhoA.  Although it has an 
inhibitory effect on RhoB and RhoC, these proteins were not further activated (GTP-loaded) in 
cardiomyocytes exposed to ET-1 (Fig. 4.2C).  C3T does not modify other Rho-family members, such 
as Rac1 or Cdc42 (Aktories et al, 1992;Kaibuchi et al, 1999;Bishop and Hall, 2000).  Thus C3T was 
an entirely appropriate and specific tool that could be used to inhibit RhoA signalling in this study.  
C3 toxin is not cell-permeable and, in previous studies, microinjection or adenoviral-mediated transfer 
was the only means of efficient transport of the toxin across the plasma membrane (Hagg et al, 2001).  
The version used here was linked to a cell-penetrating moiety, allowing rapid and efficient transport 
into the cardiomyocytes with a short (2 h) pre-incubation.  Long incubation periods and/or larger 
amounts of C3T used in previous studies (Seasholtz et al, 1999) are disruptive to basic cellular 
functions (Fig. 4.3).  Other studies have used adenoviral-infection to overexpress a dominant-negative 
form of RhoA, but the level of inhibition achieved by, for example, N19RhoA is less than can be 
obtained with C3T (Qiu et al, 1995;Lehmann et al, 1999;Bhowmick et al, 2001).   
 
Hydroxymethylglutaryl CoA reductase inhibitors ("statins") are often used as inhibitors of Rho-family 
signalling but these inhibitors have a range of effects apart from inhibiting RhoA signalling (Liao and 
Laufs, 2005).  By inhibiting L-mevalonic acid synthesis, statins also prevent the synthesis of other 
important isoprenoid intermediates of the cholesterol biosynthetic pathway, such as farnesyl-
pyrophosphate and geranyl-geranyl-pyrophosphate (Goldstein and Brown, 1990).  These 
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intermediates serve as important lipid attachments for the post-translational modification of a variety 
of cell-signalling proteins, not just RhoA.  Protein isoprenylation allows for the covalent attachment, 
subcellular localization and intracellular trafficking of membrane-associated proteins (Van Aelst and 
D'Souza-Schorey, 1997).  A range of other small and heterotrimeric G proteins all require 
isoprenylation for correct functioning and are clearly targets for inhibition by statins.  Furthermore, 
statin myotoxicity in patients is believed to be associated the secondary disruptive effects on cell 
membrane structure and function and mitochondrial dysfunction (Sirvent et al, 2008).  Overall, it 
seems unwise to consider using statins as a selective means of inhibiting RhoA signalling. 
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CHAPTER 5: EFFECTORS OF RHOA IN THE CARDIOMYOCYTE 
RESPONSE TO ET-1   
 
5.1.  Introduction  
 
In Chapter 4, the involvement of RhoA in the regulation of gene expression induced by ET-1 in 
cardiomyocytes was elucidated using the specific Rho inhibitor, C3 toxin (C3T).  RhoA exerts its 
effects through various downstream effectors including ROCK1/2 and PKN1/2.    
 
ROCK1 and ROCK2 were the first effectors of RhoA.GTP to be identified and are probably the most 
well studied (Ridley and Hall, 1992;Ishizaki et al, 1997).  Activation of ROCK1/2 leads to a series of 
events that promote contractile force and morphological changes.  These events contribute directly to 
a number of actin/myosin-mediated processes, such as cell motility, adhesion, smooth muscle 
contraction, neurite retraction and phagocytosis (Ishizaki et al, 1997;Kuwahara et al, 1999;Coleman et 
al, 2001).  So far there is no evidence that ROCK1 and ROCK2 have different functions although they 
can be differentially regulated.  RhoA, RhoB and RhoC associate with and activate ROCK1/2 while 
other GTP-binding proteins (e.g. Rnd3) are inhibitory (Riento et al, 2003;Wennerberg et al, 2003).  As 
discussed in chapter 1 (section 1.5.5.1), ROCK1/2 play a major role in regulating phosphorylation of 
MLC by phosphorylating and inhibiting the protein phosphatase MYPT1 in addition to increasing 
phosphorylation of MLC directly.  In smooth muscle cells, the net effect is to promote contraction.  
Activated RhoA also binds to and activates PKNs.  As discussed in chapter 1, PKNs are implicated in 
regulating cytoskeletal structures (section 1.5.5.2).  However, PKNs are also implicated in the 
regulation of transcription factor activities (Kitagawa et al, 1998;Takanaga et al, 1998), mitogenesis 
(Gao et al, 2000) and cell cycle regulation (Misaki et al, 2001).  PKN1 and PKN2 also play a role in 
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apoptosis, being activated by caspase-3 (Takahashi et al, 1998) and being involved in the regulation of 
PKB (Koh et al, 2000).  With the activity of PKNs involved in so many processes linked to disease 
progression, further dissection of their role and regulation is of widespread interest. 
 
Small molecule inhibitors are often used to verify whether a cellular response is dependent on 
activation of either ROCK1/2 or PKN1/2.  Several inhibitors of ROCK1/2 have been developed.  The 
most widely used is the pyridine-derived drug, Y-27632 ([(+)-(R)-trans-4-(1-aminoethyl)-N-(4-
pyridyl) cyclohexanecarboxamide dihydrochloride], which inhibits ROCK1/2 activity by competing 
for the ATP-binding site.  This compound inhibits smooth muscle contractility and normalises high 
blood pressure in rat models of hypertension by preventing ROCK1/2 from inhibiting smooth muscle 
protein phosphatase (Kimura et al, 1996;Uehata et al, 1997).  Y-27632 also inhibits RhoA-mediated 
cell transformation (Sahai et al, 1999), tumour cell invasion (Itoh et al, 1999) and neutrophil 
chemotaxis (Niggli, 1999).  In addition to inhibiting ROCK1/2 however, Y-27632 inhibits PKN2 
(which has a similar catalytic domain to PKN1) in vitro and at a concentration that is similar to that 
required for ROCK inhibition (Davies et al, 2000).  Another small molecule inhibitor, HA-1077 
[fasudil hydrochloride; (4-methyl-5-isoquinoline)sulfonyl]-homopiperazine], is marketed as being 
specific to ROCK1 and ROCK2 but has a substantial inhibitory effect on PKN2 (Davies et al, 
2000;Olson, 2008).  Given that Y-27632 and HA-1077 are used widely as inhibitors of ROCK1/2 and 
inhibit PKN1/2, I have explored whether or not they may provide useful information on the role of 
these kinases in the changes in cardiomyocyte gene expression induced by ET-1. 
 
5.2.  Methods 
 
Cardiomyocytes were unstimulated (Control) or exposed to 100 nM ET-1 (for the times indicated), 10 
κM Y-27632 or 20 µM HA-1077.  Otherwise cardiomyocytes were incubated with ET-1 following 
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pre-treatment with Y-27632 and HA-1077 (10 min or 30 min respectively).  Immunoblotting of 
cardiomyocyte extracts was performed as described in section 2.4.  For analysis of phosphorylation of 
MYPT1, proteins were separated on 8% (w/v) polyacrylamide gels.  Primary antibodies for 
phosphorylated MYPT1 (Thr-853) or total MYPT1 were used (Table 2.2).  The bands were visualised 
by enhanced chemiluminescence as described in section 2.6.  Total RNA was extracted and cDNAs 
synthesized using random primers (see section 2.8).  Forward and reverse primers for Egr1, Egr2, 
Tnfaip3, Tfpi2, Arc, Slc25a25, Bmp2, Pvr, Bdnf, IL-6, Crem mRNAs and the hypothetical transcripts 
LOC498272, LOC363060 and LOC365395 were designed for qPCR (Table 2.3).  qPCR was 
performed using absolute quantification with the standard curve protocol.  Values for selected RNAs 
were normalised to Gapdh expression and then to control values.  Statistical analysis was performed 
using Graphpad Prism 4.  A one-way ANOVA with a multiple comparisons Tukey post-test was 
conducted in order to establish the statistical significance.  Densitometric analysis and qPCR data are 
shown as means ± SEM.  
  
5.3.  Results 
 
5.3.1.  Phosphorylation of MYPT1 by ET-1 is inhibited by Y-27632 and HA-1077 
 
MYPT1 is established as a substrate for ROCK1/2.  Phosphorylation of MYPT1 was used to assess 
the efficacy of Y-27632 and HA-1077 in inhibiting these kinases.  The effect of ET-1 (100 nM; 0 – 30 
min exposure) on the phosphorylation of MYPT1 on residue Thr-853 was examined by 
immunoblotting.  MYPT1 was rapidly phosphorylated in cardiomyocytes exposed to ET-1, with 
detectable phosphorylation within 2 min (2.2 ± 0.4-fold relative to control), maximal phosphorylation 
at ~5 min (6.9 ± 0.8-fold) and a gradual return to basal levels by 20 min (Fig. 5.1A).  As expected, 
there was no significant change in the total protein levels over the time course studied.  Pre-incubation 
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with Y-27632 (10 µM, 10 min pre-treatment) or HA-1077 (20 µM, 30 min pre-treatment) inhibited 
the increase in phosphorylation of MYPT1 induced by ET-1 (5 min) (Fig. 5.1B).  Notably, levels of 
MYPT1 phosphorylation were reduced to less than the basal levels seen in the control cells.  Thus, Y-
27632 and HA-1077 are effective at the concentrations used. 
 
Figure 5.1.  Phosphorylation of MYPT1 in cardiomyocytes.  Cardiomyocytes were unstimulated 
(Control) or exposed to 100 nM ET-1, 10 µM Y27632, 20 µM HA1077 or ET-1 in the presence of 
each inhibitor. (A) Cardiomyocytes were exposed to ET-1 for the times indicated. (B) 
Cardiomyocytes were exposed to ET-1 for 5 min.  MYPT1 phosphorylation was assessed by Western 
blotting with antibodies to phosphorylated MYPT1(Thr-853) (upper panels) or total-MYPT1 (centre 
panels) antibodies. Densitometric analysis is shown in the lower panels as means ± SEM (n = 3 
independent experiments). *p<0.05, ***p<0.001 relative to control, ###p<0.001 relative to ET-1 
alone (one-way ANOVA with Tukey post-test).   
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5.3.2.  Effects of Y-27632/HA-1077 on cardiomyocyte gene expression 
 
The effects of Y-27632 or HA-1077 on expression of 14 selected mRNAs (chosen on the basis of 
upregulation in cardiomyocytes exposed to ET-1 for 1 h; Chapter 4) was studied by qPCR.  Selected 
mRNAs for established genes were Egr1, Egr2, Tnfaip3, Tfpi2, Arc, Slc25a25, Bmp2, Pvr, Bdnf, IL-6 
and Crem.  I also selected three genes that are hypothetical transcripts on the rat genome 
(LOC498272, LOC363060 and LOC365395).  As indicated below, thirteen of the fourteen mRNAs 
studied were upregulated in response to ET-1, consistent with the microarray data and were therefore 
validated in this respect.  In all but one case (Crem), Y-27632 and HA-1077 had similar effects on the 
increase in mRNA expression induced by ET-1 albeit to different degrees.   
 
Upregulation of Egr2 and Arc mRNAs in response to ET-1 was maximal at 30 min and this was 
inhibited substantially by Y-27632 (Egr2: 36.6%; Arc: 39.4%) or HA-1077 (Egr2: 57.5%; Arc: 44.4 
%) at this time point (Figs. 5.2, A–D; Table 5.1).  The increase in expression of Egr2 or Arc mRNA 
expression induced by ET-1 at 1 or 2 h was similarly ablated by either inhibitor (Figs. 5.2, A–D; Table 
5.1).  In the case of Arc, the inhibitory effects of Y-27632 or HA-1077 on mRNA expression were 
greater than that observed with C3T in Chapter 4 but were consistent in their effect (Fig. 5.2G; Table 
5.1 and 4.10).  Egr2 mRNA expression was significantly inhibited by of Y-27632 or HA-1077 which 
was in contrast to the effect of C3T which did not significantly inhibit its upregulation as established 
in Chapter 4 (Fig. 5.2G; Table 4.7). The obvious implication of the Egr2 result is that the inhibitory 
effect of Y-27632 or HA-1077 on the upregulation of Egr2 is a non-specific effect of the inhibitors 
(i.e. the inhibitors are having an effect on signalling intermediates other than the downstream Rho 
effectors, ROCK and PKN) because Rho has been shown to not be implicated in Egr2 upregulation in 
the microarray study (Table 4.7).  Expression of Slc25a25 mRNA was maximal following 1 h 
exposure to ET-1 and was also inhibited consistently by either Y-27632 (72.5%) or HA-1077 (91.3%) 
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(Fig. 5.2, E and F; Table 5.1).  In this case, the degree of inhibition was much greater than that of C3T 
(35.7% inhibition; Fig. 5.2G).   The effects of Y-27632 and HA-1077 on ET-1-induced changes in 
expression of mRNAs encoding Egr1, Tnfaip3 and Tfpi2 were studied only at the 1 h time point 
(Table 5.2).  The increase in expression of these mRNAs was inhibited by Y-27632 (Egr1, 63.5%; 
Tnfaip3, 73.8%; Tfpi2, 65.2%) or HA-1077 (Egr1, 47.8%; Tnfaip3, 80.1%; Tfpi2, 89.7%) (Tables 5.1 
and 5.2).  As in the case of Egr2, the other Egr family member studied, Egr1 is another example of 
further non-specific effects of the inhibitors. This is highlighted by the fact that both HA-1077 and Y-
27632 inhibited Egr1 mRNA upregulation whereas C3T did not (Table 4.7) implying that other 
signalling pathways that are inhibited by HA-1077/Y-27632 are involved in Egr1 regulation. In 
contrast, the downregulation of Tnfaip3 and Tfpi2 by HA-1077 or Y-27632 mirrors the effects of C3T 
inhibition of ET-1-induced upregulation observed in Chapter 4 (Tables 5.1 and 5.2). 
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Figure 5.2. Y-27632/HA-1077 inhibit the upregulation of Egr2, Arc or Slc25a25 mRNAs induced 
by ET-1. Cardiomyocytes were unstimulated (Controls), exposed to 100 nM ET-1, 10 κM Y-27632, 
20 µM HA-1077 or exposed to ET-1 (0.5, 1 or 2 h) following pre-treatment with Y-27632 or HA-
1077. RNA was extracted and mRNA expression analysed by qPCR. The effects of Y-27632 (blue) or 
HA-1077 (red) on RNA expression (A & B, Egr2; C & D, Arc; E & F, Slc25a25) following ET-1 
incubation (black) are indicated. G, Data from the microarray study for the effects of C3T on mRNA 
expression (from Chapter 4)*.   Results are relative to controls and are means ± SEM (n = 3). *p<0.05, 
**p<0.01, ***p<0.001 relative to Controls; #p<0.05, ##p<0.01, ###p<0.001 relative to ET-1 alone 
(one way ANOVA with TUKEY post-test).*it must be noted that the apparent inhibition of Egr2 
expression by C3T in G is in fact not statistically significant whereas that of Arc and Slc25a25 is.  
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Table 5.1. Effects of Y-27632, HA-1077 or C3T on mRNA expression induced by ET-1.  
Cardiomyocytes were unstimulated (Controls), exposed to 100 nM ET-1 (0.5, 1 or 2 h), 10 κM Y-
27632, 20 µM HA-1077 or exposed to ET-1 following pre-treatment with Y-27632 or HA-1077. RNA 
was extracted and mRNA expression analysed by qPCR. Percentage inhibition (↓) was calculated as 
(1 – [(inhibitor + ET)-(inhibitor)]/(ET) – (Control)])  100.Percentage enhancement (↑) was 
calculated by ([(inhibitor + ET)-(inhbitor)]/(ET) – (Control) - 1])  100. * Not statistically significant.  
 
Gene Inhibitor % Inhibition (↓)or 
% Enhancement 
(↑) with Inhibitor 
(ET-1 30 min) 
% Inhibition (↓) or 
% Enhancement 
(↑) with Inhibitor 
(ET-1 1 h) 
% Inhibition (↓) or 
% Enhancement 
(↑) with Inhibitor 
(ET-1 2 h) 
Egr2 Y-27632 36.6 ↓ 44.2 ↓ 94.0 ↓ 
HA-1077 57.5 ↓ 70.7 ↓ 41.4 ↓ 
C3 toxin - 32.5 ↓* - 
Arc Y-27632 39.4 ↓ 47.3 ↓ 67.6 ↓ 
HA-1077 44.4 ↓ 64.9 ↓ 90.0 ↓ 
C3 toxin - 33.7 ↓ - 
Slc25a25 Y-27632 70.0 ↓ 72.5 ↓ 99.0 ↓ 
HA-1077 80.8 ↓ 91.3 ↓ 98.6 ↓ 
C3 toxin - 35.7 ↓ - 
Egr1 Y-27632 - 63.5 ↓ - 
HA-1077 - 47.8 ↓ - 
C3 toxin - 18.9 ↓* - 
Tnfaip3 Y-27632 - 73.8 ↓ - 
HA-1077 - 80.1 ↓ - 
C3 toxin - 74.8 ↓ - 
Tfpi2 Y-27632 - 65.2 ↓ - 
HA-1077 - 89.7 ↓ - 
C3 toxin - 43.9 ↓ - 
Bmp2 Y-27632 5.4 ↑ 31.5 ↑ 48.3 ↑ 
HA-1077 36.5 ↑ 41.9 ↑ 57.7 ↑ 
C3 toxin - 105.3 ↑ - 
LOC363060 Y-27632 102.7 ↑ 77.9 ↑ 52.1 ↑ 
HA-1077 59.2 ↑ 84.7 ↑ 67.3 ↑ 
C3 toxin - 340.1 ↑ - 
LOC498272 Y-27632 69.7 ↑ 2.2 ↑ 89.0 ↑ 
HA-1077 79.7 ↑ 37.7 ↑ 115.4 ↑ 
C3 toxin - 192.0 ↑ - 
Pvr Y-27632 54.6 ↓ 39.2 ↓ 46.2 ↓ 
HA-1077 32.3 ↓ 24.6 ↓ 26.7 ↓ 
C3 toxin  85.8 ↑  
Il-6 Y-27632 81.2 ↓ 71.9 ↓ 57.1 ↓ 
HA-1077 67.5 ↓ 58.8 ↓ 56.7 ↓ 
C3 toxin - 91.2 ↑ - 
Bdnf Y-27632 57.8 ↓ 43.0 ↓ 58.1 ↓ 
HA-1077 82.2 ↓ 35.9 ↓ 81.0 ↓ 
C3 toxin - 123.3 ↑ - 
Crem Y-27632 14.4 ↑ 22.0 ↑ 2.6 ↑ 
HA-1077 72.8 ↓ 32.2 ↓ 39.7 ↓ 
C3 toxin - 118.2 ↓ - 
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Table 5.2. Inhibition of ET-1 induced upregulation of Egr1, Tnfaip3 and Tfpi2 mRNA by Y-
27632 or HA-1077. Cardiomyocytes were unstimulated (Controls), exposed to 100 nM ET-1, 10 κM 
Y-27632, 20 µM HA-1077 or exposed to ET-1 (1 h) following pre-treatment with Y-27632 or HA-
1077. RNA was extracted and mRNA expression analysed by qPCR.  Results are relative to controls 
and are means ± SEM (n = 4). **p<0.001, ***p<0.001 relative to Controls; #p<0.05, ##p<0.01, 
###p<0.001 relative to ET-1 alone (one way ANOVA with TUKEY post-test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
mRNA Inhibitor Inhibitor ET-1
Inhibitor + 
ET-1
Egr1 Y-27632 0.7  0.3 21.8  3.2** 8.3  2.7###
Egr1 HA-1077 0.9  0.1 21.3  2.8*** 11.5 v 3.2##
Egr1 C3T 1.5  0.2 4.7  0.1*** 4.5  0.5
Tnfaip3 Y-27632 1.8  0.4 19.7  1.5*** 6.7  2.4###
Tnfaip3 HA-1077 2.8  1.5 14.1  4.1*** 5.4  2.9##
Tnfaip3 C3T 2.1  1.4 12.1  0.3*** 4.9  0.4###
Tfpi2 Y-27632 1.7  0.2 7.9  0.7*** 4.1  0.8##
Tfpi2 HA-1077 1.0  0.1 4.9  0.8** 1.4  0.2###
Tfpi2 C3T 1.3  0.1 6.7  0.1*** 4.5  1.2#
Chapter 5 
Page | 181  
 
The mRNA expression levels of Bmp2 and the two hypothetical transcripts, LOC363060 and 
LOC498272 were consistently and uniformly upregulated by ET-1 at 30 min, 1 h and 2 h (Fig. 5.3).   
In contrast to the mRNAs in section 5.3.2.2, the inhibitors Y-27632 and HA-1077 further increased 
expression of these mRNAs at each time (Fig. 5.3).  Bmp2 upregulation was enhanced 28.4% by Y-
27632 (Fig. 5.3A) and 45.3% by HA-1077 (Fig. 5.3B).  Although the effects of Y-27632 and HA-
1077 were consistent with that of C3T on the upregulation of Bmp2 by ET-1 (105.3% enhancement 
with C3T; Fig. 5.3G and Table 5.1), the level of enhancement was much less.  The hypothetical 
transcript LOC363060 was upregulated ~2-fold relative to controls at 30 min, 1 h and 2 h ET-1 (Fig. 
5.3, C and D).  This upregulation in expression was again increased by Y-27632 (~78%; Fig. 5.3C) 
and HA-1077 (~70%; Fig. 5.3D).  In the microarray study (Chapter 4), the change in expression of 
LOC363060 mRNA at 1 h ET-1 was amongst those most profoundly affected by C3T with an 
enhancement of ~340% (Fig. 5.3G and Table 5.1).  This was obviously a much greater enhancement 
than that seen with Y-27632 or HA-1077 at any ET-1 time point when studied by qPCR.  The other 
hypothetical transcript, LOC498272, was also upregulated by ET-1 at all three time points (Fig. 5.3, E 
and F).  Here, because of the effects of the Y-27632 on baseline LOC498272 mRNA expression, the 
further enhancement in ET-1-induced mRNA upregulation by Y-27632 was only 2.2% (Fig. 5.3E).  
The effect of HA-1077 in enhancing expression of LOC498272 mRNA was much greater (37.7%) 
(Fig. 5.3F).  As with LOC363060 expression, C3T had a greater enhancing effect (192%) than either 
Y-27632 or HA-1077 (Fig. 5.3G and Table 5.1). 
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Figure 5.3. Effects of Y-27632 or HA-1077 on the upregulation of Bmp2, LOC363060 and 
LOC498272 mRNAs induced by ET-1. Cardiomyocytes were unstimulated (Controls), exposed to 
100 nM ET-1, 10 κM Y-27632, 20 µM HA-1077 or exposed to ET-1 following pre-treatment with Y-
27632 and HA-1077. RNA was extracted and mRNA expression analysed by qPCR.  The data 
showing the effects of Y-27632 (blue) or HA-1077 (red) on mRNA expression (A and B, Bmp2; C 
and D, LOC363060; E and F, LOC498272) following ET-1 incubation (black).  G, Data from the 
microarray study for the effects of C3 toxin on mRNA expression (from Chapter 4). Results are 
relative to controls and are means ± SEM (n = 4). *p<0.05, **p<0.01, ***p<0.001 relative to 
Controls; #p<0.05, ##p<0.01, ###p<0.001 relative to ET-1 alone (one way ANOVA with TUKEY 
post-test). 
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The relative effects of Y-27632/HA-1077 and C3T on ET-1-induced upregulation in expression of 
mRNAs encoding Pvr, IL-6 and Bdnf were very different (Fig. 5.4).  Pvr mRNA expression was 
maximal following stimulation with ET-1 for 1 h (2.9-fold relative to control).  This upregulation was 
inhibited 39.2% with Y-27632 (Fig. 5.4A) and 24.6% with HA-1077 (Fig. 5.4B).  This was in 
complete contrast to the effect of C3T, which enhanced ET-1-induced upregulation of Pvr mRNA 
expression (85.8%; Fig. 5.4G and Table 5.1).  IL-6 mRNA expression was marginally greater at 2 h 
(8.7-fold) vs 1 h (7.9-fold) stimulation with ET-1.  The effects of Y-27632 (64.5% inhibition; Fig. 
5.4C) and HA-1077 (58.4% inhibition; Fig. 5.4D) on this upregulation were consistent (Table 5.1).  
However, the effect of C3T on the upregulation of IL-6 by ET-1 did not mirror this (Fig. 5.4G).  C3T 
promoted a greater degree of upregulation than that induced by ET-1 alone (91.2% enhancement; 
Table 5.1).  As with Pvr, the upregulation of Bdnf mRNA expression by ET-1 was maximal at 1 h 
(3.1-fold; Figs. 5.4, E and F).  This upregulation was inhibited 43.0% with Y-27632 (Fig. 5.4E) and 
35.9% with HA-1077 (Fig. 5.4F).  This too was in contrast to the large (123.3%) enhancement in Bdnf 
mRNA expression induced by C3T of the upregulation induced by ET-1 alone (Fig. 5.4G and Table 
5.1). 
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Figure 5.4. Effects of Y-27632 or HA-1077 on upregulation of Pvr, IL-6 and Bdnf mRNAs 
induced by ET-1. Cardiomyocytes were unstimulated (Controls), exposed to 100 nM ET-1, 10 κM 
Y-27632, 20 µM HA-1077 or exposed to ET-1 following pre-treatment with Y-27632 and HA-1077.  
RNA was extracted and mRNA expression was analysed by qPCR.  The data show the effects of Y-
27632 (blue) or HA-1077 (red) on the regulation of RNA expression (A and B, PVR; C and D, IL-6; 
E and F, Bdnf) following ET-1 incubation (black).  G, Data from the microarray study for the effects 
of C3T on mRNA expression.  Results are relative to controls and are means ± SEM (n = 4). *p<0.05, 
**p<0.01, ***p<0.001 relative to Controls; #p<0.05, ##p<0.01, ###p<0.001 relative to ET-1 alone 
(one way ANOVA with TUKEY post-test). 
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Uniquely among the fourteen RNAs investigated here, Y-27632, HA-1077 and C3T all had differing 
effects on Crem mRNA expression (Fig. 5.5).  Crem mRNA expression was maximal following 1 h 
stimulation with ET-1 (4.4-fold relative to control; Fig. 5.5 A).  This was inhibited 32.2% by HA-
1077 but was enhanced 22.0% by Y-27632 (Fig. 5.5, A and B; Table 5.1).  In contrast, C3T enhanced 
the level of expression by 118.2% (Fig. 5.5C; Table 5.1).   
 
 
 
Figure 5.5.  Effects of Y-27632 or HA-1077 on upregulation of Crem mRNA expression by ET-1. 
Cardiomyocytes were unstimulated (Controls), exposed to 100 nM ET-1, 10 κM Y-27632, 20 µM 
HA-1077 or exposed to ET-1 following pre-treatment with Y-27632 and HA-1077.  RNA was 
extracted and mRNA expression analysed by qPCR.  The data show the effects of Y-27632 (blue) or 
HA-1077 (red) on CREM mRNA following ET-1 incubation (black).  C, Data from the microarray 
study for the effects of C3 toxin on mRNA expression.  Results are relative to controls and are means 
± SEM (n = 4).  *p<0.05, **p<0.01, ***p<0.001 relative to Controls; #p<0.05, ##p<0.01, ###p<0.001 
relative to ET-1 alone (one way ANOVA with TUKEY post-test). 
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The expression profile for LOC365395 could not be validated by qPCR (Fig. 5.6).   An alternative 
hypothetical transcript, LOC363060, was validated (Fig. 5.5, C and D) demonstrating that it is 
possible to confirm expression of hypothetical mRNAs.  Comparison of qPCR amplification plots for 
LOC365395 (Fig. 5.6A) vs LOC363060 (Fig. 5.6B) shows distinctly different profiles.  Relative 
concentrations of RNA during the exponential phase of the reaction are determined by plotting 
fluorescence against cycle number on a logarithmic scale.  The quantity of RNA theoretically doubles 
every cycle during the exponential phase and relative amounts of RNA are calculated from this.  The 
exponential phase for LOC363060 is seen and mRNA levels measured.  However, there was no 
amplification of LOC365395, even by 40 cycles.    
 
Figure 5.6. qPCR amplification plots for hypothetical mRNAs. qPCR was performed using 
primers designed for LOC363060 (A) or LOC365395 (B).  Rn is the report signal normalised to the 
passive ROX reference dye and is a log scale. ΔRn calculates the magnitude of the signal generated by 
the given set of PCR conditions.  No RT control contains no reverse transcriptase in the reaction mix. 
A: LOC363060 qPCR amplification plot
B: LOC365395 qPCR amplification plot
No RT control
Individual samples 
R
n
Cycle Number
R
n
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5.4.  Discussion 
 
5.4.1.  Phosphorylation of MYPT1 and inhibition by Y27632 or HA1077 
 
The primary purpose of the studies of phosphorylation of MYPT1 was to establish effective 
conditions (e.g. concentration and duration of pre-treatment) for the use of Y-27632 and HA-1077.  
However, it is perhaps worth considering the implications of the data themselves.  ET-1 promoted 
phosphorylation of the myosin-binding subunit of MLCP, MYPT1 on residue Thr-853, a response that 
was inhibited by established inhibitors of ROCK/PKN, HA-1077 and Y-27632 (Fig. 5.1).  Although 
the inhibitory
 
site of MYPT1 phosphorylated by ROCK1/2 was originally identified as Thr-
696, agonist-induced
 
increases in phosphorylation of Thr-853 have been more commonly studied 
(Kitazawa et al, 2003).  Thr-853 is not thought to be an inhibitory site, but its phosphorylation 
critically affects localisation
 
of MLCP and the positioning of its catalytic subunit on myosin (Velasco 
et al, 2002).  Phosphorylation of Thr-853 is therefore responsible
 
for inhibition of MLCP when Thr-
696 is constitutively
 
phosphorylated.  MLCP is responsible for dephosphorylation of MLC, to 
counteract the phosphorylation induced by MLCK.  Inhibition of MLCP in response to ET-1 may 
therefore lead to an increase in phosphorylation of MLC which may influence contractility or even 
sarcomeric organisation.  Given the effects of Y-27632 and HA-1077 (Fig. 5.1B), it seems likely that 
[as in smooth muscle (Kimura et al, 1996)], ROCK1/2 (though potentially also PKN1/2) are required 
to maintain MLCP in its inactive state through the phosphorylation of the MYPT1 subunit.   
 
5.4.2.  Rho signalling to cardiomyocyte mRNAs that are upregulated by ET-1 
 
The focus of this chapter was to further investigate the role of Rho signalling in specific changes in 
cardiomyocyte mRNA expression induced by ET-1.  Fourteen RNAs were selected based on either 
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their upregulation in expression in response to ET-1 (1 h) or on their apparent dependency on RhoA 
signalling to facilitate these changes, as observed in the microarray study (Chapter 4).  Here, their 
expression changes, and the effects of Y-27632 or HA-1077 on these changes, were investigated by 
qPCR.  The small molecule inhibitors Y-27632 and HA-1077 are widely used in various cell types 
and serve as useful tools for dissecting the roles of ROCK1/2
 
in cellular responses (Nagumo et al, 
2000;Darenfed et al, 2007).  In vitro, both compounds also equipotently inhibit PKN1/2 by the same 
mechanism (Davies et al, 2000).  Given that ROCK1/2 and PKN1/2 are well established Rho-effectors 
and the inhibitors are widely used, it was possible that they could have been used for further studies 
here. 
 
As discussed above, for many of the mRNAs studied Y-27632 and HA-1077 gave very similar results 
to each other and to C3T (Arc, Tfpi2, Tnfaip3, Slc25a25, Bmp2, LOC363060, LOC498272; Figs. 5.2 
and 5.3; Tables 5.1 and 5.2).  However, in some cases Y-27632 and HA-1077 had similar effects on 
mRNA expression that were opposite to those of C3T (Pvr, IL-6, Bdnf; Fig. 5.4; Table 5.2) and, for 
Crem, there was no consistency in the effects of the three different inhibitors on mRNA expression 
(Fig. 5.5; Table 5.2). For Egr1 and Egr2 expression, Y-27632 and HA-1077 had a more enhanced (and 
statistically significant) inhibitory effect on mRNA expression whereas C3T did not (as observed in 
Table 4.7). This further highlights the potential off-target effects of the inhibitors on other non-Rho-
related signalling pathways.  It must therefore be with caveats that Y-27632 and/or HA-1077 should 
be used to dissect the role of Rho-dependent protein kinase signalling in any cellular response.   
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5.4.4.  The use of Y-27632 and HA-1077 as selective inhibitors of ROCK1/2 and/or 
PKN1/2 
 
Although Y-27632 and HA-1077 have similar inhibitory effects on ROCK1/2 and PKN1/2, both 
compounds also exhibit non-specific inhibition of other protein kinases in vitro (Davies et al, 2000) 
(Fig. 5.7).  At higher concentrations, Y-27632 inhibits MSK1, RSK2 and PHK, whereas HA-1077 not 
only inhibits MSK1 2.5-fold more effectively than Y-27632, it also targets RSKs and PKA with 
significant efficacy (Davies et al, 2000;Ikenoya et al, 2002).  At high concentrations, Y-27632 may 
also inhibit citron kinase (Ishizaki et al, 2000) (Fig. 5.7). Of these enzymes, RSKs are clearly 
activated by ET-1 in cardiomyocytes (Sadoshima et al, 1995) and, since MSKs are activated by PE 
(Deak et al, 1998;Markou and Lazou, 2002), it is probable that these enzymes are also activated by 
ET-1.  However, the lack of specificity of both Y-27632 and HA-1077 has not been shown in vivo and 
there are exceptions.  For example, myotonic dystrophy kinase is not inhibited by Y-27632 or HA-
1077, although its kinase domain is almost identical to that of ROCK1/2 (Muranyi et al, 2001).  
Furthermore, both inhibitors have been successful in many pre-clinical studies, indicating the potential 
benefit of clinical Rho pathway inhibition.  HA-1077 (fasudil) has been in clinical use in Japan for 
several years for the treatment of cerebral vasospasm following subarachnoid haemorrhage 
(Tachibana et al, 1999).  However, it remains to be determined whether ROCK1/2 is the critical target, 
or the simultaneous inhibition of several targets is required for the clinical effects. 
 
Therefore, while Y-27632 and HA-1077 cannot be used here to definitively establish physiological 
roles for ROCK1/2 or PKN1/2, they can be useful in excluding or otherwise the involvement of these 
kinases in the regulation of expression of target genes.  Nevertheless, there are obvious caveats and 
limitations associated with the results and other, more specific approaches are required for further 
delineation of RhoA signalling in cardiomyocytes.  Knock-down (with siRNA), inhibition (by 
Chapter 5 
Page | 190  
 
overexpression of dominant-negative proteins) or overexpression of ROCK1/2 or PKN1/2 using 
adenovirally expressed constructs to infect cardiomyocytes may be useful.  Given that PKN1/2 is 
implicated in regulating mRNA expression in cardiomyocyte hypertrophy, these would appear to be 
the prime candidates. 
 
 
Figure 5.7. Structures of Y-27632 and HA-1077 and their effects on different protein kinases. 
(A) Structures of Y-27632 and HA-1077.  (B) The effects of Y-27632 and HA-1077 on protein kinase 
activities (adapted from Davies et al. 2000).  Results are the percentage of activity relative to control 
incubations (i.e. in the absence of inhibitor) and are the means ± SD of duplicate determinations. ATP 
was present at 0.1 mM in all assays.   
 
Protein kinase
Activity of kinase (% of control)
Y27632 (10 µM) HA1077 (20 µM)
RSK2 72 ± 13 37 ± 6
MSK1 57 ± 2 19 ± 2
PKA 91 ± 2 35 ± 2
S6K1 94 ± 3 32 ± 1
ROCKII 13 ± 2 7 ± 1
PKN2 6 ± 1 13 ± 1
Y-27632 dihydrochloride HA-1077 dihydrochloride
A
B
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CHAPTER 6:  ACTIVATION OF PKN1 IN CARDIOMYOCYTES 
 
6.1.  Introduction 
 
PKN1 and PKN2 are members of the PKC superfamily.  PKN1, also known as PKC-related kinase 1 
(PRK1),
 
is a serine/threonine kinase with a relative molecular mass
 
of ~120 kDa (Mukai and Ono, 
1994;Palmer et al, 1994).  The related kinase, PKN2, has a relative molecular mass of ~140 kDa 
(Palmer et al, 1995b).  PKN1 is highly expressed in the heart relative to other tissues, and both PKN1 
and PKN2 are expressed in cardiomyocytes (Mukai and Ono, 1994;Palmer et al, 1995b;Quilliam et al, 
1996).   PKN1 localises
 
mainly to the cytosolic fraction and, in non-cardiomyocytes, is implicated in a 
wide variety
 
of functions, such as cytoskeletal regulation, cell adhesion,
 
vesicle transport and cell 
cycle regulation (Mukai, 2003). 
 
As for all members of the PKC superfamily, PKNs appear to require lipids (usually phospholipids) for 
activation and PKN1 may be activated by cardiolipin, PtdIns(4,5)P2, PtdIns(3,4,5)P3, arachidonic 
acid and/or lysophospholipids (Mukai et al, 1994;Yu et al, 1997;Zhu et al, 2004).  Studies suggest that 
the extreme C-terminus of the protein is required for this lipid sensitivity (Palmer et al, 1995a;Yu et 
al, 1997) although it seems probable that, by analogy with other PKCs, the actual lipid binding region 
should lie within the N-terminal regulatory domain.  PKN1 binds to and is activated by Rho-family 
small G proteins, notably RhoA, RhoB and Rac1, in their active GTP-bound states (Watanabe et al, 
1996;Vincent and Settleman, 1997;Flynn et al, 1998).  Rho GTPases are also responsible for the 
location of PKN1, with RhoB causing localisation to an endosomal compartment in fibroblasts, a 
translocation event which is associated with the accumulation of a more phosphorylated form of the 
kinase (Mellor et al, 1998).  PKNs are phosphorylated on a critical residue in their activation loops 
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(T774 for PKN, T816 for PKN2 as per the human sequence) and this is probably mediated by PDK1 
(Balendran et al, 1999;Dong et al, 2000;Flynn et al, 2000).  Rho-dependent activation of PKN1
 
via 
PDK1 has been reported (Parekh et al, 2000).  Activated RhoA binds
 
to PKN1 and induces a 
conformational change that facilitates binding to PDK1.  PDK1 phosphorylates PKN1 in the 
activation
 
loop and stimulates its protein kinase activity (Balendran et al, 1999).  This
 
model adds to 
an interesting study in vivo, in which overexpression
 
of RhoB recruits PDK1 to an endosomal 
compartment only when
 
PKN1 is co-expressed, suggesting that a complex
 
is formed between these 
molecules (Flynn et al, 2000).  Other than the activation loop phosphorylation of PKN1 (T774) and 
PKN2 (T816), there are many other phosphorylation sites in PKN1 (and probably PKN2) including 
T64, S377, T504, S534, S577, S579, S612 and T778 (Fig. 1.5) (Peng et al, 1996;Yoshinaga et al, 
1999).  At least some of these are auto-phosphorylations, but the functional role of none of these 
phosphorylations is entirely clear.      
 
In addition to the Rho GTPases, other proteins have been identified to interact with the PKNs.  These 
include signalling proteins such as p38-MAPKs, MKK3, MKK6, PDK1, MEKK2, PKB and 
phospholipase D (Quilliam et al, 1996;Flynn et al, 2000;Koh et al, 2000;Sun et al, 2000;Shibata et al, 
2001;Cottone et al, 2006), transcription factors such as the androgen receptor, NRDF/NeuroD2 and 
PCD17 (Takanaga et al, 1998;Metzger et al, 2003), and cytoskeletal proteins such as neurofilament 
protein, vimentin and α-actinin (Mukai et al, 1996b;Matsuzawa et al, 1997;Mukai et al, 1997).  
However, in most cases, the physiological significance of these interactions has yet to be determined.  
PKNs may be cleaved by caspase 3 (Takahashi et al, 1998) to generate a truncated and constitutively-
active form.  This has been detected in ischemia/reperfusion models of
 
the rat retina (Sumioka et al, 
2000) and brain (Ueyama et al, 2001), suggesting that PKNs may modulate
 
cell survival or death 
during ischemia/reperfusion.  Consistent with their putative role as Rho effectors, PKN1 and PKN2 
are also implicated in regulation of the actin cytoskeleton (Dong et al, 2000;Bourguignon et al, 
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2004;Lim et al, 2004;Darenfed et al, 2007).  Members of the PKN family reside in the cytosol but 
exhibit the capacity to translocate to the nucleus in a signal-dependent manner.  As such, it has been 
proposed that PKNs may play an important role in transcriptional regulation of gene expression.  For 
example, PKN1 can regulate SRF-dependent transcription, and is implicated in regulating gene 
expression via the p38-MAPK pathway (Marinissen et al, 2001;Gudi et al, 2002;Deaton et al, 2005).  
In addition, PKN has also been shown to bind to the androgen receptor and stimulate its 
transcriptional activity (Metzger et al, 2003). 
 
In cardiomyocytes, PKN1 activates ANF mRNA expression (Morissette et al, 2000;Fischer et al, 
2007).  Very recent studies indicate that it can be activated by simulated ischemia/reperfusion in 
cardiomyocytes and suggests that activation
 
of PKN1 in the heart may be an endogenous mechanism 
of cardioprotection against
 
ischemia/reperfusion injury (Takagi et al, 2010;Kajimoto et al, 2011).  
Given that RhoA is activated by ET-1 in cardiomyocytes and that PKN1 may be activated by RhoA 
and RhoA/PKN1 are implicated in the regulation of transcription, the focus of this chapter is to 
investigate the activation of PKN1 in neonatal rat cardiomyocytes.   
 
6.2.  Methods 
 
6.2.1.  Cardiomyocyte cultures, adenovirus infections and preparation of whole 
cell extracts. 
 
Cardiomyocytes were prepared as described in section 2.3.  Unless experiments involved adenoviral 
(AdV) infection, serum was withdrawn 24 h before experimentation.  Cardiomyocytes were then 
unstimulated (Control, 0 min) or were exposed to 100 nM ET-1, 0.2 mM H2O2, 1 mM H2O2, 200 nM 
Calyculin A, 50 mU/ml insulin or 0.5 M Sorbitol for the times indicated.  Incubations were terminated 
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simultaneously with timed additions of agonists.  Agonist incubation times were dependent upon the 
time at which the different MAPKs are activated maximally: 5 min ET-1 for activation of ERK1/2 
(Clerk et al, 1996) or p38-MAPKs (Clerk et al, 1998b), 15 min ET-1 for activation of JNKs 
(Bogoyevitch et al, 1995a), 15 min H2O2 (with either 0.3 mM or 1 mM) for activation of ERKs, p38-
MAPK and JNKs (Clerk and Sugden, 1997b) and 30 min sorbitol for activation of ERK1/2, p38-
MAPK and JNKs (Clerk and Sugden, 1998).    
 
Adv vectors encoding rat N-terminally FLAG-tagged wild-type PKN1 (FLAG-PKN1) were generated 
(section 2.11) and cultured cardiomyocytes were infected with these viruses (section 2.11.3).  
Cardiomyocytes were used for experimentation 20 h after infection.  To establish infectivity (titre), 
different concentrations (1/800, 1/4800 and 1/24000 dilutions) of 3
rd
 and 4
th
 generation viruses were 
used to infect cardiomyocytes.  Whole cell extracts were immunoblotted with rabbit polyclonal anti-
FLAG antibody (section 2.11).  To study the effect of FLAG-PKN1 overexpression on MAPK 
phosphorylation, infected cardiomyocytes in culture were treated with ET-1 (100 nM), H2O2 (0.3 mM 
or 1 mM) or sorbitol (0.5 M) for the indicated times.  Uninfected cardiomyocytes (expressing PKN1 
endogenously) were treated with the agonists and harvested simultaneously.   MAPK phosphorylation 
was analysed by immunoblotting with antibodies selective for phosphorylated or total ERK1/2, p38-
MAPK and JNK1/2 (section 2.6).   
 
6.2.2.  Fast protein liquid chromatography (FPLC) of PKN1/2 
 
Cardiomyocytes (8 × 10
6
 cells) were unstimulated or incubated with ET-1 (100 nM, 5 min) or 
calyculin A (200 nM, 20 min).  Cell extracts were applied to a Mono-Q HR 5/5 ion-exchange column 
in order to separate PKN1/2 species on the basis of charge.  Increased phosphorylation of PKN1/2 is 
associated with increased negative charge on the protein thereby requiring a higher salt concentration 
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for elution from the positively charged column beads.  Proteins were eluted with NaCl in Buffer E 
(0.18 – 0.36 M NaCl gradient over 18 ml, 0.5 ml fractions, 0.5 ml/min flow-rate).  The full FPLC 
experimental protocol is described in the section 2.13.  Samples were taken from each fraction for 
immunoblotting with antibodies to phosphorylated PKN1/2 or total PKN2 as described in section 2.6.    
At the time of this study, a commercially-available antibody selective for PKN1 was not available.  
The bands were visualised by enhanced chemiluminescence and were quantified by densitometry 
using ImageQuant 7.0 software.  The values were normalised to the control (unstimulated 
cardiomyocytes). 
 
6.2.3.  Assays of FLAG-PKN1 activity (immunoprecipitation kinase assays) 
 
Cardiomyocytes were infected with FLAG-PKN1 virus (1/800, generation 4) as described in section 
2.11.3, then incubated with agonists/stimuli in the presence or absence of LY294002 for the indicated 
times.  FLAG-PKN1 was immunoprecipitated using EZ-view
TM
 Red ANTI-FLAG M2 affinity beads.  
The full method for this procedure is provided in section 2.12.  Immunoprecipitated FLAG-PKN1 
activity was assayed by the incorporation of radioactivity from [γ-32P]ATP into a peptide substrate 
(AKRRRKGSFFYGG) as described in section 2.12.2.  For experiments involving Y-27632 and HA-
1077, cardiomyocytes were unstimulated or incubated with 1 mM H2O2 for 5 or 15 min.  Following 
immunoprecipitation, the kinase assays were performed in the absence or presence of either Y-27632 
(10 µM) or HA-1077 (20 µM) to inhibit PKN1 directly.  PKN1 activity was taken as the difference in 
32
P incorporation between assays in the absence and presence of either inhibitor.  Further experimental 
details can be found in section 2.12.2. 
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6.2.4.  Statistical analysis 
 
Results are means ± SEM (n = 3 or 4 independent myocyte preparations).  Statistical analysis of the 
data was performed with Graphpad Prism 4 using one-way ANOVA with a Tukey multiple 
comparisons post-test.   
 
6.3.  Results  
 
6.3.1.  Phosphorylation of endogenous PKN1/2 in response to calyculin A or ET-1 
 
Calyculin A inhibits the Ser/Thr phosphatases protein phosphatase 1 and 2A (PPP1/PPP2A) 
equipotently (Suganuma et al, 1992).  Cardiomyocytes were unstimulated or were incubated with 200 
nM calyculin A for up to 20 min and cells extracts were immunoblotted with antibodies that detect 
PKN1/2 phosphorylated on the activation loop Thr (Thr774 for PKN1 and Thr816 for PKN2).  PKN1 
was detected as a band of ~120 kDa whereas PKN2 was detected as a band of ~140 kDa.  PKN1 and 
PKN2 exhibited a marked increase in phosphorylation in response to calyculin A (Fig. 6.1A).  For 
both isoforms, the increase in phosphorylation was detected within 10 min and increased further after 
20 min exposure to calyculin A (PKN2, 5.5 ± 0.2-fold; PKN1, 4.8 ± 0.3-fold).  There was no change 
in total PKN2 abundance over the 20 min time course (Fig. 6.1A).  ET-1 had no effect on 
phosphorylation of PKN1/2 and, as with calyculin A, the abundance of total PKN2 remained constant 
over the time course (Fig. 6.1B). 
 
Although, calyculin A increases phosphorylation of PKN1/2 (Thr774/816) in cardiomyocytes and this 
may increase activity (Ishihara et al, 1989), this does not necessarily indicate that PKN1/2 are indeed 
activated in this context, given that PKN1/2 are subject to additional phosphorylations [see Chapter 1, 
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section 1.5.5.2 and Fig. 1.5; (Peng et al, 1996;Yoshinaga et al, 1999)].  This can only be assessed by 
purification of the enzymes which are then assayed for activity using in vitro protein kinase assays.  
Unfortunately, it was not possible to immunoprecipitate endogenous PKN1/2 using the antibodies that 
were commercially-available.  Partial purification of PKN1/2 using FPLC was therefore attempted. 
 
Figure 6.1.  Phosphorylation of PKN1/2 in cardiomyocytes exposed calyculin A or ET-1. 
Cardiomyocytes were exposed to 200 nM calyculin A (A) or 100 nM ET-1 (B) for the times indicated. 
Cardiomyocyte extracts were immunoblotted with antibodies to phospho-PKN1/2 (Thr774/816) (top 
panels) or total PKN2 (centre panels).  Densitometric analysis is shown in the lower panels.  Results 
are means ± SEM (n = 3 independent preparations of cardiomyocytes). ***p<0.001 relative to 
controls (one-way ANOVA with Tukey post-test). 
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6.3.2.  FPLC separation of PKN1 and PKN2 
 
Phosphorylated proteins have an increase in negative charge and can often be separated from lesser or 
non-phosphorylated forms by anion-exchange chromatography.  To determine whether PKN1/2 may 
be partially purified using FPLC (for in vitro kinase assays) and to examine how the phosphorylation 
status of PKN1/2 may be regulated, cardiomyocyte extracts were subjected to MonoQ FPLC followed 
by immunoblotting of the fractions with antibodies for phospho-PKN1/2 (Thr774/816) or total PKN2.  
Extracts from unstimulated cardiomyocytes, cardiomyocytes exposed to ET-1 (100 nM, 5 min) and 
cardiomyocytes exposed to calyculin A (200 nM, 20 min) were compared.  Using extracts from 
unstimulated cardiomyocytes, phospho-PKN1/2 (Thr774/816) eluted as a broad peak between ~0.22 
and 0.28 M NaCl (fractions 29 – 32) (Fig. 6.2A).  Total PKN2 in unstimulated cardiomyocyte samples 
eluted between ~0.21 and 0.33 M NaCl (fraction 28 – 34) (Fig. 6.2A).  The elution profiles were 
similar for extracts from cardiomyocytes exposed to ET-1 (Fig. 6.2B).  With extracts from 
cardiomyocytes exposed to calyculin A, phospho-PKN1/2 (Thr774/816) eluted as a much broader 
peak that was slightly shifted to higher NaCl concentrations (~0.23-0.31 M NaCl; fractions 30-38) 
(Fig. 6.2C).  The degree of phosphorylation of PKN1/2 following exposure to calyculin A appeared 
greater than in unstimulated cells, consistent with the increase in phosphorylation of PKN1/PKN2 
detected by immunoblotting of whole extracts (Fig. 6.1A).  With calyculin A, total PKN2 also eluted 
in a broader peak (0.22 – 0.32 M NaCl; fractions 29 – 38) (Fig. 6.2C).  The data are consistent with an 
increase in phosphorylation of PKN1/2 in addition to the activation loop phosphorylation sites.  The 
similarity of the MonoQ FPLC profiles for PKN1/2 from unstimulated cardiomyocytes and 
cardiomyocytes exposed to ET-1, and the shift to elution at higher NaCl concentrations is further 
highlighted by the densitometric profiles of the blots (Fig. 6.2D).  Unfortunately, the elution profiles 
of PKN1/2 was very broad and it proved impossible to develop a specific assay for the enzyme.  In 
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order to examine further the mechanism of activation of PKN1, I therefore constructed adenoviruses 
for overexpression of an epitope-tagged form of the protein that could be immunoprecipitated. 
 
Figure 6.2. MonoQ FPLC profiles for PKN1/2 in cardiomyocyte extracts: effects of ET-1 or 
calyculin A.  Cardiomyocytes were unstimulated (Control), or exposed to ET-1 (100 nM, 5 min) or 
calyculin A (200 nM, 20 min).  Extracts were subjected to MonoQ FPLC to separate the proteins on 
the basis of their charge. Fractions were immunoblotted with antibodies to phospho-PKN1/2 
(Thr774/816) or total PKN2.  Representative immunoblots for fractions 20 – 43 are shown for 
controls (A), ET-1 stimulation (B) or calyculin A treatment (C).  Results are representative of 3 
independent experiments.  (D) Densitometric analysis of the immunoblots shown in panels A-C.  The 
mean data for 3 independent experiments are plotted. 
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6.3.3. Overexpression and immunoprecipitation of FLAG-PKN1 in 
cardiomyocytes 
 
Adenoviruses were generated for expression of FLAG-PKN1 in cardiomyocytes.  The infectivity and 
potency of the viruses was amplified through sequential re-infections of HEK293 cells.  Different 
generations of virus were used to infect cardiomyocytes and expression of FLAG-PKN1 in 
cardiomyocyte extracts was assessed by immunoblotting with antibodies to the FLAG epitope.  
FLAG-PKN1 was readily detected as a dominant band of ~120 kDa in extracts from cardiomyocytes 
infected with 3rd or 4th generation viruses (Fig. 6.3A, top panel).  Endogenous PKN2 was unchanged 
in infected cardiomyocytes overexpressing FLAG-PKN1 (Fig. 6.3A, lower panel).  All subsequent 
experiments used generation 4 viruses at 1:800 dilution.  Overexpressed FLAG-PKN1 could be 
immunoprecipitated from cardiomyocyte extracts using antibodies to the FLAG epitope (Fig. 6.3B). 
 
Figure 6.3. Overexpression of FLAG-PKN1 in cardiomyocytes. Cardiomyocytes were uninfected 
(control), or infected (24 h) with increasing concentrations of 3rd or 4th generation adenoviruses 
encoding FLAG-PKN1 (A), or with 4th generation viruses at 1:800 dilution (B).  (A) Extracts were 
immunoblotted with polyclonal antibodies for the FLAG epitope (upper panel) or for endogenous 
PKN2 (lower panel).  (B), Immunoblot of overexpressed FLAG-PKN1 in total extracts or following 
immunoprecipitation (pellet extract) using monooclonal antibodies for the FLAG epitope. 
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6.3.4.  The effect of ET-1 and calyculin A on PKN1 activation in cardiomyocytes  
 
To determine whether ET-1 and/or calyculin A affects PKN1 activity, cardiomyocytes were infected 
with adenoviruses encoding FLAG-PKN1 and the activity of immunoprecipitated FLAG-PKN1 was 
measured using in vitro protein kinase assays.  An assay was developed using a peptide substrate 
(AKRRRKGSFFYGG, 100 µM).  The activity of FLAG-PKN1 was not changed following exposure 
to ET-1 (Fig. 6.4).  However, FLAG-PKN1 activity was significantly increased by calyculin A (200 
nM, 20 min) to a level of 9.2 ± 3.4-fold, relative to FLAG-PKN1 from unstimulated controls.   
 
Figure 6.4. Effect of ET-1 or calyculin A on the activity of FLAG-PKN1.  Cardiomyocytes were 
infected with adenoviruses encoding FLAG-PKN1 (24 h).  Infected cardiomyocytes were 
unstimulated or exposed to ET-1 (100 nM, 5 min) or calyculin A (200 nM, 20 min).  FLAG-PKN1 
was immunoprecipitated and the activity measured using in vitro kinase assays.  Results are expressed 
relative to controls as means ± SEM for 4 independent experiments.  *p<0.05 relative to control (one-
way ANOVA with Tukey post-test). 
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6.3.5.  Effects of overexpression of PKN1 on phosphorylation of MAPKs  
 
PKN1 is implicated in the regulation of p38-MAPKs (Deaton et al, 2005) and recent work with PKN1 
null cells (mouse embryonic fibroblasts) suggest that it promotes activation of JNKs in the context of 
cellular stress (Professor Peter J. Parker, personal communication).  p38-MAPKs and JNKs are both 
activated by ET-1 (Bogoyevitch et al, 1995a;Clerk et al, 1998b) but are particularly activated by 
cellular stresses including hyperosmotic shock and oxidative stress (Sugden and Clerk, 1998b).  I 
therefore examined the effects of overexpression of FLAG-PKN1 on MAPK activation by ET-1 or 
H2O2.  Cardiomyocytes were uninfected or infected with adenoviruses encoding FLAG-PKN1 and 
exposed to ET-1, H2O2 or 0.5 M sorbitol.  The infected cardiomyocytes showed a consistent and high 
level of overexpression of FLAG-PKN1 (Fig. 6.4).  Exposure of infected cardiomyocytes to ET-1, 
H2O2 or 0.5 M sorbitol had no effect on FLAG-PKN1 expression levels and levels of PKN2 remained 
stable (Fig. 6.5).   
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Figure 6.5. Overexpression of FLAG-PKN1 in cardiomyocytes exposed to ET-1, H2O2 or 
hyperosmotic shock.  Cardiomyocytes were infected with adenovirusus encoding FLAG-PKN1 (+) or 
were uninfected (-).  After 24 h, cardiomyocytes were exposed to ET-1 (100 nM), H2O2 (0.3 mM or 
1mM) or sorbitol (0.5 M) for the times indicated.  Expression of FLAG-PKN1 was analysed by 
Western blotting using rabbit polyclonal anti-FLAG antibodies (upper panel).  Total PKN2 was also 
assessed by immunoblotting (centre panel).  Densitometric analysis of the expression levels of FLAG-
PKN1 is shown in the lower panel.  Results are means ± SEM for n = 3 independent experiments.   
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The effect of FLAG-PKN1 expression on activation of MAPKs was analysed by immunoblotting with 
antibodies to the phosphorylated (i.e. activated) MAPKs and, to allow for any effect of infection on 
basal MAPK levels, total MAPKs.  In uninfected cardiomyocytes exposed to ET-1 for 5 min, the 
degree of phosphorylation of ERK1 and ERK2 were 5.1 ± 0.1-fold and 4.9 ± 0.4-fold relative to 
controls (n = 3) (Fig. 6.6).  This activation was significantly inhibited by overexpressed FLAG-PKN1 
(levels of phosphorylation were reduced to 2.8 ± 0.1-fold for ERK1 and 3.1 ± 0.1-fold for ERK2).  A 
similar effect was seen in cardiomyocytes exposed to ET-1 for 15 min.  Total ERK1/2 abundance was 
similar in uninfected and infected cardiomyocytes.  For p38-MAPK, the level of phosphorylation was 
substantially increased in cardiomyocytes exposed to ET-1 (16.3 ± 2.2-fold at 15 min, relative to 
controls) and this was not affected significantly by overexpression of FLAG-PKN1 (Fig. 6.7). Total 
p38-MAPK expression was also similar in uninfected and infected cardiomyocytes.  Phosphorylation 
of JNKs (p46 and p54 JNKs) was substantially increased in uninfected cardiomyocytes exposed to 
ET-1 for 15 min (17.4 ± 1.1-fold for p46 JNKs and 12.1 ± 0.9-fold for p54 JNKs) (Fig. 6.8).   
Overexpression of FLAG-PKN1 increased this level of phosphorylation significantly (26.2 ± 2.1-fold 
for p46 JNKs; 23.1 ± 3.9-fold for p54JNKs).  The abundance of total JNKs was unaffected by the 
overexpression of PKN1 or the addition of ET-1.  In summary, overexpressing FLAG-PKN1 had a 
negative effect on the activation of ERK1/2 in response to ET-1 but had a positive effect on JNKs.  
The activation of p38-MAPK by ET-1 was unaffected by overexpressing PKN1.  
 
The effects of overexpression of FLAG-PKN1 on MAPK phosphorylation induced by H2O2 or 0.5 M 
sorbitol (hyperosmotic shock) were analysed by immunoblotting.  ERK1/2, p38-MAPK and JNKs 
were all substantially activated by H2O2 or hyperosmotic shock (0.5 M sorbitol).  However, 
overexpression of FLAG-PKN1 had no effect on the degree of phosphorylation or on the total levels 
of expression of any of the MAPKs studied (ERK1/2, Fig. 6.9; p38-MAPK, Fig. 6.10; JNKs, Fig. 
6.11). 
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Figure 6.6. Overexpression of FLAG-PKN1 inhibits phosphorylation of ERK1/2 in response to 
ET-1.  Cardiomyocytes were infected adenoviruses encoding FLAG-PKN1 (+) or were uninfected (-). 
After 24 h, cardiomyocytes were exposed to ET-1 (100 nM) for the times indicated.  Protein extracts 
were immunoblotted with antibodies to phosphorylated ERK1/2 (upper panel) or total ERK1/2 (centre 
panel).  Representative immunoblots are shown.  Densitometric analysis of ERK1/2 phosphorylation 
is shown in the lower panel.  Results are means ± SEM (n = 3).  #p<0.05 and ##p<0.01 relative to 
ERK1/2 phosphorylation in uninfected cardiomyocytes (one-way ANOVA with multiple comparisons 
Tukey post-test).   
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Figure 6.7. Overexpression of FLAG-PKN1 has no significant effect on phosphorylation of p38-
MAPKs induced by ET-1 in cardiomyocytes. Cardiomyocytes were infected adenoviruses encoding 
FLAG-PKN1 (+) or were uninfected (-). After 24 h, cardiomyocytes were exposed to ET-1 (100 nM) 
for the times indicated.  Protein extracts were immunoblotted with antibodies to phosphorylated p38-
MAPK (upper panel) or total p38-MAPK (centre panel).  Representative immunoblots are shown. 
Densitometric analysis of p38-MAPK phosphorylation is shown in the lower panel.  Results are 
means ± SEM (n = 3).    
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Figure 6.8. Overexpression of FLAG-PKN1 enhances phosphorylation of JNKs induced by ET-1 
in cardiomyocytes. Cardiomyocytes were infected adenoviruses encoding FLAG-PKN1 (+) or were 
uninfected (-). After 24 h, cardiomyocytes were exposed to ET-1 (100 nM) for the times indicated.  
Protein extracts were immunoblotted with antibodies to phosphorylated JNKs (upper panel) or total 
JNKs (centre panel). Representative immunoblots are shown. Densitometric analysis of 
phosphorylation of JNKs is shown in the lower panel.  Results are means ± SEM (n = 3).  #p<0.05 
relative to phosphorylation of JNKs in uninfected cardiomyocytes (one-way ANOVA with multiple 
comparisons Tukey post-test).   
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Figure 6.9. Overexpression of FLAG-PKN1 does not affect phosphorylation of ERK1/2 induced 
by H2O2 or hyperosmotic shock in cardiomyocytes.  Cardiomyocytes were infected adenoviruses 
encoding FLAG-PKN1 (+) or were uninfected (-). After 24 h, cardiomyocytes were exposed to H2O2 
(0.3 mM or 1mM) or sorbitol (0.5 M) for the times indicated.  Protein extracts were immunoblotted 
with antibodies to phosphorylated ERK1/2 (upper panel) or total ERK1/2 (centre panel).  
Representative immunoblots are shown.  Densitometric analysis of ERK1/2 phosphorylation is shown 
in the lower panel.  Results are means ± SEM (n = 3).  
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Figure 6.10. Overexpression of FLAG-PKN1 does not affect phosphorylation of p38-MAPK 
induced by H2O2 or hyperosmotic shock in cardiomyocytes.  Cardiomyocytes were infected 
adenoviruses encoding FLAG-PKN1 (+) or were uninfected (-). After 24 h, cardiomyocytes were 
exposed to H2O2 (0.3 mM or 1mM) or sorbitol (0.5 M) for the times indicated.  Protein extracts were 
immunoblotted with antibodies to phosphorylated p38-MAPK (upper panel) or total p38-MAPK 
(centre panel).  Representative immunoblots are shown.  Densitometric analysis of p38-MAPK 
phosphorylation is shown in the lower panel.  Results are means ± SEM (n = 3).  
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Figure 6.11. Overexpression of FLAG-PKN1 does not affect phosphorylation of JNKs induced 
by H2O2 or hyperosmotic shock in cardiomyocytes.  Cardiomyocytes were infected adenoviruses 
encoding FLAG-PKN1 (+) or were uninfected (-). After 24 h, cardiomyocytes were exposed to H2O2 
(0.3 mM or 1mM) or sorbitol (0.5 M) for the times indicated.  Protein extracts were immunoblotted 
with antibodies to phosphorylated ERK1/2 (upper panel) or total JNKs (centre panel).  Representative 
immunoblots are shown.  Densitometric analysis of JNKs phosphorylation is shown in the lower 
panel.  Results are means ± SEM (n = 3).  
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6.3.6.  Activation of FLAG-PKN1 in cardiomyocytes 
 
ET-1 does not appear to activate endogenous PKN1 (Figs. 6.1 and 6.2) or overexpressed FLAG-PKN1 
(Fig. 6.4) in cardiomyocytes, but can be activated by calyculin A.  I therefore examined which other 
stimuli may activate overexpressed FLAG-PKN1 in cardiomyocytes using in vitro kinase assays of 
immunoprecipitated proteins.  H2O2 (1 mM) increased the activity of FLAG-PKN1 within 1 min of 
stimulation (3.1 ± 0.9-fold, n = 4) with maximal activity at 3 min (6.1 ± 1.9 fold) (Fig. 6.12A).  The 
activity remained elevated at 5 and 15 min.  FLAG-PKN1 activity was completely inhibited by 
including 20 µM HA-1077 or 10 µM Y-27632 in the assay (Fig. 6.13B), confirming that the activity 
does indeed derive from FLAG-PKN1 rather than any possible contaminated enzyme.  Other stimuli 
that activated FLAG-PKN1 were insulin (50 mU/ml; 5 min) that increased FLAG-PKNs activity to 
3.6 ± 1.3-fold relative to controls, hyperosmotic shock (0.5 M sorbitol; 30 min) that induced a 
substantial increase in activity (6.4 ± 0.9-fold relative to controls), and PDGF (20 ng/ml; 10 min) that 
stimulated the activity of FLAG-PKN1 to 6.9 ± 0.9-fold relative to controls (Fig. 6.13). 
 
Given that H2O2, insulin and PDGF all activate PI3K in cardiomyocytes (Pham et al, 2000;Clerk et al, 
2006) (it is not known if hyperosmotic shock activates PI3K in these cells), I examined whether 
activation of FLAG-PKN1 by insulin or H2O2 may require PI3K signalling.  Cardiomyocytes infected 
with adenoviruses encoding PKN1 were either exposed to insulin (50 mU/ml; 5 min), H2O2 (1 mM; 5 
min), LY294002 (50 µM; 15 min) or pre-incubated with LY294002 for 10 min prior to addition of 
insulin or either H2O2.  LY294002 did appear to reduce the activation of FLAG-PKN1 by H2O2 or 
insulin, although the effect was not statistically significant (Fig. 6.13B). 
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Figure 6.12. Activation of FLAG-PKN1 in cardiomyocytes exposed to H2O2. Cardiomyocytes 
were infected with adenoviruses encoding FLAG-PKN1 (24 h).  Infected cardiomyocytes were 
unstimulated or exposed to 1 mM H2O2 for the times indicated.  FLAG-PKN1 was 
immunoprecipitated and the activity measured using in vitro kinase assays.  In B, HA-1077 or Y27632 
were included in the assay.  Results are expressed relative to controls as means ± SEM for 4 
independent experiments.  *p<0.05; **p<0.01 relative to control, ###p<0.001 relative to H2O2 alone 
(one-way ANOVA with Tukey post-test). 
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Figure 6.13. Activation of FLAG-PKN1 by insulin, PDGF or hyperosmotic shock and the role of 
PI3K signalling in activation of FLAG-PKN1. Cardiomyocytes were infected with adenoviruses 
encoding FLAG-PKN1 (24 h).  Infected cardiomyocytes were unstimulated or exposed to PDGF (20 
ng/ml, 10 min), hyperosmotic shock (0.5 M sorbitol, 30 min), insulin (50 mU/ml, 5 min), H2O2 (1 
mM, 5 min) or LY294002 (50 µM, 15 min) or to insulin or H2O2 (5 min) following pre-treatment with 
LY294002 for 10 min.  FLAG-PKN1 was immunoprecipitated and the activity measured using in 
vitro kinase assays.  Results are expressed relative to controls and are means ± SEM for 4 independent 
experiments. *p<0.05; **p<0.01 relative to control, #p<0.05 relative to agonist alone (one-way 
ANOVA with Tukey post-test). 
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6.4.  Discussion 
 
PKN1 has been established as an effector of Rho/Rac signalling.  However, the physiological context 
of activation, the mode of activation (RhoA-dependent/independent) and the roles of the various 
phosphorylation events are not well understood in any cell, but particularly so in cardiomyocytes and 
the heart.  Here, I have started to elucidate the mechanisms of regulation of PKN1 in cardiomyocytes. 
 
6.4.1.  Activation of PKN1 in cardiomyocytes 
 
ET-1 rapidly promotes GTP-loading (and activation) of RhoA in cardiomyocytes (section 4.3.1) 
(Clerk et al, 2001) and PKN1 is established as an effector of RhoA in various cells including 
cardiomyocytes (Flynn et al, 1998), so it was expected that ET-1 should activate PKN1.  However, 
although phospho-PKN1 (Thr774/816) were detected in cardiomyocytes and the degree of 
phosphorylation was increased by calyculin A (Fig. 6.1A), the levels of phospho-PKN1 (T774/T816) 
were unchanged following stimulation with ET-1 (Figs. 6.1B).  Furthermore, MonoQ FPLC elution 
profiles of phospho-PKN1/2 (Thr774/816) or total PKN2 were similar for extracts from unstimulated 
cardiomyocytes or cardiomyocytes exposed to ET-1 (Fig. 6.2, A, B and D), so there is no evidence for 
any further phosphorylation events that may be associated with activation of PKN1/2.  Finally, the 
activity of overexpressed FLAG-PKN1 was not increased in cardiomyocytes exposed to ET-1 (Fig. 
6.4).  The data therefore suggest that ET-1 does not activate PKN1 in cardiomyocytes despite its 
activation of RhoA. 
 
In contrast to ET-1, calyculin A did promote a shift with PKN1/2 eluting at higher salt concentrations 
(Fig. 6.2C).  This is indicative of an increase in the negative charge on the protein which often 
indicates an increase in phosphorylation status (consistent with calyculin A being a Ser/Thr 
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phosphatase inhibitor).  Although T774 (for PKN1) and T816 (for PKN2) are crucial for activation of 
PKN1/2 as shown by the complete loss of activation when these sites are mutated (Flynn et al, 2000), 
there is evidence of numerous other phosphorylations in different regions of PKN1/2 (Fig. 1.5).  
Calyculin A also increased the activity of overexpressed FLAG-PKN1 (Fig. 6.4), presumably as a 
consequence of Ser/Thr phosphatase inhibition and the associated increase in phosphorylation status 
of PKN1/2 (Figs. 6.1 and 6.2).  Thus, PKN1 can be activated in cardiomyocytes.   
 
In vitro kinase assays of overexpressed FLAG-PKN1 demonstrated that H2O2, insulin, hyperosmotic 
shock or PDGF (Figs. 6.12 and 6.13) consistently increased kinase activity.  It is notable that H2O2, 
insulin and PDGF all activate PKB in cardiomyocytes through PI3K (Pham et al, 2000;Clerk et al, 
2006), though the effects of hyperosmotic shock on this pathway in these cells are unknown.  It 
therefore seemed possible that the principal mode of activation of PKN1 in cardiomyocytes may be 
through PI3K signalling.  Studies performed in vitro indicate that PtdIns3,4,5P3 does increase PKN1 
activity (Palmer et al, 1995a), although PtdIns4,5P2 may be equally as effective.  Very preliminary 
data are further supportive of a role for PI3K signalling in the activation of FLAG-PKN1 given that its 
activation by H2O2 or insulin was reduced by the PI3K inhibitor, LY294002 (Figs. 6.13).  
Unfortunately, these studies were conducted at the end of the project and further experiments are 
necessary to confirm the results.  Assuming PI3K signalling is indeed required for activation of 
PKN1, additional studies may become appropriate to delineate the pathway and to determine the 
functional consequences.  One possibility is that PKN1 stimulates glucose uptake as has been 
suggested in other cells (Standaert et al, 1998).  Enhanced glucose uptake in cardiomyocytes by PKN1 
would be consistent with the cardioprotective effect proposed by Takagi et al. (2010) in which 
activation of PKN1 is shown to reduce cardiomyocyte apoptosis.   
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6.4.2  Signalling through PKN1 to MAPKs 
 
The studies of the effects of FLAG-PKN1 were based on published data to demonstrate that PKN1 
may signal to p38-MAPKs and a personal communication from Professor Peter Parker to indicate that 
it may signal to JNKs, if only in the context of hyperosmotic shock.  Interestingly, although p38-
MAPK activation by ET-1 was unaffected by overexpression of FLAG-PKN1 (Fig. 6.7), ET-1 
induced ERK1/2 activation was significantly inhibited by FLAG-PKN1 (Fig. 6.6) whereas activation 
of JNKs was enhanced (Fig. 6.8).  Notably, activation of each of the three MAPK cascades by 
oxidative stress or hyperosmotic shock (i.e. cellular stresses) was not affected by overexpression of 
FLAG-PKN1.  It is difficult to draw any conclusions from these studies.  However, it would seem that 
any effect of PKN1 on ERK1/2 and JNK signalling depends on the context of activation of the 
pathway.  For the ERK1/2 cascade, the point of signal integration presumably lies above the level of 
MEK1/2 since all three stimuli activate MEK1/2 and ERK1/2 (Bogoyevitch et al, 1993;Clerk et al, 
1994;Bogoyevitch et al, 1995a), but the upstream activators for oxidative stress and hyperosmotic 
shock have not been identified.  For JNKs, the involvement or otherwise of MKK4 vs MKK7 has not 
been established for each of the stimuli and the kinases that operate at the MAPKKK level are 
essentially unknown.   
 
6.4.3.  The use of recombinant adenoviral vectors for PKN1 overexpression 
 
In this chapter, an important part of the experiments involved the use of recombinant adenoviruses 
(prepared as described in section 2.11) to infect cardiomyocytes and overexpress FLAG-PKN1 protein 
in the cells.  These experiments therefore allowed a comparison of the effect of overexpressed FLAG-
PKN1 vs. endogenous PKN1 on MAPK activation in the cardiomyocyte following stimulation.  
Because endogenous PKN1 is not abundant in the cardiomyocyte, overexpressing and  
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immunoprecipitating the FLAG-PKN1 protein also meant that kinase activity assays could be 
performed specifically on PKN1 following agonist stimulation.  In each case, uninfected 
cardiomyocytes (expressing PKN1 endogenously) were treated with the same agonists and harvested 
simultaneously.  
 
In order to establish the titre (or degree of infectivity, at least) of the adenovirus used, different 
concentrations (1/800, 1/4800 and 1/24000 dilutions) were used to infect cardiomyocytes.   The cell 
extracts were then immunoblotted with anti-FLAG antibody and a relative measure of the infectivity 
of the virus ascertained.   Ideally, an accurate PFU/ml calculation (and therefore a MOI) should have 
been conducted in order to ensure that the same numbers of virus particles were being added to the 
cultured cells each time the experiment was performed.  Unfortunately, time and resources did not 
permit this.  The process of titreing a virus by traditional means (the only used in our laboratory at the 
time) is a lengthy process that involves utilising plaque-based assays and a confluent monolayer of 
HEK-293 cells to act as targets for the serially-diluted virus.  Such assays allow the PFU of a virus 
sample to be calculated (section 1.7).  Although the level of overexpression of FLAG-PKN1 (Fig. 
6.3A) gives an indication of the infectivity of the adenovirus at the concentrations, a more accurate 
PFU/MOI is necessary future experiments.  Fortunately, the experiments performed here used only 
one adenoviral construct and therefore the process of accurately matching different recombinant 
vectors for their multiplicity of infections was not a requirement.   
 
The fact that there is not an empty adenoviral vector control in the experiments (especially in the 
MAPK activation assays) poses a difficulty that would need to be addressed if time allowed.  The 
construction of adenoviral vectors from the initial cloning steps to the final suitably high titre virus 
that can be added to cardiomyocytes in culture is a very labour-intensive process - none more so than 
the low efficiency and difficulty in screening for homologous recombination in the latter stages.  At 
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the time I conducted these experiments, I considered that having equivalent (yet uninfected) control 
cardiomyocytes in culture at every point in the experiment was a sufficient control for monitoring the 
effects of infection on the cells.  However, the process of infecting the cardiomyocytes with the 
adenoviruses (irrespective of overexpressing FLAG-PKN1) may have an effect on the cells and cause 
various stress-related signalling pathways to be activated.   Without an empty (expressing FLAG only, 
for example) vector, it is impossible to account for this in such experiments as the MAPK activity 
ones.  Where I have used the adenovirus to overexpress FLAG-PKN1 in the cell and study its activity 
in response to different agonist, the problem of a lack of empty vector control remains.  It is perhaps 
of slightly less concern in this case because the aim of these experiments was to determine if various 
agonists activated PKN1 in cardiomyocytes and what was needed was the cell to act as “test-tube” in 
order to overexpress the protein to quantifiable levels.  Again however, an empty vector recombinant 
would need to be engineered in the future for the full relevance of these data to be determined. 
 
6.4.4  Emerging studies of PKN1 
 
This data in this chapter represent initial phases in the study of the biochemistry of the regulation of 
PKN1 in cardiomyocytes.  Two papers have very recently been published that focus on PKN1 in the 
heart. Firstly, the functional role of PKN1 during myocardial
 
ischemia/reperfusion (I/R) was 
investigated (Takagi et al, 2010).  The experiments were performed both in cultured cardiomyocytes 
and in transgenic mice cardio-specifically overexpressing constitutively-active or dominant-negative 
forms of PKN1.  The results showed that PKN1 was activated by I/R and that it inhibited apoptosis of 
cardiomyocytes.  This implies that PKN1 has a positive role in cardioprotection from I/R injury. It is 
thought that by mediating the phosphorylation
 
of αB crystallin and stimulating proteasome activity, 
PKN1 asserts this protective effect in the heart.  The in vitro results of oxidative stress promoting 
PKN1 phosphorylation are consistent with what I have shown in this thesis, although in this case it is 
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the actual activation of PKN1 by H2O2 that I have investigated (Fig. 6.13).  Further to this, and 
consistent with the evidence of cellular stresses activating PKN1 (Takagi et al, 2010), I also showed 
that hyperosmotic shock (in the form of sorbitol) activated PKN1 substantially (Fig. 6.13). 
 
The most recent research paper on the role of PKN1 in the heart also focused on I/R in the 
myocardium and specifically on hypotonic stress-induced cardiomyocyte swelling which can be 
induced by pathological conditions such as I/R and which affects the activities of ion channels 
(Kajimoto et al, 2011).  Both RhoA and PKN1 were rapidly activated by hypotonic stress in 
cardiomyocytes.  This was associated with a concomitant activation of PDK1, a potential upstream 
regulator of PKN1 (section 1.5.5.2).  However, in contrast to my results, overexpression of PKN1 
significantly increased ERK1/2 phosphorylation, whereas PKN1 downregulation inhibited hypotonic 
stress-induced ERK phosphorylation and reduced the survival of cardiomyocytes in the presence of 
hypotonic stress.  This evidence further suggests that the signalling pathways involving PKN1 may 
promote cardiomyocyte survival.  One result which Kajimoto et al. describe but which is in contrast to 
my investigation is that PKN2 is not expressed in cardiomyocytes.  The Western blots shown in this 
thesis (using an antibody for phospho-PKN1/2) consistently show a second band at 140 kDa which is 
almost certainly PKN2.  Another difference between the studies is that Kajimoto et al. used 
adenoviruses overexpressing only the constitutively-active catalytic domain of PKN1.  My adenovirus 
overexpresses the full length PKN1 with the N-terminal regulatory domains included.  This may 
explain some of the differences observed between the results.  However, my studies have shown that 
overexpression of full length PKN1 does increase JNK activation and that hyperosmotic shock 
activates PKN1.  JNK is a classic stress-activated MAPK (Bogoyevitch et al, 1995a;Clerk and 
Sugden, 1997b) and therefore its activation is in line with the theory that PKN1 is involved in the 
cardiomyocyte signalling response to stress stimuli.  
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CHAPTER 7:  DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS  
 
7.1.  Summary of results 
 
Regulation of RhoA, RhoB, RhoC, Rnd1 and Rnd3 in cardiomyocytes 
 ET-1 or H2O2 promoted significant and rapid increases in RhoB.   
 Rnd1 was potently upregulated by ET-1.  Rnd1 mRNA was also increased by H2O2, IL-1β or 
TNFα. 
 RhoA and Rnd3 were upregulated by ET-1 (not H2O2, IL-1β or TNFα). 
 RhoC mRNA was statistically unchanged in response to any stimuli, but ET-1 caused a slight 
increase in RhoC mRNA expression and had a more marked effect at the protein level. 
 
Role of ERK1/2 vs RhoA signalling in regulating changes in RNA expression: microarray 
studies 
 Of 273 RNAs that were upregulated by ET-1 within 1 h, ERK1/2 signalling positively 
regulated ~65% with a negative effect on a small proportion (~2%), whereas RhoA signalling 
positively regulated ~10% with a negative effect on a greater proportion (~14%).  
 Of RNAs non-responsive to ET-1, 66 or 448 were regulated by PD184352 or C3T, 
respectively, indicating that RhoA signalling has a more significant effect on baseline RNA 
expression than ERK1/2 signalling. 
 Some RNAs were not significantly regulated by either ERK1/2 or RhoA signalling, 
implicating additional pathways in the cardiomyocyte IEG response to ET-1. 
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Using Y-27632 and HA-1077 to determine the role of ROCK1/2 and/or PKN1/2 in the 
cardiomyocyte response to ET-1   
 ET-1-induced phosphorylation of MYPT1 was inhibited by Y-27632 and HA-1077. 
 For most RNAs studied, the role of RhoA signalling in positive (Arc, Slc25a25, Tfpi2, 
Tnfaip3) or negative (Bmp2, LOC363060, LOC498272) regulation was confirmed. 
 For some RNAs (Pvr, IL-6, Bdnf), Y-27632 or HA-1077 inhibited the increase in mRNA 
expression induced by ET-1, in contrast to enhancement by C3T.  Upregulation of Crem by 
ET-1 was inhibited by HA-1077, enhanced by C3T but unaffected by Y-27632.  For these 
responses, it is difficult to draw any conclusions with respect to the role of RhoA signalling. 
 
Activation of PKN1 in cardiomyocytes 
 Endogenous phospho-PKN1/2 was detected in unstimulated NRVMs, but ET-1 did not appear 
to activate them. 
 Calyculin A activated endogenous PKN2 as demonstrated by increased phosphorylation in the 
activation loop and a shift to elution at higher salt concentrations on MonoQ FPLC.    
 In vitro kinase assays for overexpressed FLAG-PKN1 further indicated that ET-1 did not 
increase PKN1 activity; FLAG-PKN1 was activated by calyculin A, H2O2, insulin, 
hyperosmotic shock or PDGF. 
 
7.2.  Discussion of results 
 
Cardiac hypertrophy is a multi-faceted, complex disorder involving various stimuli and signals.  These 
effects are reflected at the cardiomyocyte level and a catalogue of potential components of the 
hypertrophic response has developed (Sugden and Clerk, 1998b;Dorn et al, 2003;Brown et al, 
2006;Clerk et al, 2007a).  Rho-family small G proteins potentially regulate gene expression and 
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modulate actin structures to effect changes in the adapting cardiomyocyte, and are therefore strongly 
implicated in the hypertrophic response (Wang et al, 1997;Kuwahara et al, 2005;Brown et al, 2006).   
 
7.2.1.  RhoA signalling in the cardiomyocyte response to ET-1 
 
Inhibitors of the ERK1/2 cascade and of RhoA signalling in cardiomyocytes were employed to 
investigate the early gene expression changes that occur in cardiomyocytes in response to ET-1.  Both 
of these signalling pathways are activated rapidly by ET-1 in cardiomyocytes as shown previously 
(Clerk et al, 1994;Clerk et al, 2001) and confirmed here (chapter 4).  However, the question of 
whether a particular signalling pathway dominates in controlling global RNA expression changes in 
response to such stimulus was unknown.  ERK1/2 was resoundingly indentified as being a significant 
node in the early gene response to ET-1, particularly with respect to positive regulation of RNA 
expression, whereas RhoA was shown to have a less significant role with approximately equal 
positive and negative effects on RNA expression.  Some RNAs were not significantly regulated by 
either ERK1/2 or RhoA, implicating additional pathways in the cardiomyocyte early gene response to 
ET-1.  As described in detail in section 4.4, the data involving the ERK1/2 inhibitor PD184352 are 
consistent with other studies also identifying ERK1/2 as a key node in the early response to growth 
stimuli (Bromann et al, 2005; Amit et al, 2007).  However, some studies have identified a more 
positive role for RhoA in regulating RNA expression (Sen-Banerjee et al, 2005;Walsh et al, 2008).  
Notably, such studies have not been performed in cardiomyocytes and the experiments differ 
considerably to the approach used in this thesis.  Therefore, the reasons for differences in the results 
may reflect the methods used, times studied, stimuli and/or specific cell types.  I selected the minimum 
effective time and concentration of a cell-permeable form of C3T that could be used to inhibit RhoA.  
I also ensured that the cytoskeletal structure of the cardiomyocytes was not compromised by this 
concentration of C3T (as was the case with a higher concentration).  Others have  used higher 
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concentrations with prolonged incubation which may have secondary and added stress-related effects 
on the cultured cells (Seasholtz et al, 1999;Hagg et al, 2001).  
 
There is, as yet, no single set of genes that can absolutely define “cardiac hypertrophy”.  Instead, large 
numbers of genes may be regulated in combination depending on the relative contributions of each 
component of an ensemble of neurohormones, cytokines and growth factors in the heart.  As in the 
regulation of Rho proteins in chapter 3 and in terms of the response to ET-1 that was observed in 
Chapter 4, a major factor that must be considered and one which may confer additional structure and 
order to the system is the time and duration of the stimulus signal.  For example, a single stimulus 
(such as ET-1) may initiate cardiomyocyte hypertrophy but, since signalling and gene expression 
responses are rapid and transient, other factors acting at later times may be required for a fully 
developed response.  Interestingly, the positive ERK1/2 and RhoA signals converged at one point to 
increase expression of Abra and Srf mRNAs, factors which are both implicated in regulating gene 
expression in the heart (section 1.6.2) (Arai et al, 2002; Miralles et al, 2003; Kuwahara et al, 2005; 
Kuwahara et al, 2007).  The convergence of signals that result in upregulation of Abra and Srf implies 
that RhoA signalling may be of greater significance in positive regulation of RNA expression over a 
longer period of time.  In support of this theory, it was observed in Chapter 3 that RhoA mRNA and 
protein levels also increased gradually (but significantly) over 6 h in response to ET-1.  
 
To return to the early events following cell stimulation, clearly, ET-1 has an important role in 
influencing expression of transcription factors (e.g. Srf, Egr family, Klf family transcription factors) 
and it also modulates expression of a range of paracrine/autocrine factors including Egf receptor 
ligands (e.g. Areg, Ereg, Hbegf), gp130 ligands (e.g. IL-6, Lif) and ligands of the transforming growth 
factor (Tgf) β family (e.g. Inhba; Bmp2; Tgfb3).  In combination, these are likely to propagate the 
response acting in both an autocrine and paracrine manner.  Feasibly, in an in vivo scenario there is 
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most likely a low-level of exposure to various stimuli.  The increase of transcription that occurs during 
remodelling may result from subtle modification of the properties of the individual transcription 
factors and mediators.  A change in frequency or broadening of the signalling input may be sufficient 
to change the programme of gene transcription.  Therefore, it is plausible that such networks of signals 
facilitate progression from a multiplicity of receptor starting points to a similar end-stage hypertrophic 
phenotype.  Furthermore, cardiomyocyte hypertrophy is characterised not only by alterations in 
cardiac gene expression, but also by the coordinated control of protein synthesis, protein degradation 
and rRNA production.  How these different regulatory mechanisms relate to each other at different 
stages is undoubtedly very complex, but studies such as this begin to establish a framework which 
may be used to help elucidate latter signalling events.  
 
A major question addressed in this thesis related to whether the few genes that were upregulated by 
ET-1 and which were dependent on RhoA signalling (according to the results with C3T) were 
regulated by either of the two most well-established downstream effector systems of RhoA, namely 
ROCK1/2 and PKN1/2.  The data in chapters 5 and 6 clearly indicated that Y-27632 and HA-1077 
inhibit ROCK1/2 and PKN1/2 to a similar extent and, consistent with this, with exception only of 
Crem, the two inhibitors proved to have very similar effects on the upregulation of different genes by 
ET-1.  In the case of Crem, HA-1077 inhibited the upregulation induced by ET-1, whereas Y-27632 
appeared to marginally enhance it, and this may reflect some differences in the inhibition profiles of 
the compounds with respect to other protein kinases (Davies et al, 2000).  For some transcripts (Pvr, 
Bdnf, IL-6 and Crem), direct inhibition of RhoA with C3T had a completely different effect on ET-1-
induced mRNA upregulation to the effects of Y-27632 and HA-1077.  This might either result from 
some lack of specificity of the inhibitors or it could suggest that a different signalling pathway may be 
involved apart from ROCK1/2 or PKN1/2. 
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7.2.2.  PKN1 activity is regulated by insulin or oxidative stress 
 
Having established that ROCK1/2 and/or PKN1/2 regulate cardiomyocyte gene expression in the 
context of stimulation with ET-1, it was important to determin99e which may play the more 
significant role.  ROCK1/2 are well-established in cardiovascular system biology as a key modulator 
of the cytoskeleton.   PKN1 is been shown to be expressed in the heart (Mukai and Ono, 1994;Palmer 
et al, 1995;Quilliam et al, 1996), but it was completely unknown how much of a role PKN1/2 may 
play in cardiomyocytes.  Because RhoA has consistently been shown to be activated by ET-1 (Clerk et 
al, 2001), and RhoA is known to be an upstream effector of PKN1 (Watanabe et al, 1996;Maesaki et 
al, 1999), the obvious assumption was that ET-1 would activate PKN1.  Interestingly, this was not the 
case.  In multiple experiments both with endogenous and overexpressed PKN1, I could find no 
evidence that ET-1 either increased the phosphorylation status of PKN1/2 or activated PKN1.  Having 
no indication that ET-1 activates PKN1, it became necessary to determine what could activate it in 
cardiomyocytes.  Insulin acts through the PI3K pathway to stimulate protein synthesis (Pham et al, 
2001), but does not stimulate ERK1/2 signalling to any great extent in cardiomyocytes and does not 
induce a full hypertrophic response (Clerk et al, 2006).  It was therefore a novel finding that insulin 
appea33999red to be the most potent stimulus for increasing PKN1 activity.  Although PKN1 is 
activated by RhoA in other cells, the data here suggest that this is not necessarily the case in 
cardiomyocytes and PI3K signalling may be more relevant in PKN1 activation.  Consistent with 
recent in vivo data (Takagi et al, 2010;Kajimoto et al, 2011), activation of PKN1 in cardiomyocytes 
may constitute one element of the cardioprotective pathways attributed to PI3K and PKB signalling. 
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7.2.3.  Regulation of Rho-family G proteins in cardiomyocytes 
 
A central theme of this thesis has been to investigate the changes in mRNA and protein expression in 
NRVMs following exposure to different stimuli but mainly to ET-1.  This included examining the 
regulation of several Rho-family members (other than just RhoA, Rac1 and Cdc42) in 
cardiomyocytes.  Importantly, the increased expression of mRNAs for RhoB and Rnd1 in response to 
ET-1 and oxidative stress, as observed in previous microarray experiments (Kennedy et al, 2006;Clerk 
et al, 2007b;Cullingford et al, 2008), were validated both at the mRNA and protein level.  The 
regulation of Rnd1 and Rnd3 is considered particularly important because they behave very 
differently to the classic “molecular switch” paradigm of Rho GTPases.  They are in fact 
constitutively-active and are believed to antagonise RhoA function and cytoskeletal organisation 
(Wennerberg et al, 2003;Chardin, 2006).  Increases (or possibly more likely, decreases) in the protein 
abundance of Rnd1 and Rnd3 would therefore be expected to have a considerable role in the initial 
stages of hypertrophic signalling in an adapting cardiomyocyte.   
 
Both RhoB and Rnd1 were indeed upregulated in response to ET-1 or H2O2 as shown by the qPCR 
experiments in chapter 3.  This not only validated the previous microarray data but shed further light 
on their regulation by highlighting the transience of RhoB upregulation and, for Rnd1, the large extent 
of the increases.  Apart from RhoB and Rnd1, the abundances of RhoA, RhoC and Rnd3 were not 
acutely modulated by hypertrophic stimuli, oxidative stress or pro-inflammatory cytokines.  Indeed, 
IL-1β and TNFα only altered the regulation of Rnd1 mRNA.  It should be noted, however, that the 
minor positive changes that were observed in RhoA, Rnd3 and even slightly with RhoC 
mRNA/protein abundances in response to ET-1 were statistically significant by the 6 h time point.  
Although it can only be considered speculation without performing studies with longer time points, 
one could presume that the levels of these Rho proteins may continue to rise.  Cellular remodelling 
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and the changes in morphology in response to hypertrophic stimuli are not obvious before ~8 h after 
exposure to ET-1 (Clerk et al, 2007b).  The fact that these Rho proteins are implicated in many of 
these changes (Hall, 1998) and are upregulated over a longer time period is consistent with a theory 
that they may be involved in more long term structural changes.  While more immediate “regulatory” 
genes that may encode transcription factors are rapidly upregulated by ET-1 [the more classic IEGs 
e.g. c-jun, c-fos, Egr-1 (Cullingford et al, 2008)], the more “structural” genes are expected to 
gradually become significant in the cells response.   However, RhoB is upregulated early and 
transiently and, as in other cells (Mellor et al, 1998;Adini et al, 2003), may play a more immediate 
role in protein trafficking in cardiomyocytes.   
 
In addition to their direct effects on the cytoskeleton, Rho proteins can induce transcriptional changes 
that may indirectly impact on cytoskeletal organisation.  RhoA activates transcription by the 
MRTF/SRF transcription factor complex by altering the level of monomeric G-actin in cells (Miralles 
et al, 2003; Kuwahara et al, 2007).  Interestingly RhoB (but not RhoA) represses the transcription of 
the TGFβ receptor by reducing binding of the AP1 transcription factor to its promoter (Adnane et al, 
2002).  This indicates that RhoB and RhoA have distinct mechanisms for regulating transcription, and 
could thereby have different long-term effects on cell motility and the cytoskeleton.  Rnd1 may also 
be assumed to have an important role in regulating the system in these early stages, possibly by 
antagonising the effects of endogenously expressed RhoA on the cytoskeleton (Wennerberg et al, 
2003).  From the oxidative stress perspective, changes in gene expression which appear to modulate 
the cardiomyocytes progress through apoptosis and eventually necrosis are less well understood.  It is 
known, however, that stimuli which promote apoptosis also modulate RNA expression (Clerk et al, 
2007b).  Possibly the changes in the mRNA/protein profiles of RhoB or Rnd1 in response to H2O2 
modulate the apoptotic response in some way, either to rescue cardiomyocytes before they commit to 
cell death pathways or even to modulate the balance between apoptosis and necrosis. 
Chapter 7 
Page | 228  
 
7.3.  Future directions 
 
I believe that the data in this thesis have opened up two major areas for future research, as discussed 
below. 
 
7.3.1.  The role of Rho-family proteins in cardiomyocytes over prolonged periods 
 
The data in this thesis suggest that, although RhoA signalling per se may play only a relatively minor 
role in promoting cardiomyocyte gene expression in response to ET-1 (as an example) in the short 
term, it and other Rho-family proteins may play a more significant role in the longer term.  Thus, 
more detailed studies over prolonged periods are necessary to establish how Rho-family small G 
proteins are regulated and regulate gene expression in cardiomyocytes in culture over 24 - 48 h.  It 
would be interesting to correlate such changes with changes in cardiomyocyte morphology, with 
particular attention to the actin cytoskeleton.  Further studies of the effects of inhibiting expression of, 
for example, Rnd1 or Rnd3 proteins, either by siRNA or antisense RNA, would be useful in assessing 
their role in antagonising RhoA activation and if they may collapse certain cytoskeletal structures. 
 
7.3.2. The role of PKN1 in the heart  
 
An important next step in the continuation of the PKN1 study would be to generate an empty 
adenoviral control vector (as described in chapter 6 discussion) for use in both the overexpression 
studies and in future experiments. This should be done in conjunction with calculating accurate PFU 
values for these adenoviruses and for any additional viruses that might be generated so as to be sure of 
the amount of viable adenoviral particles that are being added to the cultured cells.  
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 Although, surprisingly, PKN1 did not appear to be regulated by ET-1 in cardiomyocytes, the data 
generated in this thesis indicate that further studies of PKN1 in cardiomyocytes and the heart are 
merited.  In parallel with the studies of overexpressed PKN1, methods to inhibit either its activation or 
expression should be employed.  For example, siRNA may be useful in downregulating PKN1 
expression in cardiomyocytes.  Studies have already been conducted using transgenic mice (Takagi et 
al, 2010), but such studies are not easy to interpret as discussed in chapters 1 and 6.  The development 
of mouse models which are null PKN1 may be an important step in clarifying its role in 
cardiomyocytes.   
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APPENDIX I:  GENERAL REAGENTS AND CHEMICALS 
Supplier Product 
Alexis Biochemicals Microcystin LR 
AMS Biotechnology (Europe)  RNA-Bee RNA isolation reagent 
Applied Biosystems Optical 96-well reaction plates 
Bachem Endothelin-1 
BDH chemicals (through 
VWR) 
Acrylamide (40% solution) 
Bis-acrylamide (2% solution) 
Bisbenzimide (H33258) 
Boric acid 
EDTA 
Ethanol 
Glucose 
Glycine 
Glycerol 
Glycerophosphate 
HEPES 
Isopropanol 
MgCl2 
MgSO4 
Methanol 
Methylated spirits 
KCl 
NaCl 
NaF 
Na2HPO4 
Na3VO4 
Sodium dodecyl sulphate 
Sucrose 
Tris base 
Triton X100 
Tween 20 
Whatman 3MM paper 
Whatman P81 paper  
BioRad Bradford protein assay reagent 
Dako 
Horseradish peroxidase-conjugated secondary antibody 
Fluorescent mounting medium  
GE Healthcare 
Full-range rainbow molecular weight markers 
Hyperfilm MP 
ECL DualVue western blotting markers 
ECL Plus western blotting detection reagents 
Invitrogen 
100 bp DNA ladder 
Agarose 
dATP, dCTP, dGTP, dTTP 
Dulbecco’s modified Eagle’s medium 
Foetal calf serum 
M199 media 
Nuclease free water 
Penicillin and streptomycin 
Phosphate buffered saline (10 ×)  
RNaseOUT recombinant ribonuclease inhibitor 
NEN Life Sciences  [γ-
32
P] ATP 
Novo Nordisk 
Pharmaceuticals  
Insulin 
Qiagen  RNeasy MinElute RNA cleanup kit  
R & D Systems IL-1β  
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TNFα 
Santa Cruz Biotechnology Luminol 
Schleicher and Schuell Nitrocellulose membrane  
Sigma-Aldrich 
Ammonium persulphate  
Bovine serum albumin 
Bromophenol blue 
Chloroform 
Dithiothreitol 
EZview Red Anti-FLAG M2 Affinity Gel 
Gelatin 
H2O2 
Leupeptin 
Pancreatin 
PMSF 
SYBR Green Jump Start Taq ReadyMix 
TEMED 
Thermo Scientific taq DNA polymerase 
Worthington Biochemicals Collagenase 
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APPENDIX II:  GEL RECIPES 
 
4% Stacking gel: 
Acrylamide, 4% (v/v) 
Bis-Acrylamide, 0.106% (v/v) 
SDS, 0.1% (w/v) 
Tris-HCl, pH 6.8, 0.125 M 
Temed, 0.1% (v/v) 
Ammonium persulphate, 0.1875% (w/v) 
 
8% Resolving gel: 
Acrylamide, 8% (v/v) 
Bis-Acrylamide, 0.212% (v/v) 
SDS, 0.1% (w/v) 
Tris-HCl, pH 6.8, 0.125 M 
Temed, 0.1% (v/v) 
Ammonium persulphate, 0.1875% (w/v) 
 
10% Resolving gel: 
Acrylamide, 10% (v/v) 
Bis-Acrylamide, 0.266% (v/v) 
SDS, 0.1% (w/v) 
Tris-HCl, pH 6.8, 0.125 M 
Temed, 0.1% (v/v) 
Ammonium persulphate, 0.1875% (w/v) 
 
12% Resolving gel: 
Acrylamide, 12% (v/v) 
Bis-Acrylamide, 0.32% (v/v) 
SDS, 0.1% (w/v) 
Tris-HCl, pH 6.8, 0.125 M 
Temed, 0.1% (v/v) 
Ammonium persulphate, 0.1875% (w/v) 
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APPENDIX III: PKN1 mRNA SEQUENCE WITH CLONING AND 
SEQUENCING PRIMERS (NM_017175) 
 
PKN1 FORWARD CLONING PRIMER WITH KPN1 RECTRICTION SITE (RED): 
5’ GACGACAAGGGTACCATGGCCGGCGACGCCGTG 3’ 
 
PKN1 REVERSE CLONING PRIMER WITH HINDIII RESTRICTION SITE (RED): 
5’ CTTATCTAGAAGCTTCTAATAGCCTCCTGCCAC 3’ 
 
PKN1 SEQUENCING PRIMER #1: 5’ CAAGATTGACATCATCCGCA 3’ 
PKN1 SEQUENCING PRIMER #2: 5’ GAGGCAGAGAATTCCACTGAG 3’ 
PKN1 SEQUENCING PRIMER #3: 5’ GAGTTCTCCAACCCACGAATC 3’ 
PKN1 SEQUENCING PRIMER #4: 5’ GAGGGCTACGTCAAGATCG 3’ 
 
 
Italics: untranslated regions 
GAATTCCGCCGAGCGCAGCAGGCCGGATCGCGCAGCGCGCCAGGGAAGGTCTGGGCTCCGCGCTTCCCGCCCCACACGCCGA
CGCGCTCGCAAGCCCTCCCTCGGCGCTGGGACCCCTGGCGGACATGGCCGGCGACGCCGTGCAGAGTGAACCTCGCAGCTGG
TCACTGCTGGAGCAGCTGGGTCTGGCTGGGGCAGACCTGGCAGCCCCTGGGGTGCAGCAGCAGCTGGAGTTAGAGCGAGAGC
GGCTGAAGCGGGAAATCCGAAAAGAGCTGAAGCTGAAGGAGGGCGCTGAGAACCTGAGGCGGGCCACCACTGACCTGGGCCG
CAGCTTGGCCCCTGTGGAACTGCTGCTGAGGGGCTCCGCTAGACGGCTTGACTTGCTGCACCAGCAGCTGCAGGAGCTGCAT
GCACATGTGGTGCTGCCCGACCCTACAGCGGGGAGTGATGCTCCCCAATCCCTTGCAGAGGGCAGCCCTGTCTGCTCATCCA
CCAACCTGAGCCGAGTGGCTGGCCTGGAGAAGCAGCTGGCCATTGAGCTCAAGGTCAAACAGGGGGCAGAAAACATGATCCA
GACCTACAGCAATGGCAGCACCAAGGACCGGAAGCTGCTGTTGACGGCCCAACAGATGCTGCAGGATAGTAAGACCAAGATT
GACATCATCCGCATGCAGCTTCGCCGGGCGCTACAAGCACTCCAGGCTGGCCAGCTGGAGAGTCAGGCAGCTCCTGATGAGG
CCCACGGAGATCCAGACCTGGGAGCCGTAGAGCTACGCATTGAGGAGCTACGACACCATTTTCGAGTAGAGCATGCAGTGGC
AGAAGGCGCCAAGAATGTCCTGCGTCTGCTCAGTGCTGCAAAGGCCCCAGACCGCAAAGCAGTCAGCGAGGCTCAGGAGAAA
TTGACTGAGTCCAACCAGAAGCTGGGCTTGCTGCGGGAGTCACTGGAGAGGCGCTTGGGGGAACTGCCTGCTGATCACCCCA
AGGGACGCCTGCTTCGGGAGGAGCTCACTGCGGCCTCATCGGCAGCCTTCAGTGCAATACTGCCTGGGCCCTTCCCTGCCAT
CACTACAGCACCTTGAGCAAGCCTGCACCACTCACAGGGACCCTGGAAGTACGAGTGGTGGGCTGCAAAAACCTTCCCGAGA
CCATCCCTTGGAGCCCTCCCCCCTCAGTCGGGGCATCTGGGACCCCCGACAGCCGCACTCCTTTCCTGAGTCGTCCAGCTCG
GGGCCTTTACAACCGAAGTGGAAGCCTTAGTGGACGGAGCAGCCTCAAGGGGGAGGCAGAGAATTCCACTGAGGTCAGCACC
GTGCTCAAGCTGGACAACACTGTGGTGGGGCAAACAGCCTGGAAGCCATGCGGCCCCAATGCCTGGGACCAGAGCTTCACCC
TGGAGCTGGAGAGGGCTCGGGAGCTGGAGTTGGCTGTGTTCTGGCGTGACCAGAGGGGTCTGTGTGCTCTCAAATTTCTGAA
GTTGGAAGACTTCTTGGACAATGAGAGGCATGAGGTGCAGCTGGACATGGAACCCCAGGGCTGCCTGGTGGCTGAGGTCACC
TTCCGTAACCCCATCATCGAGCGGATCCCTAGGCTCCAAAGGCAGAAAAAAATTTTCTCCAAGCAGCAAGGGCAGACATTTC
AGCGTGCCAGACACATGAACATCGATGTGGCCACCTGGGTGCGGCTGCTCCGGAGACTCATCCCGAACGCCGTGGCCACTGG
CTCCTTCAGCCCCAATGCATCTCCAGGCTCTGAGATCCGGAGCACTGGAGACATATCCATGGAGAAATTGAATCTCGGTGCT
GACTCAGACAGCTCGTCCCAGAAGAGCCCCGCAGGGCTGCCCTCCACCTCATGTAGCCTGAGTTCTCCAACCCACGAATCCA
CCACCTCTCCAGAGCTGCCTTCAGAGACCCAGGAGACCCCAGGCCCTGGCCTGTGCAGTCCCCTGAGGAAGTCGCCCCTGAC
GCTTGAGGACTTCAAGTTCCTGGCAGTGCTTGGTCGGGGTCACTTTGGAAAGGTGCTGCTGTCTGAATTCCACTCCAGTGGG
GAGCTCTTTGCCATTAAAGCCTTGAAGAAAGGTGACATTGTAGCCCGGGATGAGGTTGAGAGCCTGATGTGTGAGAAGCGGA
TTTTGGCGACCGTGACCAGGGCAGGACATCCCTTCCTTGTGAACCTTTTCGGCTGTTTCCAGACCCCAGAGCATGTGTGCTT
TGTGATGGAGTACTCAGCCGGTGGGGACTTGATGCTGCATATCCACAGCGACGTGTTCTCAGAGCCTCGGGCTGGCTTCTAT
TCGGCCTGTGTGGTGCTGGGACTGCAGTTCCTCCATGAACACAAGATTGTCTACAGGGACCTGAAGTTGGACAATTTGCTCC
TGGATACTGAGGGCTACGTCAAGATCGCAGACTTTGGCCTCTGCAAGGAGGGGATGGGCTATGGGGACCGGACCAGCACATT
CTGCGGAACTCCGGAGTTCCTGGCGCCGGAAGTGCTCACAGACACATCCTACACTCGAGCCGTGGACTGGTGGGGACTGGGT
GTATTTCTCTATGAGATGCTGGTTGGAGAGTCTCCGTTCCCTGGGGACGACGAGGAGGAAGTATTTGACAGCATCGTCAATG
ATGAGGTTCGTTATCCCCGCTTCCTGTCTGCGGAGGCCATCGGCATCATGAGAAGGCTACTGCGGAGGAACCCAGAGCGGAG
GTTGGGATCCACTGAGCGTGATGCAGAAGATGTGAAAAAACAGCCTTTCTTCAGGACTCTGGACTGGGATGCCCTGCTGGCC
CGTCGCCTGCCTCCACCCTTCGTGCCTACACTTTCGGGGCGCACAGACGTCAGCAACTTCGATGAGGAGTTCACTGGGGAGG
CCCCCACACTGAGCCCTCCCCGGGATGCACGGCCCCTGACAGCTGCGGAGCAGGCGGCCTTCCGGGATTTCGACTTTGTGGC
AGGAGGCTATTAGCCCTAAGCCCCTGCCTTGCCCAAGAGTTCTTGGTTTTTAAAAAAGCCTTTGGGGTTTACTCCGGAAT
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